Note: Descriptions are shown in the official language in which they were submitted.
1
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
BACKGROUND OF THE INVENTION
Protein kinases are a group of enzymes that regulate the activity of their
target proteins
by the addition of phosphate groups to the protein substrate. Kinases play an
essential role in many
physiological processes including cell division, differentiation, cellular
homeostasis and signal
transduction. Kinases can be subdivided by their target into Serine/Threonine
kinases and Tyrosine
kinases. Tyrosine kinases are further subdivided into receptor tyrosine
kinases and non-receptor tyrosine
kinases. The mammalian Janus kinase (JAK) family members are non-receptor
tyrosine kinases.
The JAK family has four members; JAK1, JAK2, JAK3 and TYK2. JAK1, JAK2 and
TYK2 are universally expressed, whereas JAK3 expression is limited to
hematopoetic cells. The JAK
family is involved in intracellular signal transduction from >70 different
cytokines. Cytokines bind to
their cell surface receptors resulting in receptor dimerization and subsequent
activation/phosphorylation
of JAK tyrosine kinases. The JAKs are either constitutively associated with
the receptor or are recruited
upon cytokine binding. Specific tyrosine residues on the receptor are then
phosphorylated by activated
JAKs and serve as docking sites for STAT proteins. STATs are phosphorylated by
JAKs, dimerize, then
translocate to the nucleus where they bind specific DNA elements and activate
gene transcription. JAK1
signals in conjunction with all JAK isoforms in a cytokine dependent manner.
JAKs are essential for multiple physiological functions. This has been
demonstrated
using genetically engineered mouse models that are deficient in specific JAKs.
Jakl-/- mice die
perinatally, while Jak24- mice have deficiencies in erythropoesis and die
around day E 12. Jak34- mice are
viable, but have a SCID phenotype with deficiencies in T cells, B cells and NK
cells. TYK2-/- mice
exhibit features of hyper IgE syndrome. These phenotypes demonstrate the
essential and non-redundant
roles of JAK activity in vivo (K. Ghoreschi, A. Laurence, J. J. O'Shea,
Immunol. Rev. 228, 273 (2009)).
Furthermore, mutations in the JAK enzymes have been associated with diseases
in
humans. Inactivating mutations in JAK3 (or the cognate common gamma chain
cytokine receptor) cause
a severe SCID phenotype (J. J. O'Shea, M. Pesu, D. C. Borie, P. S. Changelian,
Nat. Rev. Drug Discov. 3,
555 (2004)). Deletions of TYK2 result in hyper IgG syndrome and increased
infection risk (Y. Minegishi
et al., Immunity. 25, 745 (2006)). No inactivating mutations have been
reported for JAK1 or JAK2,
consistent with the data from mice that demonstrates that JAK1 and JAK2
deficient mice are not viable.
However, several mutations that result in constitutively active JAK2 have been
identified, resulting in
myeloproliferative diseases and confirming the central role of JAK2 in
hematopoesis (O. bdel-Wahab,
Cum Opin. Hematol. 18, 117 (2011)). JAK2 is the sole JAK family member
involved in signal
transduction of the critical hematopoetic cytokines IL-3, GMCSF, EPO and TPO.
The wealth of mouse and human genetic data demonstrating a central role for
JAK kinase activity in autoimmune disease, hematopoesis and oncology has been
supported by
the use of pan-JAK inhibitors in clinical trials for autoimmune diseases and
neoplasms (See K.
2
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Ghoreschi, et al, Immunol. Rev. 228, 273 (2009), and A. Quintas-Cardama, H.
Kantarjian, J.
Cortes, S. Verstovsek, Nat. Rev. Drug Discov. 10, 127 (2011)).
A considerable body of literature has accumulated that link the Jak/STAT
pathway to various diseases and disorders including hyperproliferative
disorders and cancer such
as leukemia and lymphomas, immunological and inflammatory disorders such as
transplant
rejection, asthma, chronic obstructive pulmonary disease, allergies,
rheumatoid arthritis, type I
diabetes, amyotropic lateral sclerosis and multiple sclerosis.
SUMMARY OF THE INVENTION
The present invention provides novel compounds which are inhibitors of JAKs.
The invention also provides a method for the treatment and prevention of JAK-
mediated diseases
and disorders using the novel compounds, as well as pharmaceutical
compositions containing the
compounds.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds of formula I or pharmaceutically
acceptable salts, or stereoisomers thereof:
HN
R2
CN
-N
HN
A is selected from aryl and heteroaryl;
m is 0, 1, 2, 3, or 4;
R2 is independently selected from hydrogen and Ci_6 alkyl;
R3 is selected from: hydrogen, halogen, C1_6 alkyl, C3_6 cycloalkyl, and
(C3_8)heterocycloalkyl;
wherein R2 and R3 are optionally, each independently substituted by 1, 2, or 3
R5 substituents;
R5 is independently selected from hydroxy, (C1-6)alkyl, (C1-6)alkoxy, (C1_6
alky1)0H, halogen,
-CO2H, -(C0-4)alkylCN, -0(C=0)C1-C4alkyl, NO2, trifluoromethoxy,
trifluoroethoxY,
trifluoromethyl, trifluoroethyl, C1_6 alkylsulfonyl, oxo (0=), aminosulfonyl, -
SO2NH2,
-SO2NH(C1_10 alkyl), -SO2N(C1_6 alky1)2, -S 02C1-6alkY-1, -SO2C-P3, -S02CF2H,
-C1-6 alkylsulfinyl, -0(0_1)(C1_6)ha1oa1ky1, amino(C1-6alky1)0-2 and NH2;
Rl is selected from:
halogen,
Oxo (=0),
C1_10 alkyl(oxy)o-i(carbony1)0-1C0-10 alkyl,
µpc3up 0 I -0D-pCuffinspc3up 0 I - I D
`HZIDZOS-
.4DZOS-
`'(IX3IIP 0 I I D)NIZOS-
`01C3IIP 0 I I D)HN1Z OS-
`HZ0D(I1C31IP 0 -0D)-
(IX31IP 0 I -0D)Z0D-
`ouTulp z-i(pC3up 0 I -OD)
µ1jc3up 0 I -0DIXolumnspc3up 0 I -ODIX.Ip
µ1jc3up 0 I -0DIXolumnspc3up 0 I -0 DIX.Ip ampti
µ1jc3up 0 I - ODIXolumnspc3up 0 I -0DIXTBoiolotiopicoR I - D)
µ1jc3up 0 I -0DIXolumnspc3up 0 -0 DIX3Tip opiCoR I - D)
µ1jc3up 0 I -0DIXoulpjinspC3upoio1oti 0 I - I D
µ1jc3up 0 I -0DIXolumnspc3up 0 I - I D çz
µpc3up 0 I -0DpCuojinspc3up 0 I -0D-pC.Ip
µpc3up 0 I -0DpCuojinspc3up 0 I -0:)ii'uoJooti
µpc3up 0 I -0DpCuojinspc3up 0 I -0DIXTBaloptiopicoR I - D)
µpc3up 0 I -0 DpCuojinspc3up 0 I -0 DIX3Tip opiCoR I - D)
µpc3up 0 I -0D-pCuojinspC3upoioloti 0 I - I D oz
µpc3up 0 I -0D-pCuojinspc3up 0 I - I D
µpc3up 0 I -OD I -0(pCuocppo)ouTuIppC3T1popiComolotg I - D)
µ1ic3up 0 I -OD I -0(pCuocppo)ouTuIppc3up 0 I -OD IX.IPOI01,01,1
`Iic3IIP 0 I -OD I -0 (IXIIOCIIPO) WIMP OUTUIPIX3IIP 0 I -0D IX.Ip
µ1ic3up 0 I -OD I -0(1iCuocppo) ouTtuppc3up op/coz I - D SI
µpc3up 0 I -OD I -0(pCuociipo) ouTtuppc3Tipoioloti(0 I - I D)
µ1ic3up 0 I -OD I -0(1iCuociipo) ouTtup1c3up 0 I -OD
µpc3up 0 I -OD ouTtup I -0(1iCuociipo)i-0(Xxo)pC3up 0 I -OD pC)Tip op/co
wolotiR - D)
µpc3up 0 I -OD ouTtup -0(1iCuocppo) I-0(Xxo)1iC3up 0 I -OD IX.IPOI01,01,1
`Iic3f1P 0 I -OD ouyup -0(1iCuociipo) I-0(Xxo)1iC3up 0 -0D IX.Ip 0
µpc3up 0 I -OD ouTtup -0(1iCuocppo) I-0(Xxo)1iC3up 0 I -OD pC3upopiCoz I - D
µpc3up 0 -0 D ouyup I -0(1iCuociipo)I-0(Xxo)pC3Tipoioloti(0 I - I D)
µpc3up 0 I -OD ouTtup -0(1iCuociip o) I-0(Xxo)1iC3HP 0 I -OD
µpc3up 0 -0D I -0(1iCuocppo)I-0(Xxo)pC3up 0 I -OD IiNpopiComoloti(Z I - D)
µ1ic3up 0 I -OD I -0(1iCuocppo)I-0(Xxo)pC3up 0 I -OD 'Xi:Bump-LI
µ1ic3up 0 I -OD I -0(pCuocppo)I-0(Xxo)1iC3up 0 I -OD pC3upopiCo I - D
µ1ic3up 0 I -OD I -0(pCuocppo)i-0(Xxo)pC3up 0 -0D IX.Ip
µ1ic3up 0 I -OD - 0(pCuocppo) I-0(Xxo)pCuo3up 0 I -ZD
µ1ic3up 0 -0D I -0(pCuocppo)I-0(Xxo)1C3upoiolot1 0 I - I D
66Z000/tIOZN3/13c1 61'91'I/1'IOZ OM
6T-80-STZ OLLTO6Z0 VD
4
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
C 1 _4 acylamino CO-10 alkyl,
hydroxy,
-(C 1 _1 o alky1)0H,
-CO_io alkylalkoxy,
cyano,
(Ci_6alkyl)cyano, and
C 1 _6ha1oa1ky1;
wherein Rl is independently optionally substituted with 1, 2, 3, or 4 R4
substituents and
wherein two Rl may optionally join together with the ring atoms to
which they are attached to form a 3 to 6 membered ring; and
R4 is independently selected from hydroxy, (Ci-6)alkyl, (Ci-6)alkoxy, (C1-10
alky1)0H, -(CO-
10 alkyl)CO2H, halogen, -(C1_10 alky1)0H, -CO2H, C1-10
alkyl(oxy)0_1(earbony1)0-
1C0-10 alkyl, -(C0-6)alkylCN, -CO-10 alkyl 0(C=0)C i-C6 alkyl, NO2,
trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, -N-
C(0)0(C0-6)alkyl,
-N(Rb)-C(0)0(C0-6)a1ky1, C1-10 alkylsulfonyl, oxo (0=), aminosulfonyl, -
SO2NH2, -
SO2NH(C 1-10 alkyl), -SO2N(C 1-10 alky1)2, -S02C 1 _6alkyl, -S02CF3, -S02CF2H,
-
Ci_io alkylsulfinyl, -0(0_0(C i_io)haloalkyl, amino(C1-6alky1)0-2, C3-12
cycloalkyl,
(C3_ 12)cycloheteroalkyl, and NH2, wherein Rb is C1-10 alkyl.
Representative compounds of the instant invention include, but are not limited
to the
following compounds and their pharmaceutically acceptable salts and
stereoisomers thereof:
4-(( 1 -( 1 -cyanoprop an-2-y1)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-N,N-
dimethylbenzenesulfonamide;
4-(( 1 -(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-
N, N-dimethylbenzenesulfonamide;
4-(1 -((-2-cyano- 1 -(2,2-difluoro cyclopropyl)ethyl)-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide;
4-(( 1 -(2-cyano- 1 -(2,2-dimethylcyclopropyl)ethyl)-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide;
4-(( 1 -(2-cyano- 1 -cyclobutylethyl)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-
N,N-dimethylbenzenesulfonamide;
3 -cyclobuty1-3 -(4-oxo-3 ((4-(pyrrolidin- 1 -ylsulfonyl)phenyl)amino)-4,5 -
dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)prop anenitrile;
3 -cyclopropy1-3 - { 3 - [(4-fluorophenyl)amino] -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -
yl}propanenitrile;
3 -cyclopropy1-3 [4-oxo-3-( {4-[(2,2,2-trifluoro- 1 -hydroxy- 1 -
methylethyl]phenyl} amino)-4,5-
dihydro-1H-pyrazolo [4,3 -c]pyridin- 1 -yl]prop anenitrile;
3 -cyclopropy1-3 -(3 - { [ 1 -hydroxy- 1 -(trifluoromethyl)-2,3 -dihydro- 1H-
inden-5 -yl] amino 1 -4-oxo-
4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl)prop anenitrile ;
5
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -cyclopropy1-3 - {3 - [(1 , 1 -dioxido-2,3 -dihydro- 1 -benzothiophen-5 -
yl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3- {3 -[(2-te rt-butyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-benzisothiazol-5 -
yl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} -3 -cyclopropylpropanenitrile;
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -
y1} amino)benzonitrile;
3 -cyclopropy1-3 -(4-oxo-3 - { [4-(trifluoromethyl)phenyl] amino 1 -4,5 -
dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 -(3 - { [4-(methylsulfonyl)phenyl]amino} -4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
1 0 c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3 - [(3 ,4,5 -trifluorophenyl)amino] -4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(2-methyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-
benzisothiazol-5 -yl)amino] -4-oxo-
4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(2-fluoropyridin-4-yl)amino]-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3 - [( 1 -oxo-2,3 -dihydro-1H-inden-5 -yl)amino] -4
,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 -[3 -(2,3 -dihydro- 1 -benzofuran-5 -ylamino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -yl]propanenitrile;
3 - [3 -(1 ,3 -benzodioxo1-5 -ylamino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin- 1 -y1]-3 -
cyclopropylpropanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -(quinolin-6-ylamino)-4,5 -dihydro-1H-pyrazolo [4,3
-c]pyridin- 1 -
yl]propanenitrile;
3 -cyclopropy1-3 -(3 - { [3 -fluoro-4-(methylsulfonyl)phenyl] amino 1 -4-oxo-
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -(quinoxalin-6-ylamino)-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -
yl]propanenitrile;
3- {3 -[(4-chlorophenyl)amino]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -y1} -3 -
cyclopropylpropanenitrile;
cyclopropy1-3 - [3 -( {4- [( 1 -methylethyl)sulfonyl]phenyl} amino)-4-oxo-4,5 -
dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
(3- { [4-(tert-butylsulfonyl)phenyl]aminol -4-oxo-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -y1)-3 -
cyclopropylpropanenitrile;
N-tert-butyl-4- { [(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-3 -
yl] amino 1 benzenesulfonamide;
3 - [3 -( {4-[ 1 -amino-2,2,2-trifluoroethyl]phenyl} amino)-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin- 1 -y1]-3 -cyclopropylpropanenitrile;
6
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)-
N-ethyl-N-methylbenzenesulfonamide;
3 -cyclopropy1-3 -(4-oxo-3 - { [4-(piperidin- 1 -ylsulfonyl)phenyl] amino 1 -
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)-
N-methyl-N-( 1 -methylethyl)benzenesulfonamide;
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)-
N-methylb enzenesulfonamide;
3 -cyclopropy1-3 -(4-oxo-3 - { [4-(pyrrolidin- 1 -ylsulfonyl)phenyl] amino 1 -
4,5 -dihydro- 1H-
1 0 pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)-
N,N-diethylbenzenesulfonamide;
3 -cyclopropy1-3 -[3 -( {4-[(3 ,3 -dimethylpiperidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 -[3 -( {4-[(3 ,3 -dimethylpyrrolidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3- {3 -[(2-te rt-butyl- 1 -oxo-2,3 -dihydro- 1H-isoindo1-5 -yl)amino]-4-oxo-
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} -3 -cyclopropylpropanenitrile;
3- {3 -[(2-cyclopentyl- 1 -oxo-2,3 -dihydro- 1H-isoindo1-5 -yl)amino] -4-o xo-
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} -3 -cyclopropylpropanenitrile;
3- {3 -[(2-cyclohexyl- 1 -oxo-2,3 -dihydro- 1H-isoindo1-5 -yl)amino]-4-oxo-4,5
-dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} -3 -cyclopropylpropanenitrile;
3 -cyclopropy1-3 -[3 -( {4-[(2,2-dimethylpiperidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile,
tert-butyl 1- { [4-( { 1 -[2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)phenyl]sulfonyl} piperidine-4-carboxylate,
3 -cyclopropy1-3 - {3 - [(4- { [3 -hydroxypyrrolidin- 1 -yl]sulfonyl}
phenyl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile,
tert-butyl 1- { [4-( { 1 -[2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)phenyl]sulfonyl} -D-prolinate,
3 -cyclopropy1-3 - {4-oxo-3-[(4- { [3 -(trifluoromethyl)pyrrolidin- 1 -
yl]sulfonyl} phenyl)amino] -4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3-[(4- { [2-(trifluoromethyl)pyrrolidin- 1 -
yl]sulfonyl} phenyl)amino] -4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
tert-butyl- 1 - { [4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)phenyl]sulfonyl}pyrrolidine-3-carboxylate;
3 -cyclopropy1-3 -[3 -( {4-[(2,2-dimethylpyrrolidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
7
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -cyclopropy1-3 - {3 - [(4- { [2-methylpyrrolidin- 1 -yl]sulfonyl}
phenyl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -(3 - { [4-(az etidin- 1 -ylsulfonyl)phenyl] amino 1 -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -
y1)-3 -cyclopropylpropanenitrile;
3 -cyclopropy1-3 -(3 - { [4-(morpholin-4-ylsulfonyl)phenyl]amino} -4-oxo-4,5 -
dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3 ,3 -dimethylazetidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3 -methylazetidin- 1 -yl)sulfonyl]phenyl} amino)-4-
oxo-4 ,5 -dihydro- 1H-
1 0 pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(2,2-dimethylazetidin- 1 -yl)sulfonyl]phenyl}
amino)-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4- [(3 -hydroxy-3 -methylazetidin- 1 -
yl)sulfonyl]phenyl} amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3 -hydroxyazetidin- 1 -yl)sulfonyl]phenyl} amino)-
4-oxo-4 ,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3,3-dimethylmorpholin-4-yl)sulfonyl]phenyl} amino)-
4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(2,2-dimethylmorpholin-4-yl)sulfonyl]phenyl} amino)-
4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 - {3 - [(4- { [3 -methylmorpholin-4-yl]sulfonyl}
phenyl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(4- { [3 -hydroxy-3 -(trifluoromethyl)pyrrolidin- 1 -
yl]sulfonyl} phenyl)amino]-
4-oxo-4 ,5 -dihydro-1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 43 -( {4- [hexahydrocyclopenta[b] [ 1 ,4]oxazin-4(4aH)-
ylsulfonyl]phenyl} amino)-
4-oxo-4 ,5 -dihydro-1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 - {3 - [(4- { [2,6-dimethylmorpholin-4-yl]sulfonyl}
phenyl)amino]-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(4- { [2-methylmorpholin-4-yl]sulfonyl} phenyl)amino]-
4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - { 3 -[(4- { [2-methylazetidin- 1 -yl]sulfonyl}
phenyl)amino]-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3 -methoxyazetidin- 1 -yl)sulfonyl]phenyl} amino)-
4-oxo-4 ,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {4-[(3 -fluoroazetidin- 1 -yl)sulfonyl]phenyl} amino)-4-
oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
3 -cyclopropy1-3 43 -( {3 -methyl-4- [2,2,2-trifluoro- 1 -hydroxy- 1 -
methylethyl]phenyl} amino)-4-
oxo-4,5 -dihydro-1H-pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
8
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -cyclopropy1-3 -[3 -( {4- [1-hydroxy-1-(trifluoromethyl)propyl]phenyl}
amino)-4-oxo-4,5-
dihydro-1H-pyrazolo [4,3 -c]pyridin-l-yl]propanenitrile;
tert-butyl 2-(4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo
[4,3 -c]pyridin-
3 -yl)amino)-N-methylphenylsulfonamido)-2-methylpropanoate;
3 -cyclopropy1-3 -(4-oxo-3 -((l-o xo-2-(2,2,2-trifluoroethyl)isoindolin-5 -
yl)amino)-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin-l-yl)propanenitrile;
ethyl 2-(4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo [4,3
-c]pyridin-3 -
yl)amino)-N-methylphenylsulfonamido)-2-methylpropanoate;
tert-butyl 2-(5-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo
[4,3 -c]pyridin-
3 -yl)amino)-1-oxoisoindolin-2-y1)-2-methylprop anoate;
4-( {1- [2-cyano-1-cyclopropylethy1]-4-oxo-4,5-dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -y1} amino)-
N,N,2-trimethylbenzenesulfonamide;
3 -cyclopropy1-3 -(3 - { [3 -methy1-4-(pyrrolidin-1-ylsulfonyl)phenyl] amino 1
-4-oxo-4,5-dihydro-
1H-pyrazolo [4,3 -c]pyridin-l-yl)propanenitrile;
3 -cyclopropy1-3 -(3 - { [4-(5,5-dimethy1-3-oxo-2-oxabicyclo [2 .2 .2]oct-1-
yl)phenyl] amino 1 -4 -oxo-
4,5 -dihydro-1H-pyrazolo [4,3 -c]pyridin-l-yl)propanenitrile;)
3 -cyclopropy1-3 -[3 -( {4-[-1-(dimethylamino)-2,2,2-trifluoroethyl] -3 -
methylphenyl} amino)-4-
oxo-4,5-dihydro-1H-pyrazolo [4,3 -c]pyridin-l-yl]propanenitrile;
3 -cyclopropy1-3 -[3 -( {4- [(1-methylcyclopropyl)sulfonyl]phenyl} amino)-4-
oxo-4,5 -dihydro-1H-
pyrazolo [4,3 -c]pyridin-l-yl]propanenitrile;
3- [3 -( {4-[1-(tert-butylamino)-2,2,2-trifluoroethyl]phenyll amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo [4,3 -c]pyridin-l-yl] -3 -cyclopropylpropanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -( {4-[2,2,2-trifluoro-1-pyrrolidin-1-
ylethyl]phenyl} amino)-4,5-
dihydro-1H-pyrazolo [4,3 -c]pyridin-l-yl]propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3-[(4- {2,2,2-trifluoro-1- [(1-methylethyl)amino]
ethyl} phenyl)amino] -
4,5 -dihydro-1H-pyrazolo [4,3 -c]pyridin-l-y1} propanenitrile;
3- [3 -( {4- [1-azetidin-l-y1-2,2,2-trifluoroethyl]phenyl} amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo [4,3 -c]pyridin-l-yl] -3 -cyclopropylpropanenitrile;
3 -cyclopropy1-3 -[3 -( {4-[1-(ethylamino)-2,2,2-trifluoroethyl]phenyl} amino)-
4-o xo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin-l-yl]propanenitrile;
tert-butyl 4-(5-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo
[4,3 -c]pyridin-
3-yl)amino)-1-oxoisoindolin-2-yl)cyclohexanecarboxylate;
2-(5-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -
yl)amino)-1-oxoisoindolin-2-y1)-2-methylpropanoic acid;
ethyl 3 -(4-((1-2-cyano-1-cyclopropylethyl)-4-oxo-4,5 -dihydro-1H-pyrazolo
[4,3 -c]pyridin-3 -
yl)amino)pheny1)-4,4 ,4-trifluoro-3-hydroxy-2,2 -dimethylbutanoate;
isopropyl 3 -(4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5 -dihydro-1H-
pyrazolo [4 ,3 -c]pyridin-
3 -yl)amino)pheny1)-4,4,4-trifluoro-3 -hydroxy-2,2-dimethylbutanoate;
9
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3-cyclopropy1-3-(3-(1-hydroxy-2,2-dimethy1-1-(trifluoromethyl)-2,3-dihydro-1H-
inden-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(1-(trifluoromethyl)cyclopropyl)phenyl)amino)-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(1-(2-methoxyethyl)-1H-pyrazol-3-yl)phenyl)amino)-4-oxo-
4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-(3-((3-chloro-4-(1-methy1-1H-pyrazol-3-y1)phenyl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-(3-((3-chloro-4-(1-(2-cyanoethyl)-1H-pyrazol-3-yl)phenyl)amino)-4-oxo-4,5-
dihydro-1H-
1 0 pyrazolo[4,3-c]pyridin-l-y1)-3-cyclopropylpropanenitrile;
ethyl 1-(4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-3-
yl)amino)-2-methylpheny1)-1H-pyrazole-4-carboxylate;
isopropyl 6-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-3-
yl)amino)quinoline-2-carboxylate;
3-cyclopropy1-3-(3-((2-methylbenzo[d]thiazol-6-y1)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(3-44-(oxazol-2-yl)phenyl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3,3-dimethy1-2-oxoindolin-6-yl)amino)-4-oxo-4,5-dihydro-
1H-
pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(1,1-dioxidothiomorpholine-4-carbony1)-3-
methylphenyl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-
yl)amino)benzoic acid;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N-(methylsulfonyl)benzamide;
3-cyclopropy1-3-(3-((2-morpholinoquinolin-6-yl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((2-(2,5-dimethylmorpholino)quinolin-6-yl)amino)-4-oxo-4,5-
dihydro-1H-
3 0 pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-1,1,1-trifluoro-2-methoxypropan-2-
yl)phenyl)amino)-4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-44-(3-ethylmorpholine-4-carbony1)-3-methylphenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(3-isopropylmorpholine-4-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-methy1-4-(2-methyl-1-(2H-1,2,3-triazol-2-
yl)propyl)phenyl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
10
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3-(3-((2-benzy1-1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-5-y1)amino)-4-oxo-
4,5-dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-Cyclopropy1-3-(3-((3-methy1-4-(2-methyl-1-(1H-1,2,3-triazol-1-
yl)propyl)phenyl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-43-methyl-4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-(3-44-(cyclopenty1(2H-1,2,3-triazol-2-yl)methyl)-3-methylphenyl)amino)-4-oxo-
4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-(3-((4-(1-amino-2,2,2-trifluoroethyl)-3-methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-l-y1)-3-cyclopropylpropanenitrile;
3-(3-((2-cyclohexy1-1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-5-y1)amino)-4-
oxo-4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(3-((2-(1-methylcyclohexyl)-1,1-dioxido-2,3-
dihydrobenzo[d]isothiazol-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-hydroxy-2,2-dimethy1-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-hydroxy-1,1-dioxido-3H-spiro[benzo[b]thiophene-2,1'-
cyclohexan]-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(4-oxo-34(4-(2-(trifluoromethyl)pyrrolidin-2-yl)phenyl)amino)-
4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-(3-((4-(2-azaspiro[3.3]heptan-2-ylsulfony1)-3-methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(3-((1,1-dioxido-3H-spiro[benzo[b]thiophene-2,1'-cyclopentan]-
5-yl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((1,1-dioxido-3H-spiro[benzo[b]thiophene-2,1'-cyclohexan]-5-
yl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((2,2-dimethy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-hydroxy-2-methy1-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((2-methy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-43-methyl-4-(2-(trifluoromethyl)pyrrolidin-2-
yl)phenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((1-oxo-2-(1-(trifluoromethyl)cyclohexyl)isoindolin-5-
yl)amino)-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(3-((2-(4-methyltetrahydro-2H-pyran-4-y1)-1,1-dioxido-2,3-
dihydrobenzo[d]isothiazol-5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-1-
yl)propanenitrile;
11
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3-cyclopropy1-3-(3-((4-(1-methy1-2-(trifluoromethyl)pyrrolidin-2-
yl)phenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N,2-dimethyl-N-(tetrahydro-2H-pyran-4-yl)benzamide;
3-cyclopropy1-3-(3-((3-fluoro-4-(2,2,2-trifluoro-1-
(isopropylamino)ethyl)phenyl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(1-(ethylamino)-2,2,2-trifluoroethyl)-3-
fluorophenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-(3-((4-(1-(tert-butylamino)-2,2,2-trifluoroethyl)-3-fluorophenyl)amino)-4-
oxo-4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(2-(trifluoromethyl)tetrahydrofuran-2-
yl)phenyl)amino)-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-42-hydroxy-2-(trifluoromethyl)-2,3-dihydro-1H-inden-5-
yl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(3-((3-fluoro-4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)amino)-
4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-(3-((3-chloro-4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(3-((2-hydroxy-2-methy1-2,3-dihydro-1H-inden-5-yl)amino)-4-oxo-
4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
3-(3-((4-(1-(tert-butylamino)-2,2,2-trifluoroethyl)-3-chlorophenyl)amino)-4-
oxo-4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(2-(trifluoromethyl)piperidin-2-yl)phenyl)amino)-
4,5-dihydro-1H-
pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
methyl -2-(4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-c]pyridin-3-
yl)amino)pheny1)-2-(trifluoromethyl)pyrrolidine-1-carboxylate;
3-cyclopropy1-3-(3-((2-(4,4-difluoro-1-methylcyclohexyl)-1,1-dioxido-2,3-
dihydrobenzo[d]isothiazol-5-y1)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-1-
yl)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(2,2,2-trifluoro-1-hydroxy-1-(pyridin-2-
yl)ethyl)phenyl)amino)-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(2,2,2-trifluoro-1-hydroxy-1-(pyridin-4-
yl)ethyl)phenyl)amino)-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
3-cyclopropy1-3-(4-oxo-3-((4-(2,2,2-trifluoro-1-
thiomorpholinoethyl)phenyl)amino)-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N,2-dimethyl-N-(2,2,2-trifluoroethyl)benzamide;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N-ethy1-2-methyl-N-(2,2,2-trifluoroethyl)benzamide;
12
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N-(2-(dimethylamino)ethyl)-2-methyl-N-(2,2,2-trifluoroethyl)benzamide;
3-cyclopropy1-3-(3-((3-methy1-4-(thiomorpholine-4-carbonyl)phenyl)amino)-4-oxo-
4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-methy1-4-(4-methylpiperazine-1-carbonyl)phenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-43-methyl-4-(2-(trifluoromethyl)pyrrolidine-1-
carbonyl)phenyl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N,2-dimethyl-N-(1-methylpiperidin-4-yl)benzamide;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N-ethyl-N,2-dimethylbenzamide;
3-cyclopropy1-3-(3-((3-methy1-4-(morpholine-4-carbonyl)phenyl)amino)-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(3,3-dimethylpyrrolidine-1-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(3,3-dimethylazetidine-1-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(2,2-dimethylmorpholine-4-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(2,5-dimethylpyrrolidine-1-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-44-(3-fluoropyrrolidine-1-carbony1)-3-methylphenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-methy1-4-(2-methylpiperidine-1-carbonyl)phenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((3-methy1-4-(2-methylpiperidine-1-carbonyl)phenyl)amino)-4-
oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-44-(4,4-difluoropiperidine-1-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-l-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(4-hydroxy-4-methylpiperidine-1-carbony1)-3-
methylphenyl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(4-methoxypiperidine-1-carbony1)-3-methylphenyl)amino)-
4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((4-(4-(2-hydroxypropan-2-yl)piperidine-1-carbony1)-3-
methylphenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-
yl)propanenitrile;
4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-
3-yl)amino)-
N-(3-hydroxy-3-methylbuty1)-N,2-dimethylbenzamide;
13
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -(3 -((4-(azepane- 1 -carbonyl)-3 -methylphenyl)amino)-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin- 1 -y1)-3 -cyclopropylpropanenitrile;
3 -cyclopropy1-3 -(3 -((4-(3 -fluoroazetidine- 1 -carbonyl)-3 -
methylphenyl)amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 -(3 -((4-(3 -methoxyazetidine- 1 -carbonyl)-3 -
methylphenyl)amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
3 -(3 -((4-(8-oxa-3 -azabicyclo [3 .2. 1 ]octane-3 -carbonyl)-3 -
methylphenyl)amino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1)-3 -cyclopropylpropanenitrile;
4-(( 1 -(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-
1 0 N-cyclohexyl-N,2-dimethylbenzamide;
tert-butyl (1 -(4-((1 -(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-
3 -yl)amino)-2-methylbenzoyl)piperidin-4-y1)(methyl)carbamate;
3 -(3 -((4-fluorophenyl)amino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -c]pyridine-
1 -yl)butanenitrile;
3 - [4-oxo-3 -( {4- [(2,2,2-trifluoro- 1 -hydroxy- 1 -methylethyl]phenyl}
amino)-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl]butanenitrile;
3 -(3 - { [ 1 -hydroxy- 1 -(trifluoromethyl)-2,3 -dihydro-1H-inden-5 -yl]amino
} -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)butanenitrile;
3- {3 -[( 1 , 1 -dioxido-2,3 -dihydro- 1 -benzothiophen-5 -yl)amino]-4-oxo-4,5
-dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} butanenitrile;
4-( { 1 - [2-cyano- 1 -methylethy1]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -
y1} amino)benzonitrile;
3 -(4-oxo-3 - { [4-(trifluoromethyl)phenyl] amino 1 -4,5 -dihydro-1H-pyrazolo
[4,3 -c]pyridin- 1 -
yl)butanenitrile;
3 -(3 - { [4-(methylsulfonyl)phenyl] amino 1 -4-oxo-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -
yl)butanenitrile;
3- {4-oxo-3 - [(3 ,4,5 -trifluorophenyl)amino]-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -
y1} butanenitrile;
3- {3 -[(2-methyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-benzisothiazol-5 -
yl)amino] -4-o xo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} butanenitrile;
3- {3 -[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -
y1} butanenitrile;
3- {4-oxo-3 - [(1 -oxo-2,3 -dihydro-1H-inden-5 -yl)amino] -4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-
1 -y1} butanenitrile;
3 - [3 -(2,3 -dihydro- 1 -benzofuran-5 -ylamino)-4-oxo-4,5 -dihydro-1H-
pyrazolo [4,3 -c]pyridin- 1 -
yl]butanenitrile;
3 - [3 -(1 ,3 -benzodioxo1-5 -ylamino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin- 1 -
yl]butanenitrile;
3 - [4-oxo-3 -(quinolin-6-ylamino)-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -yl]butanenitrile;
14
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -(3 - { [3 -fluoro-4-(methylsulfonyl)phenyl]amino } -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin-l-yl)butanenitrile;
3-[4-oxo-3-(quinoxalin-6-ylamino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-
yl]butanenitrile;
3- {3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-
ylIbutanenitrile;
N-tert-buty1-4-({1-[2-cyano-1-methylethyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-3-
yl} amino)b enzenesulfonamide ;
3- {3-[(2-tert-buty1-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-y1)amino]-4-
oxo-4,5-dihydro-
1H-pyrazolo[4,3-c]pyridin-1-ylIbutanenitrile;
methyl 3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-1-(2-cyano-1-
cyclopropylethyl)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxylate;
3-(3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-7-(hydroxymethyl)-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile;
3-cyclopropy1-3-(3-((1,1-dioxido-3H-spiro[benzo[b]thiophene-2,1'-cyclohexan]-5-
yl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile;
3-cyclopropy1-3-(3-((1,1-dioxido-3H-spiro[benzo[b]thiophene-2,1'-cyclopentan]-
5-yl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile; and
3-cyclopropy1-3-(3-((2,3-dimethy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-
4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile.
The invention also encompasses pharmaceutical compositions containing a
compound of formula I, and methods for treatment or prevention of JAK mediated
diseases using
compounds of formula I.
The invention is described using the following definitions unless otherwise
indicated.
As used herein except where noted, "alkyl" is intended to include both
branched-
and straight-chain saturated aliphatic hydrocarbon groups, including all
isomers, having the
specified number of carbon atoms. Commonly used abbreviations for alkyl groups
are used
throughout the specification, e.g. methyl may be represented by "Me" or CH3,
ethyl may be
represented by "Et" or CH2CH3, propyl may be represented by "Pr" or CH2CH2CH3,
butyl may
be represented by "Bu" or CH2CH2CH2CH3 , etc. "C1_6 alkyl" (or "C1-C6 alkyl")
for example,
means linear or branched chain alkyl groups, including all isomers, having the
specified number
of carbon atoms. C1_6 alkyl includes all of the hexyl alkyl and pentyl alkyl
isomers as well as n-,
iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "Ci-4 alkyl" means
n-, iso-, sec- and t-
butyl, n- and isopropyl, ethyl and methyl.
The term "alkylene" refers to both branched- and straight-chain saturated
aliphatic hydrocarbon groups, including all isomers, having the specified
number of carbons, and
having two terminal end chain attachments. For illustration, the term
"unsubstituted A-
C4alkylene-B" represents A-CH2-CH2-CH2-CH2-B.
The term "alkoxy" represents a linear or branched alkyl group of indicated
number of carbon atoms attached through an oxygen bridge.
15
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
"Acyl" means a ¨C(0)R radical Where R is optionally substituted alkyl,
alkenyl,
cycloalkyl, heterocycloalkyl, aryl heteroaryl, etc.
"Acylamino" means a ¨NRR' radical where R is H, OH, or alkoxy and R' is acyl,
as defined herein.
The term "alkyl" refers to an aliphatic hydrocarbon group which may be
straight
or branched and having the indicated number of carbon atoms. Non-limiting
examples of alkyl
groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl,
pentyl, hexyl, and the like.
The term "heteroalkyl" refers to an alkyl group where 1, 2, or 3 of the carbon
atoms is substituted by a heteroatom independently chosen from N, 0, or S.
"Alkenyl" refers to an aliphatic hydrocarbon group containing at least one
carbon-
carbon double bond and which may be straight or branched and having the
indicated number of
carbon atoms. Preferably alkenyl contains one carbon to carbon double bond,
and up to four
nonaromatic carbon-carbon double bonds may be present. Examples of alkenyl
groups include
ethenyl, propenyl, n-butenyl, 2-methyl-1-butenyl, 3-methylbut-2-enyl, n-
pentenyl, octenyl and
decenyl.
"Alkynyl" refers to an aliphatic hydrocarbon group containing at least one
carbon-carbon triple bond and which may be straight or branched and having the
indicated
number of carbon atoms. Non-limiting examples of suitable alkynyl groups
include ethynyl,
propynyl, 2-butynyl and 3-methylbutynyl.
"Alkoxy" refers to an alkyl-0- group in which the alkyl group is as described
above. C1_6a1koxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy,
and the like.
"Alkoxyalkyl" refers to an alkyl group as described above in which one or more
(in particular 1 to 3) hydrogen atoms have been replaced by alkoxy groups.
Examples include
CH2OCH3, CH2CH2OCH3 and CH(OCH3)CH3.
"Aminoalkyl" refers to an alkyl group as described above in which one hydrogen
atom has been replaced by an amino, monoalkylamino or dialkylamino group.
Examples include
CH2NH2, CH2CH2NHCH3 and CH(N(CH3)2)CH3.
The term "Co" as employed in expressions such as "C0_6 alkyl" means a direct
covalent bond; or when the term appears at the terminus of a substituent, Co_6
alkyl means
hydrogen or C1-6alkyl. Similarly, when an integer defining the presence of a
certain number of
atoms in a group is equal to zero, it means that the atoms adjacent thereto
are connected directly
by a bond. For example, in the structure T , wherein s is an integer
equal to zero, 1 or
C),?2,
1
2, the structure is T when s is zero.
The term "C3_8 cycloalkyl" (or "C3-C8 cycloalkyl") means a cyclic ring of an
alkane having three to eight total carbon atoms (i.e., cyclopropyl,
cyclobutyl, cyclopentyl,
16
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
cyclohexyl, cycloheptyl, or cyclooctyl). The terms "C3-7 cycloalkyl", "C3-6
cycloalkyl", "C5-7
cycloalkyl" and the like have analogous meanings.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and
iodine
(alternatively referred to as fluoro (F), chloro (C1), bromo (Br), and iodo
(I)).
The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems,
wherein the individual carbocyclic rings in the polyring systems are fused or
attached to each
other via a single bond. Suitable aryl groups include phenyl, naphthyl, 2,3-
dihydro-1H-indenyl,
and biphenyl.
The term "carbocycle" (and variations thereof such as "carbocyclic" or
"carbocycly1") as used herein, unless otherwise indicated, refers to (i) a C3
to C8 monocyclic,
saturated or unsaturated ring or (ii) a C7 to C12 bicyclic saturated or
unsaturated ring system.
Each ring in (ii) is either independent of, or fused to, the other ring, and
each ring is saturated or
unsaturated. The carbocycle may be attached to the rest of the molecule at any
carbon atom
which results in a stable compound. The fused bicyclic carbocycles are a
subset of the
carbocycles; i.e., the term "fused bicyclic carbocycle" generally refers to a
C7 to C10 bicyclic
ring system in which each ring is saturated or unsaturated and two adjacent
carbon atoms are
shared by each of the rings in the ring system. A fused bicyclic carbocycle in
which one ring is
saturated and the other is saturated is a saturated bicyclic ring system. A
fused bicyclic
carbocycle in which one ring is benzene and the other is saturated is an
unsaturated bicyclic ring
system. A fused bicyclic carbocycle in which one ring is benzene and the other
is unsaturated is
an unsaturated ring system. Saturated carbocyclic rings are also referred to
as cycloalkyl rings,
e.g., cyclopropyl, cyclobutyl, etc. Unless otherwise noted, carbocycle is
unsubstituted or
substituted with C1_6 alkyl, C1_6 alkenyl, C1_6 alkynyl, aryl, halogen, NH2 or
OH. A subset of
the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in
which one ring is a
benzene ring and the other ring is saturated or unsaturated, with attachment
via any carbon atom
that results in a stable compound. Representative examples of this subset
include the following:
04, se 0* 00 00 O. OS. ON
, , , , , , ,
.
"Cyanoalkyl" refers to an alkyl group as described above in which one hydrogen
atom has been replaced by a cyano group. Examples include CH2CN, CH2CH2CN and
CH(CN)CH3.
"Cycloalkyl" means a carbocyclic ring system having 3 to 12 ring carbon atoms;
said ring system may be (a) a monocyclic saturated carbocycle optionally fused
to a benzene or a
partially unsaturated carbocycle, or (b) a bicyclic saturated carbocycle. For
a bicyclic system,
within either (a) or (b), the rings are fused across two adjacent ring carbon
atoms (e.g., decalin),
at one ring carbon atom (e.g., spiro[2.2]pentane), or are bridged groups
(e.g., norbornane).
Additional examples within the above meaning include, but are not limited to,
cyclopropane,
17
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
cyclobutane, cyclopentane, cyclohexane, perhydroindan, decalin,
spiro[4.5]decane,
bicyclo[2.2.2]octane, and the like.
"Haloalkyl" refers to an alkyl group as described above wherein one or more
(in
particular 1 to 5) hydrogen atoms have been replaced by halogen atoms, with up
to complete
substitution of all hydrogen atoms with halo groups. C1_6ha1oa1ky1, for
example, includes -CF3,
-CF2CF3, CHFCH3, and the like.
"Heterocycle", "heterocyclic" or "heterocycly1" represents a monocyclic or
bicyclic 3-12 membered ring system in which at least one ring is non-aromatic
(saturated or
partially unsaturated) and containing at least one heteroatom selected from 0,
S and N. In a
bicyclic ring system, the second ring may be a heteroaryl, heterocycle or a
saturated, partially
unsaturated or aromatic carbocycle, and the point(s) of attachment to the rest
of the molecule
may be on either ring. For a bicyclic system,the rings may be fused across two
adjacent ring
atoms (e.g., quinoline), at one ring carbon atom (e.g., azaspiro[3.3]heptane),
or are bridged
groups (e.g. 2-oxabicyclo[2.2.2]octane ). "Heterocycly1" therefore includes
heteroaryls, as well
as dihydro and tetrathydro analogs thereof Attachment of a heterocyclyl
substituent can occur
via a carbon atom or via a heteroatom.
Examples of heterocycles (heterocycly1) include, but are not limited to,
azetidinyl,
pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl,
tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,
dihydroimidazolyl,
dihydroindolyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroimidazo[1,2-
a]pyrazine, 2,3-
dihydrobenzofuranyl, benzo-1,4-dioxanyl, benzoimidazolyl, benzofuranyl,
benzofurazanyl,
benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl,
carbolinyl,
cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl,
isobenzofuranyl,
isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl,
oxadiazolyl, oxazolyl,
oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl,
pyridopyridinyl,
pyridazinyl, pyridinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl,
quinoxalinyl,
tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl,
thienyl, triazolyl,
azetidinyl, aziridinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl,
piperidinyl, pyrrolidinyl,
morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl,
dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl,
dihydroimidazolyl,
dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl,
dihydrooxazolyl,
dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl,
dihydropyrrolyl,
dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl,
dihydrothienyl,
dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl,
and
tetrahydrothienyl, and N-oxides thereof
Saturated heterocyclics form a subset of the heterocycles; i.e., the terms
"saturated heterocyclic and (C3_12)heterocycloalkyl" generally refers to a
heterocycle as defined
above in which the entire ring system (whether mono- or poly-cyclic) is
saturated. The term
"saturated heterocyclic ring" refers to a 4- to 8-membered saturated
monocyclic ring or a stable
18
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
7- to 12-membered bicyclic ring system which consists of carbon atoms and one
or more
heteroatoms selected from N, 0 and S. Representative examples include
piperidinyl, piperazinyl,
azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl,
isoxazolidinyl, morpholinyl,
2-oxabicyclo[2.2.2]octyl, 8-oxa-3-azabicyclo[3.2.1]octane, thiomorpholinyl,
thiazolidinyl,
isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl)
Heteroaromatics form another subset of the heterocycles; i.e., the term
"heteroaromatic" (alternatively "heteroaryl") generally refers to a
heterocycle as defined above
in which the entire ring system (whether mono- or poly-cyclic) is an aromatic
ring system. The
term "heteroaromatic ring" refers a 5- or 6-membered monocyclic aromatic ring
or a 7- to 12-
membered bicyclic which consists of carbon atoms and one or more heteroatoms
selected from
N, 0 and S. For a bicyclic heteroaryl only one of the rings need to be
heteroaromatic, the second
ring may be a heteroaromatic or an aromatic, saturated, or partially
unsatuated carbocycle, and
the point(s) of attachment to the rest of the molecule may be on either ring.
In the case of
substituted heteroaryl rings containing at least one nitrogen atom (e.g.,
pyridine), such
substitutions can be those resulting in N-oxide formation. Examples of
heteroaryl include, but
are not limited to, furanyl, thienyl (or thiophenyl), pyrrolyl, imidazolyl,
pyrazolyl, oxazolyl,
thiazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl,
tetrazolyl, pyridyl,
pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl,
naphthyridinyl,
benzothienyl, benzofuranyl, benzimidazole, benzpyrazolyl, indolyl, isoindolyl,
indolizinyl,
indazolyl, purinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl,
benzoxazolyl,
benzisoxazolyl, 5,6,7,8-tetrahydroquinolinyl, imidazo[1,2-a]pyridinyl,
imidazo[1,2-a]-
pyrimidinyl, 5,6-dihydropyrrolo[1,2-b]pyrazolyl, pyrrolo[3,2-c]pyridinyl,
pyrrolo[2,3 -
b]pyridinyl, thieno[2,3-b]pyrrolyl, furopyridine and thienopyridine.
Representative examples of bicyclic heterocycles include benzotriazolyl,
indolyl,
isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, chromanyl,
isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl,
isoquinolinyl,
i" oj
2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl (i.e., O),
imidazo(2,1-
s
CN
=o
b)(1,3)thiazole, (i.e., ), and benzo-1,3-dioxoly1 (i.e., 0 ). In
certain contexts
=o>
herein,
0 is alternatively referred to as phenyl having as a substituent
methylenedioxy
attached to two adjacent carbon atoms.
Non-limiting examples of substituted heteroaryls include: isoindolinone,
isoindolin-l-one, 2,3-dihydro-1H-pyrazolo[4,3-c]pyridin-4(5H)-one, 2,3,4,5-
tetrahydrobenzo [61] isothiazole 1,1-dioxide, and 2,3,4,5-
tetrahydrobenzo[b]thiophene 1,1-dioxide.
"Hydroxyalkyl" refers to an alkyl group as described above in which one or
more
(in particular 1 to 3) hydrogen atoms have been replaced by hydroxy groups.
Examples include
CH2OH, CH2CHOH and CHOHCH3.
19
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
"Alkylene," "alkenylene," "alkynylene," "cycloalkylene," "arylene,"
"heteroarylene," and "heterocyclylene" refer to a divalent radical obtained by
the removal of one
hydrogen atom from an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,
and heterocyclyl
group, respectively, each of which is as defined above.
Unless expressly stated to the contrary, an "unsaturated" ring is a partially
or fully
unsaturated ring. For example, an "unsaturated monocyclic C6 carbocycle"
refers to
cyclohexene, cyclohexadiene, and benzene.
Unless expressly stated to the contrary, all ranges cited herein are
inclusive. For
example, a heterocycle described as containing from "1 to 4 heteroatoms" means
the heterocycle
can contain 1, 2, 3 or 4 heteroatoms.
When any variable occurs more than one time in any constituent or in any
formula depicting and describing compounds of the invention, its definition on
each occurrence
is independent of its definition at every other occurrence. Also, combinations
of substituents
and/or variables are permissible only if such combinations result in stable
compounds.
The term "sulfamoyl" is a suffix to denote radicals derived from sulfamide
such
as ¨SO2NH2, and -SO2N(RR1).
The term "substituted" (e.g., as in "aryl which is optionally substituted with
one
or more substituents ...") includes mono- and poly-substitution by a named
substituent to the
extent such single and multiple substitution (including multiple substitution
at the same site) is
chemically allowed.
The term "oxy" means an oxygen (0) atom. The term "thio" means a sulfur (S)
atom. The term "oxo" means "=0". The term "carbonyl" means "C=0."
When any variable (e.g., R2, R3, etc.) occurs more than one time in any
substituent or in formula I its definition in each occurrence is independent
of its definition at
every other occurrence. Also, combinations of substituents and/or variables
are permissible only
if such combinations result in stable compounds.
Under standard nomenclature used throughout this disclosure, the terminal
portion of the designated side chain is described first, followed by the
adjacent functionality
toward the point of attachment. For example, a Ci_5 alkylcarbonylamino C1_6
alkyl substituent
0
is equivalent to -C1_6 alkyl-HN^C1_5 alkyl.
In choosing compounds of the present invention, one of ordinary skill in the
art
will recognize that the various substituents, i.e. R1, R2, R3, etc., are to be
chosen in conformity
with well-known principles of chemical structure connectivity.
Lines drawn into the ring systems from substituents indicate that the
indicated
bond can be attached to any of the substitutable ring atoms. If the ring
system is polycyclic, it is
intended that the bond be attached to any of the suitable carbon atoms on the
proximal ring only.
It is understood that substituents and substitution patterns on the compounds
of
the instant invention can be selected by one of ordinary skill in the art to
provide compounds that
20
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
are chemically stable and that can be readily synthesized by techniques known
in the art, as well
as those methods set forth below, from readily available starting materials.
If a substituent is
itself substituted with more than one group, it is understood that these
multiple groups can be on
the same carbon or on different carbons, so long as a stable structure
results. The phrase
"optionally substituted with one or more substituents" should be taken to be
equivalent to the
phrase "optionally substituted with at least one substituent" and in such
cases one embodiment
will have from zero to three substituents.
Structural representations of compounds having substituents terminating with a
methyl group may display the terminal methyl group either using the characters
"CH3", e.g. "-
CH3" or using a straight line representing the presence of the methyl group,
e.g. "¨ " , i.e.,
¨ci-13 and
have equivalent meanings.
For variable definitions containing terms having repeated terms, e.g.,
(CRiRi)r,
where r is the integer 2, Ri is a defined variable, and Ri is a defined
variable, the value of Ri
may differ in each instance in which it occurs, and the value of Ri may differ
in each instance in
which it occurs. For example, if Ri and Ri are independently selected from the
group consisting
of methyl, ethyl, propyl and butyl, then (CRiRj)2 can be
1
H3CH2C¨C¨CH3
H3CH2CH2CH2C¨C¨CH2CH2CH3
1
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Therapeutically effective amount" means that amount of a drug or
pharmaceutical agent that will elicit the biological or medical response of a
tissue, a system,
animal or human that is being sought by a researcher, veterinarian, medical
doctor or other
clinician.
The term "treatment" or "treating" includes alleviating, ameliorating,
relieving or
otherwise reducing the signs and symptoms associated with a disease or
disorder.
The term "composition", as in pharmaceutical composition, is intended to
encompass a product comprising the active ingredient(s), and the inert
ingredient(s)
(pharmaceutically acceptable excipients) that make up the carrier, as well as
any product which
results, directly or indirectly, from combination, complexation or aggregation
of any two or more
of the ingredients, or from dissociation of one or more of the ingredients, or
from other types of
reactions or interactions of one or more of the ingredients. Accordingly, the
pharmaceutical
compositions of the present invention encompass any composition made by
admixing a
compound of formula I, and pharmaceutically acceptable excipients.
21
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
The term "optionally substituted" means "unsubstituted or substituted," and
therefore, the generic structural formulas described herein encompasses
compounds containing
the specified optional substituent as well as compounds that do not contain
the optional
substituent.
Each variable is independently defined each time it occurs within the generic
structural formula definitions. For example, when there is more than one
substituent for
aryl/heteroaryl, each substituent is independently selected at each
occurrence, and each
substituent can be the same or different from the other(s). As another
example, for the
group -(CR3R3)2-, each occurrence of the two R3 groups may be the same or
different. As used
herein, unless explicitly stated to the contrary, each reference to a specific
compound of the
present invention or a generic formula of compounds of the present invention
is intended to
include the compound(s) as well as pharmaceutically acceptable salts thereof
In one embodiment of the invention, A is selected from phenyl, pyridinyl, 2,3-
dihydrobenzo[d]thiazolyl, dihydroisoindolyl, dihydrobenzisothiazolyl,
dihydroindenyl, 2,3-
dihydrobenzofuranyl, 2,3-dihydro-IH-indenyl, dihydrobenzofuranyl, 1-oxo-2,3-
dihydro-IH-
indenyl, benzo [d] dioxolyl, quinolinyl, quinoxalinyl, benzothiophenyl, 1,3-
benzo [d] dioxolyl,
io s, Oil io NH 0 /NH
isoindolyl, isoindolinyl, dihydro[b]thiophenyl,I! , 0, o, and
ho
.
.
In one embodiment of the invention, A is selected from phenyl, pyridinyl, 2,3-
dihydrobenzo[d]thiazolyl, dihydroindenyl, dihydrobenzofuranyl, 2,3-dihydro-IH-
indenyl, 2,3-
dihydrobenzofuranyl, benzo [d] dioxolyl, 1,3-benzo [d] dioxolyl, quinolinyl,
quinoxalinyl,
iiP s\ ioe 0 NH
I0
benzothiophenyl, isoindolinyl, dihydro[b]thiophenyl, , o5 o,
410 h/NH
and .a.
In yet another embodiment of the invention, A is selected from phenyl,
pyridinyl,
253-dihydrobenzo [d] thiazolyl, 253-dihydro-IH-indenyl, 253-
dihydrobenzofuranyl, 1,3_
ii s ioe 0 NH
benzo[d]dioxolyl, quinolinyl, quinoxalinyl, isoindolinyl, IIµ
0 .5 o5 o,
410 /NH
h
and .a.
In one variant of the invention A is selected from phenyl and 2,3-dihydro-1H-
indenyl. In a variant of this embodiment, A is phenyl.
In another embodiment, A is selected from quinolinyl, pyridinyl, and
quinoxalinyl.
22
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
In yet another embodiment, A is selected from 2,3-dihydrobenzo[d]thiazolyl,
1,3-
benzo[d]dioxolyl, and 2,3-dihydrobenzofuranyl. In another embodiment of the
invention, A is
0s Ole * "" I01 e
selected from isoindolinyl, ilo, ., ., and rJ,' .
In one embodiment of the invention, m is 1, 2, 3, or 4. In another embodiment,
m is 1, 2, or 3. In another embodiment of the invention, m is O.
In one embodiment of the invention, R2 is independently selected from
hydrogen,
methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl, wherein R2 is
optionally, independently
substituted by 1, 2, or 3 R5 substituents. In a variant of this embodiment, R2
is hydrogen.
In one embodiment of the present invention, R3 is selected from: hydrogen,
halogen, methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl, cyclopropyl,
cyclobutyl and
cyclopentyl, wherein R3 is optionally substituted by 1, 2, or 3 R5
substituents. In a variant of this
embodiment, R3 is methyl or cyclopropyl, wherein R3 is optionally substituted
by 1, 2, or 3 R5
substituents. In another variant of this embodiment, R3 is hydrogen, methyl,
cyclobutyl, or
cyclopropyl, wherein R3 is optionally substituted by 1, 2, or 3 R5
substituents.
In one embodiment of the invention, R5 is independently selected from hydroxy,
(C1-6)alkyl, (C1-6)alkoxy, (C1_6 alky1)0H, halogen, -CO2H, trffluoromethoxy,
trifluoroethoxy,
trifluoromethyl, NH2, trffluoroethyl, oxo (0=), -SO2NH2, -S02C1_6a1ky1, and -
S02CF3. In a
variant of this embodiment, R5 is independently selected from (C1-6)alkyl, and
halogen, such as
for example, methyl and fluoro.
In one embodiment of the invention, Rl is selected from: halogen, Oxo (=0),
C1_
10 alkYl(oxY)o-i(oarbony1)0-1C0-10 alkyl, Ci_io heteroalkyhoxy)o-i(carbony1)0-
1C0-10 alkyl,
aryl C0-10 alkYl(oxY)o-i(oarbony1)0-1C0-10 alkyl, C3_12 cycloalkyl Co-10
alkyhoxy)o-
i(oarbony1)0 -1 C 0-10 alkyl, heteroaryl CO-10 alkyl(oxy)o-i (Carbony1)0 - 1 C
0 - 10 alkyl, (C3_
12)heterooYcloalkY1 CO-10 alkykoxY)o-i(carbony1)0-1C0-10 alkyl, Co_io
alkyhoxy)o-
i(oarbony1)0_iaminoC0-10 alkyl, (C1-1
0)heteroa1kY1(oxY)o_i(oarbony1)0_iaminoC0_10 alkyl,
C3_12 cycloalkyl Co_io alkykoxy)04carbony1)0-laminoCO-10 alkyl, aryl CO-10
alkYhoxY)o-
i(oarbonY1)0-lamlhoC0- 1 0 alkyl, heteroaryl CO-10
alkykoxy)0_1(carbony1)0_iaminoC0_10 alkyl,
(C3_12)heterocycloalkyl Co_io alkykoxy)0_1(carbony1)0_iaminoC0_10 alkyl, Co_io
alkylamino
(carbonyl)0-1 CO-10 alkyl, (C1-10)heteroalkylamino(carbony1)0-1C0-10 alkyl, C3-
12
cycloalkylamino(carbony1)0-1CO-10 alkyl, aryl Co_io alkylaminoamino(carbony1)0-
1C0-10
alkyl, heteroaryl CO-10 alkylamino(carbony1)0-1CO-10 alkyl, (C3_12)hetero
cyclo alkyl
amino( carbohy1)0-1C0-10 alkyl, Co_io alkylsulfony1C0_10 alkyl, Ci_io
heteroalkylsulfonY1C0-
10 alkyl, (C3-12)cyc1oa1ky1Co_ 1 0a1ky1su1fony1C 0_ 1 0 alkyl,
(C3_12)cyc1oheteroa1ky1Co_
10alkylsulfony1C 0-10 alkyl, heteroary1C 0-10 alkylsulfony1C 0 - 10 alkyl,
ary1C 0 - 10
alkylsulfonylCO-10 alkyl, C1-10 alkYlsulfamoY1C0-10 alkyl, Ci_io
heteroalkylsulfamoy1C0-10
alkyl, (C3-12)oyo1oa1kY1C0-10 alkylsulfamoy1C 0 - 10 alkyl,
(C3_12)cyc1oheteroa1ky1C0-
23
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
10a1kY1su1famoY1C0-10 alkyl, heteroary1C0-10 alkylsulfamoy1C0-10 alkyl, ary1C
0-10
alkylsulfamoy1C0-10 alkyl, (CO-10 alky1)1_2 amino, -(C0-10 alkyl)CO2H,
-SO2N(C1-10 alky1)2, hydroxy, -(C1-10 alky1)0H, cyano, and Ci_6haloalkyl;
wherein Rl is
independently optionally substituted with 1, 2, 3, or 4 R4 substituents and
wherein two Rl may
optionally join together with the ring atoms to which they are attached to
form a 3 to 6
membered ring.
In one embodiment of the invention, R' is selected from: halogen, Oxo (=0),
Ci_
alkYl(oxY)o-i(carbony1)0-1C0-10 alkyl, C1_10 heteroalkyl(oxy)o-i(carbony1)0-
1C0-10 alkyl,
aryl CO-10 alkY1(0)(Y)o-i(carbony1)0-1C0-10 alkyl, C3-12 cycloalkyl CO-10
alkyl(oxy)o-
10 i(carbony1)0-1C0-10 alkyl, heteroaryl CO-10 alkyl(oxy)o-i(carbony1)0-1C0-
10 alkyl,
(C3_12)heterocycloalkY1 CO-10 alky1(3,(Y)o-i (carbonyl)0-1 C 0-10 alkyl, CO-10
alkyl(oxy)o-
i(carbonyl)o_iaminoC0- 10 alkyl, C3_12 cycloalkyl CO-10 alkyl(oxy)o-
i(carbony1)0_ 1 amin0 CO-
10 alkyl, CO-10 alkylamino(oxy)o-i(carbony1)0-1C0-10 alkyl, (C 1-
10)hetero a1ky1amino(carbony1)0-1C0-10 alkyl, (C3 -12)hetero cyclo
alkylamino(carbony1)0-1C0-
10 alkyl, C0_10 alkylsulfony1C0_10 alkyl, C1_10 heteroalkylsulfony1C0_10
alkyl, (C3_
12)cYcloall(Y1C0-10 a1ky1su1fony1C0-10 alkyl, (C3 _12)cyclo heteroa1ky1C0-
10a1ky1su1fony1C 0-10
alkyl, C 1-10 alkylsulfamoY1C0-10 alkyl, (C3_12)cyc1oheteroa1ky1C0-
10a1ky1su1famoy1C0-10
alkyl, (C0-10 alky1)1_2 amino, -(CO-10 alkyl)CO2H, -SO2N(C1-10 alky1)2,
hydroxy, -(C1-10
alky1)0H, cyano, and Ci_6haloalkyl; wherein Rl is independently optionally
substituted with 1,
2, 3, or 4 R4 substituents and wherein two Rl may optionally join together
with the ring atoms to
which they are attached to form a 3 to 6 membered ring.
In one embodiment of the invention, Rl is independently selected from:
tert-butylsulfonyl, tert-butylsulfamoyl, amino, fluoro, methylsulfamoyl,
dimethylsulfamoyl, tert-
butyloxycarbonyl(methylethyl), diethylsulfamoyl, ethylsulfamoyl,
pyrrolidinylsulfonyl,
(methylethyl)sulfamoyl, methyl, tert-butylaminomethyl, methylaminocarbonyl,
ethyl, propyl,
piperidinylsulfonyl, thiomorpholinylcarbonyl, thiomorpholinylmethyl,
piperazinylcarbonyl,
pyrrolidinylcarbonyl, piperidinylcarbonyl, ethylaminocarbonyl,
morpholinylcarbonyl,
azetidinylcarbonyl, tert-butyl, cyclopentyl, cyclohexyl, benzyl, oxo,
hydroxymethyl, triazoly1(2-
methylpropyl), 8-oxa-3-azabicyclo[3.2.1]octanylcarbonyl, ethyloxycarbonyl,
ethoxycarbonyl(dimethyleth-2y1), hydroxy, trifluoromethyl, azetidinylsulfonyl,
cyclopropylsulfonyl, chloro, methylaminomethyl, pyrrolidinylmethyl,
cyclopropyl, pyrazolyl,
morpholinylsulfonyl, isopropylaminomethyl, isopropyloxycarbonyl, pyrrolidinyl,
azaspiro[3.3]heptylsulfonyl, piperadinyl, methylsulfonyl, isopropylsulfonyl,
isopropylsulfamoyl,
tert-butylsulfonyl, tert-butyloxycarbonyl, hexahydrocyclopenta[b][1,4]oxazin-
4(4aH)-ylsulfonyl,
2-oxabicyclo[2.2.2]octyl, azetidinylmethyl, methoxyethyl, methylamino,
triazolylmethyl,
aminomethyl, azaspiro[3.3]heptylcarbonyl, tetrahydrofuranyl,
azetidinylcarbonyl, oxazolyl,
carboxy, ethylaminomethyl, piperidinylaminocarbonyl, isopentylaminocarbonyl,
azepanylcarbonyl, aminocarbonyl, morpholinyl, tetrahydro-2H-pyranyl,
tetrahydropyranyl,
isopropyl, sulfonyl, cyano, isopropylaminomethyl, ethylaminomethyl,
24
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
tetrahydropyranylaminocarbonyl, trifluoroisopropyl, pyridinylmethyl, 2,2,2-
trifluoro(methyl)ethyl, 2,2,2-trifluoroethyl, trifluoroethylaminocarbonyl,
tert-butylaminomethyl,
cyclohexylaminocarbonyl, isopropyloxycarbonyl(dimethyleth-2y1), wherein Rl is
independently
optionally substituted with 1, 2, 3, or 4 R4 substituents and wherein two Rl
may optionally join
together with the ring atoms to which they are attached to form a 3 to 6
membered ring.
In one embodiment of the invention, R4 is independently selected from hydroxy,
(C 1 -6)alkyl, (C 1 -6)alkoxy, (C 1-10 alky1)0H, halogen, -(C1-10 alky1)0H, -
(C0_10 alkyl)CO2H,
-CO2H, C1-10 alkYl(oxY)o-i(carbony1)0-1C0-10 alkyl, -(C0-6)alkylCN, -00_10
alkyl
0(C=0)Ci-C6 alkyl, NO2, trifluoromethoxy, trifluoroethoxy, trifluoromethyl,
trifluoroethyl, -N-
C(0)0(C0-6)alkyl, -N(Rb)-C(0)0(C0-6)a1ky1, C1_10 alkylsulfonyl, oxo (0=),
aminosulfonyl, -
SO2NH2, -SO2NH(C 1 - 1 0 alkyl), -SO2N(C 1_10 alky1)2, -S02C 1 _6alkyl, -
S02CF3, -S02CF2H, -
C1_10 alkylsulfinyl, -0(0-1)(C1-10)haloalkyl, amino(C1-6a1kY1)0-2, C3-12
cycloalkyl, (C3_
12)cycloheteroalkyl, and NH2, wherein Rb is C1-10 alkyl.
In a variant of this embodiment, R4 is independently selected from hydroxy,
(Ci-
6)alkyl, (C1 -6)alkoxY, (C1-1 0 alky1)0H, halogen, -(C 1_10 alky1)0H,-(C0_ 1 0
alkyl)C 02H,
-CO2H, C1-10 alkYl(oxY)o-i(carbony1)0-1C0-10 alkyl, -(C0-6)alkylCN, -00_10
alkyl
0(C=0)Ci-C6 alkyl, trifluoromethoxy, trifluoroethoxy, trifluoromethyl,
trifluoroethyl, -N-
C(0)0(C0-6)alkyl, -N(Rb)-C(0)0(C0-6)a1ky1, C1_10 alkylsulfonyl, oxo (0=),
aminosulfonyl, -
502NH2, -SO2NH(C 1 - 1 0 alkyl), -502N(C 1_10 alky1)2, -S02C 1 _6alkyl, -
502CF3, -S02CF2H, -
C1_10 alkylsulfinyl, -0(0-1)(C1-10)haloalkyl, amino(C1-6a1kY1)0-2, C3-12
cycloalkyl, (C3_
12)cycloheteroalkyl, and NH2, wherein Rb is C1-10 alkyl.
In an embodiment, R4 is independently selected from: trifluoromethyl,
tert-butyloxycarbonylisopropyl, ethyloxycarbonylisopropyl, fluoro, hydroxy,
methyl, ethyl,
2,2,2-trifluoroethyl, dimethylamino, tert-butyloxycarbonyl, carboxyisoproyl,
amino, cyclopentyl,
methoxyethyl, cyanoethyl, ethyloxycarbonyl, oxo, methoxy, hydoxyisopropyl,
tert-
butyloxycarbonyl(methyl)amino, methylsulfonyl, isopropyl, tert-butyl, tert-
butylamino,
isopropyloxycarbonyl, isopropylamino, methoxycarbonyl, and carboxy.
One embodiment of the invention include the following compounds and their
pharmaceutically acceptable salts and stereoisomers thereof:
4-(( 1 -( 1 -cyanoprop an-2-y1)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-N,N-
dimethylbenzenesulfonamide;
4-(( 1 -(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -yl)amino)-
N,N-dimethylbenzenesulfonamide;
3 -cyclopropy1-3 - { 3 - [(4-fluorophenyl)amino] -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -
yl}propanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -( {4-[2,2,2-trifluoro- 1 -hydroxy- 1 -
methylethyl]phenyl} amino)-4,5 -
dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl]prop anenitrile;
3 -cyclopropy1-3 -(3 - { [ 1 -hydroxy- 1 -(trifluoromethyl)-2,3 -dihydro- 1H-
inden-5 -yl] amino 1 -4-oxo-
4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -yl)prop anenitrile ;
25
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -cyclopropy1-3 - {3 - [(1 , 1 -dioxido-2,3 -dihydro- 1 -benzothiophen-5 -
yl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3- {3 -[(2-te rt-butyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-benzisothiazol-5 -
yl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} -3 -cyclopropylpropanenitrile;
4-( { 1 - [2-cyano- 1 -cyclopropylethy1]-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin-3 -
y1} amino)benzonitrile;
3 -cyclopropy1-3 -(4-oxo-3 - { [4-(trifluoromethyl)phenyl] amino 1 -4,5 -
dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 -(3 - { [4-(methylsulfonyl)phenyl]amino} -4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -
1 0 c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3 - [(3 ,4,5 -trifluorophenyl)amino] -4,5 -dihydro-
1H-pyrazolo [4,3 -
c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(2-methyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-
benzisothiazol-5 -yl)amino] -4-oxo-
4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {3 - [(2-fluoropyridin-4-yl)amino]-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 - {4-oxo-3 - [( 1 -oxo-2,3 -dihydro-1H-inden-5 -yl)amino] -
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} propanenitrile;
3 -cyclopropy1-3 -[3 -(2,3 -dihydro- 1 -benzofuran-5 -ylamino)-4-oxo-4,5 -
dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -yl]propanenitrile;
3 - [3 -(1 ,3 -benzodioxo1-5 -ylamino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin- 1 -y1]-3 -
cyclopropylpropanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -(quinolin-6-ylamino)-4,5 -dihydro-1H-pyrazolo [4,3
-c]pyridin- 1 -
yl]propanenitrile;
3 -cyclopropy1-3 -(3 - { [3 -fluoro-4-(methylsulfonyl)phenyl] amino 1 -4-oxo-
4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)propanenitrile;
3 -cyclopropy1-3 -[4-oxo-3 -(quinoxalin-6-ylamino)-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -
yl]propanenitrile;
3- {3 -[(4-chlorophenyl)amino]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -y1} -3 -
cyclopropylpropanenitrile;
cyclopropy1-3 - [3 -( {4- [( 1 -methylethyl)sulfonyl]phenyl} amino)-4-oxo-4,5 -
dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl]propanenitrile;
(3- { [4-(tert-butylsulfonyl)phenyl]aminol -4-oxo-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -y1)-3 -
cyclopropylpropanenitrile;
N-tert-butyl-4- { [(2-cyano- 1 -cyclopropylethyl)-4-oxo-4,5 -dihydro-1H-
pyrazolo [4,3 -c]pyridin-3 -
yl] amino 1 benzenesulfonamide;
3 -(3 -((4-fluorophenyl)amino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -c]pyridine-
1 -yl)butanenitrile;
3 - [4-oxo-3 -( {4- [2,2,2-trifluoro- 1 -hydroxy- 1 -methylethyl]phenyl}
amino)-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl]butanenitrile;
26
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3 -(3 - { [1 -hydroxy- 1 -(trifluoromethyl)-2,3 -dihydro-1H-inden-5 -yl]amino
} -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -yl)butanenitrile;
3- {3 -[( 1 , 1 -dioxido-2,3 -dihydro- 1 -benzothiophen-5 -yl)amino]-4-oxo-4,5
-dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} butanenitrile;
3- {3-[( 1 , 1 -dioxido- 1 -benzothiophen-5 -yl)amino]-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-
1 -y1} butanenitrile;
4-( { 1 - [2-cyano- 1 -methylethy1]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin-3 -
y1} amino)benzonitrile;
3 -(4-oxo-3 - { [4-(trifluoromethyl)phenyl] amino 1 -4,5 -dihydro-1H-pyrazolo
[4,3 -c]pyridin- 1 -
1 0 yl)butanenitrile;
3 -(3 - { [4-(methylsulfonyl)phenyl] amino 1 -4-oxo-4,5 -dihydro- 1H-pyrazolo
[4,3 -c]pyridin- 1 -
yl)butanenitrile;
3- {4-oxo-3 - [(3 ,4,5 -trifluorophenyl)amino]-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -
y1} butanenitrile;
3- {3 -[(2-methyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-benzisothiazol-5 -
yl)amino] -4-o xo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin- 1 -y1} butanenitrile;
3- {3 -[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -
c]pyridin- 1 -
y1} butanenitrile;
3- {4-oxo-3 - [(1 -oxo-2,3 -dihydro-1H-inden-5 -yl)amino] -4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-
1 -y1} butanenitrile;
3 - [3 -(2,3 -dihydro- 1 -benzofuran-5 -ylamino)-4-oxo-4,5 -dihydro-1H-
pyrazolo [4,3 -c]pyridin- 1 -
yl]butanenitrile;
3 - [3 -(1 ,3 -benzodioxo1-5 -ylamino)-4-oxo-4,5 -dihydro-1H-pyrazolo [4,3 -
c]pyridin- 1 -
yl]butanenitrile;
3 - [4-oxo-3 -(quinolin-6-ylamino)-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -yl]butanenitrile;
3 -(3 - { [3 -fluoro-4-(methylsulfonyl)phenyl]amino } -4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -
c]pyridin- 1 -yl)butanenitrile;
3 - [4-oxo-3 -(quinoxalin-6-ylamino)-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -yl]butanenitrile;
3- {3 -[(4-chlorophenyl)amino]-4-oxo-4,5 -dihydro- 1H-pyrazolo [4,3 -c]pyridin-
1 -y1} butanenitrile;
N-tert-butyl-4-( { 1 -[2-cyano- 1 -methylethy1]-4-oxo-4,5 -dihydro- 1H-
pyrazolo [4,3 -c]pyridin-3 -
y1} amino)benzenesulfonamide; and
3- { 3 -[(2-te rt-butyl- 1 , 1 -dioxido-2,3 -dihydro- 1 ,2-benzisothiazol-5 -
yl)amino]-4-oxo-4,5 -dihydro-
1H-pyrazolo [4,3 -c]pyridin- 1 -y1} butanenitrile.
27
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Optical Isomers - Diastereomers - Geometric Isomers ¨ Tautomers
Compounds of formula I contain one or more asymmetric centers and can thus
occur as racemates and racemic mixtures, single enantiomers, diastereomeric
mixtures and
individual diastereomers. The present invention is meant to comprehend all
such isomeric forms
of the compounds of formula I, either as single species or mixtures thereof.
Some of the compounds described herein contain olefinic double bonds, and
unless specified otherwise, are meant to include both E and Z geometric
isomers.
Some of the compounds described herein may exist with different points of
attachment of hydrogen, referred to as tautomers. Such an example may be a
ketone and its enol
form known as keto-enol tautomers. The individual tautomers as well as mixture
thereof are
encompassed with compounds of formula I.
Specific embodiments of the present invention include a compound which is
selected from the group consisting of the subject compounds of the Examples
herein or a
pharmaceutically acceptable salt thereof.
The compounds of the present invention may contain one or more asymmetric
centers and can thus occur as "stereoisomers" including racemates and racemic
mixtures,
enantiomeric mixtures, single enantiomers, diastereomeric mixtures and
individual diastereomers.
Additional asymmetric centers may be present depending upon the nature of the
various
substituents on the molecule. Each such asymmetric center will independently
produce two
optical isomers and it is intended that all of the possible optical isomers
and diastereomers in
mixtures and as pure or partially purified compounds are included within the
scope of this
invention. The present invention is meant to comprehend all such isomeric
forms of these
compounds. When bonds to the chiral carbon are depicted as straight lines in
the Formulas of
the invention, it is understood that both the (R) and (S) configurations of
the chiral carbon, and
hence both enantiomers and mixtures thereof, are embraced within the Formula.
For example,
Formula I shows the structure of the class of compounds without specific
stereochemistry.
When the compounds of the present invention contain one chiral center, the
term "stereoisomer"
includes both enantiomers and mixtures of enantiomers, such as the specific
50:50 mixture
referred to as racemic mixtures.
The compounds of Formula (I) may contain asymmetric or chiral centers, and,
therefore, exist in different stereoisomeric forms. It is intended that all
stereoisomeric forms of
the compounds of Formula (I) as well as mixtures thereof, including racemic
mixtures, form part
of the present invention. In addition, the present invention embraces all
geometric and positional
isomers. For example, if a compound of Formula (I) incorporates a double bond
or a fused ring,
both the cis- and trans-forms, as well as mixtures, are embraced within the
scope of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers
on
the basis of their physical chemical differences by methods well known to
those skilled in the art,
such as, for example, by chromatography and/or fractional crystallization.
Enantiomers can be
separated by converting the enantiomeric mixture into a diastereomeric mixture
by reaction with
28
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
an appropriate optically active compound (e.g., chiral auxiliary such as a
chiral alcohol or
Mosher's acid chloride), separating the diastereomers and converting (e.g.,
hydrolyzing) the
individual diastereomers to the corresponding pure enantiomers. Also, some of
the compounds
of Formula (I) may be atropisomers (e.g., substituted biaryls) and are
considered as part of this
invention. Enantiomers can also be separated by use of chiral HPLC column.
It is also possible that the compounds of Formula (I) may exist in different
tautomeric forms, and all such forms are embraced within the scope of the
invention. Also, for
example, all keto-enol and imine-enamine forms of the compounds are included
in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the
like)
of the present compounds (including those of the salts, solvates, esters and
prodrugs of the
compounds as well as the salts, solvates and esters of the prodrugs), such as
those which may
exist due to asymmetric carbons on various substituents, including
enantiomeric forms (which
may exist even in the absence of asymmetric carbons), rotameric forms,
atropisomers, and
diastereomeric forms, are contemplated within the scope of this invention, as
are positional
isomers (such as, for example, 4-pyridyl and 3-pyridy1). (For example, if a
compound of
Formula (I) incorporates a double bond or a fused ring, both the cis- and
trans-forms, as well as
mixtures, are embraced within the scope of the invention. Also, for example,
all keto-enol and
imine-enamine forms of the compounds are included in the invention.)
Individual stereoisomers
of the compounds of the invention may, for example, be substantially free of
other isomers, or
may be admixed, for example, as racemates or with all other, or other
selected, stereoisomers.
The chiral centers of the present invention can have the S or R configuration
as defined by the
IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester",
"prodrug" and
the like, is intended to equally apply to the salt, solvate, ester and prodrug
of enantiomers,
stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs
of the inventive
compounds.
In the present application when a particular stereomeric compound is named
using an "and" in the stereomeric designation, the "and" indicates a racemic
mixture of the
enantiomers. That is, the individual enantiomers were not individually
isolated.
When the stereomeric nomenclature includes "or", for example, (3R or S)-3- {3-
[(1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino]-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-ylIbutanenitrile, the "or" indicates that chiral resolution of
racemate into individual
enantiomers was accomplished but the actual optical activity of the specific
enantiomer was not
nessissarily determined.
The independent syntheses of these diastereomers or their chromatographic
separations may be achieved as known in the art by appropriate modification of
the methodology
disclosed herein. Their absolute stereochemistry may be determined by the x-
ray
crystallography of crystalline products or crystalline intermediates which are
derivatized, if
necessary, with a reagent containing an asymmetric center of known absolute
configuration. If
desired, racemic mixtures of the compounds may be separated so that the
individual enantiomers
29
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
are isolated. The separation can be carried out by methods well known in the
art, such as the
coupling of a racemic mixture of compounds to an enantiomerically pure
compound to form a
diastereomeric mixture, followed by separation of the individual diastereomers
by standard
methods, such as fractional crystallization or chromatography. The coupling
reaction is often the
formation of salts using an enantiomerically pure acid or base. The
diasteromeric derivatives
may then be converted to the pure enantiomers by cleavage of the added chiral
residue. The
racemic mixture of the compounds can also be separated directly by
chromatographic methods
utilizing chiral stationary phases, which methods are well known in the art.
Alternatively, any
enantiomer of a compound can be obtained by stereoselective synthesis using
optically pure
starting materials or reagents of known configuration by methods well known in
the art.
Salts
The term "pharmaceutically acceptable salts" refers to salts prepared from
pharmaceutically acceptable non-toxic bases including inorganic bases and
organic bases. Salts
derived from inorganic bases include aluminum, ammonium, calcium, copper,
ferric, ferrous,
lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and
the like.
Particularly preferred are the ammonium, calcium, magnesium, potassium, and
sodium salts.
Salts derived from pharmaceutically acceptable organic non-toxic bases include
salts of primary,
secondary, and tertiary amines, substituted amines including naturally
occurring substituted
amines, cyclic amines, and basic ion exchange resins, such as arginine,
betaine, caffeine, choline,
N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-
dimethylaminoethanol,
ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine,
glucamine, glucosamine,
histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine,
piperazine,
piperidine, polyamine resins, procaine, purines, theobromine, triethylamine,
trimethylamine,
tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared
from
pharmaceutically acceptable non-toxic acids, including inorganic and organic
acids. Such acids
include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric,
ethanesulfonic, fumaric,
gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic,
malic, mandelic,
methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic,
sulfuric, tartaric, p-
toluenesulfonic acid, 1-hydroxy-2-naphthoic acid (xinafoate) and the like.
Particularly preferred
are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and
tartaric acids.
It will be understood that, unless otherwise specified, references to the
compound
of formula I subsets thereof, embodiments thereof, as well as specific
compounds are meant to
also include the pharmaceutically acceptable salts and stereoisomers thereof
Furthermore, some of the crystalline forms for compounds of the present
invention may exist as polymorphs and as such all forms are intended to be
included in the
present invention In addition, some of the compounds of the instant invention
may form solvates
30
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
with water (hydrates) or common organic solvents. Such solvates are
encompassed within the
scope of this invention.
Labelled Compounds
In the compounds of generic Formula I, the atoms may exhibit their natural
isotopic abundances, or one or more of the atoms may be artificially enriched
in a particular
isotope having the same atomic number, but an atomic mass or mass number
different from the
atomic mass or mass number predominantly found in nature. The present
invention is meant to
include all suitable isotopic variations of the compounds of generic Formula
I. For example,
different isotopic forms of hydrogen (H) include protium (1H) and deuterium
(2H). Protium is
the predominant hydrogen isotope found in nature. Enriching for deuterium may
afford certain
therapeutic advantages, such as increasing in vivo half-life or reducing
dosage requirements, or
may provide a compound useful as a standard for characterization of biological
samples.
Isotopically-enriched compounds within generic Formula I can be prepared
without undue
experimentation by conventional techniques well known to those skilled in the
art or by
processes analogous to those described in the Schemes and Examples herein
using appropriate
isotopically-enriched reagents and/or intermediates.
Utilities
Compound of formula I or its pharmaceutically acceptable salts and
pharmaceutical compositions can be used to treat or prevent a variety of
conditions or diseases
mediated by Janus kinases, in particular diseases or conditions that can be
ameliorated by the
inhibition of a Janus kinase such as JAK1, JAK2, JAK3 or TYK2. Such conditions
and diseases
include, but are not limited to: (1) arthritis, including rheumatoid
arthritis, juvenile arthritis, and
psoriatic arthritis; (2) asthma and other obstructive airways diseases,
including chronic asthma,
late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma,
allergic asthma, intrinsic
asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and
chronic obstruction
pulmonary disease including emphysema; (3) autoimmune diseases or disorders,
including those
designated as single organ or single cell-type autoimmune disorders, for
example Hashimoto's
thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of
pernicious anemia,
autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease,
autoimmune
thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease,
primary biliary
cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous
glomerulopathy, those
designated as involving systemic autoimmune disorder, for example systemic
lupus
erythematosis, rheumatoid arthritis, Sjogren's syndrome, Reiter's syndrome,
polymyositis-
dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis
and bullous
pemphigoid, and additional autoimmune diseases, which can be B-cell (humoral)
based or T-cell
based, including Cogan's syndrome, ankylosing spondylitis, Wegener's
granulomatosis,
autoimmune alopecia, Type I or juvenile onset diabetes, and thyroiditis; (4)
cancers or tumors,
31
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
including alimentary/gastrointestinal tract cancer, colon cancer, liver
cancer, skin cancer
including mast cell tumor and squamous cell carcinoma, breast and mammary
cancer, ovarian
cancer, prostate cancer, lymphoma, leukemia, including acute myelogenous
leukemia and
chronic myelogenous leukemia, kidney cancer, lung cancer, muscle cancer, bone
cancer, bladder
cancer, brain cancer, melanoma including oral and metastatic melanoma,
Kaposi's sarcoma,
myelomas including multiple myeloma, myeloproliferative disorders,
proliferative diabetic
retinopathy, and angiogenic-associated disorders including solid tumors; (5)
diabetes, including
Type I diabetes and complications from diabetes; (6) eye diseases, disorders
or conditions
including autoimmune diseases of the eye, keratoconjunctivitis, vernal
conjunctivitis, uveitis
including uveitis associated with Behcet's disease and lens-induced uveitis,
keratitis, herpetic
keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma,
ocular premphigus,
Mooren's ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada
syndrome,
keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis,
endocrine
ophthalmopathy, sympathetic ophthalmitis, allergic conjunctivitis, and ocular
neovascularization;
(7) intestinal inflammations, allergies or conditions including Crohn's
disease and/or ulcerative
colitis, inflammatory bowel disease, coeliac diseases, proctitis, eosinophilic
gastroenteritis, and
mastocytosis; (8) neurodegenerative diseases including motor neuron disease,
Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's
disease, cerebral
ischemia, or neurodegenerative disease caused by traumatic injury, strike,
glutamate
neurotoxicity or hypoxia; ischemic/reperfusion injury in stroke, myocardial
ischemica, renal
ischemia, heart attacks, cardiac hypertrophy, atherosclerosis and
arteriosclerosis, organ hypoxia,
and platelet aggregation; (9) skin diseases, conditions or disorders including
atopic dermatitis,
eczema, psoriasis, scleroderma, pruritus and other pruritic conditions; (10)
allergic reactions
including anaphylaxis, allergic rhinitis, allergic dermatitis, allergic
urticaria, angioedema,
allergic asthma, or allergic reaction to insect bites, food, drugs, or pollen;
(11) transplant
rejection, including pancreas islet transplant rejection, bone marrow
transplant rejection, graft-
versus-host disease, organ and cell transplant rejection such as bone marrow,
cartilage, cornea,
heart, intervertebral disc, islet, kidney, limb, liver, lung, muscle,
myoblast, nerve, pancreas, skin,
small intestine, or trachea, and xeno transplantation.
Accordingly, another aspect of the present invention provides a method for the
treatment or prevention of a JAK-mediated disease or disorder comprising
administering to a
mammal in need thereof a therapeutically effective amount of a compound of
formula I. In one
embodiment such diseases include asthma and rheumatoid arthritis.
Another aspect of the present invention provides for the use of a compound of
formula I in the manufacture of a medicament for the treatment or prevention
of a JAK-mediated
diseases or disorder.
One aspect of the invention is the use of a compound of Formula I or a
pharmaceutically acceptable salt or a stereoisomer thereof in the manufacture
of a medicament
32
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
for the treatment of a disease or a disorder ameliorated by selective
inhibition of Janus kinases
JAK1 and JAK2.
Another aspect of the invention is the use of a compound of Formula I or a
pharmaceutically acceptable salt or a stereoisomer thereof and a second active
agent in the
manufacture of a medicament for the treatment of a disease or a disorder
ameliorated by
selective inhibition of Janus kinases JAK1 and JAK2.
Dose Ranges
The magnitude of prophylactic or therapeutic dose of a compound of formula I
will, of course, vary with the nature and the severity of the condition to be
treated and with the
particular compound of formula I and its route of administration. It will also
vary according to a
variety of factors including the age, weight, general health, sex, diet, time
of administration, rate
of excretion, drug combination and response of the individual patient. In
general, the daily dose
from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably
0.01 mg to
about 10 mg per kg. On the other hand, it may be necessary to use dosages
outside these limits
in some cases.
The amount of active ingredient that may be combined with the carrier
materials
to produce a single dosage form will vary depending upon the host treated and
the particular
mode of administration. For example, a formulation intended for the oral
administration of
humans may contain from 0.05 mg to 5 g, of active agent compounded with an
appropriate and
convenient amount of carrier material which may vary from about 5 to about
99.95 percent of the
total composition. In some cases, the dosage unit forms may contain from about
0.05 to about
3g of active ingredient. Dosage unit forms will generally contain between from
about 0.1 mg to
about 0.4 g of an active ingredient, typically 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg,
0.5 mg, 1 mg, 2 mg,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.
33
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Pharmaceutical Compositions
Another aspect of the present invention provides pharmaceutical compositions
comprising a compound of formula I with a pharmaceutically acceptable carrier.
For the
treatment of any of the prostanoid mediated diseases compounds of formula I
may be
administered orally, by inhalation spray, topically, parenterally or rectally
in dosage unit
formulations containing conventional non-toxic pharmaceutically acceptable
carriers, adjuvants
and vehicles. The term parenteral as used herein includes subcutaneous
injections, intravenous,
intramuscular, intrasternal injection or infusion techniques. In addition to
the treatment of
warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats,
etc., the compound of
the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a
form suitable for oral use, for example, as tablets, troches, lozenges,
aqueous or oily suspensions,
dispersible powders or granules, emulsions, hard or soft capsules, or syrups
or elixirs.
Compositions intended for oral use may be prepared according to any method
known to the art
for the manufacture of pharmaceutical compositions and such compositions may
contain one or
more agents selected from the group consisting of sweetening agents, flavoring
agents, coloring
agents and preserving agents in order to provide pharmaceutically elegant and
palatable
preparations. Tablets contain the active ingredient in admixture with non-
toxic pharmaceutically
acceptable excipients which are suitable for the manufacture of tablets. These
excipients may be
for example, inert diluents, such as calcium carbonate, sodium carbonate,
lactose, calcium
phosphate or sodium phosphate; granulating and disintegrating agents, for
example, corn starch,
or alginic acid; binding agents, for example starch, gelatin or acacia, and
lubricating agents, for
example, magnesium stearate, stearic acid or talc. The tablets may be uncoated
or they may be
coated by known techniques to delay disintegration and absorption in the
gastrointestinal tract
and thereby provide a sustained action over a longer period. For example, a
time delay material
such as glyceryl monostearate or glyceryl distearate may be employed. They may
also be coated
by the technique described in the U.S. Patent 4,256,108; 4,166,452; and
4,265,874 to form
osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules
wherein
the active ingredient is mixed with an inert solid diluent, for example,
calcium carbonate,
calcium phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredients is mixed
with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an
oil medium, for
example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients
suitable for the manufacture of aqueous suspensions. Such excipients are
suspending agents, for
example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl
methylcellulose,
sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia;
dispersing or wetting
agents may be a naturally-occurring phosphatide, for example lecithin, or
condensation products
of an alkylene oxide with fatty acids, for example polyoxyethylene stearate,
or condensation
34
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
products of ethylene oxide with long chain aliphatic alcohols, for example
heptadecaethylene-
oxycetanol, or condensation products of ethylene oxide with partial esters
derived from fatty
acids and a hexitol such as polyoxyethylene sorbitol monooleate, or
condensation products of
ethylene oxide with partial esters derived from fatty acids and hexitol
anhydrides, for example
polyethylene sorbitan monooleate. The aqueous suspensions may also contain one
or more
preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more
coloring agents,
one or more flavoring agents, and one or more sweetening agents, such as
sucrose, saccharin or
aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a
vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil,
or in mineral oil such
as liquid paraffin. The oily suspensions may contain a thickening agent, for
example beeswax,
hard paraffin or cetyl alcohol. Sweetening agents such as those set forth
above, and flavoring
agents may be added to provide a palatable oral preparation. These
compositions may be
preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous
suspension by the addition of water provide the active ingredient in admixture
with a dispersing
or wetting agent, suspending agent and one or more preservatives. Suitable
dispersing or
wetting agents and suspending agents are exemplified by those already
mentioned above.
Additional excipients, for example sweetening, flavoring and coloring agents,
may also be
present.
The pharmaceutical compositions of the invention may also be in the form of an
oil-in-water emulsion. The oily phase may be a vegetable oil, for example
olive oil or arachis oil,
or a mineral oil, for example liquid paraffin or mixtures of these. Suitable
emulsifying agents
may be naturally-occurring phosphatides, for example soy bean, lecithin, and
esters or partial
esters derived from fatty acids and hexitol anhydrides, for example sorbitan
monooleate, and
condensation products of the said partial esters with ethylene oxide, for
example
polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening
and
flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example
glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also
contain a demulcent,
a preservative, and flavoring and coloring agents. The pharmaceutical
compositions may be in
the form of a sterile injectable aqueous or oleagenous suspension. This
suspension may be
formulated according to the known art using those suitable dispersing or
wetting agents and
suspending agents which have been mentioned above. The sterile injectable
preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally-acceptable diluent
or solvent, for example as a solution in 1,3-butane diol. Among the acceptable
vehicles and
solvents that may be employed are water, Ringer's solution and isotonic sodium
chloride solution.
Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also
be used. In
addition, sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For
35
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
this purpose any bland fixed oil may be employed including synthetic mono- or
diglycerides. In
addition, fatty acids such as oleic acid find use in the preparation of
injectables.
Dosage forms for inhaled administration may conveniently be formulated as
aerosols or dry powders. For compositions suitable and/or adapted for inhaled
administration, it
is preferred that the active substance is in a particle-size-reduced form, and
more preferably the
size-reduced form is obtained or obtainable by micronization.
In one embodiment the medicinal preparation is adapted for use with a
pressurized metered dose inhaler (pMDI) which releases a metered dose of
medicine upon each
actuation. The formulation for pMDIs can be in the form of solutions or
suspensions in
halogenated hydrocarbon propellants. The type of propellant being used in
pMDIs is being
shifted to hydrofluoroalkanes (HFAs), also known as hydrofluorocarbons (HFCs).
In particular,
1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA
227) are used
in several currently marketed pharmaceutical inhalation products. The
composition may include
other pharmaceutically acceptable excipients for inhalation use such as
ethanol, oleic acid,
polyvinylpyrrolidone and the like.
Pressurized MDIs typically have two components. Firstly, there is a canister
component in which the drug particles are stored under pressure in a
suspension or solution form.
Secondly, there is a receptacle component used to hold and actuate the
canister. Typically, a
canister will contain multiple doses of the formulation, although it is
possible to have single dose
canisters as well. The canister component typically includes a valve outlet
from which the
contents of the canister can be discharged. Aerosol medication is dispensed
from the pMDI by
applying a force on the canister component to push it into the receptacle
component thereby
opening the valve outlet and causing the medication particles to be conveyed
from the valve
outlet through the receptacle component and discharged from an outlet of the
receptacle. Upon
discharge from the canister, the medication particles are "atomized", forming
an aerosol. It is
intended that the patient coordinate the discharge of aerosolized medication
with his or her
inhalation, so that the medication particles are entrained in the patient's
aspiratory flow and
conveyed to the lungs. Typically, pMDIs use propellants to pressurize the
contents of the
canister and to propel the medication particles out of the outlet of the
receptacle component. In
pMDIs, the formulation is provided in a liquid or suspension form, and resides
within the
container along with the propellant. The propellant can take a variety of
forms. For example,
the propellant can comprise a compressed gas or liquefied gas.
In another embodiment the medicinal preparation is adapted for use with a dry
powder inhaler (DPI). The inhalation composition suitable for use in DPIs
typically comprises
particles of the active ingredient and particles of a pharmaceutically
acceptable carrier. The
particle size of the active material may vary from about 0.1 um to about 10
um; however, for
effective delivery to the distal lung, at least 95 percent of the active agent
particles are 5 um or
smaller. Each of the active agent can be present in a concentration of 0.01 -
99%. Typically
36
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
however, each of the active agents is present in a concentration of about 0.05
to 50%, more
typically about 0.2 - 20% of the total weight of the composition.
As noted above, in addition to the active ingredients, the inhalable powder
preferably includes pharmaceutically acceptable carrier, which may be composed
of any
pharmacologically inert material or combination of materials which is
acceptable for inhalation.
Advantageously, the carrier particles are composed of one or more crystalline
sugars; the carrier
particles may be composed of one or more sugar alcohols or polyols.
Preferably, the carrier
particles are particles of dextrose or lactose, especially lactose. In
embodiments of the present
invention which utilize conventional dry powder inhalers, such as the
HandihalerTM, RotohalerTM,
DiskhalerTM, TwisthalerTm and TurbohalerTm, the particle size of the carrier
particles may range
from about 10 microns to about 1000 microns. In certain of these embodiments,
the particle size
of the carrier particles may range from about 20 microns to about 120 microns.
In certain other
embodiments, the size of at least 90% by weight of the carrier particles is
less than 1000 microns
and preferably lies between 60 microns and 1000 microns. The relatively large
size of these
carrier particles gives good flow and entrainment characteristics. Where
present, the amount of
carrier particles will generally be up to 95%, for example, up to 90%,
advantageously up to 80%
and preferably up to 50% by weight based on the total weight of the powder.
The amount of any
fine excipient material, if present, may be up to 50% and advantageously up to
30%, especially
up to 20%, by weight, based on the total weight of the powder. The powder may
optionally
contain a performance modifier such as L-leucine or another amino acid, and/or
metals salts of
stearic acid such as magnesium or calcium stearate.
Compounds of formula I may also be administered in the form of suppositories
for rectal administration of the drug. These compositions can be prepared by
mixing the drug
with a suitable non-irritating excipient which is solid at ambient
temperatures but liquid at the
rectal temperature and will therefore melt in the rectum to release the drug.
Such materials are
cocoa butter and polyethylene glycols.
For topical use, creams, ointments, gels, solutions or suspensions, etc.,
containing
the compound of formula I are employed. (For purposes of this application,
topical application
shall include mouth washes and gargles.) Topical formulations may generally be
comprised of a
pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer,
preservative system, and
emollient.
37
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Combinations with Other Drugs
For the treatment and prevention of JAK mediated diseases, compound of formula
I may be co-administered with other therapeutic agents. Thus in another aspect
the present
invention provides pharmaceutical compositions for treating JAK mediated
diseases comprising
a therapeutically effective amount of a compound of formula I and one or more
other therapeutic
agents. In particular, for the treatment of the inflammatory diseases
rheumatoid arthritis,
psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a
compound of
formula I may be combined with agents such as: (1) TNF-a inhibitors such as
Remicade0 and
Enbre10); (2) non-selective COX-I/COX-2 inhibitors (such as piroxicam,
diclofenac, propionic
acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen,
fenamates such as
mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as
phenylbutazone,
salicylates such as aspirin); (3) COX-2 inhibitors (such as meloxicam,
celecoxib, rofecoxib,
valdecoxib and etoricoxib); (4) other agents for treatment of rheumatoid
arthritis including low
dose methotrexate, lefunomide, ciclesonide, hydroxychloroquine, d-
penicillamine, auranofin or
parenteral or oral gold; (5) leukotriene biosynthesis inhibitor, 5-
lipoxygenase (5-LO) inhibitor or
5-lipoxygenase activating protein (FLAP) antagonist such as zileuton; (6) LTD4
receptor
antagonist such as zafirlukast, montelukast and pranlukast; (7) PDE4 inhibitor
such as
roflumilast; (8) antihistaminic H1 receptor antagonists such as cetirizine,
loratadine,
desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine; (9)
al- and a2-
adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as
propylhexedrine,
phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline
hydrochloride,
oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline
hydrochloride,
and ethylnorepinephrine hydrochloride; (10) anticholinergic agents such as
ipratropium bromide,
tiotropium bromide, oxitropium bromide, aclindinium bromide, glycopyrrolate,
pirenzepine, and
telenzepine; (11) I3-adrenoceptor agonists such as metaproterenol,
isoproterenol, isoprenaline,
albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline,
bitolterol mesylate, and
pirbuterol, or methylxanthanines including theophylline and aminophylline,
sodium
cromoglycate; (12) insulin-like growth factor type I (IGF-1) mimetic; (13)
inhaled glucocorticoid
with reduced systemic side effects, such as prednisone, prednisolone,
flunisolide, triamcinolone
acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate,
ciclesonide and
mometasone furoate.
38
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
SCHEMES AND EXAMPLES
The abbreviations used herein have the following tabulated meanings.
Abbreviations not tabulated below have their meanings as commonly used unless
specifically
stated otherwise.
ACN acetonitrile
MeCN acetonitrile
BAST bis(2-methoxyethyl)aminosulfur trifluoride
Chiral SFC chiral super critical fluid chromatography
CO2 carbon dioxide
Cs2CO3 cesium carbonate
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
DCE 1,2-dichloroethane
DCM dichloromethane
DIPEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide
DMS0 dimethyl sulfoxide
DSC N,N-disuccinimidyl carbonate
EDC 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-
amine
Et0Ac ethyl acetate
HATU 0-(7-aza-1H-benzotriazol-1-y1)-N,N,N',N'-
tetramethyluronium hexafluorophosphate
hr or h hour
HC1 hydrogen chloride
HOBt 1-hydroxybenzotriazole
HPLC high pressure liquid chromatography
IPA 2-propanol
LDA lithium diisopropylamide
m-CPBA meta-chloroperoxybenzoic acid
LRMS low resolution mass spectrometry
MeI iodomethane
Me-THF 2-methyltetrahydrofuran
Mg504 magnesium sulfate
MP-(0Ac)3BH solid supported (macro porous) triacetoxyborohydride
MPLC medium pressure liquid chromatography
NaH sodium hydride
Na2504 sodium sulfate
39
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
NaBH4 sodium borohydride
NaHCO3 sodium bicarbonate
Na0Me sodium methoxide
Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)
P0C13 phosphorus (V) oxychloride
Prep preparative
PyBOP (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate
SFC Supercritical Fluid Chromatography
Sat. saturated
SEM-C1 2-(trimethylsilyl)ethoxymethyl chloride
SiliaCatO DPP-Pd silica bound diphenylphosphine palladium (II)
TBAF tetra-n-butylammonium fluoride
TBS-Cl tert-butyldimethylsilyl chloride
t-BuOH (tert-BuOH) tert-butanol
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
X-Phos 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
Me42Bu-X-Phos di-tert-butyl[3,4,5,6-tetramethy1-2',4',6'-tri(propan-2-
y1)biphenyl-2-yl]phosphane
NMO 4-methylmorpholine N-oxide
rt or RT Room temperature
Sat. aq. Saturated, aqueous
TPAP tetra-n-propylammonium perruthenate (VII)
HCOOH formic acid
Kt0Bu potassium tert-butoxide
Na25205 sodium metabisulfite
NMR nuclear magnetic resonance
TLC thin layer chromatography
(Et0)2P(0)CH2CN diethyl (cyanomethyl)phosphonate
MsC1 methanesulfonyl chloride
Ts0H p-toluenesulfonic acid
KCN potassium cyanide
Si-DMT silica supported Dimercaptotriazine
TMS trimethylsilane
CF3TMS (trifluoromethyl)trimethylsilane
40
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
PhI(OAc)2 Iodosobenzene diacetate
Ti(OEt)4 Titanium (IV) ethoxide
Ti(Oi-Pr)4 Titanium (IV) isopropoxide
TMSCF3 trimethyl(trifluoromethyl)silane
BH3 borane
S0C12 Thionyl chloride
LiHMDS Lithium bis(trimethylsilyl)amide
BOC20 Boc-anhydride, or di-tert-butyl dicarbonate
NaBH4 Sodium borohydride
i-PrMgC1 Isopropylmagnesium chloride
KOAc Potassium acetate
K3PO4 Potassium phosphate tribasic
PG Protecting group
IBX 2-Iodoxybenzoic acid
HNRR A disubstituted amine
Ph3PMeBr Methyltriphenylphosphonium bromide
A1C13 Aluminum trichloride
Alkyl Group Abbreviations
Me methyl
Et ethyl
n-Pr normal propyl
i-Pr isopropyl
n-Bu normal butyl
i-Bu isobutyl
s-Bu secondary butyl
t-Bu tertiary butyl
c-Pr cyclopropyl
c-Bu cyclobutyl
c-Pen cyclopentyl
c-Hex cyclohexyl
41
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
METHODS OF SYNTHESIS
The compounds of the present invention can be prepared according to the
following general schemes using appropriate materials, and are further
exemplified by the
subsequent specific examples. The compounds illustrated in the examples are
not to be
construed as forming the only genus that is considered as the invention. The
illustrative
Examples below, therefore, are not limited by the compounds listed or by any
particular
substituents employed for illustrative purposes. Substituent numbering as
shown in the schemes
does not necessarily correlate to that used in the claims and often, for
clarity, a single substituent
is shown attached to the compound where multiple substituents are allowed
under the definitions
of the instant invention herein above.
Those skilled in the art will readily understand that known variations of the
conditions and processes of the following preparative procedures can be used
to prepare these
compounds. The invention will now be illustrated in the following non-limiting
Examples in
which, unless otherwise stated:
All reactions were stirred (mechanically, stir bar/stir plate, or shaken) and
conducted under an
inert atmosphere of nitrogen or argon unless specifically stated otherwise.
All starting materials used to prepare the intermediates and final compounds
described herein
were obtained from commercial vendors, and were used as is upon receipt.
All temperatures are degrees Celsius ( C) unless otherwise noted.
Ambient temperature is 15-25 C.
Most compounds were purified by reverse-phase preparative HPLC, MPLC on silica
gel,
recrystallization and/or swish (suspension in a solvent followed by filtration
of the solid).
The course of the reactions was followed by thin layer chromatography (TLC)
and/or LCMS
and/or NMR and reaction times are given for illustration only.
All end products were analyzed by NMR and LCMS. Intermediates were analyzed by
NMR
and/or TLC and/or LCMS.
Method 1
General procedures to prepare intermediates of the instant invention are
described
in Scheme 1. Using standard enolization conditions, such as KOt-Bu or
TEA/LiBr, in a suitable
solvent, such as THF, PhMe, at a temperature between 0 C and room temperature
aldehyde 1A
can undergo olefination to yield a,13-unsaturated nitrile 1B. Using an
appropriate base, such as
DBU, in a suitable solvent, such as MeCN, Et0H, n-BuOH or tert-BuOH, at a
temperature
between 25-110 C either protected pyrazolopyridone 1C (PG = a suitable
protecting group) can
undergo conjugate addition to optionally substituted nitriles 1B to yield
adduct 1D, in racemic
form. The stereoisomers of intermediate 1D can be separated into its
respective individual
optical isomers using the appropriate chromatographic method (achiral and/or
chiral).
Intermediate 1D is cross coupled to substituted aryl and heteroaryl halides 1E
using an
appropriate catalytic palladium/ligand system, such as Pd2(dba)3 or
Pd2(dba)3=CHC13, and 2-di-
42
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
tert-butylphosphino-2' ,4' ,6'-triisopropylbiphenyl (t-Bu XPhos) or di-tert-
butyl[3,4,5,6-
tetramethy1-2',4',6'-tri(propan-2-y1)biphenyl-2-yl]phosphane (Me4 13u-XPhos),
or 2-
dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos). Typical
conditions employ 1-2
equivalents of the aryl/heteroaryl halide relative to the pyrazolopyrimidine
with 10-25% Pd
precatalyst loading, using an approximate Pd:ligand ratio of 1:2 to 1:2.5.
Typically, the cross
coupling is carried out using either 2-propanol or t-amyl alcohol solvents,
and between 1-3.1
equivalents of KOAc or K3PO4 base. Reactions were typically carried out
between 65-89 C, to
yield intermediates 1F of the instant invention. Intermediates 1F can be
deprotected using either
hydrogenolysis conditions (H2 gas, Pd/C, in a suitable solvent such as Et0Ac,
Et0H, Me0H, or
using combinations of solvents thereof), or promoted by a suitable acid to
afford Examples 1G
of the instant invention.
SCHEME 1
0
(Et0)2P(0)CH2CN R4 R1 1:0\ 1) DBU
====., R3
v., _______ j ( R2 + PGO _______________ 1 NH
PGO N-----
., ....
R4 0,2 Kt0Bu N__ R3 77-14 2)
chiral SFC ¨14 R5 R4
R3 or H2N H2N
LiBr/TEA
1A 1B 1C 1D
+
HN R3 CN N R3 CN
X
4--- 1
TFA or Pd/C, H2PGO rr ___ K3PO4 or KOAc
W:(11
0 N 1 I
---14 R5 R4 --N R5 ' D `4 XPhos, t-Bu
XPhos or
HN HN Me4 tBu-XPhos Ri
1
R2 1G 1F Pd2(dba)3 or Pd2(dba)3
CHCI3
-."."\ 1E
Q \
\x/z...,zR
INTERMEDIATES
The following experimental procedures detail the preparation of chemical
materials used in the synthesis of Examples of the instant invention. The
exemplified procedures
are for illustrative purposes only, and are not intended to limit the scope of
the instant invention
in any way.
Intermediate 1
4-(Benzyloxy)-1H-p yr azolo [4,3- c]p yr idin -3-amine
NH2
7
HN \16_,
-- OBn
I
N N
I-1
Step 1: 2-(Benzyloxy)-4-methoxynicotinonitrile
43
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
N
I I
Me00Bn
I
N I-la
To a solution of 2-hydroxy-4-methoxynicotinonitrile (60 g, 0.4 mol) in toluene
(0.6 L) was added Ag2CO3 (140 g, 0.51 mol) and BnBr (87 g, 0.51 mol) at room
temperature.
The mixture was stirred at 50 C for 3h. TLC showed the reaction was complete.
The mixture
was filtered off solids, washed with DCM and concentrated in vacuum. Petroleum
ether (100
mL) was added to the residue, the solid was collected by filter to give
compound I-la as a white
solid. 1H NMR (400 MHz, DMSO-d6): 6 8.32 (d, 1H), 7.31-7.45 (m, 5H), 6.97 (d,
1H), 5.47(s,
2H), 3.98 (s, 3H).
Step 2: 4-(Benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine
A suspension of 2-(benzyloxy)-4-methoxynicotinonitrile (100 g, 410 mmol) in
hydrazine hydrate (200 g, 4.1 mol) and n-BuOH (600 mL) was heated to reflux
overnight. The
mixture was concentrated in vacuum and purified by chromatography (petroleum
ether: ethyl
acetate = 3:1) to give I-1 as a white solid. 1H NMR (400 MHz, DMSO-d6): 611.89
(s, 1H), 7.69
(d, 1H), 7.50 (d, 2H), 7.38-7.39 (d, 2H), 7.31 (d, 1H), 6.82 (d, 1H), 5.51 (s,
2H), 5.17 (s, 2H).
Intermediate 2A and 2B
2- (4-br om op heny1)-1,1,1-tr iflu or opr op an -2-ol
Br 0Me
HO CF3 1-2
To 4'-bromo-2,2,2-trifluoroacetophenone (890 mg, 3. 52 mmol) in
tetrahydrofuran (11.73 ml) under an atmosphere of N2 at 0 C was added methyl
magnesium
bromide (17.6 mL, 17.6 mmol). The reaction was stirred at that temperature for
1 hour, and then
warmed to room temperature overnight. The reaction was quenched with sat.
NH4C1, and
diluted with Et0Ac (20 mL). The layers were separated, and the aqueous layer
was extracted
with Et0Ac (3 x 20 mL). The combined organic layers were washed with brine,
dried over
Na2SO4, and concentrated in vacuo. The resulting oil was purified using an
ISCO
chromatography system, eluting with 5-50% EA/hexanes. The desired fractions
were
concentrated in vacuo to afford 2-(4-bromophenyl) 1,1,1-trifluoropropan-2-ol 1-
2 as a colorless
oil. LRMS (ESI) calc'd for C9H9BrF30 [M+H]': 269, found 269. 1H NMR (500 MHz,
CDC13):
6 7.52 (d, J = 7.0 Hz, 2H), 7.45 (d, J = 7.5 Hz, 2H), 1.78 (s, 3H).
44
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Resolution of enantiomers was achieved by SFC purification using a Chiral
Technology AZ-H 2.1 X 25cm, 5uM column, at 70 mL/min with 5%/95%
(methanol/CO2)
solvent system. Retention times were 2.55 minutes (Intermediate I-2A) & 3.19
minutes
(Intermediate I-2B).
I-2A (S or R)- 2-(4-bromopheny1)-1,1,1-trifluoropropan-2-ol. LRMS (ESI) calc'd
for
C9H9BrF30 [M+H] ': 270, found 270.
I-2B (S or R)- 2-(4-bromopheny1)-1,1,1-trifluoropropan-2-ol. LRMS (ESI) calc'd
for
C9H9BrF30 [M+H] ': 270, found 270.
Intermediate I-3A and I-3B
5-br omo-1-(tr ifluor omethyl)-2,3-dihydr o-1H -inden -1-ol
Br
Oil
HO CF3 1_3
To 5-bromo-2,3-dihydro-1H-inden-1-one (500 mg, 2.37 mmol) in tetrahydrofuran
(2.39 mL) under an atmosphere of N2 at 0 C was added
(trifluoromethyl)trimethylsilane (9.48
mL, 4.74 mmol), and tetrabutylammonium fluoride (2.37 mL, 2.37 mmol). The
reaction was
stirred at 0 C for 1 hour, and then warmed to room temperature overnight. The
reaction was
quenched with sat. NaHCO3, and diluted with Et0Ac (20 mL). The layers were
separated, and
the aqueous layer was extracted with Et0Ac (3 x 20 mL). The combined organic
layers were
washed with brine, dried over Na2504, and concentrated in vacuo. The resulting
oil was purified
using an ISCO chromatography system, eluting with 5-50% EA/hexanes. The
desired fractions
were concentrated in vacuo to afford 5-bromo-1-(trifluoromethyl)-2,3-dihydro-
1H-inden-1-ol, I-
3 as brown solid. LRMS (ESI) calc'd for C10H9BrF30 [M+H] ': 282, found 282. 1H
NMR (500
MHz, CDC13): 6 7.46 ¨ 7.43 (m, 2H), 7.37 ¨ 7.35 (d, J= 7.5 Hz, 1H), 3.16 ¨
3.12 (m, 1H), 3.10 ¨
3.03 (m, 1H), 2.70 ¨ 2.60 (m, 1H), 2.29 ¨ 2.21 (m, 1H).
Resolution of enantiomers was achieved by SFC purification using a Chiral
Technology AZ-H 2.1 X 25cm, 5uM column, at 70 mL/min with 15%/85%
(methanol/CO2)
solvent system. Retention times were 1.73 minutes (Intermediate I-3A) & 2.13
minutes
(Intermediate I-3B).
I-3A (S or R)- 5-bromo-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol. LRMS
(ESI) calc'd for
C10H9BrF30 [M+H]': 282, found 282.
I-3B (S or R)- 5-bromo-1-(trifluoromethyl)-2,3-dihydro-1H-inden-1-ol. LRMS
(ESI) calc'd for
C10H9BrF30 [M+H]': 282, found 282.
Following analogous methodology to that outlined for Intermediate 1-3 above,
the
following intermediates in Table 1 were synthesized.
45
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
Table 1.
Intermediate Structure Name NMR
5-Bromo-2,2- 1H NMR (CDC13, 500MHz): 6
1-4 F3C OH
dimethy1-1- 7.43 ¨ 7.41 (m, 2 H), 7.33
(d, J=
Se Me m e
(trifluoromethyl)-2,3- 8.11 Hz, 1H), 2.89 (d, J=
15.69
Br dihydro-1H-inden-1-ol Hz, 1H), 2.82 (d, J= 15.64 Hz,
1H), 1.27 (s, 3H), 1.16 (s, 3H).
5'-bromo-l'- 1H NMR (CDC13, 500MHz): 6
F3C OH (trifluoromethyl)-1',3'- 7.46 ¨ 7.38 (m, 2H), 7.35 (d, J=
1-5 10 lip 4 dihydrospiro[cyclopro 15.78 Hz, 1H), 3.33 (d, J=
16.20
Br pane-1,2'-inden]-1'-ol Hz, 1H), 2.66 (d, J=
16.20 Hz,
1H), 2.26 (br s, 1H), 1.08 ¨ 1.01
(m, 2H), 0.98 ¨ 0.88 (m, 2H).
2-(4-bromopheny1)- 1H NMR (CDC13, 500MHz): 6
F3C OH 1,1,1-trifluoro-3,3- 7.55 ¨ 7.47 (m, 4H),
1.04 (s, 9H).
i I& Me
1-6 dimethylbutan-2-ol
Br W Me Me
(R or S)-2-(4-
1H NMR (400 MHz, CDC13): 6
bromopheny1)-1,1,1-
OH 7.51-7.50 (d, J = 8.80 Hz, 2H),
trifluorobutan-2-ol
7.40 -7.38 (d, J = 8.80 Hz, 2 H),
I-7A 401 CF3 (Peak 1, Chiralpak,
Br
2.25 (s, 1 H), 2.21-2.14 (m, 1 H),
AD-H, 10% Me0H in
2.04 -1.98(m, 1 H), 0.77(t, J = 7.04
CO2, rT = 2.55
Hz, 3 H).
minutes)
(R or S)-2-(4-
bromopheny1)-1,1,1- 1H NMR (400 MHz, CDC13): 6
OH trifluorobutan-2-ol 7.51-7.50 (d, J = 8.80
Hz, 2H),
SFC retention time 7.40 -7.38 (d, J = 8.80 Hz,
2 H),
I-7B (110 CF3
(Peak 1, Chiralpak, 2.25 (s, 1 H), 2.21-2.14 (m,
1 H),
Br
AD-H, 10% Me0H in 2.04 -1.98(m, 1 H), 0.77(t, J = 7.04
CO2, rT = 2.86 Hz, 3 H).
minutes)
1-(4-bromopheny1)- 1H NMR (CDC13, 500MHz): 6
F3C OH
2,2,2-trifluoro-1- 8.59 (d, J = 4.89 Hz, 1H),
7.75 (td,
1-8 0 1N (pyridin-2-34)ethanol J= 7.77, 1.73 Hz, 1H),
7.52-7.44
Br (m, 5H), 7.37-7.35 (m, 1H), 7.00
(br s, 1H).
46
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
1-(4-bromopheny1)- 1H NMR (CDC13, 500MHz):
6
F3C OH
2,2,2-trifluoro-1- 8.45 (br s, 1H), 7.53-
7.38 (m, 6H),
1-9
0 /\ (pyridin-4-yl)ethanol 7.36-7.31 (m,
2H).
Br
-N
Intermediate I-10
1-(4-Br omo-2-methylpheny1)-2,2,2-tr iflu or oeth an ol
OH
110 CF3
Br I-10a
1-(4-Bromo-2-methylpheny1)-2,2,2-trifluoroethanone (2.00 g, 7.49 mmol) was
dissolved in THF (7.0 mL) and treated with sodium borohydride (0.312 g, 8.24
mmol) at 0 C.
The ice bath was removed and the reaction was warmed to room temperature and
stirred
overnight. The reaction was then diluted with dichloromethane and washed with
water and brine.
The organic layer was dried over sodium sulfate, filtered, concentrated in
vacuo and the residue
oil was purified by silica chromatography, eluting with 5-30% to give 1-(4-
bromo-2-
methylpheny1)-2,2,2-trifluoroethanol I-10a. 1H NMR (600 MHz, CDC13) 6 7.48 (d,
1H, J = 7.8
Hz), 7.42 (dd, 1H, J= 1.2, 8.4 Hz), 7.37 (br s, 1H), 5.27 (m, 1H), 2.61 (d,
1H, J = 4.2 Hz), 2.36
(s, 3H).
Intermediate I-11
5-br omo-2,3-dihydr ob enzo [b lthiophene 1,1-dioxide
Br sS
02 1-11
To a solution of 5-bromo-benzo[b]thiophene 1,1-dioxide (1.0 g, 4.08 mmol) in
ethanol (13.6 mL) at 0 C, sodium borohydride (965 mg, 20.2 mmol) was added.
The reaction
mixture was warmed to room temperature, and stirred overnight. The solution
was cooled to
0 C, quenched with 1N HC1 (15 mL), and diluted with ethyl acetate (25 mL), the
layers were
separated, and the aqeous layer was extracted with ethyl acetate (3 x 25 mL).
The combined
organic layers were washed with brine, dried over Na2SO4, and concentrated in
vacuo. The
crude oil was purified using an ISCO chroImatography system eluting with
Hexanes/Et0Ac (5:1)
to give 5-bromo-2,3-dihydrobenzo[b]thiophene 1,1-dioxide, I-11. 1H NMR (500
MHz, CDC13):
6 7.62 ¨ 7.53 (m, 2 H), 7.51 (s, 1 H), 3.55 ¨ 3.45 (m, 2 H), 3.39 ¨ 3.29 (m, 2
H).
47
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-12
5-br omo-2-(tert-butyl)-2,3-dihydr ob en zo [d] isothiazole 1,1-dioxide
Br 40 Me
,N*Me
S Me
02 I-12
Step 1: 4-bromo-2-methylbenzene-1-sulfonyl chloride
Br 40 Me
S02CI I-12a
Chlorosulfonic acid (63 g, 0.54 mol) was added slowly to a cold solution (0 C)
of
1-bromo-3-methylbenzene (10.0 g, 58 mmol) in CHC13 (100 mL). The reaction was
allowed to
proceed with stirring for 2 hours at 0 C, then reaction mixture was poured
into ice water and
extracted with Et0Ac, and the organic layer was washed with brine, dried over
Na2SO4, filtered
and concentrated in vacuo to afford compound I-12a. 1H NMR (400 MHz, CDC13) 6
7.90 (d, J =
8.4 Hz, 1H), 7.59-7.53 (m, 2H), 2.75 (s, 3H).
Step 2: 4-bromo-N-(tert-butyl)-2-methylbenzenesulfonamide
Br 0 Me
H
N Me
S- )hA
<
2 Me ¨e I-12b
To a solution of 4-bromo-2-methylbenzene-l-sulfonyl chloride, I-12a, (2.0 g,
7.4
mmol) in CH2C12 (15 mL) was added a solution of 2-methylpropan-2-amine (0.65
g, 8.9 mmol)
and triethylamine (0.90 g, 8.9 mmol) in CH2C12 (30 mL) at 0 C. The reaction
mixture was
stirred at 0 C for 2 hours, and then at room temperature for 16 hours. The
mixture was washed
with 0.1 M HC1, saturated aqueous NaHCO3, dried over Na2504, filtered and the
filtrate was
concentrated in vacuo. After removal of the solvent under reduced pressure, I-
12b was obtained.
1H NMR (400 MHz, CDC13) 6 7.78 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H),
7.59-7.56 (m,
2H), 2.57 (s, 3H), 1.09(s, 9H).
Step 3: 5-bromo-2-(tert-butyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide
0
Br is Me
,N*Me
S Me
02 I-12c
A mixture of H5I06 (5.9 g, 26 mmol) in acetonitrile (50 mL) was stirred at
room
temperature for 1 hour, then Cr03 (33 mg, 0.33 mmol) was added followed by
acetic anhydride
(2.67 g, 26 mmol). The resulting orange solution was cooled to 0 C, and to it
was added 4-
bromo-N-(tert-buty1)-2-methyl benzenesulfonamide, I-10b, (1.0 g, 3.3 mmol).
After stirring at
48
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
0 C for 15 minutes, the reaction was allowed to warm to room temperature and
was stirred for
16 hours. The solvent was removed in vacuo, and the residue was extracted with
Et0Ac (3x),
the combined organic layers were washed with saturated aqueous NaHCO3, brine,
dried over
Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was
purified by silica
chromatography, eluting with 5% Et0Ac in hexanes and the desired fractions
were concentrated
in vacuo to afford I-12c as a white solid. 1H NMR (400 MHz, CDC13): 6 8.82-
8.14 (m, 3H),
1.66 (s, 9H).
Step 4: 5-bromo-2-(tert-buty1)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
To a solution of I-12c (0.20 g, 0.63 mmol) in THF (4 mL) was added BH3=Me2S
(240 mg, 3.16 mmol). The reaction mixture was refluxed for 16 hours. After
being cooled to
room temperature, the reaction was quenched with 2 M HC1, and extracted with
Et0Ac (2x), the
combined extracts were wash with brine, dried over Na2SO4, filtered, and the
filtrate was
concentrated in vacuo. The residue was purified by preparative TLC to afford 1-
12. 1H NMR
(400 MHz, CDC13) 6 7.83-7.56 (m, 3H), 4.55 (s, 2H), 1.46 (s, 9H).
Following analogous methodology to that outlined for Intermediate 1-12 above,
the following intermediate in Table 2 was synthesized.
49
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Table 1.
Intermediate Structure Name NMR
5-bromo-2-methyl-2,3- 1H NMR (400 MHz,
Br 0
N¨Me dihydrobenzo[d]isothiazole CDC13): 6 7.63-7.60 (m,
I-13 s'
1,1-dioxide 2H), 7.5 (s, 1H),
4.25 (s,
02
2H), 2.89 (s, 3H).
Intermediate 1-14
1-br omo-4-(tert-butylsulfonyl)b en zene
Br
. Me..
)<me
S Me
02 1-14
To a solution of (4-bromophenyl)(tert-butyl)sulfane (1.00 g, 4.08 mmol) in DCM
(10.0 mL) was added m-CPBA (2.01 g, 8.97 mmol, 77 wt.%) at room temperature.
The resulting
solution was stirred at room temperature for one hour, and then quenched with
saturated aqueous
Na2S203 and saturated aqueous Na2CO3. The reaction was extracted with DCM
(3x), dried over
Na2SO4, filtered and concentrated in vacuo to afford 1-14. 1H NMR (600 MHz,
CDC13): 6 7.89
(d, J = 8.7 Hz, 2H), 7.75 (d, J = 8.7 Hz, 2H), 1.24 (s, 9H).
Intermediate 15A and 15B
1-(4-br omopheny1)-2,2,2-tr iflu or oethanamine
Br
1.1
F3C NH2 1-15
To a solution of 1-(4-bromopheny1)-2,2,2-trifluoroethanone (1.00 g, 3.95 mmol)
in toluene (14 mL) at room temperature, was added (dropwise) a solution of
lithium
bis(trimethylsilyl)amide (4.35 mL, 4.35 mmol, 1M in THF). The reaction was
stirred at room
temperature for 15 minutes and then BH3=THF (7.90 mL, 7.90 mmol, 1M in THF)
was added.
The reaction was stirred at room temperature for 20 minutes, then quenched at
0 C by slow
addition of 2M aqueous NaOH (5.93 mL, 11.9 mmol). The mixture was stirred at
room
temperature for 90 minutes, then the organic layer was separated and washed
with 1N aqueous
NaOH solution, dried over Na2SO4, filtered and concentrated in vacuo . SFC
separation of the
enantiomers on the crude reaction mixture was achieved using a ChiralPak AZ-H,
with 7%
methanol modifier in CO2: retention times = 2.37 (I-15A) & 2.89 (I-15B)
minutes. LRMS (ESI)
50
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
calc'd for C8H8NBrF3 [M+H] ': 255, found 255. 1H NMR (600 MHz, CDC13): 6 7.53
(d, J= 8.5
Hz, 2H), 7.32 (d, J= 8.5 Hz, 2H), 4.38 (q, J= 7.5 Hz, 1H), 1.78 (br s, 2H).
Intermediate 16
4-br omo-N-isopr opylbenzenesulfonamide
Br
101 1
-S m)\
0-
0H I-16
To a solution of propan-2-amine (160 mg, 2.6 mmol) and DIPEA (780 mg, 6.0
mmol) in CH2C12 (7 mL) was added a solution of 4-bromobenzene-1-sulfonyl
chloride (510 mg,
2.0 mmol) in CH2C12 (14 mL). The resulting reaction mixture was stirred at rt
overnight, then
was poured into water (20 mL), and extracted with CH2C12 (3 x 15 m1). The
combined organic
layers were concentrated in vacuo to afford a residue that was purified by
column
chromatography on silica (pet ether/Et0Ac: 20/1) to give 4-bromo-N-
isopropylbenzenesulfonamide. 1H NMR (400 MHz, CDC13): 6 7.75 ¨ 7.72 (m, 2 H),
7.65 ¨ 7.62
(m, 2 H), 4.43 (d, J= 7.52 Hz, 1 H), 3.49 ¨ 3.44 (m, 1 H), 1.08 (d, J= 6.4 Hz,
6 H).
Table 3 discloses intermediates that were prepared in an analogous manner to
that of
Intermediate 16.
Table 3.
Intermediate Structure Compound Name NMR/ MS
F F (R or S)-1-((4- LRMS (ESI)
F
bromophenyl )sulfony1)-3- calc'd for
I-17A 0 m
%,.14--- (trifluoromethyl) pyrrolidine SFC
C11H12BrF3NO2S
0\\ retention time (Chiralpak , IF, 20%
[M+H]+: 359,
Br Me0H in CO2) = 1.91 minutes. found 359
F F F (R or S)-1-((4-bromophenyl) LRMS (ESI)
sulfony1)-3-(trifluoromethyl) calc'd for
I-17B0
µµS'N pyrrolidine SFC retention time C 1
iHi2BrF3NO2S
0\\ (Chiralpak , IF, 20% Me0H in [M+H]+:
359,
Br CO2) = 2.23 minutes. found 359
(R or S)-1-((4- LRMS (ESI)
I-18A
gµs'i\ri bromophenyl )sulfony1)-2- calc'd for
lel b F (trifluoromethyl) pyrrolidine SFC
C11H12BrF3NO2S
F
B Fr
retention time (Chiralpak , IF, 15% [M+H]+: 359,
51
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
isopropanol in CO2) = 1.88 found 359
minutes.
(R or S)-1-((4-
LRMS (ESI)
bromophenyl)sulfony1)-2-
0 m calc' d for
\\s'¨ (trifluoromethyl)pyrrolidine
I-18B C11H12BrF3NO2S
1101 \\CI F SFC retention time (Chiralpak , IF,
F F [M+H]+: 359,
Br
15% isopropanol in CO2) = 2.21
found 359
minutes.
(R or S)-1-((4-
LRMS (ESI)
.... bromophenyl)sulfony1)-2-
0 calc' d for
4-?
\\
S methylpyrrolidine
I-19A 0 b SFC retention time (Chiralpak , Ci iHisBrNO2S
[M+H]+: 305,
Br
AD-H, 15% Me0H in CO2) = 3.03
found 305
minutes.
(R or S)-1-((4-bromophenyl) LRMS (ESI)
CZ\ ,N sulfony1)-2-methylpyrrolidine SFC calc'd for
S
I-19B 0 b retention time (Chiralpak , AD-H, C11H15BrNO2S
Br 15% Me0H in CO2) = 4.40 [M+H]+: 305,
minutes. found 305
(R or S)-4-((4-bromophenyl) LRMS (ESI)
r0µµ N ] o su1fony1)-3-methy1morpho1ine calc' d
for
I-20A I. Sµ\0' SFC retention time (Chiralpak , C11H15BrNO3S
AZ-H, 15% Me0H in CO2) = 3.29 [M+H]+: 321,
Br
minutes. found 321
(R or S)-4-((4-bromophenyl) LRMS (ESI)
r0µµ N ] o su1fony1)-3-methy1morpho1ine calc' d
for
S'
I-20B =µb SFC retention time (Chiralpak , C11H15BrNO3S
AZ-H, 15% Me0H in CO2) = 5.52 [M+H]+: 321,
Br
minutes. found 321
(R or S)-1-((4-bromophenyl) LRMS (ESI)
R <OH sulfony1)-3-(trifluoromethyl) calc' d for
`s-N C F3
I-21A 0 b pyrrolidin-3-ol SFC retention time
C11H12BrF3NO3S
Br (Chiralpak , AZ-H, 15% Me0H in [M+H]+: 375,
CO2) = 2.01 minutes. found 375
R O<OH (R or S)-1-((4- LRMS (ESI)
µs- C F3
bromophenyl)sulfony1)-3- calc' d for
leiI-21B µµ() (trifluoromethyl)pyrrolidin-3-ol
C11H12BrF3NO3S
Br
SFC retention time (Chiralpak , [M+H]+: 375,
52
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
AZ-H, 15% Me0H in CO2) = 4.02 found 375
minutes.
(4a R or S,7a R or S)-4-((4-
LRMS (ESI)
r0 bromophenyl)sulfonyl)octahydroc
0
m calc'd for
µµ õIN yclopenta[b][1,4]oxazine
I-22A S
lel 0
\\ '.6
SFC retention time (Chiralpak , C13H17BrNO3S
[M+H]+: 347,
Br AD-H, 25% Me0H in CO2) = 3.85
found 347
minutes.
(4a R or S,7a R or S)-4-((4-
LRMS (ESI)
r0 bromophenyl)sulfonyl)octahydroc
0
m calc'd for
µµ õIN yclopenta[b][1,4]oxazine
I-22B S
lel 0
\\ '.6
SFC retention time (Chiralpak , C13H17BrNO3S
[M+H]+: 347,
Br AD-H, 25% Me0H in CO2) = 4.98
found 347
minutes.
(R or S)-4-((4-bromophenyl) LRMS (ESI)
ro
C
N sulfony1)-2-methylmorpholine calc'd for Zµ .)
I-23A 0 Sµb- SFC retention time (Chiralpak , C11H15BrNO3S
AD-H, 20% Me0H in CO2) = 3.15 [M+H]+: 321,
Br
minutes. found 321
(R or S)-4-((4-bromophenyl) LRMS (ESI)
ro
C
N sulfony1)-2-methylmorpholine calc'd for Zµ .)
I-23B 0 Sµb- SFC retention time (Chiralpak , C11H15BrNO3S
AD-H, 20% Me0H in CO2) = 3.85 [M+H]+: 321,
Br
minutes. found 321
(R or S)-1-((4-bromophenyl) LRMS (ESI)
0\ N sulfony1)-2-methylazetidine SFC calc'd for
µS'
I-24A =b retention time (Chiralpak , AD-H, C10H13BrNO2S
Br 10% Me0H in CO2) = 3.92 [M+H]+: 291,
minutes. found 291
(R or S)-1-((4-bromophenyl) LRMS (ESI)
0 sulfony1)-2-methylazetidine SFC calc'd for
\\S'N
I-24B =b retention time (Chiralpak , AD-H, C10H13BrNO2S
Br 10% Me0H in CO2) = 4.54 [M+H]+: 291,
minutes. found 291
(Dµ LRMS (ESI)
s NO
1-((4-bromophenyl)sulfonyl) calc'd for
I-25
µ azetidine C9H11BrNO2S
Br [M+H]+: 277,
53
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
found 277
LRMS (ESI)
calc'd for
oµsi\o/
methylazetidine
144-bromophenyl)sulfony1)-3-
CioHnBrNO2S
01 )
µ
[M+H]+: 291,
I-26
Br
found 291
LRMS (ESI)
(:)
calc'd for
4((4-bromophenyl)sulfony1)-2,2-
0
I-27 \> Ci2Hi7BrNO3S
dimethylmorpholine
[M+H]+: 335,
Br
found 335
Br s LRMS (ESI)
calc'd for
1-28 - -
4 ((4 bromophenyl)sulfony1)-3,3-
C12H17BrNO3S
dimethylmorpholine
[M+H]+: 335,
..,...,.......õ,0
found 335
LRMS (ESI)
HL0 calc'd for
o (cis)-444-((4-
I-29 µs"1 C12H17BrNO3S
0 N 2,6-dimethylmorpholine
[M+H]+: 335,
Br
found 335
LRMS (ESI)
_
_
ro (trans)-4-((4- calc'd for
1-30 C"'s-N/c bromophenyl)sulfony1)-2,6- C12H17BrNO3S
lei b dimethylmorpholine [M+H]+: 335,
Br
found 335
LRMS (ESI)
calc'd for
czµs,9 144-bromophenyl)sulfony1)-2,2-
I-31 0 b dimethylpyrrolidine Ci2Hi7BrNO2S
Br [M+H]+: 319,
found 319
LRMS (ESI)
0 1
--\\ N calc'd for
is µ0 4-bromo-N-isopropyl-N-
I-32 C10H15BrNO2S
methylbenzenesulfonamide
Br [M+H]+: 293,
found 293
54
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
LRMS (ESI)
RNI calc' d for
\ ", ---
s' 4-bromo-N-ethyl-N-
I-33 110 \\O C9HoBrNO2S
methylbenzenesulfonamide
Br [M+H]+: 279,
found 279
LRMS (ESI)
n calc' d for
I-34 = \O
--\\S\'N 144-
bromophenyl)sulfonyl)piperidine Ci 1 HisBrNO2S
[M+H]+: 305,
Br
found 305
LRMS (ESI)
(:)µµ 0calc' d for
S' 1-((4-
C10H13BrNO2S
1-35 0 b bromophenyl)sulfonyl)pyrrolidine
Br [M+H]+: 291,
found 291
LRMS (ESI)
calc' d for
0 r
--\\ N
4-bromo-N,N-
1-36
01 b diethylbenzenesulfonamide C10H15BrNO2S
[M+H]+: 293,
Br
found 293
LRMS (ESI)
p Ai calc' d for
Br
1((4-bromophenyl)sulfony1)-3,3-
I-37 W Si,N/ CoHi9BrNO2S
// dimethylpiperidine
[M+H]+: 333,
found 333
LRMS (ESI)
calc' d for
IR\ N 144-bromophenyl)sulfony1)-3,3-
1-38 S' C12H17BrNO2S
. b dimethylpyrrolidine
[M+H]+: 319,
Br
found 319
LRMS (ESI)
Br
calc' d for
P \ / 144-bromophenyl)sulfony1)-2,2-
I-39 Wi ,SI,N CoHi9BrNO2S
.
01 dimethylpiperidine
[M+H]+: 333,
found 333
o 1
R o'l tert-butyl 1-((4- LRMS (ESI)
µs-10)
bromophenyl)sulfonyl)piperidine- calc' d for
1-40
0 Br b 4-carboxylate C16i23BrNO4S
55
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
[M+H]+: 405,
found 405
LRMS (ESI)
9` -NIN)
OS
b E (R) (R)-tert-butyl 1-((4- calc' d for
1-41 Br ce,0
bromophenyl)sulfonyl)pyrrolidine- C15H21BrNO4S
2-carboxylate [M+H]+: 391,
found 413
LRMS (ESI)
µµ NIDL 144-bromophenyl)sulfony1)-3,3- calc' d for
1-42 S'
`b dimethylazetidine CliHisBrNO2S
40
[M+H]+: 305,
Br
found 306
LRMS (ESI)
calc' d for
oµki\R----- 144-bromophenyl)sulfony1)-2,2-
1-43 01 b C11H15BrNO2S
dimethylazetidine
Br [M+H]+: 305,
found 306
LRMS (ESI)
R NrjOH
µS'calc' d for
1-44 0 \\O 144-bromophenyl)sulfony1)-3-
C10H13BrNO3S
methylazetidin-3-ol
Br [M+H]+: 307,
found 308
LRMS (ESI)
,OH
0 / j calc' d for
µ
µS-N1 1-((4-bromophenyl)sulfonyl)
1-45
=b" azetidin-3-ol
C9H11BrNO3S
Br [M+H]+: 294,
found 294
LRMS (ESI)
R ii calc' d for
µS'N 144-bromophenyl)sulfony1)-3-
1-46 0 b methoxyazetidine C10H13BrNO3S
Br [M+H]+: 307,
found 308
LRMS (ESI)
,
R / j calc' d for
µ'N F 1-((4-bromophenyl)sulfonyl)
1-47
0 "SµC) azetidin-3-ol C9HioBrFNO2S
Br [M+H]+: 295,
found 295
56
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-48
(S)-(4-Br omo-2-methylphenyl)(2-methylpiper idin -1-yl)meth an one
Br
I.
0 N
1-48
Step 1: 4-bromo-2-methylbenzoyl chloride
Br
401
0 CI I-48a
4-Bromo-2-methylbenzoic acid (1.40 g, 6.50 mmol) was dissolved in thionyl
chloride (20 mL). The mixture was heated at 80 C for 2 hours and then
concentrated in vacuo to
afford 1.35 g of crude title acid chloride as a yellow solid.
57
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 2: (S)-(4-bromo-2-methylphenyl)(2-methylpiperidin-1-y1)methadone
Br
1101
0 N
.,". 1-48
A 50 mL round-bottom flask was charged with triethylamine (1.43 g, 14.22 mmol)
and (S)-2-methylpiperidine (0.52 g, 5.21 mmol) in DCM (20 mL). The resulting
solution was
cooled in an ice bath. A solution of 4-bromo-2-methylbenzoyl chloride (1.10 g,
4.74 mmol) in
DCM (20 mL) was added dropwise at 0-4 C. The cooling bath was removed and the
reaction
stirred at ambient temperature for 2 hours at which time water (10 mL) was
added. The queched
reactiuon was extracted with Et0Ac (2 x 30 mL), and combined organic layers
washed with
brine (2 x 20 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was
concentrated in
vacuo and the resulted residue purified by silica gel column chromatography
eluting with
Et0Ac/petroleum ether (1/8) to afford the title amide. LCMS (ESI) calc'd for
C141-118BrNO [M +
H] ': 296, 298 (1:1), found 296, 298 (1:1); 1FINMR (300 MHz, DMSO-d6) 6 7.51-
7.41 (m, 2H),
7.12-7.02 (m, 1H), 4.85-4.35 (m, 1H), 3.71-3.45 (m, 0.5H), 3.07-3.04 (m, 1H),
2.90-2.71 (m,
0.5H), 2.23-2.14 (m, 3H), 1.66-1.45 (m, 4H), 1.17-0.95 (m, 5H).
Table 4 discloses intermediates that were prepared in an analogous manner to
that for (S)-(4-
bromo-2-methylphenyl)(2-methylpiperidin-1-y1)methadone 1-48 using appropriate
bromobenzoic acids and amines.
Table 4.
Intermediate Structure Name 1H NMR / MS
(R)-(4-bromo-2- 1H NMR (600 MHz,
0 methylphenyl)(2- CDC13) 6 7.77 (d, 1H, J =
1-49 la N methylpiperidin-1- 8.4 Hz), 7.48 (s,
1H), 7.44
yl)methanone (dd, 1H, J = 8.4,
1.8 Hz),
Br Me
3.29 (m, 4H), 2.61 (s, 3H),
1.90 (m, 4H).
(4-bromo-2- LRMS (ESI) calc'd
for
1-50 0 methylphenyl)(2- Ci4Hi7BrNO [M +
H]+:
40 NI azaspiro[3.3]heptan-2- 296, 298
(1:1), found 296,
%
yl)methanone 298 (1:1).
Br
1H NMR (400 MHz,
CDC13) 6 7.42 (d, J= 1.2
Hz, 1H), 7.42-7.34 (m, 1H),
58
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
7.12 (d, J = 8.4 Hz, 1H),
4.87-4.77 (m, 4H), 4.34 (s,
2H), 4.09 (s, 2H), 2.39 (d, J
= 7.6 Hz, 3H).
Intermediate 1-51
tert-butyl 2-(4-bromo-N-methylphenylsulfonamido)-2-methylpropanoate
Br
40 Me 0
IV
IS )L0tBu
01 \OMe Me 1-51
Step 1: tert-butyl 2-(4-bromophenylsulfonamido)-2-methylpropanoate
Br isH C)ii
ISNOtBu
0/ µ0 Me Me I-51a
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with 4-bromobenzene-1-sulfonyl chloride (1 g, 4 mmol), DCM (9
mL), and
triethylamine (1.3 mL, 9.4 mmol). The solution was cooled to 0 C, and tert-
butyl 2-amino-2-
methylpropanoate (0.5 g, 3.1 mmol) was added. The reaction mixture stirred and
warmed to rt
overnight. The reaction was quenched with sat. NH4C1 and diluted with DCM (50
mL). The
organic layer was washed with brine (20 mL), dried over Na2SO4, filtered
through celite, and
concentrated in vacuo . The crude tert-butyl 2-(4-bromophenylsulfonamido)-2-
methylpropanoate
I-51a was of sufficient purity to carry on to the next step. 1H NMR (CDC13,
500MHz): 6 7.75 ¨
7.73 (m, 2H), 7.62 ¨ 7.60 (m, 2H), 5.40 (bs, 1H), 1.44 (s, 9H), 1.40 (s, 6H).
59
CA 02901770 2015-08-19
W02014/146493
PCT/CN2014/000299
Step 2: tert-butyl 2-(4-bromo-N-methylphenylsulfonamido)-2-methylpropanoate
Br isMe 0
,SNOtBu
0' bMe Me 1-51
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with tert-butyl 2-(4-bromophenylsulfonamido)-2-methylpropanoate
I-51a (815
mg, 2.2 mmol), and DMF (6.5 mL). The solution was cooled to 0 C, and sodium
hydride (129
mg, 3.2 mmol) was added. The reaction mixture was stirred for 30 min followed
by the addition
of methyl iodide (0.4 mL, 6.5 mmol). The reaction was warmed to rt over 1-2 h.
The quenched
with sat. NH4C1 (20 mL) and diluted with Et20 (50 mL). The organic layer was
washed with
brine (20 mL), dried over Na2SO4, filtered through celite, and concentrated in
vacuo . The crude
tert-butyl 2-(4-bromo-N-methylphenylsulfonamido)-2-methylpropanoate 1-51 was
purified by
column chromatography on silica gel (hexanes/Et0Ac gradient). 1H NMR (CDC13,
500MHz): 6
7.87 ¨ 7.85 (m, 2H), 7.64 ¨ 7.62 (m, 2H), 2.72 (s, 3H), 1.48 (s, 15H).
Intermediate 1-52
ethyl 2-(4-bromo-N-methylphenylsulfonamido)-2-methylpropanoate
Br
Me 0
S-0Et
0 OMe Me 1-52
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with 4-bromobenzene-1-sulfonyl chloride (1.1 g, 4.3 mmol), DCM
(9 mL), and
triethylamine (1.4 mL, 10.3 mmol). The solution was cooled to 0 C, and ethyl 2-
methy1-2-
(methylamino)propanoate (0.5 g, 3.4 mmol) was added. The reaction mixture
stirred and
warmed to rt overnight. The reaction was quenched with sat. NH4C1 and diluted
with DCM (50
mL). The organic layer was washed with brine (20 mL), dried over Na2SO4,
filtered through
celite, and concentrated in vacuo. The residue was purified by column
chromatography on silica
gel (hexanes/Et0Ac gradient) to yield ethyl 2-(4-bromo-N-
methylphenylsulfonamido)-2-
methylpropanoate 1-52. 1H NMR (CDC13, 500MHz): 6 7.86 (d, J = 8.20 Hz, 2H),
7.64 (d, J =
8.15 Hz, 2H), 4.25 (q, J = 7.07 Hz, 2H), 2.72 (s, 3H), 1.58 (s, 6H), 1.30 ¨
1.26 (m, 3H).
60
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-53
tert-butyl 2-(5-bromo-1-oxoisoindolin-2-y1)-2-methylpropanoate
Br Me
lel N*Me
irOtBu
00 1-53
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with methyl 4-bromo-2-(bromomethyl)benzoate (1 g, 3.3 mmol),
tBuOH (15.5
mL), triethylamine (0.7 mL, 4.9 mmol), and tert-butyl 2-amino-2-
methylpropanoate (775 mg, 4.9
mmol). The solution was heated to reflux for 24 h. The reaction mixture was
concentrated in
vacuo, and the residue was purified by column chromatography on silica gel
(hexanes/Et0Ac
gradient) to yield tert-butyl 2-(5-bromo-1-oxoisoindolin-2-y1)-2-
methylpropanoate 1-53. 1H
NMR (CDC13, 500MHz): 6 7.68 (d, J= 7.95 Hz, 1H), 7.59 - 7.57 (m, 2H), 4.46 (s,
2H), 1.63 (s,
6H), 1.45 (s, 9H).
Intermediate 1-54
tert-butyl 4-(5-br omo-1-oxoisoindolin-2-yl)cyclohexanecarboxylate
0
lel N-04
Br OtBu 1_54
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with methyl 4-bromo-2-(bromomethyl)benzoate (500 mg, 1.6 mmol),
THF (4.8
mL), triethylamine (0.6 mL, 4.1 mmol), and tert-butyl 4-
aminocyclohexanecarboxylate (647 mg,
3.3 mmol). The reaction mixture was heated to reflux for 12 - 16 h, and was
concentrated in
vacuo. The crude oil was purified by column chromatography on silica gel
eluting with
Hexanes/Et0Ac gradient to yield tert-butyl 4-(5-bromo-1-oxoisoindolin-2-
yl)cyclohexanecarboxylate 1-54. 1H NMR (500 MHz, CDC13): 6 7.70 (d, J = 7.92
Hz, 1H), 7.62
- 7.58 (m, 2H), 4.33 - 4.29 (m, 2H), 4.24 (m, 1H), 2.60 (m, 1H), 1.74 - 1.66
(m, 3H), 1.60 -
1.52 (m, 5H).
1-Br omo-4-((1-methylcyclopr op yl)sulfonyl)benzene
0=S 411 Br
8 1-55
To 1-bromo-4-(cyclopropanesulfonyl)benzene (100 mg, 0.383 mmol) in THF (1.5
mL) at -78 C, was added TMEDA (69.4 L, 0.460 mmol) followed by BuLi (239 L,
0.383
61
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
mmol) and the reaction was stirred at this temperature for 45 minutes, then
iodomethane (239 1,
3.83 mmol) was added and the reaction was stirred to room temperature
overnight. The reaction
was concentrated and purified by loading onto silica directly and eluting with
5-40%
Et0Ac/hexanes afforded 1-Bromo-441-methylcyclopropyl)sulfonyl)benzene. 1H NMR
(600
MHz, CDC13) 6 7.74 (d, 2H, J= 8.4 Hz), 7.71 (d, 2H, J= 8.4 Hz), 1.60 (m, 2H),
1.35 (s, 3H),
0.84 (m, 2H).
Intermediate 1-56
4-Br omo-N,N,2-tr imethylb en zen esulfon amide
N
0= = Br
ii
0
1-56
To a stirred solution of 4-bromo-2-methylbenzene-l-sulfonyl chloride (0.300 g,
1.11 mmol) in DCM (2.0 mL) was added TEA (0.310 mL, 2.23 mmol) followed by
dimethylamine (1.11 ml, 2.23 mmol, 2M in THF). The resulting solution was
stirred at room
temperature for 3 hours, then the reaction was concentrated in vacuo and the
reaction was loaded
directly onto silica, and purified by column chromatography on silica gel
eluting with 5-40%
Et0Ac/Hexanes. 1H NMR (600 MHz, CDC13) 6 7.74 (d, 1H, J = 7.8 Hz), 7.49 (s,
1H), 7.46 (dm,
1H, J= 8.4 Hz), 2.79 (s, 6H), 2.60 (s, 3H).
Intermediate 1-57
1-(4-Br omopheny1)-5 ,5-dimethy1-2-oxab icyclo [2.2.2] octan-3-one
0---=_- 0 410,
Br
1-57
To 1-bromo-4-iodobenzene (600 mg, 2.12 mmol) in THF (7.1 mL) at -78 C was
added (dropwise) n-BuLi (1.46 mL, 2.33 mmol, 1.60 M in hexanes) and the
reaction was stirred
at -78 C for 2 hours before a solution of methyl 2,2-dimethy1-4-
oxocyclohexanecarboxylate (430
mg, 2.33 mmol) in THF (1.5 mL) was added dropwise and the reaction was stirred
to room
temperature overnight. The reaction was then quenched by pouring into a
separatory funnel
containing water and was extracted with ethyl acetate (3 x50 mL). The organic
layers were
combined and dried over Na2SO4, filtered, and concentrated in vacuo. The crude
product was
then purified by silica chromatography, eluting with 0-50% Et0Ac/hexane. The
product was
collected and concentrated to afford the desired product. LRMS (ESI) calc'd
for Ci5Hi8BrO2
[M+H] ': 309, found 309.
62
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-58
N-(1-(4-Br om op h eny1)-2,2,2-tr ifluor oethyl)-2-methylpr op an-2-amine
HN
0 CF3
Br 1-58
Step 1: 1-(4-Bromopheny1)-2,2,2-trifluoroethanol
OH
0 CF3
Br I-58a
1-(4-Bromopheny1)-2,2,2-trifluoroethanone (1.73 g, 6.84 mmol) was dissolved in
THF (3.4 mL) and treated with sodium borohydride (0.285 g, 7.52 mmol) at 0 C.
The reaction
was then warmed to room temperature and stirred overnight. The reaction
mixture was then
diluted with DCM and washed with water and brine. The combined organic layers
were dried
over Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue
was purified by
silica chromatography, eluting with 5-30% Et0Ac in hexanes and the desired
fractions were
concentrated in vacuo to afford 1-(4-Bromopheny1)-2,2,2-trifluoroethanol. 1H
NMR (500 MHz,
CDC13) 6 7.56 (d, J= 8.5 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 5.06-4.96 (m, 1H),
2.63 (d, J = 4.5
Hz, 1H).
Step 2: 1-(4-Bromopheny1)-2,2,2-trifluoroethyl trifluoromethanesulfonate
Tf0
40 CF3
Br I-58b
A solution of 1-(4-bromopheny1)-2,2,2-trifluoroethanol (1.5 g, 5.9 mmol) and
2,6-
lutidine (1.10 mL, 9.41 mmol) in DCE (12 mL) was cooled to -15 C and triflic
anhydride (8.82
mL, 8.82 mmol, 1.0 M DCM) was added dropwise. The reaction stirred between -15
C and rt
for 1 hr. The reaction mixture was diluted with DCM and washed with water, HC1
(1 N), and
brine. The combined organic layers were dried over Na2504, filtered, and the
filtrate was
concentrated in vacuo to give 1-(4-Bromopheny1)-2,2,2-trifluoroethyl
trifluoromethanesulfonate.
1H NMR (500 MHz, CDC13) 6 7.64 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.3 Hz, 2H),
5.85-5.74 (m,
1H).
Step 3: N-(1-(4-Bromopheny1)-2,2,2-trifluoroethyl)-2-methylpropan-2-amine
1-(4-Bromopheny1)-2,2,2-trifluoroethyl trifluoromethanesulfonate (7.59 g, 19.6
mmol) was dissolved in cyclohexane (70 mL) and 2-methylpropan-2-amine (6.23
mL, 58.8
63
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
mmol), DMAP (0.240 g, 1.96 mmol), and ground, dried potassium carbonate (5.42
g, 39.2 mmol)
(dried over vacuum at 60 C for one hour) was added. The reaction mixture was
heated to 75 C
and stirred for 48 hours. The reaction mixture was diluted with DCM and washed
with water.
The combined organic layers were dried over Na2SO4, filtered, and the filtrate
was concentrated
in vacuo. The residue was purified by silica chromatography, eluting with 2-
20% Et0Ac in
hexanes and the desired fractions were concentrated in vacuo to afford N-(1-(4-
Bromopheny1)-
2,2,2-trifluoroethyl)-2-methylpropan-2-amine. LRMS (ESI) calc'd for
Ci2H16BrF3N [M+H]':
310, found 310.
Following analogous methodology to that outlined for Intermediate 1-58 above,
the following intermediates in Table 5 were synthesized. In select cases, the
general procedure
was modified by not using DMAP and/or the crude product was used as is, and/or
to
alternatively utilize 2.0-3.0 equivalents of amine and/or 1.5-3.0 equivalents
of ground, dried
potassium carbonate.
Table 5.
Intermediate Structure Name LCMS
N) 1-(1-(4-bromopheny1)- LRMS (ESI) calc'd
for
2,2,2-trifluoroethyl) C12H14BrF3N
[M+H]+:
1-59
0 CF3 pyrrolidine 308, found 308
Br
HN N-(1-(4-bromopheny1)- LRMS (ESI) calc'd
for
CF3 0
1-60 2,2,2-trifluoroethyl) C11H14BrF3N
[M+H]+:
Br propan-2-amine 296, found 296
N 1-(1-(4-bromopheny1)- LRMS (ESI) calc'd
for
1-61
40 CF3 2'2'2-trifluoroethyl) C11H12BrF3N
[M+H]+:
azetidine 294, found 294
Br
HN 1-(4-bromopheny1)-N- LRMS (ESI) calc'd
for
1-62 40 CF3 ethyl-2,2,2- C10H12BrF3N
[M+H]+:
Br trifluoroethanamine 282, found 282
N Nr 1-(4-bromo-2- LRMS (ESI) calc'd
for
methylpheny1)-2,2,2- C11H14BrF3N
[M+H]+:
1-63 = CF3 trifluoro-N,N- 296, found 296.
Br dimethylethanamine
64
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
1-(1-(4-bromo-2- 1H NMR (600 MHz,
) methylpheny1)-2,2,2- CDC13) 6 7.77
(d, 1H, J =
1-64 N trifluoroethyl)pyrrolidine 8.4 Hz),
7.48 (s, 1H), 7.44
40 CF3 (dd, 1H, J= 8.4,
1.8 Hz),
Br 3.29 (m, 4H), 2.61
(s, 3H),
1.90 (m, 4H).
Intermediate 1-65
Ethyl 3-(4-br omopheny1)-4,4,4-trifluoro-3-hydr oxy-2,2-dimethylbutanoate
F3C OH
OEt
01 Me Me
Br 1-65
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with ethyl isobutyrate (689 mg, 5.9 mmol) and THF (2.5 m1). The
solution was
cooled to -78 C, and lithium diisopropylamide (3.0 mL, 5.9 mmol, 2.0 M in THF)
was added.
The reaction mixture stirred for 30 min followed by the addition of 1-(4-
bromopheny1)-2,2,2-
trifluoroethanone (0.5 g, 2.0 mmol). The reaction mixture was warmed to rt
over 1-2 h, and was
quenched by the addition of saturated aqueous NH4C1 (10 mL). The resulting
mixture was
extracted with Et0Ac (3x 10 mL), and the combined organic layers were
concentrated in vacuo
to afford a residue that was purified by column chromatography on silica gel
(hexanes/Et0Ac
gradient) to yield ethyl 3-(4-bromopheny1)-4,4,4-trifluoro-3-hydroxy-2,2-
dimethylbutanoate 1-65.
LRMS (ESI) calc'd for C14H17BrF303 [M-Ftl]': 370, found 370. 1H NMR (CDC13,
500MHz): 6
7.60 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H), 4.31 -4.27 (m, 2H), 1.38
(d, J= 3.5 Hz, 3H),
1.30 (s, 6H).
Intermediate 1-66
Isopropyl 3-(4-bromopheny1)-4,4,4-trifluoro-3-hydroxy-2,2-dimethylbutanoate
F3C OH
OiPr
10 Me Me
Br 1-66
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with isopropyl isobutyrate (772 mg, 5.9 mmol) and THF (2.5 m1).
The solution
was cooled to -78 C, and lithium diisopropylamide (3.0 mL, 5.9 mmol, 2.0 M in
THF) was
added. The reaction mixture stirred for 30 min followed by the addition of 1-
(4-bromopheny1)-
2,2,2-trifluoroethanone (0.5 g, 2.0 mmol). The reaction mixture was warmed to
rt over 1-2 h,
and was quenched by the addition of saturated aqueous NH4C1 (10 mL). The
resulting mixture
65
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
was extracted with Et0Ac (3x 10 mL), and the combined organic layers were
concentrated in
vacuo to afford a residue that was purified by column chromatography on silica
gel
(hexanes/Et0Ac gradient) to yield isopropyl 3-(4-bromopheny1)-4,4,4-trifluoro-
3-hydroxy-2,2-
dimethylbutanoate 1-66. 1H NMR (CDC13, 500MHz): 6 7.60 (d, J = 8.2 Hz, 2H),
7.53 (d, J = 8.5
Hz, 2H), 4.31 (m, 1H), 1.30 (s, 6H), 1.27 (d, J= 1.2 Hz, 3H), 1.16 (d, J= 1.3
Hz, 3H).
Intermediate 1-67
4-(4-Br omo-2-chlor opheny1)-1-methy1-1H-pyr azole
Br
I N CI
, /
N-
/ 1-67
4-Bromo-2-chloro-1-iodobenzene (500 mg, 1.58 mmol), 1-methy1-4-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-1H-pyrazole (295 mg, 1.41 mmol),
PdC12(dppf) (115 mg,
0.158 mmol), and potassium phosphate tribasic (1.03 g, 4.73 mmol) were
combined in a 20 mL
microwave vial and dissolved in dioxane (10 mL) and water (1.0 mL). The vial
was sealed and
flushed with argon. The reaction was stirred at 90 C for 2 hours. The vial was
then cooled to
room temperature and diluted with ethyl acetate. The organic layer was washed
with water and
brine and then dried using magnesium sulfate. The solution was then filtered
and concentrated
in vacuo. The crude material was purified by silica chromatography, eluting
with 10-50%
Et0Ac in hexanes and the desired fractions were concentrated in vacuo to give
4-(4-bromo-2-
chloropheny1)-1-methyl-1H-pyrazole. LRMS (ESI) calc'd for C10H9BrC1N2 [M+H] ':
273, found
273.
Intermediate 1-68
4-(4-Br omopheny1)-1- (2-meth oxyethyl)-1H -pyr azole
Br
0
Z /
N¨N
5
0
\ 1-68
66
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
4-(4-Bromophenyl)pyrazole (150 mg, 0.672 mmol) and cesium carbonate (876
mg, 2.69 mmol) were combined in a 20 mL vial and dissolved in DMF (1.3 mL). 2-
bromoethyl
methyl ether (0.253 mL, 2.69 mmol) was then added. The reaction was stirred
overnight at 60 C.
The reaction was then diluted with ethyl acetate and washed with water (x 2).
The organic
solution was dried with MgSO4 and concentrated in vacuo to afford 4-(4-
bromopheny1)-1-(2-
methoxyethyl)-1H-pyrazole which was carried onto the next step without further
purification.
LRMS (ESI) calc'd for C12F114BrN20 [M+H] ': 283, found 283.
Intermediate 1-69
Isopropyl 6-bromoquinoline-2-carboxylate
Br
110
N 1
0 0
1-69
6-Bromoquinoline-2-carboxylic acid (40 mg, 0.16 mmol) and HATU (121 mg,
0.317 mmol) were dissolved in DMF (0.5 mL) in a 4 mL vial and allowed to stir
at room
temperature for 5 minutes. 2-Propanol (24 L, 0.31 mmol) and N,N-
diisopropylethylamine (83
L, 0.48 mmol) in DMF (0.5 mL) was then added to the reaction. The reaction
mixture was
stirred at room temperature for 1 hour. The reaction was then diluted with
ethyl acetate and
washed with copious amounts of water. The organic layer was then dried using
MgSO4, filtered,
and concentrated in vacuo to give isopropyl 6-bromoquinoline-2-carboxylate
which was carried
onto the next step without further purification. LRMS (ESI) calc'd for
C13F113BrNO2 [M+H]':
294, found 294.
67
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-70
3-(4-(4-Br omo-2-methylpheny1)-1H-p yr azol-1-yl)pr op anenitr ile
Br
0
-r/
N¨N
)
N 1-70
5-Bromo-2-iodotoluene (0.077 mL, 0.539 mmol), 3-(4-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1H-pyrazol-1-yl)propanenitrile (120 mg, 0.485 mmol),
PdC12(dppf) (39.4 mg,
0.054 mmol), and potassium phosphate tribasic (343 mg, 1.62 mmol) were
combined in a 20 mL
microwave vial and dissolved in dioxane (2.5 mL) and water (0.25 mL). The vial
was sealed and
flushed with argon. The reaction was stirred at 90 C for 2 hours. The vial was
then cooled to
room temperature and diluted with ethyl acetate. The organic layer was washed
with water and
brine and then dried using magnesium sulfate. The solution was then filtered
and concentrated
in vacuo. The crude material was purified by silica chromatography, eluting
with 10-50%
Et0Ac in hexanes. The desired fractions were concentrated in vacuo to give 3-
(4-(4-bromo-2-
methylpheny1)-1H-pyrazol-1-y1)propanenitrile. LRMS (ESI) calc'd for Ci3Hi3BrN3
[M+H]':
290, found 290.
Intermediate 1-71
(4-br omo-2-methylphenyl)(1,1-dioxidothiomor ph olin o)meth an one
0
N S/O\
\--/ \
. Me
Br 1-71
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with 4-bromo-2-methylbenzoic acid (300 mg, 1.4 mmol), DMF (3.9
mL), (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate;
HATU) (663 mg, 1.7 mmol), Huenig's base (0.73 mL, 4.2 mmol), and
thiomorpholine-1,1-
dioxide (236 mg, 1.7 mmol). The resulting reaction mixture was stirred for 12 -
16 h, and was
concentrated in vacuo. T he crude oil was purified by column chromatography on
silica gel
eluting with Hexanes/Et0Ac gradient to yield (4-bromo-2-methylphenyl)(1,1-
dioxidothiomorpholino)methanone 1-71. 1H NMR (500 MHz, CDC13): 6 7.44 ¨ 7.39
(m, 2H),
68
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
7.06 (d, J = 8.09 Hz, 1H), 4.46 ¨ 4.42 (m, 2H), 3.77 ¨ 3.73 (m, 2H), 3.19 ¨
3.15 (m, 2H), 2.93 ¨
2.89 (m, 2H), 2.30 (s, 3H).
The following compounds outlined in Table 6 were prepared by analogy using the
general procedure outlined above for Intermediate 1-71 above.
Table 6.
Intermediate Structure Name 1H NMR / MS
Me 0 Me (4-bromo-2- LRMS (ESI) calc'd
for
methylphenyl)(2- C14H19BrNO2 [M+H]+:
313,
0 N
1-72 ethylpiperidin-1- found 313
Br yl)methanone
me me (4-bromo-2- LRMS (ESI) calc'd for
Me 0
methylphenyl)(2- C15H21BrNO2 [M+H]:
327,
1-73 NI isopropylpiperidin-1- found 327
Br yl)methanone
Intermediate 1-74
(2R ,5S)-4-(6-br omoquinolin-2-y1)-2,5-dimethylmor pholine
Me-
-0
N N ,
0 Me
Br 1-74
An oven dried microwave vial with magnetic sir bar under an atmosphere of N2
was charged with 6-bromo-2-chloroquinoline (200 mg, 0.8 mmol), ACN (0.4 mL),
triethylamine
(0.8 mL, 5.8 mmol), and (2R,5S)-dimethylmorpholine (475 mg, 4.1 mmol). The
reaction
mixture was heated to 90 C for 12 - 16 h, and was concentrated in vacuo. The
crude oil was
purified by column chromatography on silica gel eluting with Hexanes/Et0Ac
gradient to yield
(2R,5S)-4-(6-bromoquinolin-2-y1)-2,5-dimethylmorpholine 1-74. 1H NMR (500 MHz,
CDC13): 6
7.81 (d, J = 9.19 Hz, 1H), 7.74 (s, 1H), 7.60 ¨ 7.55 (m, 2H), 6.94 (d, J= 9.22
Hz, 1H), 4.39 (m,
1H), 4.28 (m, 1H), 3.89 ¨ 3.85 (m, 2H), 3.66 (m, 1H), 2.90 (m, 1H), 1.34 ¨
1.29 (m, 6H).
Intermediate 1-75
(25,55)-4-(6-bromoquinolin-2-y1)-2,5-dimethylmorpholine
Me-
-0
N N
0 Me
Br 1-75
69
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
An oven dried microwave vial with magnetic sir bar under an atmosphere of N2
was charged with 6-bromo-2-chloroquinoline (200 mg, 0.8 mmol), ACN (0.4 mL),
triethylamine
(0.8 mL, 5.8 mmol), and (2S,5S)-2,5-dimethylmorpholine (475 mg, 4.1 mmol). The
reaction
mixture was heated to 90 C for 12 - 16 h, and was concentrated in vacuo. The
crude oil was
purified by column chromatography on silica gel eluting with Hexanes/Et0Ac
gradient to yield
(2S,5S)-4-(6-bromoquinolin-2-y1)-2,5-dimethylmorpholine 1-75. 1H NMR (500 MHz,
CDC13): 6
7.81 (d, J = 9.19 Hz, 1H), 7.74 (s, 1H), 7.60 - 7.55 (m, 2H), 6.94 (d, J= 9.22
Hz, 1H), 4.39 (m,
1H), 4.28 (m, 1H), 3.89 - 3.85 (m, 2H), 3.66 (m, 1H), 2.90 (m, 1H), 1.34 -
1.29 (m, 6H).
Intermediate 1-76
(2R,5R)-4-(6-br omoquinolin-2-y1)-2,5-dimethylmor pholine
me,,,r0
N NJ,,
01 Me
/
Br 1-76
An oven dried microwave vial with magnetic sir bar under an atmosphere of N2
was charged with 6-bromo-2-chloroquinoline (200 mg, 0.8 mmol), ACN (0.4 mL),
triethylamine
(0.8 mL, 5.8 mmol), and (2R,5R)-2,5-dimethylmorpholine (475 mg, 4.1 mmol). The
reaction
mixture was heated to 90 C for 12 - 16 h, and was concentrated in vacuo. The
crude oil was
purified by column chromatography on silica gel eluting with Hexanes/Et0Ac
gradient to yield
(2R,5R)-4-(6-bromoquinolin-2-y1)-2,5-dimethylmorpholine 1-76. 1H NMR (500 MHz,
CDC13):
6 7.81 (d, J= 9.19 Hz, 1H), 7.74 (s, 1H), 7.60 - 7.55 (m, 2H), 6.94 (d, J=
9.22 Hz, 1H), 4.39 (m,
1H), 4.28 (m, 1H), 3.89 - 3.85 (m, 2H), 3.66 (m, 1H), 2.90 (m, 1H), 1.34 -
1.29 (m, 6H).
70
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-77 and 1-78
2-(1-(4-Br omophenyl)ethyl)-2H-1,2,3-triazole 1-77 and 1-(1-(4-br
omophenyl)ethyl)-4,5-
dihydr o-1H-1,2,3-triazole 1-78
Br Br
101
-N
NN
N )
N=---/ 1-77 and 1-78
Step 1: 1-bromo-4-(1-bromoethyl)benzene
Br
Br I-77a
To a 100 mL 3-necked round-bottom flask were placed 1-bromo-4-ethylbenzene
(5.10 g, 27.6 mmol, 1.0 equiv), N-bromosuccinimide (5.77 g, 32.4 mmol, 1.2
equiv) and azo-bis-
isobutyronitrile (0.89 g, 5.4 mmol, 0.2 equiv) in chloroform (100 mL). The
mixture was heated
at reflux for 3 hours and cooled to ambient temperature. Then water (100 mL)
was added and
the organic layer washed with brine, dried over anhydrous sodium sulfate and
filtered. The
filtrate was concentrated under reduced pressure and the residue purified by
silica gel column
chromatography eluting with ethyl acetate/petroleum ether (1:20) to afford the
title compound.
1H NMR (300 MHz, CDC13) 6 7.44 (d, J= 8.4 Hz, 2H), 7.31 (d, J= 8.4 Hz, 2H),
5.15 (q, J = 6.9
Hz, 1H), 2.01 (d, J = 6.9 Hz, 3H)
Step 2: 2-(1-(4-bromophenyl)ethyl)-2H-1,2,3-triazole and 1-(1-(4-
Bromophenyl)ethyl)-4,5-
dihydro-1H-1,2,3-triazole
Br Br
101
-N
1\\I
N ¨
In a 100 mL 3-necked round-bottom flask, 1-bromo-4-(1-bromoethyl)benzene
(4.60 g, 17.5 mmol) was combined with N,N-dimethylformamide (60 mL). 1H-1,2,3-
Triazole
(1.45 g, 21 mmol) and potassium carbonate (6.04 g, 43.75 mmol) were added. The
solution was
heated at 80 C for 5 hours at which time it was poured in water (100 mL). The
resulting
mixture was extracted with ethyl acetate (3 x 60 mL) and the organic layers
combined, dried
over anhydrous sodium sulfate and filtered. The filtrate was concentrated
under reduced
71
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
pressure; the resulting solid was triturated with ethyl acetate/petroleum
ether (1/3, 10 mL) and
filtered to give the two title products. 2-(1-(4-Bromophenyl)ethyl)-2H-1,2,3-
triazole, LCMS
(ESI) calc'd for Ciofli iBrN3 [M + H]': 252, 254 (1:1), found 252, 254 (1:1)
and Ci0HliBrN3 [M
¨ 69] ': 183, 185 (1:1), found 183, 185 (1:1); 1H NMR (300 MHz, CDC13) 6 7.62
(s, 2H), 7.44 (d,
J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 5.82 (q, J= 7.2 Hz, 1H), 1.96 (d,
J= 7.2 Hz, 3H). 1-
(1-(4-Bromophenyl)ethyl)-4,5-dihydro-1H-1,2,3-triazole, LCMS (ESI) calc'd for
CloHliBrN3 [M
+ H]': 252, 254 (1:1), found 252, 254 (1:1) and CiotliiBrN3 [M ¨ 69] ': 183,
185 (1:1), found 183,
185 (1:1); 1H NMR (300 MHz, CDC13) 6 7.72 (s, 1H), 7.49 (d, J= 8.4 Hz, 2H),
7.44 (s, 1H),
7.14 (d, J= 8.4 Hz, 2H), 5.81 (q, J= 7.2 Hz, 1H), 1.98 (d, J= 7.2Hz, 3H).
Table 7 discloses the compound prepared in an analogous procedure to that for
1-(1-(4-
bromophenyl)ethyl)-4,5-dihydro-1H-1,2,3-triazole using 1-bromo-4-(1-bromo-2-
methylpropyl)benzene.
Table 7.
Intermediate Structure Compound Name MS/1H NMR
2-(1-(4-bromopheny1)- LCMS (ESI) calc'd for
Br 2-methylpropy1)-2H-
Ci2H14BrN3 [M + 1] : 280, 282
l, 'H
(1:1), found 280, 282 (1:1);
1H NMR (300 MHz, CDC13) 6
1-79 N
7.76 (s, 1H), 7.71 (s, 1H), 7.54
-
N ss (d, J = 8.4 Hz, 2H), 7.33 (d, J =
..___....ziNI
8.4 Hz, 2H), 5.07 (d, J = 10.8
Hz, 1H), 2.81 (m, 1H), 0.92-0.86
(m, 6H).
Intermediate 1-80 and 1-81
1-(2-(4-Br omo-2-methylphenyl)pr op an -2-y1)-1H-1,2,3-tr iazole and 2-(2-(4-
br omo-2-
methylphenyl)pr op an -2-y1)-2H-1,2,3-tr iazole
Br Br
10 110
-N m....N
IZ ,
It...)
Nz---1 1-80 and 1-81
Step 1: 2-(4-bromo-2-methylphenyl)propan-2-ol
72
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Br
01
OH I-80a
In a 3-necked round bottom flask, methyl 4-bromo-2-methylbenzoate (10.00 g,
43.70 mmol) was combined with tetrahydrofuran (60 mL) under nitrogen
atmosphere.
Methylmagesium bromide ether solution (3 M, 58.2 mL, 175.00 mmol) was added
dropwise at -
40 C. The solution was stirred at the same temperature for 30 min andwarmed to
ambient
temperature. After being stirred at ambient temperature for additional 3
hours, the reaction was
quenched by adding a saturated aqueous ammonium chloride solutionfollowed by
extraction
with ethyl acetate (2 x 200 mL). The combined organic layers was washed with
brine (2 x 100
mL), dried over anhydrous sodium sulfate and filtered. The filtrate was
concentrated under
vacuum to afford the title compound. 1H NMR (300 MHz, CDC13) 6 7.33-7.24 (m,
3H), 2.56 (s,
3H), 1.63 (s, 6H).
Step 2: 1-(2-(4-bromo-2-methylphenyl)propan-2-y1)-1H-1,2,3-triazole and 2-(2-
(4-bromo-2-
methylphenyl)propan-2-y1)-2H-1,2,3-triazole
Br Br
101 0
N ,N
In a round-bottom flask, 2-(4-bromo-2-methylphenyl)propan-2-ol (2.00 g, 8.77
mmol), acetonitrile (12 mL), iron(III) chloride (0.28 g, 8.29 mmol) and 1H-
1,2,3-triazole (1.21 g,
17.54 mmol) were combined. The reaction was heated at 80 C for 16 hour and
then quenched
by a saturated aqueous ammonium chloride solution. The mixture was extracted
with ethyl
acetate (2 x 60 mL) andthe combined organic layers washed with brine (2 x 10
mL), dried over
anhydrous sodium sulfate and filtered. The filtrate was concentrated under
vacuum andthe
residue purified by reversed phase C18 flash chromatography eluting with
acetonitrile/water
(0.05 % 2,2,2-trifluoroacetic acid, 45% to 70% in 15 min) to afford the title
compounds. 1-(2-
(4-Bromo-2-methylphenyl)propan-2-y1)-1H-1,2,3-triazole, LCMS (ESI) calc'd for
Cl2H15BrN3
[M + H] ' 280, 282 (1:1) found 280, 282 (1:1); 1H NMR (300 MHz, CDC13) 6 7.74
(s, 1H), 7.42-
7.26 (m, 4H), 2.06 (s, 6H), 1.67 (s, 3H). 2-(2-(4-Bromo-2-methylphenyl)propan-
2-y1)-2H-1,2,3-
triazole, LCMS (ESI) calc'd for Ci2H15BrN3 [M + H] '280, 282 (1:1) found 280,
282 (1:1); 1H
NMR (300 MHz, CDC13) 6 7.63 (s, 2H), 7.36-7.33 (m, 2H), 7.26-7.25 (m, 1H),
2.02 (s, 6H), 1.55
(s, 3H).
73
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-82 and 1-83
1- (2- (4-Br omophenyl)pr op an -2-y1)-1H-1,2,3-tr iazole and 2-(2-(4-br
omophenyl)pr op an -2-
y1)-2H-1,2,3-triazole
Br Br
el 0
N
N1 N
,-D-
s - N
N" ,,, " 1-82 and 1-83
To a 50 mL round-bottom flask were placed 2-(4-bromophenyl) propan-2-ol (5.10
g, 23.71 mmol), 2H-1,2,3-triazole (3.28 g, 47.4 mmol), acetonitrile (10 mL)
and iron (III)
trichloride (1.50 g, 9.48 mmol). The reaction mixture was heated at 60 C for
16 hours and then
quenched by a saturated aqueous ammonium chloride solution (50 mL). The
mixture was
extracted with ethyl acetate (3 x 80 mL) and the combined organic layers dried
over sodium
sulfate and filtered. The filtrate was concentrated under vacuum to afford
3.50 g of the crude
product mixture as a yellow oil that was then purified by prep-HPLC (ccolumn:
X Bridge C18,
19 x 150 mm, 5 um; mobile phase A: water/0.05% trifluoroacetic acid, mobile
phase B:
acetonitrile; flow rate: 20 mL/min; gradient: 30%B to 70%B in 10 min; 220 nm)
to give the title
compounds: 1-(2-(4-Bromophenyl)propan-2-y1)-1H-1,2,3-triazole, LCMS (ESI)
calc'd for
CiiHi3BrN3 [M + H]': 266, 268 (1:1), found 266, 268 (1:1); 1H NMR (400 MHz,
CDC13) 6 7.68
(s, 2H), 7.43 (d, J= 8.8 Hz, 2H), 6.93 (d, J= 8.8 Hz, 2H), 2.10 (s, 6H); 24244-
Bromophenyl)propan-2-y1)-2H-1,2,3-triazole, LCMS (ESI) calc'd for CiiHi3BrN3
[M + H] ': 266,
268 (1:1), found 266, 268 (1:1); 1H NMR (400 MHz, DMSO-d6) 6 8.28 (s, 1H),
7.82 (s, 1H),7.54
(d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 2.02 (s, 6H).
74
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-84
5-Br omo-2- (tetr ahydr o-2H-p yr an -4-y1)-2,3-dihydr obenzo[d]isothiazole
1,1-dioxide
Br
0 _________________________________________
0 1-84
Step 1: 4-bromo-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide
Br
0 1
\-0 I-84a
To a 250 mL 3-necked round-bottom flask was placed a solution of tetrahydro-
2H-pyran-4-amine (2.00 g, 19.7 mmol) in DCM (100 mL) followed by triethyl
amine (7.97 g,
78.8 mmol) at ambient temperature. 4-Bromo-2-methylbenzene-1-sulfonyl chloride
(5.00 g,
19.7 mmol) was then added at the same temperature. The reaction was stirred at
ambient
temperature for 2 hours and then poured into water (100 mL). The organic layer
was separated
and washed with brine, dried over anhydrous sodium sulfate and filtered. The
filtrate was
concentrated under reduced pressure to afford a residue which was purified by
silica gel column
chromatography eluting with petroleum ether/Et0Ac (1/1) to afford the title
compound. LCMS
(ESI) calc'd for Ci2H17BrNO3S [M + H] 334, 336 (1:1), found 334, 336 (1:1); 1H
NMR (400
MHz, CDC13) 6 7.90 (d, J= 4.8 Hz, 1H), 7.52-7.48 (m, 2H), 4.70 (d, J = 8.0 Hz,
1H), 3.92-3.87
(m, 2H), 3.41-3.32 (m, 3H), 2.67 (s, 3H), 1.79-1.75 (m, 2H), 1.56-1.50 (m,
2H).
Step 2: 4-bromo-2-(bromomethyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide
Br
01 Br
0=S¨NH
8 _________________________________________
0 I-84b
To a chloroform solution (200 mL), of 4-bromo-2-methyl-N- tetrahydro-2H-
pyran-4-y1) benzenesulfonamide (3.80 g, 11.37 mmol) was added at ambient
temperature N-
bromosuccinimide (2.43 g, 13.64 mmol) followed by azo-bis-isobutyronitrile
(0.37 g, 2.27
75
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
mmol). The resulting solution was heated at reflux for 14 hours and quenched
by addition of
water (200 mL). The resulting mixture was washed with brine, dried over
anhydrous Na2SO4
and filtered. The filtrate was concentrated in vacuo, and the residue purified
by silica gel column
chromatography eluting with ethyl acetate/petroleum ether (1/1) to afford 2.00
g of a mixture of
starting material, 4-bromo-2-methyl-N-(tetrahydro-2H-pyran-4-
yl)benzenesulfonamide, and the
title benzylbromide. This mixture was used in the next step without further
purification. LCMS
(ESI) calc'd for C12F116Br2NO2S [M + H] ': 414, 416 (1:1), found 414, 416
(1:1).
Step 3: 5-bromo-2-(tetrahydro-2H-pyran-4-y1)-2,3-dihydrobenzo [61] isothiazole
1,1-dioxide
Br
101
0-1-N
0 _________________________________________
0 1-84
To a 250 mL 3-necked round-bottom flask was placed 2.00 g of the mixture of 4-
bromo-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide and 4-bromo-2-
(bromomethyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide in
acetonitrile/water (100 mL,
1/1). Then saturated aqueous sodium bicarbonate (1.63 g, 19 mmol, 4.00 equiv)
was added in
one portion. The reaction mixture was heated at reflux for 14 hours at which
time it was,
allowed to cool to ambient temperature and extracted with Et0Ac (3 x 100 mL).
The combined
organic layers was washed with brine, dried over anhydrous Na2504 and
filtered. The filtrate
was concentrated in vacuo and resulting crude product purified by silica gel
column
chromatography with petroleum ether/ehtyl acetate (1/1) to afford the title
compound. LCMS
(ESI) calc'd for C12I-115BrNO3S [M + H] ': 332, 334 (1:1), found 332, 334
(1:1);1H NMR (400
MHz, CDC13) 6 7.72-7.69 (m, 2H), 7.62 (s, 1H), 4.41 (s, 2H). 4.11-4.08 (m,
2H), 3.97-3.89 (m,
1H), 3.56-3.53 (m, 2H), 2.08-1.92 (m, 4H).
Table 8 discloses intermediates that were prepared in an analogous manner to
that for 5-bromo-
2-(tetrahydro-2H-pyran-4-y1)-2,3-dihydrobenzo [61] isothiazole 1,1-dioxide I-
84, using
cyclohexanamine to replace tetrahydro-2H-pyran-4-amine.
76
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Table 8.
Intermediate Structure Compound Name MS/1H NMR
Br 5-bromo-2-cyclohexyl- LCMS (ESI) calc'd for
2,3-dihydrobenzo [d] C13H17BrNO2S [M + H]+: 330,
332
el isothiazole 1,1-dioxide (1:1), found 330, 332
(1:1);
1H NMR (300 MHz, CDC13) 6 7.68-
1-85 0:------N
0 b 7.63 (m, 2H), 7.56 (s, 1H),
4.37 (s,
2H), 3.63-3.73 (m, 1H), 2.26-2.25
(m, 2H), 1.84-1.89 (m, 2H), 1.10-
1.72 (m, 6H).
Br 5-bromo-2-(N-tert-butyl LCMS (ESI) calc'd for
carbomatepiperidine-4- C17H24BrN204S [M + H]+:
431, 433
1.1 yl)cyclohexy1-2,3- (1:1), found 431, 433
(1:1);
dihydrobenzo[d]isothiaz 1H NMR (400 MHz, CDC13) 6 7.66
0=¨N
1-860 ole 1,1-dioxide (s, 2H), 7.57 (s, 1H), 4.35
(s, 2H),
4.20 (d, J= 13.6 Hz, 2H), 3.81 (t, J=
N
Boc 11.2 Hz, 1H), 2.89 (t, J=
12.4 Hz,
'
2H), 2.03 (d, J = 12.8 Hz, 2H), 1.81-
1.71 (m, 2H), 1.47 (s, 9H).
5-bromo-2-(4- LCMS (ESI) calc'd for
Br
methyltetrahydro-2H- C13H17BrNO3S [M + H]+: 346,
348
ISI pyran-4-y1)-2,3- (1:1), found 346, 348
(1:1);
dihydrobenzo[d]isothiaz 1H NMR (400 MHz, CDC13) 6 7.69-
1-87
ON ole 1,1-dioxide 7.63 (m, 2H), 7.58 (s, 1H),
4.42 (s,
0
2H), 3.94-3.88 (m, 2H), 3.81-3.75
0 (m, 2H), 2.36-2.32 (m, 2H),
1.89-
1.79 (m, 2H), 1.69 (s, 3H).
Intermediate 1-88
5-Br omo-2,2-dimethylbenzo[b]thiophen-3(2H)-one 1,1-dioxide
Br
0
01
0 1-88
Step 1: methyl 2-((4-bromophenyl)thio)acetate
77
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Br
Si
s
u u I-88a
To a 250 mL round-bottom flask were placed 4-bromobenzenethiol (5.00 g, 26.4
mmol), methyl-2-bromoacetate (6.07 g, 39.7 mmol), triethylamine (7.37 mL, 52.9
mmol) and
tetrahydrofuran (130 mL). The mixture was heated at 70 C for 4 hours and then
concentrated in
cacuo. The residue was dissolved in water (100 mL) and then extracted with
ethyl acetate (3 x
150 mL). The organic layers were combined, washed with brine (100 mL), dried
over anhydrous
sodium sulfate and filtered. The filtrate was concentrated under vacuum to
afford the title
compound. GCMS (ES) calc'd for C9H10BrO2S [M]': 260, 262 (1:1), found 260, 262
(1:1).
Step 2: 2-((4-bromophenyl)thio)acetic acid
Br
1$1
s
Cf0H i_88b
To a 500 mL round-bottom flask were placed methyl 2-((4-bromophenyl)thio)
acetate (7.40 g, 28.3 mmol), sodium hydroxide (2.26 g, 56.6 mmol) in methanol
(200 mL) and
water (20 mL). The mixture was stirred at ambient temperature for 16 hours and
then
concentrated under vacuum. Water (100 mL) was added to the residue followed by
hydrochloric
acid (6 M) until pH ¨5. The mixture was extracted with ethyl acetate (3 x 100
mL) and the
combined organic layers washed with brine (100 mL), dried over anhydrous
sodium sulfate and
filtered. The filtrate was concentrate under vacuum to afford the title acid.
GCMS (ES) calc'd
for C8H8BrO2S [M] ': 246, 248 (1:1), found 246, 248 (1:1).
Step 3: 2-((4-bromophenyl)thio)acetyl chloride
Br
Si
s
0 CI I-88c
78
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
A solution of 2-((4-bromophenyl)thio)acetic acid (6.20 g, 25.09 mmol) in
thionyl
chloride (150 mL) was heated at reflux for 1 hour and then concentrated under
vacuum to afford
(crude) of 2-((4-bromophenyl)thio)acetyl chloride that was used directly in
the next step.
Step 4: 5-bromobenzo[b]thiophen-3(2H)-one
Br
ISI 0
S I-88d
2-((4-Bromophenyl)thio)acetyl chloride (21.00 g, 79 mmol) was added dropwised
to a suspension of aluminum chloride (13.71 g, 103 mmol) in 1,2-dichloroethane
(150 mL) at 0-
4 C. The mixture was warmed and maintained at ambient temperature for 16
hours. The
reaction mixture was added to hydrochloric acid (1.5 M, 150 mL) and then
extracted with 1,2-
dichloroethane (3 x 300 mL). The combined organic layers was washed with brine
(2 x 200 mL),
dried over anhydrous sodium sulfate and filtered. The filtrate was
concentrated under reduced
pressure and the residue purified by silica gel column chromatography eluting
with ethyl
acetate/petroleum ether (1/30) to afford the title compound. 1H NMR (300 MHz,
CDC13) 6 7.88
(d, J= 2.1 Hz, 1H), 7.66-7.62 (m, 1H), 7.31 (d, J = 8.4 Hz, 1H), 3.83 (s, 2H).
Step 5: 5-bromobenzo[b]thiophen-3(2H)-one 1,1-dioxide
Br
ISI 0
0=S
ii
0 I-88e
To a 500 mL round-bottom flask was placed at 0-4 C 5-bromobenzo[b]thiophen-
3(2H)-one (10.00 g, 43.7 mmol) in 1,2-dichloroethane (200 mL) followed by 3-
chlorobenzoperoxoic acid (22.60 g, 131 mmol). The reaction was stirred at
ambient temperature
for 5 hours and saturated sodium bicarbonate (150 mL) and water (200 mL) were
added and the
mixture extracted with 1,2-dichloroethane (3 x 500 mL). The combined organic
fractions was
washed with brine (saturated, 2 x 200 mL), dried with sodium sulfate and
filtered. The filtrate
was concentrated under reduced pressure. The residue was purified by silica
gel column
chromatography eluting with ethyl acetate/petroleum ether (1/10) to give the
title compound. 1H
NMR (300 MHz, CDC13) 6 8.15 (d, J = 1.8 Hz, 1H), 8.08-8.04 (m, 1H), 7.86 (d,
J= 8.4 Hz, 1H),
4.13 (s, 2H).
79
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 6: 5-bromo-2,2-dimethylbenzo [b.] thiophen-3(2H)-one
Br
1.1 0
0=S
ii
0 I-88f
To a 50 mL round-bottom flask were added 5-bromobenzo[b]thiophen-3(2H)-one
1,1-dioxide (0.51 g, 1.95 mmol), iodomethane (0.69 g, 4.88 mmol) and 1,5-
diazabicyclo [4.3.0]
non-5-ene (0.73 mL, 4.88 mmol) in tetrahydrofuran (20 mL). The mixture was
heated at 70 C
for 3 hours at which time it was cooled. Water (50 mL) was added and the
resulting mixture
extracted with ethyl acetate (3 x 50 mL). The organic layers was combined,
washed with brine
(2 x 100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate
was concentrated
under vacuum and the residue purified by silica gel column chromatography
eluting with ethyl
acetate/petroleum ether (1/30) to afford the title compound. GCMS (ES) calc'd
for C10H10BrO3S
[M] :288, 290 (1:1), found 288, 290 (1:1); 1H NMR (400 MHz, CDC13) 6 8.17 (d,
J = 1.8 Hz,
1H), 8.09-8.07 (m, 1H), 7.91 (d, J= 6.4 Hz, 1H), 1.65 (s, 6H).
Intermediate 1-89
Br omo-3-hydr oxy-2,2-dimethy1-2,3-dihydr obenzo[b]thiophene-1,1-dioxide
Br
'OH
01
0 1-89
To a 50 mL round-bottom flask was placed 5-bromo-2,2-
dimethylbenzo[b]thiophen-3 (2H)-one 1,1-dioxide (0.60 g, 2.08 mmol) in
methanol (20 mL).
Sodium borohydride (0.45 g, 10.40 mmol) was added. The reaction was stirred
for 1 h and then
quenched by water (2 mL). The mixture was extracted with ethyl acetate (3 x 20
mL). The
organic layers were combined, dried over anhydrous sodium sulfate and
filtered. The filtrate
was concentrated under vacuum to afford the title compound. 1H NMR (400 MHz,
DMSO-d6) 6
7.85-7.80 (m, 3H), 6.62 (d, J= 6.0 Hz, 1H), 5.99 (d, J= 6.0 Hz, 1H), 1.46 (s,
3H), 1.18 (s, 3H).
80
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-90
5-Br omo-3-hydr oxy-3H- sp ir o[benzo[b]thiophene-2,1' -cyclop entane] -1,1-
dioxide
Br
0 OH
0=S
0 411
0
1-90
Step 1: 5-bromo-3H-spiro[benzo[b]thiophene-2,1'-cyclopentane]-3-one-1,1-
dioxide
Br
0
00
0=S
0
0
1-90
To a 250 mL round-bottom flask were placed 5-bromobenzo[b]thiophen-3(2H)-
one-1,1-dioxide (2.00 g, 7.60 mmol), 1,4-diiodobutane (6.80 g, 22.80 mmol),
1,8-
diazabicyclo[4.4.0]undec-7-ene (3.50 g, 22.80 mmol) and tetrahydrofuran (150
mL). The
reaction mixture was heated at 70 C for 2 hours and then quenched by addition
of water (20 mL).
The mixture was extracted with ethyl acetate (3 x 100 mL) and the combined
organic layers
washed with brine (2 x 100 mL), dried over anhydrous sodium sulfate and
filtered. The filtrate
was concentrated in vacuo and the residue purified by silica gel column
chromatography eluting
with ethyl acetate/petroleum ether (1/8) to afford the title compound. 1H NMR
(300 MHz,
DMSO-d6) 6 8.06 (d, J= 1.2 Hz, 1H), 7.98-7.95 (m, 1H), 7.82 (d, J= 8.4 Hz,
1H), 2.18-2.07 (m,
4H), 1.92-1.87 (m, 4H).
Step 2: 5-bromo-3-hydroxy-3H-spiro[benzo [b.] thiophene-2,1'-cyclopentane]-1,1-
dioxide
Br
0 OH
0=S
0 411
0
1-90
To a 50 mL round-bottom flask were placed 5-bromo-3H-
spiro[benzo[b]thiophene -2,1'-cyclopentane]-3-one-1,1-dioxide (0.36 g, 1.13
mmol), sodium
borohydride (0.25 g, 6.65 mmol) and methanol (20 mL). The reaction was stirred
at ambient
temperature for 1 hour and then quenched by water (50 mL). The resulting
solution was
extracted with ethyl acetate (3 x 100 mL) and the combined organic layers
washed with brine (2
81
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
x 100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was
concentrated
under vacuum to afford title compound. 1H NMR (300 MHz, DMSO-d6) 6 7.79-7.73
(m, 3H),
6.62 (d, J = 6.3 Hz, 1H), 5.54 (d, J = 6.3 Hz, 1H), 2.24-1.73 (m, 8H).
The compound in Table 9 was prepared in an analogous manner to that for 5-
bromo-3-hydroxy-
3H-spiro[benzo [b] thiophene-2,1'-cyclopentane] 1,1-dioxide using 1,5-
diiodopentane as an
electrophile.
Table 9.
Inter mediate Compound Name MS/1H NMR
Structure
Br
1H NMR (300 MHz, DMSO-d6) 6
1-91 la OH 5-Bromo-3-hydroxy-3H-
spiro[benzo[b]thiophene- 7.78-7.74 (m, 3H),
6.43 (d, J= 6
Hz, 1H), 5.96 (d, J = 5.4 Hz, 1H),
2,1'-cyclohexane] 1,1-
0=S 1.98-1.96 (m, 2H),
1.69-1.41 (m,
0 dioxide
8H).
Intermediate 1-92
Br omo-2-(1- (tr iflu or omethyl)cyclohexyl)isoindolin-1-one
Br
0
N CF3
0 b
1-92
Step 1: N-cyclohexylidene-l-phenylmethanamine
NBn
O I-92a
A suspension of magnesium sulfate (24.53 g, 204 mmol), phenylmethanamine
(21.84 g, 0.21 mol) and cyclohexanone (20.00 g, 0.21 mol) in DCM (200 mL) was
stirred at
ambient temperature for 5 days. The mixture was filtered and the filtrate
concentrated in vacuo
to afford the crude product. LCMS (ESI) calc'd for Ci3Hi8N [M + H]1: 188,
found 188.
82
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 2: N-benzy1-1-(trifluoromethyl)cyclohexanamine
H
F3C N-Bn
O I-92b
To a solution of crude N-cyclohexylidene-l-phenylmethanamine (10.00 g, 53.40
mmol) in acetonitrile (50 mL) were added at ambient temperature
trifluoroacetic acid (4.11 mL,
53.40 mmol), potassium hydrogen fluoride (4.17 g, 53.40 mmol) and N,N-
dimethylformamide (5
mL). The mixture was stirred at ambient temperature for 30 min at which time
it was cooled to
0 C followed by addition of trimethyl(trifluoromethyl)silane (15.19 g, 0.11
mol). Then the
mixture was warmed to ambient temperature and stirred at the same temperature
for additional 5
hours. Saturated aqueous Na2CO3 (40 mL) was added and the resulting mixture
stirred for 5 min
before it was diluted with water (50 mL). It was extracted with Et0Ac (3 x 50
mL) and
combined organic layers washed with water (50 mL)/brine (50 mL), dried over
anhydrous
Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica
gel column
chromatography eluting with petroleum ether to afford the title product. LCMS
(ESI) calc'd for
C14H19F3N [M + H]': 258, found 258; 1H NMR (300 MHz, DMSO-d6) 6 7.41-7.20 (m,
5H), 3.75
(d, J= 7.5 Hz, 2H), 2.35-2.30 (m, 1H), 1.84-1.09 (m, 10H).
Step 3: 1-(trifluoromethyl)cyclohexanamine hydrochloride salt
F3C NH2 HCI
a I-92c
A suspension of N-benzy1-1-(trifluoromethyl)cyclohexanamine (1.40 g, 5.44
mmol), concentrated HC1 (12 N, 0.5 mL) and palladium on carbon (0.87 g, 0.82
mmol, 10% wet)
in methanol (20 mL) was vigorously stirred under hydrogen (1.5 atm) atmosphere
at ambient
temperature for 18 hours. The catalyst was removed by filtration and the
filtrate concentrated in
vacuo to afford the title amine. LCMS (ESI) calc'd for C7H14F3NC1 [M ¨ HC1+
H]': 168, found
168; 1H NMR (300 MHz, CDC13) 6 9.21 (br, 3H), 1.96-1.51 (m, 10H).
Step 4: methyl 4-bromo-2-(41-(trifluoromethyl)cyclohexyl)
amino)methyl)benzoate
Br
1.1
CF3
0 OH No
I
I-92d
A mixture of potassium carbonate (2.04 g, 14.73 mmol), methyl 4-bromo-2-
(bromomethyl)benzoate (1.82 g, 5.89 mmol) and 1-
(trifluoromethyl)cyclohexanamine
hydrochloride (0.60 g, 2.95 mmol) in acetonitrile (50 mL) was heated at 90 C
for 96 hours. The
83
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
solid was removed byfiltration after the reaction was cooled to ambient
temperature. The filtrate
was concentrated in vacuo and the residue purified by silica gel column
chromatography eluting
with Et0Ac/petroleum ether (1/50) to afford the title compound. LCMS (ESI)
calc'd for
C16H20BrF3NO2 [M + H] ': 394, 396 (1:1) found 394, 396 (1:1).
Step 5: 4-bromo-2-(((1-(trifluoromethyl)cyclohexyl)amino)methyl)benzoic acid
Br
0
i_im CF3
0 0WoI-92e
Potassium hydroxide (78 mg, 1.40 mmol) was added in one portion to a solution
of methyl 4-bromo-2-(((1-(trifluoromethyl)cyclohexyl)amino)methyl)benzoate (55
mg, 0.14
mmol) in THF (2 mL) and water (2 mL) at ambient temperature. The reaction
mixture was
heated at 40 C for one day and then cooled. It was acidified with hydrochloric
acid (2 N) to pH
6 and then extracted with Et0Ac (3 x 20 mL), dried over anhydrous Na2504 and
filtered. The
filtrate was concentrated in vacuo to afford the title product. LCMS (ESI)
calc'd for
C15F118BrF3NO2 [M + H] ': 380, 382 (1:1), found 380, 382 (1:1).
Step 6: 5-bromo-2-(1-(trifluoromethyl)cyclohexyl)isoindolin-1-one
Br
0
N CF3
0 b
1-92
A solution of 2-(7-aza-1H-benzotriazole-1-y1)-1,1,3,3-tetramethyluronium
hexafluorophosphate (84 mg, 0.22 mmol) and 4-bromo-2-(41-
(trifluoromethyl)cyclohexyl)amino)methyl)benzoic acid (42 mg, 0.11 mmol) in
N,N-
dimethylformamide (1 mL) was heated at 55 C for 20 hours. The reaction was
poured into water
(10 mL), extracted with Et0Ac (3 x 10 mL). The combined organic layers was
washed with
brine (15 mL), dried over anhydrous Na2504 and filtered. The filtrate was
concentratedin vacuo.
The residue was purified by prep-TLC with Et0Ac/petroleum ether (1/10) to
afford the title
product. LCMS (ESI) calc'd for C15F116BrF3NO [M + H] ': 362, 364 (1:1), found
362, 364 (1:1);
11-INMR (400 MHz, CDC13) 6 7.77-7.70 (m, 1H), 7.62 (d, J= 8.0 Hz, 2H), 4.58
(s, 2H), 3.12-
2.98 (m, 2H), 1.85-1.37 (m, 8H).
84
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-93
3-(5-Bromo-1-oxoisoindolin-2-y1)-3-methylbutanoate
Br
ISI
.......K jo(N
0
O*1_93
Step 1: ethyl 3-(5-bromo-1-oxoisoindolin-2-y1)-3-methylbutanoate
Br
0
0
OX I-93a
To a 500 mL round-bottom flask were placed at ambient temperature methyl 4-
bromo-2-(bromomethyl)benzoate (10.00 g, 32.50 mmol), ethyl 3-amino-3-
methylbutanoate (7.06
g, 39.00 mmol), triethylamine (9.85 g, 97.50 mmol) and toluene (300 mL). The
resulting
solution was heated at 110 C for 16 hours. The reaction was then quenched by
addition of water
(50 mL) and resulting mixture extracted with Et0Ac (3 x 100 mL). The organic
layers was
combined, washed with brine (2 x 10 mL), dried over anhydrous Na2SO4, filtered
and
concentrated in vacuo . The residue was purified by silica gel column
chromatography eluting
with Et0Ac/petroleum ether (1/6) to afford the title compound. LCMS (ESI)
calc'd for
C151-119BrNO3 [M + 1-1]': 340, 342 (1:1), found 340, 342 (1:1).
Step 2: 3-(5-bromo-1-oxoisoindolin-2-y1)-3-methyl butanoic acid
Br
101
,N)1 a
0
OH I-93b
To a Me0H solution (30 mL) of ethyl 3-(5-bromo-1-oxoisoindolin-2-y1)-3-
methylbutanoate (3.20 g, 9.40 mmol) cooled in an ice bath was added in one
portion an queous
solution (5 mL) of sodium hydroxide (0.75 g, 18.80 mmol). Then the ice bath
was removed and
reaction maintained at 0 C to ambient temperature for 1 hour. The mixture was
concentrated in
vavuo to remove Me0H and resulted aqueous mixture acidified with hydrochloric
acid (4 M)
until pH 5-6 followed byextraction with Et0Ac (3 x 100 mL). The organic layers
was combined,
85
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
washed with brine (2 x 100 mL), dried over anhydrous Na2SO4 and filtered. The
filtrate was
concentrated in vacuo to afford the title compound. LCMS (ESI) calc'd for
C13H15BrNO3 [M +
H] ': 312, 314 (1:1), found 312, 314 (1:1).
Step 3: tert-butyl 3-(5-bromo-1-oxoisoindolin-2-y1)-3-methylbutanoate
Br
1.1
N
0 0
Xµ(
0¨ki_93
3-(5-Bromo-1-oxoisoindolin-2-y1)-3-methyl butanoic acid (1.00 g, 3.20 mmol)
and tert-butyl-2,2,2-trichloroacetimidate (2.10 g, 9.60 mmol) were combined in
DCM (5 mL),
and resulting solution maitained at ambient temperaturefor 36 hours at which
time the reaction
was quenched by addition of water (10 mL). The mixture was extracted with
Et0Ac (3 x 50
mL), and organic layers washed with brine (2 x 50 mL), dried over anhydrous
Na2504 and
filtered. The filtrate was concentrated in vacuo, and the residue purified by
silica gel column
chromatography eluting with Et0Ac/petroleum ether (1/3) to afford the title
product. LCMS
(ESI) calc'd for C17H23BrNO3 [M + H]': 368, 370 (1:1), found 368, 370 (1:1);
1H NMR (300
MHz, DMSO-d6) 6 7.68-7.66 (m, 1H), 7.60-7.58 (m, 2H), 4.55 (s, 2H), 3.07 (s,
2H), 1.64 (s, 6H),
1.31 (s, 9H).
Intermediate I-94A and I-94B
(R) and (S)-2-(4-br omopheny1)-2-(tr iflu or omethyl)pyrr olidine
Br
CF3
HN
I-94A and I-94B
86
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 1: 3-(4-bromobenzoy1)-1-vinylpyrrolidin-2-one as a colorless solid
0
1.1
Br 0 N
7/ I-94a
Potassium tert-butoxide (6.26 g, 55.80 mmol) was added to a solution of 1-
vinylpyrrolidin-2-one (6.20 g, 55.80 mmol) and methyl 4-bromobenzoate (10.00
g, 46.50 mmol)
in tetrahydrofuran (150 mL). The mixture was stirred at ambient temperature
for an hour at
which time water (200 mL) was added and pH adjusted to 7 (pH paper) with
hydrochloric acid
(1 M). The resulting mixture was extracted with Et0Ac (3 x 200 mL). The
combined organic
layers was dried over anhydrous Na2SO4, filtered and concentrated in vacuo .
The resulting
residue was purified by silica gel column chromatography eluting with
Et0Ac/petroleum ether
(0/1 - 1/4) to afford the title ketone. LCMS (ESI) calc'd for C13I-113BrNO2 [M
+ H] ': 294, 296
(1:1), found 294, 296 (1:1); 1H NMR (300 MHz, CDC13) 6 7.90 (d, J = 6.6 Hz,
2H), 7.65 (d, J =
6.6 Hz, 2H), 7.06-6.97 (m, 1H), 4.55-4.50 (m, 3H), 3.77-3.68 (m, 1H), 3.62-
3.55 (m, 1H), 2.80-
2.71 (m, 1H), 2.37-2.28 (m, 1H).
Step 2: 5-(4-bromopheny1)-3,4-dihydro-2H-pyrrole
Br
0
N'
I-94b
A suspension of 3-(4-bromobenzoy1)-1-vinylpyrrolidin-2-one (5.00 g, 17.00
mmol) in HC1 (8 M, 20 mL, 160 mmol) was heated at reflux for 16 hours. The
mixture was
cooled to ambient temperature and extracted with Et0Ac (3 x 20 mL). The
aqueous layer was
basified to pH 13 with NaOH (15% aqueous solution) and then extracted with DCM
(5 x 20 mL).
The combined organic layers was dried over anhydrous Na2504, filtered and
concentrated in
vacuo. The esulting residue was purified by silica gel column chromatography
eluting with
Et0Ac/petroleum ether (0/1 to 1/4) to afford the title dihydropyrrole. LCMS
(ESI) calc'd for
CiofliiBrN [M + H] ': 224, 226 (1:1), found 224, 226 (1:1); 1H NMR (300 MHz,
CDC13) 6 7.74-
7.69 (m, 2H), 7.56-7.52 (m, 2H), 4.09-4.02 (m, 2H), 2.96-2.88 (m, 2H), 2.10-
2.00 (m, 2H).
87
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 3: kS) and (R)-2-(4-bromopheny1)-2-(trifluoromethyl)pyrrolidine
Br
0
CF3
HN
I-94A and I-94B
To an ice-cooled solution of 5-(4-bromopheny1)-3,4-dihydro-2H-pyrrole (0.80 g,
3.57 mmol) in dry acetonitrile (3 mL) were added trifluoromethanesulfonic acid
(0.67 g, 4.46
mmol), potassium hydrogen fluoride (0.84 g, 10.71 mmol) and
trimethyl(trifluoromethyl)silane
(5.08 g, 35.70 mmol) successively. The resulted mixture was warmed to ambient
temperature
and maintained at the same temperature for 48 hour at which time saturated
aqueous NaHCO3
was added with caution until pH > 7. The solution was extracted with Et0Ac (3
x 10 mL). The
combined organic layers was dried over anhydrous Na2SO4, filtered
andconcentrated in vacuo .
The residue was purified by silica gel column chromatography eluting with
DCM/petroleum
ether (0/1 to 1/5) to afford the title compound. LCMS (ESI) calc'd for
C11H12BrF3N [M + H] ':
294, 296 (1:1), found 294, 296 (1:1); 1H NMR (300 MHz, CDC13) 6 7.49 (d, J =
5.4 Hz, 2H),
7.42 (d, J= 5.4 Hz, 2H), 3.29-3.21 (m, 1H), 3.16-3.08 (m, 1H), 2.60-2.51 (m,
1H), 2.25-2.16 (m,
1H), 2.08-1.94 (m, 1H), 1.89-1.75 (m, 1H). This racemic mixture was resolved
by preparative
chiral HPLC (column: CHIRALPAK AD-H SFC 5 x 25 cm, 5 um; mobile phase:
methanol
(0.2% DEA), detector 254/220 nm to afford (R or S)-2-(4-bromopheny1)-2-
(trifluoromethyppyrrolidine I-94A (retention time = 4.41 min), and (R or S)-2-
(4-bromopheny1)-
2-(trifluoromethyl)pyrrolidine I-94B (retention time = 5.23 min).
Intermediate 1-95
2-(4-Br omo-2-methylpheny1)-2-(tr iflu or omethyl)pyr r olidine
Br
I.
HN CF3
The titled compound was prepared in an analogous manner to that described for
2-(4-bromopheny1)-2-(trifluoromethyl)pyrrolidine 1-94 starting with methyl 4-
bromo-2-
methylbenzoate to replace methyl 4-bromobenzoate. LRMS (ESI) calc'd for:
C12H14BrF3N [M +
H] ': 308, 310 (1:1), found 308, 310 (1:1); 1H NMR (300 MHz, CDC13) 6 7.47 (d,
J = 8.1 Hz, 1H),
7.35 (s, 1H), 7.33 (d, J= 8.1 Hz, 1H), 3.31-3.15 (m, 2H), 2.81-2.72 (m, 1H),
2.53 (s, 3H), 2.34-
2.13 (m, 1H), 2.06-1.86 (m, 2H).
88
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-96
(R or S)-2-(4-Br omopheny1)-1-methy1-2-(tr iflu or omethyl)pyr r olidine
Br
0
CF3
---"N
1-96
A solution of (R or S)-2-(4-bromopheny1)-2-(trifluoromethyppyrrolidine I-
94A(80 mg, 0.27 mmol), iodomethane (0.39 g, 2.72 mmol) and NaH (60% in mineral
oil, 0.11 g,
2.72 mmol) in N,N-dimethylformamide (2.7 mL) was stirred at ambient
temperature for 16 hours.
The mixture was concentrated in vacuo and the resulting residue poured into
saturated NaHCO3
(20 mL). The mixture was extracted with Et0Ac (3 x 20 mL) and combined organic
layers dried
over anhydrous Na2SO4 and filtered. The filtrate was concentrated in vacuo and
resulting crude
product purified by silica gel column chromatography eluting with
DCM/petroleum ether (0/1-
1/1) to afford the title product. LCMS (ESI) calc'd for C12H14BrF3N [M + H]1:
308, 310 (1:1),
found 308, 310 (1:1); 1H NMR (300 MHz, CDC13) 6 7.61-7.47 (m, 4H), 3.55-3.45
(m, 1H), 3.31-
3.23 (m, 1H), 2.73-2.66 (m, 1H), 2.64 (s, 3H), 2.41-2.16 (m, 1H), 2.07-2.03
(m, 2H).
The compound in Table 10 was prepared in an analogous manner to that described
for (R or S)-
2-(4-bromopheny1)-1-methy1-2-(trifluoromethyl)pyrrolidine 1-96 starting from
(S or R)-2-(4-
bromopheny1)-2-(trifluoromethyl)pyrrolidine I-94B.
Table 10.
Intermediate Structure Compound Name 11-1 NMR/MS
1-97 (S or R)-2-(4- LRMS (ESI) calc'd for: C12H14BrF3N
Br
bromopheny1)-1-methyl-2- [M + H]+: 308, 310 (1:1), found 308,
101 (trifluoromethyl)
310 (1:1).
pyrrolidine
1H NMR (300 MHz, CDC13) 6 7.61-
C F3
7.47 (m, 4H), 3.55-3.45 (m, 1H),
---N
3.31-3.23 (m, 1H), 2.73-2.66 (m, 1H),
2.64 (s, 3H), 2.41-2.16 (m, 1H), 2.07-
2.03 (m, 2H).
89
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-98
1-(4-Br omo-2-methylpheny1)-2,2,2-tr iflu or oeth an amine hydr ochlor ide
Br
101
HCI
F3C NH2 1-98
To an anhydrous toluene solution (20 mL) of 1-(4-bromo-2- methylpheny1)-2,2,2-
trifluoroethanone (2.53 g, 9.42 mmol) was added dropwise over 10 min at
ambient temperature a
THF solution of lithium bis(trimethylsilyl)amide (1 M, 10.6 mL, 10.55 mmol)
followed by
borane-methyl sulfide complex (10 M in THF, 1.88 mL, 18.80 mmol). The mixture
was stirred
at ambient temperature for 30 min at which time it was quenched by addition of
water (10 mL).
The resulting mixture was extracted with ethyl acetate (3 x 30 mL) and the
combined organic
layers washed with brine (3 x 50 mL), dried over anhydrous sodium sulfate and
filtered. The
filtrate was concentrated under vacuum and the residue dissolved in ethyl
acetate (5 mL)
followed by treatment with an Et0Ac solution of acetate (5 mL). The resulting
solid was
collected by filtration and dried under vacuum to give the title compound. 1H
NMR (300 MHz,
DMSO-d6) 6 9.68 (br, 3H), 7.68-7.45 (m, 3H), 5.56-5.49 (m, 1H), 2.40 (s, 3H).
Intermediate 1-99
Racemic 2-(4-Br omopheny1)-2-(tr ifluor omethyl)-tetr ahydr ofur an
Br
0 CF3
1-99
Step 1: 1-(4-bromopheny1)-4-hydroxybutan-1-one
Br
SI
OH
0 I-99a
25 To a 250 mL round-bottom flask was placed a THF solution (200 mL) of
4-(4-
bromopheny1)-4-oxobutanoic acid (4.00 g, 16.01 mmol), and the resulting
solution coold in an
ice bath. Borane THF solution (1 M, 40 mL, 40.00 mmol)) was added at 0 C. The
mixture was
stirred at ambient temperature for 2 hours and then quenched by addition of
ice water (20 mL).
90
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
The mixture was extracted with Et0Ac (2 x 40 mL), amd combinedorganic layers
washed with
brine (2 x 30 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was
concentrated in
vacuo to afford the title compound. LCMS (ESI) calc'd for C10H12Br02[M + H]':
243, 245
(1:1), found 243, 245 (1:1).
Step 2: 4-(4-bromopheny1)-5,5,5-trifluoropentane-1,4-diol
Br
O
HO H
I-99b
To a 8 mL vial was placed a solution of 1-(4-bromopheny1)-4-hydroxybutan-1-
one (0.30 g, 1.23 mmol) and tetramethylammonium fluoride (23 mg, 0.25 mmol) in
CH2C12 (4
mL). The mixture was degassed with nitrogen for 3 times, and then
trimethyl(trifluoromethyl)silane (0.35 g, 2.47 mmol) added at -50 C. The
reaction was warmed
to ambient temperature and maitained at the temperature for 16 hours. It was
quenched by
addition of ice water (10 mL). The mixture was extracted with Et0Ac (2 x 20
mL), and
combined organic layers washed with brine (2 x 20 mL), dried over anhydrous
sodium sulfate
and filtered. The filtrate was concentrated in vacuo. The residue was
dissolved in
tetrahydrofuran (10 mL) and tetrabutylammonium fluoride (1.60 g, 6.15 mmol)
was added. The
mixture was stirred at ambient temperature for 2 hours at which time water (10
mL) was added.
The quenched reaction was extracted with Et0Ac (3 x 30 mL) and combined
organic
phases,washed with brine (2 x 20 mL), dried over anhydrous sodium sulfate and
filtered. The
filtrate was concentrated under vacuum. The residue was purified by silica gel
column
chromatography eluting with Et0Ac/petroleum ether (1/3) to afford the title
diol. LCMS (ESI)
calc'd for C11H13BrF302 [M+H] 313, 315 (1:1), found 313, 315 (1:1).
Step 3: 2-(4-bromopheny1)-2-(trifluoromethyl)tetrahydrofuran
Br
0 C F3
1-99
To a 8 mL vial was placed a solution of 4-(4-bromopheny1)-5,5,5¨
trifluoropentane -1,4-diol (80 mg, 0.26 mmol) and tributylphosphine (0.13 g,
0.51 mmol) in
anhydrous THF (5 mL). N1,N1,N2,N2-teramethyldiazene-1,2-dicarboxamide (88 mg,
0.51 mmol)
was then added. The resulted solution was stirred at ambient temperature for
16 hours at which
time the reaction was diluted with water (20 mL) followed by extraction with
DCM (2 x 20 mL).
The combined organic layers was washed with water (2 x 20 mL), brine (2 x 20
mL), dried over
91
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified
by silica gel
column chromatography eluting with Et0Ac/petroleum ether (3/97) to afford the
title compound.
GCMS (EI) calc'd for CiiHi iBrF30 [M]1: 294, 296 (1:1), found 294, 296 (1:1);
1HNMR (300
MHz, CDC13) 6 7.44-7.42 (m, 2H), 7.35-7.32 (m, 2H), 4.06-3.91 (m, 2H), 2.62-
2.54 (m, 2H),
2.21-2.03 (m, 2H).
Intermediate I-100
Racemic N- (1- (4-br omopheny1)-2,2,2-tr iflu or oethyl)-2-methylpr op an-2-
amine
Br
0
HN CF3
il\ 1-100
Step 1: 1-(4-bromopheny1)-2,2,2-trifluoroethanol
Br
01
HO F3I-100a
To a Me0H solution (100 mL) of 1-(4-bromopheny1)-2,2,2-trifluoroethanone was
added portionwise at 0-4 C sodium borohydride (4.50 g, 120.00 mmol). The
reaction mixture
was stirred at ambient temperature for an hour and then quenched by addition
of water (150 mL).
The mixture was extracted by Et0Ac (3 x 50 mL); combined organic layers was
washed with
water (100 mL) then brine (100 mL), dried over anhydrous Na2504 and filtered.
The filtrate was
concentrated in vacuo to give the title alcohol. 1H NMR (300 MHz, CDC13) 6
7.62 (d, J = 8.4
Hz, 2H), 7.45 (d, J= 8.4 Hz, 2H), 6.94-6.85 (m 1H), 5.25-5.16 (m, 1H).
92
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 2: 1-(4-bromopheny1)-2,2,2-trifluoroethyl trifluoromethanesulfonate
Br
Tf CF3I-100b
In a 100 mL round-bottom flask, 1-(4-bromopheny1)-2,2,2-trifluoroethanol (3.00
g, 11.76 mmol), 2,6-lutidine (1.52 g, 14.18 mmol) were combined with DCM (40
mL). The
resulting solution was cooled in an ice bath, and trifluoromethanesulfonic
anhydride (5.00 mL,
23.6 mmol) added portionwise. The reaction was stirred at 0-4 C for 1.5 hours
and then
quenched by addition of water (100 mL). The mixture was extracted with DCM (3
x 30 mL);
the combined organic layers was washed with water (3 x 100 mL) followed by
brine (3 x 100
mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated
in vacuo to give
the title triflate as that was used without further purification.
Step 3: N-(1-(4-bromopheny1)-2,2,2-trifluoroethyl)-2-methylpropan-2-amine
Br
HN CF3
I-100
In a 100 mL round-bottom flask, 1-(4-bromopheny1)-2,2,2-trifluoroethyl
trifluoromethanesulfonate (4.20 g, 10.88 mmol), tert-butylamine (1.90 mL,
17.72 mmol), and
potassium carbonate (2.93 g, 21.24 mmol) were combined with DCM (40 mL). The
resulting
solution was heated at 75 C for 16 hours at which time it was cooled, diluted
with DCM (100
mL) and washed with HC1 (1 N, 150 mL) followed by brine (150 mL). The organic
layer was
separated, dried over anhydrous Na2504 and filtered. The filtrate was
concentrated in vacuo,
and the resulting residue purified by silica gel column chromatography eluting
with petroleum
ether to afford the title amine. LCMS (ESI) calc'd for C12F116BrF3N [M + H]':
310, 312 (1:1),
found 310, 312 (1:1); 1H NMR (300 MHz, DMSO-d6) 6 7.57 (s, 4H), 4.57-4.53 (m,
1H), 2.55-
2.50 (m, 1H), 0.96 (s, 9H).
Table 11 discloses intermediates that were prepared in an analogous manner to
that of N-(1-(4-
bromopheny1)-2,2,2-trifluoroethyl)-2-methylpropan-2-amine I-100 using
different amines.
93
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Table 11.
Intermediate Structure Compound Name MS/1H NMR
LRMS (ESI) calc'd for C11H13BrF4N
Br
[M + H]+: 314, 316 (1:1), found 314,
ISI N-(1-(4-bromo-2- 316(1:1).
101
F fluoropheny1)-2,2,2- 1H NMR (300 MHz, CDC13) 6
7.40-
1-
HN CF3 trifluoroethyl)propan-2- 7.28 (m, 2H), 7.28 (d, J=
0.9 Hz,
amine 1H), 4.62 (q, J= 15 Hz, 1H),
2.78-
2.70 (m, 1H), 1.06 (d, J = 6.0 Hz,
6H).
LRMS (ESI) calc'd for C10H11BrF4N
Br
[M + H]+: 300, 302(1:1) found 300,
1-(4-bromo-2-
302 (1:1).
fluoropheny1)-N-ethyl-
1-102 F I. 1H NMR (300 MHz, CDC13) 6 7.43-
2,2,2-
F-)I N CF3 7.34 (m, 2H), 7.31-7.26 (m,
1H),
trifluoroethanamine
4.56 (q, J= 14.4 Hz, 1H), 2.70-2.57
(m, 2H), 1.11 (t, J= 7.2 Hz, 3H).
Br LRMS (ESI) calc'd for C12H15BrF4N
110 N-(1-(4-bromo-2-
3[M30+01] ).: 328, 330 (1:1), found 328,
1-103 F fluoropheny1)-2,2,2-
trifluoroethyl)-2- 1H NMR (300 MHz, CDC13) 6 7.46-
HN CF3
----c methylpropan-2-amine 7.25 (m, 3H), 4.61 (q, J=
7.8 Hz,
1H), 1.06 (s, 9H).
Br LRMS (ESI) calc'd for
C12H15BrC1F3N [M + H]+: 344, 346
1-104 Cl 01 N-(1-(4-Bromo-2-
chloropheny1)-2,2,2- (1:1), found 344, 346 (1:1).
1H NMR (300 MHz, CDC13) 6 7.81-
trifluoroethyl)-2-
HN CF37.70 (m, 1H), 7.62-7.58 (m, 1H),
-- methylpropan-2-amine
.---
7.53-7.49 (m, 1H), 5.03-4.97 (m,
1H), 1.60 (s, 9H).
LRMS (ESI) calc'd for
Br C13H14BrF3NO [M + H]+: 336, 338
0 6-(1-(4-Bromopheny1)- (1:1), found 336, 338
(1:1).
2,2,2-trifluoroethyl)-2- 1H NMR (300 MHz, CDC13) 6 7.51
1-105
\1
oxa-6- (dd, J= 6.6, 1.8 Hz, 2H), 7.24
(dd, J
11 C F3
0 azaspiro[3.3]heptane = 6.6, 1.8 Hz, 2H), 4.73
(s, 4H), 3.69
---/¨'
(q, J = 6.6 Hz, 1H), 3.50-3.40 (m,
4H).
94
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(R or S)-4-(1-(4-
Br bromopheny1)-2,2,2-
40 trifluoroethyl)thiomorp
holine, SFC retention LRMS (ESI) calc'd for
I-106a
time (Chiralcel OJ-3, C12H14BrF3NS [M + H]+:
341.
c3
s) 0.46*15cm,3um,
Hexane/Et0H, 95:05) =
3.79 minutes.
(R or S)-4-(1-(4-
Br bromopheny1)-2,2,2-
is trifluoroethyl)thiomorp
holine, SFC retention LRMS (ESI) calc'd for
I-106b
time (Chiralcel OJ-3, C12H14BrF3NS [M + H]+:
341.
c3
s) 0.46*15cm,3um,
Hexane/Et0H, 95:05) =
6.26 minutes.
Intermediate I-107A and 107B
(S) and (R)-5-br omo-2-(trifluor omethyl)-2,3-dihydr o-1H-inden-2-ol
Br O. OH
CF3I-107A and 107B
(Trifluoromethyl)trimethylsilane (6.06 g, 42.60 mmol) was added dropwise over
5 min to a solution of cesium fluoride (0.22 g, 1.42 mmol) and 5-bromo-1H-
inden-2(3H)-one
(3.00 g, 14.21 mmol) in THF (70 mL) at 0-4 C. The resulting solution was
stirred at ambient
temperature for 3 hours at which time tetrabutylammonium fluoride (5.90 g,
22.65 mmol) was
added. The mixture was stirred at ambient temperature for 3 additional hours,
and water (100
mL) added to quench the reaction. The resulting mixture was extracted with
Et0Ac (3 x 200
mL) and combined organic layers washed with brine (2 x 200 mL), dried over
anhydrous
sodium sulfate and filtered. The filtrate was concentrated in vacuo, and
resulting residue
purified by silica gel column chromatgraphy eluting with petroleum ether/ethyl
acetate (5/1) to
afford 0.55 g (17%) of racemic sample of the title alcohol as a brown oil. 1H
NMR (300 MHz,
CDC13) 6 7.49-7.33 (m, 2H), 7.13 (d, J= 8.1 Hz, 1H), 3.55-3.35 (m, 2H), 3.13-
2.93 (m, 2H).
This racemate (0.30 g, 1.07 mmol) was resolved by chiral prep-HPLC using the
conditions:
chiralpak IA-3 column (0.46 x 15 cm, 3 m); mobile phase, hexane/ethanol
(95/5); flow at 1.0
mL/min; detector: UV-220 nm. This chiral purification provided (S or R)-5-
bromo-2-
(trifluoromethyl)-2,3-dihydro-1H-inden-2-ol I-107A (retention time = 7.50
min): 1H NMR (300
MHz, CDC13) 6 7.48 (d, J= 2.1 Hz, 1H), 7.44-7.33 (m, 1H), 7.22 (d, J= 8.1 Hz,
1H), 6.30 (s, 1H),
95
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3.37-3.17 (m, 2H), 3.12-2.90 (m, 2H); and (S or R)-5-bromo-2-(trifluoromethyl)-
2,3-dihydro-
1H-inden-2-ol I-107B (retention time = 9.93 min): 1H NMR (300 MHz, CDC13) 6
7.48 (d, J = 2.1
Hz, 1H), 7.45-7.33 (m, 1H), 7.23 (d, J= 8.1 Hz, 1H), 6.30 (s, 1H), 3.39-3.17
(m, 2H), 3.12-2.92
(m, 2H).
Intermediate I-108A and I-108B
(S) and (R)-5-br omo-2-methyl-2 ,3-dihy dr o-11-1-inden-2-ol
Br Ogik OH
lir Me
I-108A and 108B
Methylmagnesium bromide Et20 solution (3 M, 1.58 mL, 4.74 mmol) was diluted
with 12 mL of anhydrous Et20 at 0-4 C. Then an Et20 (1 mL) solution of 5-bromo-
1H-inden-
2(3H)-one (0.50 g, 2.37 mmol) was added dropwise over 2 min. The reaction was
allowed to
warm to ambient temperature and maintained at the same temperature for
additional 2 hours. It
was then quenched by addition of saturated aqueous ammonium chloride (10 mL;
the queched
reactionwas extracted with Et0Ac (3 x 10 mL), and combined organic layers
washed with brine
(2 x 50 mL), dried over anhydrous Na2SO4and filtered; the filtrate was
concentrated in vacuo;
the resulting residue was purified by silica gel column chromatography,
eluting with petroleum
ether/Et0Ac (5/1) to afford 0.35 g (65%) of the racemic title alcohols as a
light oil. 1H NMR
(300 MHz, DMSO-d6) 6 7.43-7.32 (m, 1H), 7.32-7.23 (m, 1H), 7.11 (d, J = 8.0
Hz, 1H), 4.74 (s,
1H), 2.86 (s, 2H), 2.81 (s, 2H), 1.33 (s, 3H). This racemate (0.32 g, 1.41
mmol) was purified
further by chiral prep-HPLC (column: chiralpak IA 2 x 25 cm, 5 i.tm; detector
UV 254/220;
mobile phase A: hexane (95%)/B: Et0H (5%); flow rate 20 mL/min) to give 0.12 g
(38%) of (S
or R)-5-bromo-2-methyl-2,3-dihydro-1H-inden-2-ol I-108A (retention time = 9.31
min): 1H
NMR (300 MHz, DMSO-d6) 6 7.38-7.33 (m, 1H), 7.31-7.23 (m, 1H), 7.11 (d, J= 8.0
Hz, 1H),
4.74 (s, 1H), 2.86 (s, 2H), 2.81 (s, 2H), 1.33 (s, 3H), and 0.12 g (38%) of (S
or R)-5-bromo-2-
methy1-2,3-dihydro-1H-inden-2-ol I-108B (retention time = 11.79 min): 1H NMR
(300 MHz,
DMSO-d6) 6 7.39-7.32 (m, 1H), 7.31-7.23 (m, 1H), 7.11 (d, J= 8.0 Hz, 1H), 4.73
(s, 1H), 2.87 (s,
2H), 2.81 (s, 2H), 1.33 (s, 3H).
Intermediate I-109A and 109B
(R) and (S)-2- (4-br omopheny1)-2-(tr iflu or omethyl)piper idine
Br 0C F3
HN
I-109A and 109B
Step 1: 4-bromobenzoyl chloride
96
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Br
0
0 CI I-109a
A solution of 4-bromobenzoic acid (10.00 g, 49.70 mmol) in sulfurous
dichloride
(59.20 g, 0.50 mol) was heated at 80 C for 16 hours. The mixture was then
concentrated in
vacuo to afford crude product that was used without further purification.
Step 2: tert-butyl 3-(4-bromobenzoy1)-2-oxopiperidine-1-carboxylate
Br
0 0 0
0 N A0
I-109b
Lithium bis(trimethylsilyl)amide (1 M THF solution, 2.11 mL, 2.11 mmol) was
added to a solution of tert-butyl 2-oxopiperidine-1-carboxylate (0.20 g, 1.00
mmol) in THF (2
mL) at -78 C. The resulting mixture was stirred at the same temperature for 10
min at which
time 4-bromobenzoyl chloride (0.22 g, 1.00 mmol) was added. The reaction was
warmed to
ambient temperature and stirred for an additional hour before the addition of
saturated aqueous
ammonium chloride solution (20 mL). The quenched reaction was extracted with
Et0Ac (3 x 10
mL), and the combined organic phases dried over anhydrous Na2SO4, filtered
andconcentrated in
vacuo . The residue was purified by silica gel column chromatography eluting
with
Et0Ac/petroleum (0/1 to 1/1) to afford crude tert-butyl 3-(4-bromobenzoy1)-2-
oxopiperidine-1-
carboxylate. LCMS (ESI) calc'd for: C17H21BrN04[M + H] ': 382, 384 (1:1),
found 382, 384
(1:1).
97
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 3: 6-(4-bromopheny1)-2,3,4,5-tetrahydropyridine
Br
N
I-109c
tert-Butyl 3-(4-bromobenzoy1)-2-oxopiperidine-1-carboxylate (2.00 g, 5.23
mmol)
was combined with HC1 (8 M, 43.6 mL, 0.52 mol) at ambient temperature. The
resulting
solution was heated at 80 C for 16 hours. The reaction was then poured into
saturated aqueous
Na2CO3 (50 mL) and extracted with Et0Ac (3 x 50 mL). The combined organic
layers was
dried over Na2SO4 filtered andconcentrated in vacuo. The residue was purified
by silica gel
column chromatography eluting with Et0Ac/petroleum (0/1-1/1) to afford the
title imine.
LCMS (ESI) calc'd for: C11H13BrN [M + H] 238, 240 (1:1), found 238, 240 (1:1);
1H NMR
(300 MHz, CDC13) 6 7.66-7.63 (m, 2H), 7.52-7.47 (m, 2H), 3.92-3.80 (m, 2H),
2.62-2.56 (m,
2H), 1.88-1.79 (m, 2H),1.78-1.66 (m, 2H).
Step 4: (R) and (S)-2-(4-bromopheny1)-2-(trifluoromethyl)piperidine
Br
CF3
HN
I-109A and 109B
To a solution of 6-(4-bromopheny1)-2,3,4,5-tetrahydropyridine in dry
acetonitrile
(3 mL) were added trifluoromethanesulfonic acid (3.30 g, 21.96 mmol),
potassium hydrogen
fluoride (3.94 g, 50.40 mmol) and trimethyl(trifluoromethyl)silane (5.97 g,
42.00 mmol)
successively at 0-4 C. The resulted mixture was stirred at ambient temperature
for 48 hours.
Then the reaction was quenched by addition of saturated aqueous NaHCO3 (50 mL)
followed by
extraction with Et0Ac (3 x 30 mL). The combined organic layers was dried over
anhydrous
Na2504, filtered and concentrated in vacuo . The residue was purified by
silica gel column
chromatography eluting with DCM/petroleum (0/1-1/1) to afford 0.70 g (54%) of
racemic
sample of the title products. This racemate (0.60 g, 1.95 mmol) was then
subjected to
preparative chiral HPLC chromatography (column: Chiralpak IA, 2 x 25cm; mobile
phase: 10%
Et0H in hexane, VN) to afford (R or S)-2-(4-bromopheny1)-2-
(trifluoromethyl)piperidine I-
109A (retention time = 4.74 min); LRMS (ESI) calc'd for C12H14BrF3N [M + H]':
308, 310 (1:1),
found 308, 310 (1:1); 1H NMR (300 MHz, CDC13) 6 7.67-7.65 (m, 2H), 7.60-7.57
(m, 2H), 3.16-
3.03 (m, 1H), 2.73-2.63 (m, 1H), 2.50-2.42 (m, 1H), 2.25-1.93 (m, 1H), 1.79-
1.71 (m, 1H), 1.67-
1.53 (m, 3H), 1.36-1.30 (m, 1H), and (R or S)-2-(4-bromopheny1)-2-
(trifluoromethyl)piperidine
I-109B (retention time = 5.48 min). LRMS (ESI) calc'd for C12H14BrF3N [M + H]
308, 310
(1:1), found 308, 310 (1:1); 1H NMR (300 MHz, CDC13) 6 7.67-7.65 (m, 2H), 7.59-
7.49 (m, 2H),
98
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
3.10-2.95 (m, 1H), 2.73-2.63 (m, 1H), 2.50-2.42 (m, 1H), 2.25-1.93 (m, 1H),
1.79-1.71 (m, 1H),
1.67-1.53 (m, 3H), 1.38-1.32 (m, 1H).
Intermediates I-110A and 110B
3-(3-amino-4- (b enzyloxy)-1H-p yr azolo [4,3-clp yr idin-1-yl)butanenitr ile
NC
\
N-N
N H2
cy\
N OBn I-110A and 110B
To 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine (5.00 g, 20.8 mmol) in
acetonitrile (69.4 ml) was added (E)-but-2-enenitrile (1.54 g, 22.9 mmol) and
DBU (3.45 ml,
22.89 mmol). The flask was sealed and heated to 25 C for 23 hours, before
being concentrated
and purified directly on silica, eluting with 5-50% EA/hexanes. The desired
fractions were
concentrated in vcauo to afford the desired product. LRMS (ESI) calc'd for
C17H18N50 [M+H]':
308, found 308 1H NMR (600 MHz, CDC13): 6 7.84 (d, J = 6.0 Hz, 1H), 7.45 (d, J
= 7.2 Hz, 2H),
7.37 (m, 2H), 7.32 (m, 1H), 6.73 (d, J = 6.6 Hz, 1H), 5.51 (s, 2H), 4.67 (br
s, 1H), 4.46 (br s, 2H),
2.92 (dd, J= 16.8, 7.8 Hz, 1H), 2.82 (dd, J= 16.8, 7.8 Hz, 1H), 1.59 (d, J =
6.6 Hz, 3H).
Resolution of enantiomers was achieved by SFC purification using a Chiralpak
AD-H,
21 x 250 mm column, at 70 mL/min with 20% methanol modifier. Retention times
were 3.74
minutes (Intermediate I-110A) & 4.41 minutes (Intermediate I-110B).
I-110A (S or R)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-y1)-3-
cyclopropylpropanenitrile. LRMS (ESI) calc'd for Ci9H20N50 [M+H]': 334, found
334.
I-110B (S or R)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-y1)-3-
cyclopropylpropanenitrile. LRMS (ESI) calc'd for Ci9H20N50 [M+H]': 334, found
334.
The following examples outlined in Table 12 were prepared by analogy using the
general
procedure outlined above for Intermediates I-110A & I-110B above.
Table 12.
Inter mediate Structure Compound Name MS
(S)-3-(3-amino-4-
(benzyloxy)-1H-
NCpyrazolo[4,3-c]pyridin-l-y1)- LRMS (ESI) calc'd
Hs N 3-cyclopropylpropanenitrile for
Ci9H20N50
I-111A / \ ;N
(Derived from Peak 1 via [M+H]: 334,
N ¨ NH2 SFC: Phenomenex Lux-2, 21 found 334
OBn
x 250 (mm), 25% Me0H in
CO2, rT = 4.36)
99
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(R)-3-(3-amino-4-
(benzyloxy)-1H-
NC')IA pyrazolo[4,3-c]pyridin-1-y1)- LRMS (ESI)
calc'd
H
N 3-cyclopropylpropanenitrile for C19H20N50
I-111B / N
\ ;
(Derived from Peak 2 via [M+H]+: 334,
N ¨ NH2 SFC: Phenomenex Lux-2, 21 found 334
OBn
x 250 (mm), 25% Me0H in
CO2, rT = 5.21)
(S or R)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
[4,3-c]pyridin-1-y1)-34(S or
V CN R)-2,2-difluorocyclopropyl) LRMS (ESI) calc'd
FN¨N propanenitrile (Derived from for C19H18F2N50
I-112A-1ci.......¨NH2
diastereomer 1, Peak 1 via [M+H]+: 370,
\
/
N OBn
SFC: Phenomenex Lux-2, 21 found 370.
x 250 (mm), 20% methanol
containing 0.25% DMEA in
CO2, rT = 3.16)
(S or R)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
[4,3-c]pyridin-1-y1)-34(S or
V CN R)-2,2-difluorocyclopropyl) LRMS (ESI) calc'd
FN¨N propanenitrile (Derived from for C19H18F2N50
I-112A-2ci.......¨NH2
diastereomer 1, Peak 2 via [M+H]+: 370,
\
/
N OBn
SFC: Phenomenex Lux-2, 21 found 370.
x 250 (mm), 20% methanol
containing 0.25% DMEA in
CO2, rT = 4.02)
(S or R)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
[4,3-c]pyridin-1-y1)-34(S or
CN R)-2,2-difluorocyclopropyl) LRMS (ESI) calc'd
I-112B-1 ¨NH2
FVN¨N propanenitrile (Derived from for C19H18F2N50
ci.......
diastereomer 2, Peak 1 via [M+H]+: 370,
\
/
N OBn
SFC: Phenomenex Lux-2, 21 found 370.
x 250 (mm), 20% methanol
containing 0.25% DMEA in
CO2, rT = 3.16)
100
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(S or R)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
[4,3-c]pyridin-1-y1)-34(S or
V CN R)-2,2-difluorocyclopropyl) LRMS (ESI) calc'd
FN-N propanenitrile (Derived from for C19H18F2N50
I-112B-2ci.......¨NH2
diastereomer 2, Peak 2 via [M+H]+: 370,
\ N/ OBn SFC: Phenomenex Lux-2, 21 found 370.
x 250 (mm), 20% methanol
containing 0.25% DMEA in
CO2, rT = 4.02)
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-34(S or LRMS (ESI)
calc'd
Me....
...= (- N R)-2,2-dimethylcyclopropyl) for C21H24N50
N-
I-113A-1 e...._¨NH2 propanenitrile (Derived from [M+H]+: 362,
\
N ' OBn diastereomer 1, Peak 1 via found 362.
SFC: Phenomenex Lux-2, 21
x 250 (mm), 20% methanol
in CO2, rT = 5.04)
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-34(S or LRMS (ESI)
calc'd
Me....
...= (- N R)-2,2-dimethylcyclopropyl) for C21H24N50
N-
I-113A-2 e...._¨NH2 propanenitrile (Derived from [M+H]+: 362,
\
N ' OBn diastereomer 1, Peak 2 via found 362.
SFC: Phenomenex Lux-2, 21
x 250 (mm), 20% methanol
in CO2, rT = 6.47)
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-34(S or LRMS (ESI)
calc'd
Me....
...= (- N R)-2,2-dimethylcyclopropyl) for C21H24N50
N-
I-113B-1 e...._\¨NH2 propanenitrile (Derived from [M+H]+: 362,
\'
N OBn diastereomer 2, Peak 1 via found 362.
SFC: Phenomenex Lux-2, 21
x 250 (mm), 20% methanol
in CO2, rT = 5.21)
101
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-34(S or LRMS
(ESI) calc'd
Me
R)-2,2-dimethylcyclopropyl) for C21H24N50
N
I-113B-2 propanenitrile (Derived from [M+H]+:
362,
N
OBn diastereomer 2, Peak 2 via found
362.
SFC: Phenomenex Lux-2, 21
x 250 (mm), 20% methanol
in CO2, rT = 6.31)
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-3- LRMS (ESI)
calc'd
I-114A NH2 cyclobutylpropanenitrile for
C20H22N50
(Derived from Peak 1 via [M+H]+: 348,
1\1/ OBn SFC: Chiralpak, AS-H, 21 x found 348.
250 (mm), 15% methanol in
CO2, rT = 3.30)
(R or S)-3-(3-amino-4-
(benzyloxy)-1H-pyrazolo
CN [4,3-c]pyridin-1-y1)-3- LRMS (ESI)
calc'd
I-114B NH2 cyclobutylpropanenitrile for
C20H22N50
(Derived from Peak 2 via [M+H]+: 348,
1\1/ OBn SFC: Chiralpak, AS-H, 21 x found 348.
250 (mm), 15% methanol in
CO2, rT = 3.61)
Example II-1
(R or S)-4-((1-(1-cyanopr op an -2-y1)-4-oxo-4,5-dihydr o-1H-pyr azolo [4,3-
c]pyr idin -3-
yl)amin o)-N,N-dimethylbenzenesulfon amide
NC
00
\\
S,N,
H II-1
Step 1: (R or S)-4-((4-(benzyloxy)- 1 -(1 -cyanopropan-2-y1)- 1H-pyrazolo [4,3
-c]pyridin-3 -
yl)amino)-N,N-dimethylbenzenesulfonamide
102
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
NC
0 0
S,N,
NN ,
OBn
N
II-la
To (R or S)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-
yl)butanenitrile (I-108A) (40 mg, 0.13 mmol), N,N-dimethy1-4-bromophenyl
sulfonamide (68.8
mg, 0.260 mmol), Pd2dba3 (30 mg, 0.033 mmol), 2-di-tert-butylphosphino-3,4,5,6-
tetramethyl-
2',4',6'-triisopropy1-1,1'-biphenyl (47 mg, 0.098 mmol), and potassium
phosphate tribasic (55.3
mg, 0.260 mmol) in a degassed sealed microwave vial, was added t-amyl alcohol
(1.74 mL) and
the reaction was degassed again by successive evacuation/argon backfill (x3)
prior to heating at
75 C overnight. The reaction was concentrated and purified directly by silica
chromatography,
eluting with 5-40% Et0Ac/hexane. The product was collected and concentrated to
afford the
desired product, 1-1a, as a light colorless solid. LRMS (ESI) calc'd for
C25H27N603S [M+H]
491, found 491.
Step 2: (R or S)-4-((1-(1-cyanopropan-2-y1)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-3-
yl)amino)-N,N-dimethylbenzenesulfonamide
To (R or S)-4-((4-(benzyloxy)-1-(1-cyanopropan-2-y1)-1H-pyrazolo[4,3-
c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide, 1-1a, (84.2 mg, 0.172
mmol) was
added Pd/C (18 mg, 0.17 mmol, 10 wt.% Pd loading) and ethyl acetate (0.60 mL)
and the
reaction was evacuated/backfilled with hydrogen and stirred at 25 C under 1
atm overnight. The
reaction was then diluted with DCM and filtered through Celite and washed with
DCM and the
filtrate was concentrated in vacuo and purified by silica chromatrography,
eluting with 0-5%
Me0H/DCM to afford a white solid, II-1. LRMS (ESI) calc'd for C18H21N6035
[M+H]': 401,
found 401 1H NMR (600 MHz, CDC13): 6 11.17 (d, J= 6.0 Hz, 1H), 8.67 (s, 1H),
7.93 (d, J=
9.0 Hz, 2H), 7.62 (d, J = 9.0 Hz, 2H), 7.25 (app. t, J = 6.6 Hz, 1H), 6.65 (d,
J= 7.2 Hz, 1H), 5.04
(app. sextet, J= 6.6 Hz, 1H), 3.20-3.10 (m, 2H), 2.58 (s, 6H), 1.51 (d, J =
6.0 Hz, 3H).
The following Intermediates outlined in Table 13 were prepared by analogy
using the general
procedure outlined above for Intermediate II-1 above.
Table 13.
Example Structure Name MS
NC
0 ', , (R or S)-4-((1-(1-cyanopropan-2- LRMS
(ESI)
II-2 y0-4-oxo-4,5-dihydro-1H-pyrazol
calc'd for
/ o[4,3-c]pyridin-3-yl)amino)-N,N-
CisH21N603S
H dimethylbenzenesulfonami
de [M+1-1]:
401,
103
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(derived from I-108B) found 401
NCA (S)-4-((1-(2-cyano-1- LRMS (ESI)
H' N Me, cyclopropylethyl)-4-oxo-4,5- calc'd for
/ \ s,N N¨Me
H 3-yl)amino)-N,N-dimethylbenzene- [M+H]+: 427,
II-3 =
' . go2 dihydro-1H-pyrazolo[4,3-c]pyridin- C20H23N6035
N
HN
0
sulfonamide (derived from I-109A) found 427
NC (R)-4-((1-(2-cyano-1-cyclopropyl LRMS (ESI)
H
N Me, ethyl)-4-oxo-4,5-dihydro-1H- calc'd for
11-4 / \ ;N NyMe
= go2 PYrazolo[4,3-c]pyridin-3-y0amino)- C20H23N6035
HN
N,N-dimethylbenzenesulfonamide [M+H]+: 427,
HN
0
(derived from I-109B) found 427
4-((1-((S or R)-2-cyano-1-((S or R)-
F
õo 2,2-difluorocyclopropyl)ethyl)-4-
LRMS (ESI)
o
calc'd for
11-5i
ss oxo-4,5-dihydro-1H-pyrazolo[4,3-
i Ai N
I C20H21F2N603S
/ \ N WI c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 463,
N
H o dimethylbenzenesulfonamide
found 463
(derived from I-110A-1)
4-((1-((S or R)-2-cyano-1-((S or R)-
F
õo 2,2-difluorocyclopropyl)ethyl)-4-
LRMS (ESI)
0
calc'd for
11-6\I-ii
ss oxo-4,5-dihydro-1H-pyrazolo[4,3-
c ... N
I C20H21F2N603S
/ \ N WI c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 463,
N
H o dimethylbenzenesulfonamide
found 463
(derived from I-110A-2)
4-((1-((S or R)-2-cyano-1-((S or R)-
F
oõo 2,2-difluorocyclopropyl)ethyl)-4-
LRMS (ESI)
calc'd for
I1-72
ss oxo-4,5-dihydro-1H-pyrazolo[4,3-
(,1 N
I C20H21F2N603S
/ \ N WI c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 463,
N
H o dimethylbenzenesulfonamide
found 463
(derived from I-110B-1)
4-((1-((S or R)-2-cyano-1-((S or R)-
F
õo 2,2-difluorocyclopropyl)ethyl)-4-
LRMS (ESI)
0
calc'd for
11-8\I-ii
ss oxo-4,5-dihydro-1H-pyrazolo[4,3-
c ... N
I C20H21F2N603S
/ \ N WI c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 463,
N
H o dimethylbenzenesulfonamide
found 463
(derived from I-110B-2)
104
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
4-((1-((S or R)-2-cyano-1-((S or R)-
Me LRMS (ESI)
Met>____c_CN 2,2-dimethylcyclopropyl)ethyl)-4-
oõo calc'd for
II-9 N-N \SN oxo-4,5-dihydro-1H-pyrazolo [4,3-
C22H27N603S
c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 455,
N
H o dimethylbenzenesulfonamide
found 455
(derived from I-111A-1)
4-((1-((S or R)-2-cyano-1-((S or R)-
Me LRMS (ESI)
2,2-dimethylcyclopropyl)ethyl)-4-
oõo calc'd for
II-10 N-N \SN oxo-4,5-dihydro-1H-pyrazolo [4,3-
C22H27N603S
c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 455,
N
H o dimethylbenzenesulfonamide
found 455
(derived from I-111A-2)
4-((1-((S or R)-2-cyano-1-((S or R)-
Me LRMS (ESI)
Me___(__CN 2,2-dimethylcyclopropyl)ethyl)-4-
0õ0 calc'd for
II-11 N-N \SN oxo-4,5-dihydro-1H-pyrazolo [4,3-
c]pyridin-3-yl)amino)-N,N- C22H27N603S
WI
H [M+H]+: 455,
N
H o dimethylbenzenesulfonamide
found 455
(derived from I-111B-1)
4-((1-((S or R)-2-cyano-1-((S or R)-
Me LRMS (ESI)
Met>____c_CN 2,2-dimethylcyclopropyl)ethyl)-4-
oõo calc'd for
11-12 N-N \SN oxo-4,5-dihydro-1H-pyrazolo [4,3-
C22H27N603S
/\\ NW I c]pyridin-3-yl)amino)-N,N-
H [M+H]+: 455,
N
H o dimethylbenzenesulfonamide
found 455
(derived from I-111B-2)
(S or R)-4-((1-(2-cyano-1- LRMS (ESI)
oõo
,s , cyclobutylethyl)-4-oxo-4,5- calc'd for
N-N 0o
N
I
dihydro-1H-pyrazolo[4,3-c]pyridin- C 21 H25N603 S
11-13
H
N 3-yl)amino)-N,N-dimethylbenzene [M+H]+: 441,
H o
sulfonamide (derived from I-112A) found 441
(S or R)-4-((1-(2-cyano-1- LRMS (ESI)
oõo
,s , cyclobutylethyl)-4-oxo-4,5- calc'd for
N-N 0o
N
I
dihydro-1H-pyrazolo[4,3-c]pyridin- C 21 H25N603 S
11-14
H
N 3-yl)amino)-N,N-dimethylbenzene [M+H]+: 441,
H o
sulfonamide (derived from I-112B) found 441
0 0 (S or R)-3-cyclobuty1-3-(4-oxo-3- LRMS (ESI)
sNs'
11-15 NINI al NvD ((4-(pyrrolidin-1-ylsulfonyl)phenyl) calc'd
for
/ \ N
H amino)-4,5-dihydro-1H-pyrazolo C 23 H2 gN603 S
N
H o [4,3-c]pyridin-1-yl)propanenitrile [M+H]+:
467,
105
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(derived from I-112A) found 467
CN (S or R)-3-cyclobuty1-3-(4-oxo-3- LRMS (ESI)
II =0 0
((4-(pyrrolidin-1-ylsulfonyl)phenyl) calc'd for
- 0
16
N amino)-4,5-dihydro-1H-pyrazolo C23 H28N603 S
[4,3-c]pyridin-1-y1) propanenitrile [M+H]+:
467,
H
(derived from I-112B) found 467
Example 11-17
(3S)-3-cyclopr opy1-3-13- R4-fluor ophenyl)amin o1-4-oxo-4,5-dihydr o-1H -pyr
azolo [4,3-
c]p yr idin -1-y1 }pr op anenitrile
CN
N, H
iN
HN HN
0 II-17
To (S)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-y1)-3-
cyclopropylpropanenitrile (I-109A) (30 mg, 0.09 mmol), 1-bromo-4-fluoro-
benzene(24.5 mg,
0.135 mmol), Pd2(dba)3 (20.6 mg, 0.022 mmol), 2-di-tert-butylphosphino-3,4,5,6-
tetramethyl-
2',4',6'-triisopropy1-1,1'-biphenyl (26 mg, 0.054 mmol), and potassium acetate
(17.7 mg, 0.180
mmol) in a degassed sealed reaction vial, was added isopropanol (0.360 mL).
The reaction
mixture was heated to 80 C overnight. The reaction was cooled to rt, and 0.2
mL of
trifluoroacetic acid was added. The reaction was stirred at room temperature
for an additional 3
h. The reaction mixture was diluted with 3.5mL of DMSO, filtered using a 0.2
micron
WHATMAN syringe, and purified with reverse phase chromatography, to afford
compound II-
17. LRMS (ESI) calc'd for C181-116F N50 [M+H] 338.1, found 338.14.
The following examples outlined in Table 14 were prepared by analogy using the
general
procedure outlined above for Example 11-17 above.
Table 14.
Example Structure Compound Name
MS
(35)-3-cyclopropy1-3-[4-oxo-3- LRMS
(ESI)
( {4-[(1R or S)-2,2,2-trifluoro-1- calc'd
for
11-18
;N
CF3 hydroxy-l-methylethyl]phenyl}
C21 H21 F3N5 02
HN HN = OH Me amino)-4,5-dihydro-1H-
[M+H]+: 432,
pyrazolo[4,3-c]pyridin-1- found
432
106
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
yl]propanenitrile (from I-2A)
(3S)-3-cyclopropy1-3-[4-oxo-3-
LRMS (ESI)
({4-[(1S or R)-2,2,2-trifluoro-l-
sCN calc'd
for
II-19 H hydroxy-l-methylethyl]phenyl}
N C211-121F3N502
CF3 amino)-4,5-dihydro-1H-
[M+H]+: 432,
HN HN . OH pyrazolo[4,3-c]pyridin-1-
Me found 432
O yl]propanenitrile (from I-2B)
(3S)-3-cyclopropy1-3-(3-{[(1R or
LRMS (ESI)
S)-1-hydroxy-1-(trifluoromethyl)-
CN calc'd
for
N, H 2,3-dihydro-1H-inden-5-yl]
C22H21F3N502
11-20
40 C amino} -4-oxo-4,5-dihydro-1H-
F3 pyrazolo[4,3-c]pyridin-1-
[M+H]+: 444,
HN HN OH found
444.
O yl)propanenitrile (from I-3A)
(35)-3-cyclopropy1-3-(3- {[(1S or
LRMS (ESI)
R)-1-hydroxy-1-(trifluoromethyl)-
CN calc'd
for
II-21 H 2,3-dihydro-1H-inden-5-yl]
N C22H21F3N502
40 C amino} -4-oxo-4,5-dihydro-1H-
F3 pyrazolo[4,3-c]pyridin-1-
[M+H]+: 444,
HN HN OH found
444.
O yl)propanenitrile (from I-3B)
A
(35)-3-cyclopropy1-3-{3-[(1,1- LRMS (ESI) sCN
N, H dioxido-2,3-dihydro-1- calc'd
for
11-22
benzothiophen-5-yl)amino]-4-oxo- C201-120N503S
HN HN 41k, so2 4,5-
dihydro-1H-pyrazolo [4,3- [M+H]+: 410,
0 c]pyridin-1-y1} propanenitrile found
410.
(35)-3-{3-[(2-tert-buty1-1,1-
sCN LRMS (ESI)
N , H 1\/1)e.N/le dioxido-2,3-dihydro-1,2-
11-23 / \ iN N Me benzisothiazol-5-yl)amino]-4-oxo-
calc'd for
HN HN . k12 4,5-dihydro-1H-pyrazolo [4,3-
C23H27N6035
[M+H]+: 467,
0 c]pyridin-l-y1} -3-
found 467.
cyclopropylpropanenitrile
LRMS (ESI)
AsCN CN 4-({1-[(1S)-2-cyano-l-
N, H calc'd
for
11-24 cyclopropylethy1]-4-oxo-4,5-
Ci9Hi7N60
dihydro-1H-pyrazolo[4,3-c]
HN HN 41,
pyridin-3-yl}amino)benzonitrile
[M+H]+: 345,
0 found
345.
107
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
A
CN
(3S)-3-cyclopropy1-3-(4-oxo-3- LRMS (ESI) i<s
N, H {[4-(trifluoromethyl) calc'd for
/ \ IN phenyl]amino}-4,5-dihydro-1H-
C19H17F3N50
II-25
HN HN = C F3 pyrazolo[4,3-c]pyridin-1- [M+H]+: 388,
0 yl)propanenitrile found 388.
Al<sCN (35)-3-cyclopropy1-3-(3-{[4-
LRMS (ESI)
N,H calc'd for
11-26 (methylsulfonyl)phenyl]amino} -4-
/ \ /N C 191120N-5 03S
oxo-4,5-dihydro-1H-pyrazolo[4,3-
HN HN 41, SO2Me c]py [M+H]+: 398,
ridin-l-yl)propanenitrile
0 found 398.
Ai<sCN (35)-3-cyclopropy1-3-{4-oxo-3-
LRMS (ESI)
N, H calc'd for
I1-27 N F [(3,4,5-trifluorophenyl)amino]-
/ \ / C18H15F3N50
. F 4,5-dihydro-1H-pyrazolo[4,3-
111q-1(IN [M+H]+: 374,
0 c]pyridin-l-yl}propanenitrile
F found 374.
CN
(35)-3-cyclopropy1-3-{3-[(2- LRMS (ESI)
N,H
methyl-1,1-dioxido-2,3-dihydro- calc'd for
Me
/ \ iN N- 1,2-benzisothiazol-5-yl)amino]-4- C201-
121N603S
11-28
HN HN . S 2 oxo-4,5-dihydro-1H-pyrazolo[4,3- [M+H]+:
425,
0 c]pyridin-l-yl}propanenitrile found 425.
Ai<sCN (35)-3-cyclopropy1-3-{3-[(2-
LRMS (ESI)
N,H calc'd for
11-29 F fluoropyridin-4-yl)amino]-4-oxo-
/ \ /N ____dõ Ci7H16FN6
4,5-dihydro-1H-pyrazolo[4,3-
H
HN N N [M+H]+: 339,
\ /
c]pyridin-l-yl}propanenitrile
0 found 339.
A
CN (35)-3-cyclopropy1-3-{4-oxo-3- LRMS
(ESI) i<s
H [(1-oxo-2,3-dihydro-1H-inden-5- calc'd
for
11-30 N
yl)amino]-4,5-dihydro-1H- C211120N502
HN HN .4111 0 pyrazolo[4,3-c]pyridin-1-y1} [M+H]+:
374,
0 propanenitrile found 374.
Ai<sCN (35)-3-cyclopropy1-3-[3-(2,3-
LRMS (ESI)
N,H calc'd for
II-31 dihydro-l-benzofuran-5-ylamino)-
/ \ /N C20H2ON5 02
HN HN 4. 0 4-oxo-4,5-dihydro-1H-pyrazolo
[4,3-c]pyridin-1-yl]propanenitrile [M+H]+: 362,
0 found 362.
108
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
LRMS (ESI)
'isCN (3S)-3-[3-(1,3-benzodioxo1-5-
N,H calc'd for
0
I1-32 ylamino)-4-oxo-4,5-dihydro-1H-
-Th
I C19H18N503
HN HN
# 0 PYrazolo[4,3-c]pyridin-l-y1]-3-
[M+H]+: 364,
cyclopropylpropanenitrile
O found 364.
LRMS (ESI)
" CN (35)-3-cyclopropy1-3-[4-oxo-3-
N, H calc'd for
(quinolin-6-ylamino)-4,5-dihydro-
-
/ 1H-pyrazolo[4,3-c]pyridin-l-yl] C21}119N60
11-33
HN HN . N [M+H]+: 371,
propanenitrile
O found 371.
A
(35)-3-cyclopropy1-3-(3-{[3- LRMS (ESI) s
" CN
N,H fluoro-4-(methylsulfonyl) calc'd for
11-34 F
phenyl]amino}-4-oxo-4,5-dihydro- C19H19FN5 03 S
HN HN 41, SO2Me 1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 416,
O
yl)propanenitrile found 416.
LRMS (ESI)
" CN (35)-3-cyclopropy1-3-[4-oxo-3-
N, H calc'd for
N
11-35 (quinoxalin-6-ylamino)-4,5-
i . Ni pyridin-l-yl]propanenitril
dihydro-1H-pyrazolo[4,3-c] C20H18N7
HN HN [M+H]+: 372,
e
O found 372.
LRMS (ESI)
" CN (35)-3- {3-[(4-chlorophenyl)
N, H calc'd for
11-36 amino]-4-oxo-4,5-dihydro-1H-
/ C18H17C1N50
pyrazolo[4,3-c]pyridin-l-y1} -3-
HN HN . Cl [M+H]+: 354,
cyclopropylpropanenitrile
O found 354.
' CN (35)-cyclopropy1-3434 {4- [(1-
LRMS (ESI)
N , H calc'd for
N )--Me C211-124N503S
II-37 Me methylethyl)sulfonyl]phenyl}amin
/ \ /
o)-4-oxo-4,5-dihydro-1H-pyrazolo
HN SO,
HN . .- [4,3-c]pyridin-1-yl]propanenitrile
[M+H]+: 426,
O found 426.
' CN (3S)-(3-{[4-(tert-butylsulfonyl) LRMS
(ESI)
N, H calc'd for
N )L¨Mee C22H26N5 03 S
11-38 . .- Me Me phenyl]amino}-4-oxo-4,5-dihydro-
/ \ /
1H-pyrazolo[4,3-c]pyridin-l-y1)-3-
HN SO,
H [M+H]+: 440,
N
cyclopropylpropanenitrile
O found 440.
109
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
CN N-tert-butyl-4-{[1S-(2-cyano-1- LRMS
(ESI)
N, H
/1V17, cyclopropylethyl)-4-oxo-4,5- calc'd for
11-39 HN---\"'e
. g02 Me dihydro-1H-pyrazolo[4,3-c] C22H27N6035
HN HN
pyridin-3-yl]amino} [M+H]+: 455,
0
benzenesulfonamide found 455.
CN (35)-3434{44(1R or 1S)-1- LRMS (ESI)
N,H
II-40 amino-2,2,2-trifluoroethyl] calc'd for
CF3
Me phenyl} amino)-4-oxo-4,5-dihydro- C24H28F3N60
HN HN . N..4---Me
1H-pyrazolo[4,3-c]pyridin-l-y1]-3- [M+H]+: 473,
0 H Me
cyclopropylpropanenitrile found 473
(35)-3434{44(1S or 1R)-1-
CN LRMS (ESI)
H
11-40 N amino-2,2,2-trifluoroethyl]
CF3 m phenyl} amino)-4-oxo-4,5-dihydro- calc'd
for
HN HN . N----kle 1H-pyrazolo[4,3-c]pyridin-l-y1]-3- C H F N
0
24 28 3 6
0 H Me [M+H]+: 473,
cyclopropylpropanenitrile
found 473
CN 4-({1-[(1S)-2-cyano-1- LRMS (ESI)
N, H
I1-41 cyclopropylethy1]-4-oxo-4,5- calc'd for
NN
dihydro-1H-pyrazolo[4,3- C21H25N6035
HN HN .Me--./Me
02
c]pyridin-3-yl}amino)-N-ethyl-N- [M+H]+: 441,
0
methylbenzenesulfonamide found 441
(3S)-3-cyclopropy1-3-(4-oxo-3- LRMS (ESI)
11-42 CN 0 {[4-(piperidin-l-ylsulfonyl) calc'd for
H
N
HN phenyl]amino}-4,5-dihydro-1H-
C23H27N6035
j\I
SO,
HN 4. - pyrazolo[4,3-c]pyridin-1-y1) [M+H]+:
467,
propanenitrile found 467
0
4-({1-[(1S)-2-cyano-1-
CN LRMS (ESI)
N, H cyclopropylethy1]-4-oxo-4,5-
'N...¨( dihydro-1H-pyrazolo[4,3-c]
II-43 Me Me calc'd for
HN HN . 02 Me pyridin-3-yl}amino)-N-methyl-N-
C22H27N603S
[M+H]+: 455,
0 (1-methylethyl)
found 455
benzenesulfonamide
110
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
A
4-( {1-[(1S)-2-cyano- 1- LRMS (ESI) sCN
II-44 H cyclopropylethy1]-4-oxo-4,5- calc'd for
N Me
NNH dihydro-1H-pyrazolo[4,3-c] C19H21N6035
HN HN . 02 pyridin-3-yl}amino)-N- [M+H]+: 413,
0 methylbenzenesulfonamide found 413
II-45 CN
(35)-3-cyclopropy1-3-(4-oxo-3- LRMS (ESI)
N, H (--- {[4-(pyrrolidin-l-ylsulfonyl) calc'd for
N" phenyl]amino} -4,5-dihydro- 1H-
C22H25N6035
HN HN . 02 pyrazolo[4,3-c]pyridin-1-y1) [M+H]+:
453,
0 propanenitrile found 453
AsCN
Me 4-( {1-[(1S)-2-cyano- 1- LRMS (ESI)
N, H
11-46 4It < cyclopropylethy1]-4-oxo-4,5- calc'd for
mõ,
g02 .-- dihydro-1H-pyrazolo[4,3- C22H27N6035
HN H N c]pyridin-3-yl}amino)-N,N- [M+H]+: 455,
0
diethylbenzenesulfonamide found 455
Me Me (35)-3-cyclopropy1-343-04-[(3,3- LRMS (ESI)
CN
II-47 H dimethylpiperidin-l-yl)sulfonyl] calc'd
for
N
/\ ;N N phenyl} amino)-4-oxo-4,5-dihydro- C25H31N603S
HN H N 4. .02 1H-pyrazolo[4,3-c] pyridin-l-yl] [M+H]+: 495,
0 propanenitrile found 495
AµCN Me Me (35)-3-cyclopropy1-3434 {44(3,3- LRMS (ESI)
H
11-48 Ndimethylpyrrolidin-l-yl)sulfonyl] calc'd for
phenyl} amino)-4-oxo-4,5-dihydro- C24H27N6035
HN HN = g02 1H-pyrazolo[4,3-c]pyridin-1- [M+H]+:
481,
0
yl]propanenitrile found 481
CN Me (35)-3- {3-[(2-tert-butyl-1-oxo-2,3- LRMS (ESI)
H \z Me Me
11-49 N dihydro-1H-isoindo1-5-yl)amino]- calc'd
for
4-oxo-4,5-dihydro-1H-pyrazolo C24H27N602
HN H N . N0
[4,3-c]pyridin-1-y1}-3-cyclopropyl [M+H]+: 431,
0
propanenitrile found 431
AiµCN rc)
N (3S)-3- {3-[(2-cyclopenty1-1-oxo- LRMS
(ESI)
11-50
H
N 2,3-dihydro-1H-isoindo1-5-y1) calc'd for
amino]-4-oxo-4,5-dihydro-1H- C25H27N602
H N H N = 0 pyrazolo[4,3-c]pyridin-1-y1} -3- [M+H]+:
443,
0
cyclopropylpropanenitrile found 443
1 1 1
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
CN
N (3S)-3- {3-[(2-cyclohexyl-l-oxo- LRMS (ESI)
H
II-51 N 2,3-dihydro-1H-isoindo1-5-y1) calc'd for
amino]-4-oxo-4,5-dihydro-1H- C26H29N602
HN HN . 0 pyrazolo[4,3-c]pyridin-1-y1} -3- [M+H]+:
457,
0
cyclopropylpropanenitrile found 457
CN (35)-3-cyclopropy1-3-[3-({4-[(2,2- LRMS (ESI)
N,H
11-52 IQ dimethylpiperidin-l-yl)sulfonyl] calc'd
for
Me
' . ki2 Me phenyl} amino)-4-oxo-4,5-dihydro- C25 H3
1N6035
HN HN
1H-pyrazolo[4,3-c]pyridin-1-yl] [M+H]+: 495,
0
propanenitrile found 495
0
3-01Bu
tert-butyl 1-{[4-({1-[(1S)-2- LRMS (ESI)
H
N cyano-l-cyclopropylethy1]-4-oxo- calc'd
for
J\J 4,5-dihydro-1H-pyrazolo[4,3-c]
C28H35N6055
II-53
HN SO,
HN # - pyridin-3-yl}amino)phenyl] [M+H]+: 567,
0
sulfonyl}piperidine-4-carboxylate found 567
AI,CN (35)-3-cyclopropy1-3-{3-[(4- LRMS (ESI)
H 0õµOH
N
11-54 N {[(35)-3-hydroxypyrrolidin-1- calc'd for
/ \ ;
HN
J\I yl]sulfonyl}phenyl)amino]-4-oxo- C22H25N6045
SO,
HN = -
4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 469,
0
c]pyridin-l-yl}propanenitrile found 469
(35)-3-cyclopropy1-3-{3-[(4- LRMS (ESI)
s' H CN
N
11-55 HNN = 0.00H
{[(3R)-3-hydroxypyrrolidin-l-yl] calc'd for
J\I
sulfonyl}phenyl)amino]-4-oxo- C22H25N6045
SO,
H -
4,5-dihydro-1H-pyrazolo[4,3-c] [M+H]+: 469,
0
pyridin-l-yl}propanenitrile found 469
tert-butyl 1-{[4-({1-[(1S)-2- LRMS (ESI)
s OtBu
11-56 A ci\I H cyano-l-cyclopropylethy1]-4-oxo- calc'd
for
N0......0
/ \ ;N N 4,5-dihydro-1H-pyrazolo[4,3-c] C27H33N6055
HN HN = 02 pyridin-3-yl}amino)phenyl] [M+H]+: 553,
0 sulfonyl} -D-prolinate found 553
(35)-3-cyclopropy1-3-{4-oxo-3- LRMS (ESI)
CN [(4- {[(3R or 3S)-3- calc'd for
/
II-57 N H 0.¨CF3
N .
(trifluoromethyl)pyrrolidin-1- C23 H24F3N603 S
\ ;
1\1
HN SO,
HN . - yl]sulfonyl}phenyl)amino]-4,5- [M+H]+:
521,
0 dihydro-1H-pyrazolo[4,3-c] found 521
112
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
pyridin-l-yl}propanenitrile
A (3S)-3-cyclopropy1-3-{4-oxo-3-
LRMS (ESI)
l<µCN [(4-{[(3R or 3S)-3-
II-58 N, H 0.--CF3 calc'd for
(trifluoromethyl)pyrrolidin-1-
rij C 23 H24F3N603
S
HN HN . SO2 yl]sulfonyl}phenyl)amino]-4,5-
[M+H]+: 521,
0 dihydro-1H-pyrazolo [4,3-c]
found 521
pyridin-l-yl}propanenitrile
(3S)-3-cyclopropy1-3-{4-oxo-3-
,CN LRMS (ESI)
N,H [(4- {[(2R or 25)-2-
11-59 (trifluoromethyl)pyrrolidin-1-
calc'd for
C 23 H24F3N603 S
HN HN = SO2 C F 3 yl]sulfonyl}phenyl)amino]-4,5-
[M+H]+: 521,
0 dihydro-1H-pyrazolo [4,3-c]
found 521
pyridin-l-yl}propanenitrile
(35)-3-cyclopropy1-3- {4-oxo-3-
,CN LRMS (ESI)
H [(4- {[(2R or 25)-2-
N
11-60 (trifluoromethyl)pyrrolidin-1-
calc'd for
C 23 H24F3N603 S
HN HN . S02 C F3 yl]sulfonyl}phenyl)amino]-4,5-
[M+H]+: 521,
0 dihydro-1H-pyrazolo [4,3-c]
found 521
pyridin-l-yl}propanenitrile
tert-butyl (35)-1- {[4-({1-[(1R or
1S)-2-cyano-1-cyclopropylethy1]-
4-oxo-4,5-dihydro-1H-pyrazolo
LRMS (ESI)
[4,3-c]pyridin-3-yl}amino)phenyl]
calc'd for
II-61 sulfonyl}pyrrolidine-3-carboxylate
As
H CN 0 (derived fron Bn protected
C271133F3N605S
N, 0A0tBu intermediate peak 1, SFC retention [M+H]+: 553,
;\1 found 553
HN HN qt, so2 time (Chiralpak , IB, 30%
0 isopropanol in CO2) = 9.44
minutes)
tert-butyl (35)-1- {[4-({1-[(1R or
1S)-2-cyano-1-cyclopropylethy1]-
4-oxo-4,5-dihydro-1H-pyrazolo LRMS (ESI)
[4,3-c]pyridin-3 yl}amino)phenyl] calc'd for
11-62
As
H CN 0 sulfonyl}pyrrolidine-3-carboxylate
C27H33F3N605 S
A0tBu (derived fron Bn protected [M+H]+: 553,
HN HN qt, 0
so2 intermediate peak 2, SFC found 553
0 retention time (Chiralpak , IB,
30% isopropanol in CO2) = 10.53
113
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
minutes)
CN (3S)-3-cyclopropy1-3-[3-({4-[(2,2- LRMS
(ESI)
N, H
11-63 Me
dimethylpyrrolidin-l-yl)sulfonyl] calc'd for
/ \ /N 1\Q-
= g02 Me phenyl} amino)-4-oxo-4,5-dihydro- C24H29N6035
HN HN
1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 481,
0
yl]propanenitrile found 481
CN (35)-3-cyclopropy1-3- {3-[(4- {[(2R LRMS
(ESI)
H
N N
II-64 or 2S)-2-methylpyrrolidin- 1- calc'd for
= d02 Me yllsulfonyl}phenyl)amino]-4-oxo- C23H27N6035
HN HN 4,5-dihydro-1H-pyrazolo[4,3- [M+H]+:
467,
0
c]pyridin-l-yl}propanenitrile found 467
CN (35)-3-cyclopropy1-3- {3-[(4- {[(2R LRMS
(ESI)
N, H
11-65 N or 25)-2-methylpyrrolidin- 1- calc'd for
. g02 Me yllsulfonyl}phenyl)amino]-4-oxo- C23H27N6035
HN HN 4,5-dihydro-1H-pyrazolo[4,3- [M+H]: 467,
0
c]pyridin-l-yl}propanenitrile found 467
(35)-3-(3- {[4-(azetidin-1- LRMS (ESI)
CN
11-66 H c3 ylsulfonyl)phenyl]amino}-4-oxo- calc'd
for
N
j\I 4,5-dihydro-1H-pyrazolo[4,3- C21H23N6035
SO2 .
HN HN c]pyridin-1 -y1)-3- [M+H]: 439,
0 cyclopropylpropanenitrile found 439
(35)-3-cyclopropy1-3-(3- {[4- LRMS (ESI)
CN r 0\
H (morpholin-4-ylsulfonyl)phenyl] calc'd
for
N
CN i amino} -4-oxo-4,5-dihydro-1H- C22H25N6045
II-67
HN HN fe d02 pyrazolo[4,3-c]pyridin-1- [M+H]: 469,
0 yl)propanenitrile found 469
CN Me MeMe (35)-3-cyclopropy1-3-[34 {44(3,3- LRMS
(ESI)
11-68 HN
H
N dimethylazetidin- 1 -yl)sulfonyl] calc'd
for
ii\I phenyl} amino)-4-oxo-4,5-dihydro-
C23H27N6035
HN fik SO2
1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 467,
0
yl]propanenitrile found 467
114
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
As
' CN Me (3S)-3-cyclopropy1-3-[3-({4-[(3- LRMS
(ESI)
H
N \-----S methylazetidin-1- calc'd for
II-69
/ H'
HN et g02 yl)sulfonyl]phenyl}amino)-4-oxo-
C22H25N6035
4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 453,
0
c]pyridin-l-yl]propanenitrile found 453
CN (35)-3-cyclopropy1-3-[3-({4-[(2,2- LRMS
(ESI)
N, H
(-..,1Vie dimethylazetidin-l-yl)sulfonyl] calc'd for
II-70 / \ iN N Me
phenyl} amino)-4-oxo-4,5-dihydro- C23H27N6035
HN # s'02
HN
1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 467,
0
yl]propanenitrile found 467
CN Me OH(35)-3-cyclopropy1-343-04-[(3- LRMS (ESI)
II-71
H
N hydroxy-3-methylazetidin-1- calc'd for
/ \ ;N N
yl)sulfonyl]phenyl}amino)-4-oxo- C22H25N6045
H N H N . g02 4,5-dihydro-1H-pyrazolo[4,3- [M+H]+:
469,
0
c]pyridin-l-yl]propanenitrile found 469
(35)-3-cyclopropy1-3-[3-({4-[(3- LRMS (ESI)
O
' H CN H
hydroxyazetidin-l-yl)sulfonyl] calc'd for
11-72 N
/ \ ;N
N phenyl} amino)-4-oxo-4,5-dihydro-
C21H23N6045
HN . SO2
HN 1H-pyrazolo[4,3-c]pyridin-1- [M+H]+:
455,
0 yl]propanenitrile found 455
CN ro (35)-3-cyclopropy1-3-[3-({4-[(3,3- LRMS
(ESI)
N,H
C ____ _..me dimethylmorpholin-4-yl)sulfonyl] calc'd for
11-73 N
' . ki2 Me phenyl} amino)-4-oxo-4,5-dihydro-
C24H29N6045
HN HN
1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 497,
0
yl]propanenitrile found 497
o Me (35)-3-cyclopropy1-343-04-[(2,2- LRMS (ESI)
N CI-Me dimethylmorpholin-4-yl)sulfonyl] calc'd for
11-74 / \ ;N N
HN HN . s102 phenyl} amino)-4-oxo-4,5-dihydro-
C24H29N6045
1H-pyrazolo[4,3-c]pyridin-1- [M+H]+: 497,
0
yl]propanenitrile found 497
CN r0 (35)-3-cyclopropy1-3-{3-[(4- {[(3R LRMS
(ESI)
H
11-75 N
cN ..._... or 35)-3-methylmorpholin-4-yl] calc'd
for
/ \ s,N
' . g02 Me sulfonyl}phenyl)amino]-4-oxo- C23H27N6045
HN =HN 4,5-dihydro-1H-pyrazolo[4,3-c] [M+H]+:
483,
0
1 1 5
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
pyridin-l-yl}propanenitrile found 483
AsCN r0 (3S)-3-cyclopropy1-3-{3-[(4- {[(3R LRMS
(ESI)
N, H
I1-76 CN_____ or 3S)-3-methylmorpholin-4- calc'd for
/ \ ,N
i . c)2 Me yl]sulfonyl}phenyl)amino]-4-oxo- C23H27N6045
HN HN 4,5-dihydro-1H-pyrazolo[4,3- [M+H]+:
483,
0
c]pyridin-l-yl}propanenitrile found 483
(35)-3-cyclopropy1-3-{3-[(4- {[(3R
CN CF3 or 3S)-3-hydroxy-3- LRMS (ESI)
11-77 . calc'd for
0
(tufluoromethyl)pyrrolidin-1-
II
J'' C23H24F3N6045
HN S02
HN =- yl]sulfonyl}phenyl)amino]-4-oxo-
[M+H]+: 537,
O 4,5-dihydro-1H-pyrazolo[4,3-
found 537
c]pyridin-l-yl}propanenitrile
(35)-3-cyclopropy1-3-{3-[(4- {[(3R
CF3 or 35)-3-hydroxy-3- LRMS (ESI)
/
11-78 N H 0-0H . calc'd for
(tufluoromethyl)pyrrolidin-1-
\ ;N
J'' C23H24F3N6045
HN SO2
HN =- yl]sulfonyl}phenyl)amino]-4-oxo-
[M+H]+: 537,
O 4,5-dihydro-1H-pyrazolo[4,3-
found 537
c]pyridin-l-yl}propanenitrile
(35)-3-cyclopropy1-3-[3-( {4-
[(4aR,7aR or 4a5,7a5)- LRMS (ESI)
Al,µCN 0
N, H hexahydrocyclopenta[b][1,4]oxazi calc'd for
11-79
N
n-4(4aH)-ylsulfonyl]phenyl} C25H29N6045
HN SO,
HN . - amino)-4-oxo-4,5-dihydro-1H- [M+H]+:
509,
O pyrazolo[4,3-c]pyridin-1-yl] found 509
propanenitrile
(35)-3-cyclopropy1-3-[3-( {4-
11-80 µCN
[(4aR,7aR or 4a5,7a5)- LRMS (ESI)
A
N, H hexahydrocyclopenta[b][1,4]oxazi calc'd for
n-4(4aH)-ylsulfonyl]phenyl} C25H29N6045
HN HN . r0h (:)2 amino)-4-oxo-4,5-dihydro-1H- [M+H]+:
509,
O pyrazolo[4,3-c]pyridin-1- found 509
yl]propanenitrile
'AsCN Me%r-0 (35)-3-cyclopropy1-3-{3-[(4- LRMS (ESI)
H \I...Me
11-81 N CN j {[(25,65)-2,6-dimethylmorpholin- calc'd for
4-yl]sulfonyl}phenyl)amino]-4- C24H29N6045
HN N # ' SO,
H -
oxo-4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 497,
0
c]pyridin-l-yl}propanenitrile found 497
1 1 6
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(3S)-3-cyclopropy1-3-{3-[(4-
, Me LRMS
(ESI)
H CN Z.-0...),Me {[(2R,6S)-2,6-dimethyl-
N calc'd
for
N morpholin-4-yl]sulfonyl}
II-82
C24H29N6045
HN
HN =
S = 102 phenyl)amino]-4-oxo-4,5-dihydro-
[M+H]+: 497,
0 1H-pyrazolo[4,3-c]pyridin-1-
found 497
yl}propanenitrile
CN 0
(Me (35)-3-cyclopropy1-3-{3-[(4- {[(2R LRMS (ESI)
H
II-83 N )¨
or 25)-2-methylmorpholin-4- calc'd
for
N---/
HN HN # '
yl]sulfonyl}phenyl)amino]-4-oxo- C23H27N6045
SO9
-
4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 483,
0
c]pyridin-l-yl}propanenitrile found
483
CN 0 (35)-3-cyclopropy1-3-{3-[(4- {[(2R LRMS
(ESI)
H
11-84 N ( )¨Me
or 25)-2-methyl-morpholin-4- calc'd
for
N
(y
HN S
HN = 102 yl]sulfonyl} phenyl)amino]-4-oxo-
C23H27N6045
4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 483,
0
c]pyridin-l-yl}propanenitrile found
483
,
" CN (35)-3-cyclopropy1-3-{3-[(4- {[(2R LRMS
(ESI)
H
11-85N \-3Me
...... or 25)-2-methylazetidin-1- calc'd
for
i
HN
. SO2
HN yl]sulfonyl}phenyl)amino]-4-oxo-
C22H25N6035
4,5-dihydro-1H-pyrazolo [4,3- [M+H]+: 453,
0
c]pyridin-l-y1} propanenitrile found
453
" CN (35)-3-cyclopropy1-3-{3-[(4- {[(2R LRMS
(ESI)
N, H
11-86 HN N or 25)-2-methylazetidin-1- calc'd
for
#
/
H SO2
yl]sulfonyl}phenyl)amino]-4-oxo- C22H25N6035
4,5-dihydro-1H-pyrazolo [4,3- [M+H]+: 453,
0
c]pyridin-l-y1} propanenitrile found
453
LRMS (ESI)
CN OMe (35)-3-cyclopropy1-3434 {44(3-
H calc'd for
methoxyazetidin-l-yl)sulfonyl]
II-87
PI C22H25N604S
phenyl} amino)-4-oxo-4,5-dihydro-
HN SO,
HN . - 1H-pyrazolo[4,3-c]pyridin-1- [M+H]+:
469,
0 found 469
yl]propanenitrile
117
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(3S)-3-cyclopropy1-3-[3-({4-[(3- LRMS (ESI)
A'CN F
11- 88
fluoroazetidin-l-yl)sulfonyl] calc'd for
N phenyl} amino)-4-oxo-4,5-dihydro-
C21H22FN603S
HN HN = SO2 1H-pyrazolo[4,3-c]pyridin-1-
[M+H]+: 457,
0 yl]propanenitrile found 457
(35)-3-cyclopropy1-3-[3-({3-
LRMS (ESI)
11-89
methyl-4-[(1R or 1S)-2,2,2-
sCN calc'd for
N,H trifluoro-l-hydroxy-1-
Me C22H23F3N502
CF3 methylethyl] phenyl} amino)-4-
HN HN # OH oxo-4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 446,
Me found 446
0 c]pyridin-l-yl] propanenitrile
(35)-3-cyclopropy1-3-[3-({3-
LRMS (ESI)
11-90
methyl-4-[(1R or 1S)-2,2,2-
sCN calc'd for
N,H trifluoro-l-hydroxy-1-
Me C22H23F3N502
CF3 methylethyl] phenyl} amino)-4-
HN HN # OH oxo-4,5-dihydro-1H-pyrazolo[4,3- [M+H]+: 446,
Me found 446
0 c]pyridin-l-yl] propanenitrile
(35)-3-cyclopropy1-3434 {4- [(1R
'sCN LRMS (ESI)
N, H or 1S)-1-hydroxy-1-
1 calc'd for
II-9
HN HN CF3 (trifluoromethyl)propyl]phenyl} a
. OH
mino)-4-oxo-4,5-dihydro-1H-
Me C22H23F3N502
[M+H]+: 446,
0 pyrazolo[4,3-c]pyridin-1-
found 446
yl]propanenitrile
(35)-3-cyclopropy1-3434 {4- [(1R
'sCN LRMS (ESI)
N, H or 1S)-1-hydroxy-1-
calc'd for
11-92
HN HN CF3 (trifluoromethyl)propyl]phenyl} a
. OH
mino)-4-oxo-4,5-dihydro-1H-
Me C22H23F3N502
[M+H]+: 446,
0 pyrazolo[4,3-c]pyridin-1-
found 446
yl]propanenitrile
(S)-tert-butyl 2-(4-((1-(2-cyano-1-
LRMS (ESI)
AsCN 0 cyclopropylethyl)-4-oxo-4,5-
II-93 N,H OtBu calc'd for
Me dihydro-1H-pyrazolo[4,3-c]
,N_rMe C271-135N605S
g02 Me pyridin-3-yl)amino)-N-
HN HN . [M+H]+: 555,
0 methylphenylsulfonamido)-2-
found 555
methylpropanoate
118
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
II-94 F3C
(S)-3-cyclopropy1-3-(4-oxo-341-((1 LRMS (ESI)
'1<sCN
H oxo-2-(2,2,2-trifluoroethyl) calc'd for
N
isoindolin-5-yl)amino)-4,5- C22H20P3N602
HN HN . N) 0 dihydro-1H-pyrazolo [4,3- [M+H]+: 457,
0 c]pyridin-l-yl)propanenitrile found 457
(S)-ethyl 2-(4-((1-(2-cyano-1-
LRMS (ESI)
cyclopropylethyl)-4-oxo-4,5-
calc'd for
11-95 CN 0 dihydro-1H-pyrazolo [4,3-c]
N,H OEt C25H31N6055
Me. __rime pyridin-3-yl)amino)-N-
/ \ /NJ 'N _*-Me 527,
HN # S102 Me methylphenylsulfonamido)-2-
HN found 527
0 methylpropanoate
(S)- tert-butyl 2-(5-((1-(2-cyano-1-
LRMS (ESI)
cyclopropylethyl)-4-oxo-4,5-
calc'd for
AsCN dihydro-1H-pyrazolo [4,3-c]
11-96
N,H > Me 0tBu Me C28H33N604 /.....( pyridin-3-
yl)amino)-1-
[M+H]+: 517,
0 oxoisoindolin-2-y1)-2-
HN N H 0 found 517
0 methylpropanoate
Ai<sCN 4-( {1- [(1S)-2-cyano- 1- LRMS (ESI)
H
N N Me cyclopropylethy1]-4-oxo-4,5- calc'd for
/ \ ;
02
HN HN = S' dihydro-1H-pyrazolo [4,3-
C21H25N6035
II-97
I\VMe c]pyridin-3-yl}amino)-N,N,2- [M+H]+: 441,
0 /
Me
trimethylbenzenesulfonamide found 441.
Al<µCN (35)-3-cyclopropy1-3-(3-{[3- LRMS (ESI)
N, N H Me methy1-4-(pyrrolidin-1-ylsulfonyl) calc'd
for
/
11-98 \ /
02 phenyl]amino}-4-oxo-4,5-dihydro-
C23H27N6035
Fgq-1(11\1 4. S'N 1H-pyrazolo[4,3-c]pyridin-1- [M+H]+:
467,
0
0 yl)propanenitrile found 467.
(35)-3-cyclopropy1-3-(3- { [445,5-
dimethy1-3-oxo-2-oxabicyclo
CN
[2.2.2]oct-1-yl)phenyl]amino} -4-
A LRMS (ESI)
N,H oxo-4,5-dihydro-1H-pyrazolo [4,3 -
Me Me calc'd for
11-99 / \ iN ---O c]pyridin-l-yl)propanenitrile (from
HN HN . 0
I-8A and racemic I-X, derived C27H30N503
[M+H]+: 472,
0 from Peak 1 (0Bn intermediate)
found 472.
obtained by SFC, Chiralpak AS-H,
20% Me0H in CO2 (Me0H with
0.25% DMEA), tR = 10.9)
119
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(3S)-3-cyclopropy1-3-(3- { [445,5-
dimethy1-3-oxo-2-oxabicyclo
CN [2.2.2]oct-1-yl)phenyl]amino} -4-
Ais LRMS (ESI)
" H
oxo-4,5-dihydro-1H-pyrazolo[4,3-
N Me Me calc'd for
II-100 / \ ;N --- c]pyridin-l-yl)propanenitrile (from
HN HN . 0
C27H3oN503
I-8A and racemic I-X, derived
[M+H]+: 472,
o from Peak 2 (0Bn intermediate)
found 472.
obtained by SFC, Chiralpak AS-H,
20% Me0H in CO2 (Me0H with
0.25% DMEA), tR = 14.0)
(3 5)-3-cyclopropy1-3 43 -( {4- [(1R
or 1S)-1-(dimethylamino)-2,2,2-
,
" CN trifluoroethy1]-3-methylphenyl} LRMS
(ESI)
H
N Me amino)-4-oxo-4,5-dihydro-1H- calc'd for
II-101
CF3
pyrazolo[4,3-c]pyridin-l-yl] C23H26N60F3
HN HN 4It N-Me propanenitrile (SFC Peak 2, [M+H]+: 459,
0 /
Me
Chiralpak AD-H, 20% Et0H in found 459.
CO2 (Et0H with 0.25% DMEA),
tR = 4.6)
(35)-3-cyclopropy1-343-({4-[(1S
or 1R)-1-(dimethylamino)-2,2,2-
,
" H CN trifluoroethy1]-3-methylphenyl} LRMS
(ESI)
N Me amino)-4-oxo-4,5-dihydro-1H- calc'd for
11-102
CF3
pyrazolo[4,3-c]pyridin-1-yl] C23H26N60F3
HN HN 4It N-Me propanenitrile (SFC Peak 1, [M+H]+: 459,
0 /
Me
Chiralpak AD-H, 20% Et0H in found 459.
CO2 (Et0H with 0.25% DMEA),
tR = 5.7)
CN (35)-3-cyclopropy1-3434 {44(1- LRMS
(ESI)
H
11-103 N methylcyclopropyl)sulfonyl]pheny calc'd
for
sN
/ \ /
02 1} amino)-4-oxo-4,5-dihydro-1H-
C22H24N5035
HN HN 4It S
..---Me pyrazolo[4,3-c]pyridin-1- [M+H]+: 438,
0
yl]propanenitrile found 438.
CN (35)-3434{44(1R or 1S)-1-(tert- LRMS
(ESI)
H
N butylamino)-2,2,2-trifluoroethyl]
calc'd for
CF3
11-104 / \ ;N
Me phenyl} amino)-4-oxo-4,5-dihydro-
C24H27F3N60N
HN HN . N....4-Me
1H-pyrazolo[4,3-c]pyridin-1-y1]-3- a [M+Na]+:
0 H Me
120
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
cyclopropylpropanenitrile (SFC 495, found 495
Peak 1, AD-H, 10% Me0H in
CO2, Tr = 5.83)
Al,CN (3S)-3-[3-({4-[(1S or 1R)-1-(tert-
N, H butylamino)-2,2,2-trifluoroethyl] LRMS (ESI)
11-105 / \ /NI
CF3 phenyl} amino)-4-oxo-4,5-dihydro- calc'd
for
Me
HN HN lk N.4¨Me 1H-pyrazolo[4,3-c]pyridin-l-y1]-3- C24H27F3N60N
0 H Me
cyclopropylpropanenitrile (SFC a [M+Na]:
Peak 2, AD-H, 10% Me0H in 495, found 495
CO2, Tr = 6.7)
(35)-3-cyclopropy1-3-[4-oxo-3-
sCN
H ( {4-[(1R or 1S)-2,2,2-trifluoro-1-
LRMS (ESI)
N
11-106 C F3 pyrrolidin-l-ylethyl]phenyl} calc'd for
HN HN 4. 10 amino)-4,5-dihydro-1H-pyrazolo C24H26F3N60
0 [4,3-c]pyridin-1-yl]propanenitrile
[M+H]+: 471,
(SFC Peak 1, OD-H, 20% Me0H found 471
in CO2, Tr = 12.7)
(35)-3-cyclopropy1-3-[4-oxo-3-
sCN
11-107 H ( {4-[(1S or 1R)-2,2,2-trifluoro-1-
LRMS (ESI)
N
C F3 pyrrolidin-l-ylethyl]phenyl} calc'd for
HN HN 4.
amino)-4,5-dihydro-1H-pyrazolo C24H26F3N60
0 [4,3-c]pyridin-1-yl]propanenitrile
[M+H]+: 471,
(SFC Peak 2, OD-H, 20% Me0H found 471
in CO2, Tr = 14.25)
(35)-3-cyclopropy1-3-{4-oxo-3-
A
11-108 sCN
N, H [(4-{(1R or 1S)-2,2,2-trifluoro-1-
LRMS (ESI)
CF3 [(1-methylethyl)amino]ethyl}
calc'd for
HN HN ft HN_KIVie phenyl)amino]-4,5-dihydro-1H-
C23H26F3N60
0 Me pyrazolo[4,3-c]pyridin-1-y1}
[M+H]+: 459,
propanenitrile (SFC Peak 1, OJ-H,
found 459
15% Me0H+0.25% DMEA in
CO2, Tr = 4.06)
11-109 (35)-3-cyclopropy1-3-{4-oxo-3-
AsCN LRMS (ESI)
N, H [(4-{(1S or 1R)-2,2,2-trifluoro-1-
calc'd for
CF3 [(1-methylethyl)amino]ethyl}
C23H26F3N60
HN HN = HN_(Me phenyl)amino]-4,5-dihydro-1H-
[M+H]+: 459,
0 Me pyrazolo[4,3-c]pyridin-1-y1}
found 459
propanenitrile (SFC Peak 2, OJ-H,
121
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
15% Me0H+0.25% DMEA in
CO2, Tr = 4.97)
(3S)-3-[3-({4-[(1R or 1S)-1-
AsCN
II-110 H azetidin-l-y1-2,2,2-trifluoroethyl]
LRMS (ESI)
N
CF3 phenyl{ amino)-4-oxo-4,5-dihydro- calc'd
for
HN HN = N 1H-pyrazolo[4,3-c]pyridin-1-y1]-3-
C23H24F3N60
0 13 cyclopropylpropanenitrile (SFC [M+H]+:
457,
Peak 1, AD-H, 20% Me0H in found 457
CO2, Tr = 4.61)
II-111(35)-3434{44(1S or 1R)-1-
AsCN
H azetidin-l-y1-2,2,2-trifluoroethyl]
LRMS (ESI)
N
CF3 phenyl{ amino)-4-oxo-4,5-dihydro- calc'd
for
HN HN = N 1H-pyrazolo[4,3-c]pyridin-1-y1]-3-
C23H24F3N60
0 13 cyclopropylpropanenitrile (SFC [M+H]+:
457,
Peak 2, AD-H, 20% Me0H in found 457
CO2, Tr = 6.05)
(35)-3-cyclopropy1-343-({4-[(1R
Ai<
11-112 sCN H or 1S)-1-(ethylamino)-2,2,2- LRMS (ESI)
N
CF3 trifluoroethyl] phenyl{ amino)-4-
calc'd for
HN HN = N Ye oxo-4,5-dihydro-1H-pyrazolo[4,3- C22H24F3N60
-----
0 H c]pyridin-l-yl]propanenitrile (SFC [M+H]+:
445,
Peak 1, AD-H, 25% Me0H in found 445
CO2, Tr = 3.06)
(35)-3-cyclopropy1-3434 {44(1 S
Ai<
11-113 sCN H or 1R)-1-(ethylamino)-2,2,2- LRMS (ESI)
N
CF3 trifluoroethyl]phenyl{ amino)-4- calc'd
for
HN HN = N Ye oxo-4,5-dihydro-1H-pyrazolo[4,3- C22H24F3N60
-----
0 H c]pyridin-l-yl]propanenitrile (SFC [M+H]+:
445,
Peak 2, AD-H, 25% Me0H in found 445
CO2, Tr = 6.44)
o
11-114 As
H CN OtBu (35)-tert-butyl 4-(5-((1-(2-cyano-
l-cyclopropylethyl)-4-oxo-4,5-
N, LRMS (ESI)
N
dihydro-1H-pyrazolo [4,3-c]
H it N HN 0
pyridin-3-yl)amino)-1- calc'd for
o C31H37N604
oxoisoindolin-2-y1) cyclohexane-
[M+H]+: 557,
carboxylate (SFC Peak 1, ES
found 557
Industries Basic, 21 x 250 (mm),
25% Me0H in CO2, Tr = 4.66)
122
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
o
11-115 As
H CN OtBu (3S)-tert-butyl 4-(5-((1-(2-cyano-
l-cyclopropylethyl)-4-oxo-4,5-
N LRMS (ESI)
N
dihydro-1H-pyrazolo[4,3-c]
H it N HN 0
pyridin-3-yl)amino)-1- calc'd for
0 C311137N604
oxoisoindolin-2-yl)cyclohexane-
[M+H]+: 557,
carboxylate (SFC Peak 2, ES
found 557
Industries Basic, 21 x 250 (mm),
25% Me0H in CO2, Tr = 5.34)
(S)-2-(5-((1-(2-cyano-1-
AsCN Me LRMS (ESI)
N
11-116 N H )e., H 0 cyclopropylethyl)-4-oxo-4,5-
calc'd for
dihydro-1H-pyrazolo[4,3-
HN HN . 0 0 c]pyridin-3-yl)amino)-1- C24H25N604
O [M+H]+: 461,
oxoisoindolin-2-y1)-2-
found 461
methylpropanoic acid
ethyl 3-(4-((1-(S)-2-cyano-1-
CN
11-117
N,H me me OEt cyclopropylethyl)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3-c] LRMS (ESI)
HN HN = CF? pyridin-3-yl)amino)pheny1)-4,4,4- calc'd for
O OH
trifluoro-3-hydroxy-2,2- C26H29F3N5 04
dimethylbutanoate (SFC Peak 1, [M+H]+: 532,
Chiralpak, IC, 21 x 250 (mm), 21 found 532
x 250 (mm), 25% Me0H in CO2,
Tr = 4.38)
ethyl 3-(44(1-((S)-2-cyano-1-
CN
11-118
N,NH me me OEt cyclopropylethyl)-4-oxo-4,5-
dihydro-1H-pyrazolo[4,3- LRMS (ESI)
HN HN = CF? c]pyridin-3-yl)amino)pheny1)- calc'd for
O OH
4,4,4-trifluoro-3-hydroxy-2,2- C26H29F3N5 04
dimethylbutanoate (SFC Peak 2, [M+H]+: 532,
Chiralpak, IC, 21 x 250 (mm), 21 found 532
x 250 (mm), 25% Me0H in CO2,
Tr = 5.53)
11-119 isopropyl 3-(4-((1-((S)-2-cyano-1-
AµCN LRMS (ESI)
N,H me oipr cyclopropylethyl)-4-oxo-4,5-
Me calc'd for
dihydro-1H-pyrazolo[4,3-
C27H3 1F3N5 04
HN HN . CF3 c]pyridin-3-yl)amino)pheny1)-
OH
4,4,4-trifluoro-3-hydroxy-2,2- [M+H]+: 546,
0
found 546
dimethylbutanoate (SFC Peak 1,
123
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
IC, 21 x 250 mm, 25% Me0H in
CO2, Tr = 3.99)
isopropyl 3-(4-((1-((S)-2-cyano-1-
AµCN
11-120
N,H me oipr cyclopropylethyl)-4-oxo-4,5-
Me LRMS (ESI)
dihydro-1H-pyrazolo[4,3-
calc'd for
HN HN . CF3 c]pyridin-3-yl)amino)pheny1)-
OH
4,4,4-trifluoro-3-hydroxy-2,2- C27H31F3N5 04
0
[M+H]+: 546,
dimethylbutanoate (SFC Peak 2,
found 546
IC, 21 x 250 mm, 25% Me0H in
CO2, Tr = 4.98)
(S)-3-cyclopropy1-3-(3-(((S or R)-
A<
11-121 sCN
N,H Me 1-hydroxy-2,2-dimethy1-1-
LRMS (ESI)
Me (trifluoromethyl)-2,3-dihydro-1H-
HN HN fill CF3
inden-5-yl)amino)-4-oxo-4,5- calc'd for
OH
C24H25F3N5 02
0 dihydro-1H-pyrazolo[4,3-
[M+H]+: 472,
c]pyridin-l-yl)propanenitrile
found 472
(SFC Peak 1, Lux-4, 21 x 250 mm,
30% Me0H in CO2, Tr = 3.23)
11-122 sCN
(S)-3-cyclopropy1-3-(3-(((S or R)-
A<
N,H Me 1-hydroxy-2,2-dimethy1-1-
LRMS (ESI)
Me (trifluoromethyl)-2,3-dihydro-1H-
HN HN fill CF3
inden-5-yl)amino)-4-oxo-4,5- calc'd for
OH
C24H25F3N5 02
0 dihydro-1H-pyrazolo[4,3-
[M+H]+: 472,
c]pyridin-l-yl)propanenitrile
found 472
(SFC Peak 2, Lux-4, 21 x 250 mm,
30% Me0H in CO2, Tr = 4.92)
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
A<µCN
11-123 H (1-(trifluoromethyl)cyclopropyl) calc'd
for
N
HN HN
1110" phenyl)amino)-4,5-dihydro-1H-
C22H21F3N5 0
. r
-F3 pyrazolo[4,3-c]pyridin-1- [M+H]: 428,
0 yl)propanenitrile found 428
H CN (0Me (S)-3-cyclopropy1-3-(3#4-(1-(2-
LRMS (ESI)
\ ) N methoxyethyl)-1H-pyrazol-3- calc'd for
'N
N-N
11-124
HN/ . N 4. / yl)phenyl)amino)-4-oxo-4,5- C24H26N702
0 dihydro-1H-pyrazolo[4,3- [M+H]: 444,
c]pyridin-l-yl)propanenitrile found 444
124
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
H
A NN,sC (S)-3-(3-((3-chloro-4-(1-methyl- LRMS
(ESI)
Me
11-125 Cl 1H-pyrazol-3-yl)phenyl)amino)-4- calc'd
for
\ N
N-N"
HN/ . N 4. / -' oxo-4,5-dihydro-1H-pyrazolo[4,3-
C22H21C1N70
0 c]pyridin-1-y1)-3- [M+H]+: 434,
cyclopropylpropanenitrile found 434
AsCNN--N CN (S)-3-(3-((3-chloro-4-(1-(2- LRMS (ESI)
N , H
11-126 CI cyano ethyl)- 1H-pyrazol-3 -y1) calc'd
for
\ N
H11-1 N it phenyl)amino)-4-oxo-4,5-dihydro- C24H23N80
o 1H-pyrazolo[4,3-c]pyridin-1-y1)-3- [M+H]+: 439,
cyclopropylpropanenitrile found 439
s
H CN
o (S)-ethyl 1-(4-((1-(2-cyano-1-
LRMS (ESI)
11-127 N, Me cyclopropylethyl)-4-oxo-4,5-
OEt calc'd for
HN HN = N
dihydro-1H-pyrazolo [4,3-c]
'N---;
C25H26N703
0 pyridin-3-yl)amino)-2-
[M+H]+: 472,
methylpheny1)-1H-pyrazole-4-
found 472
carboxylate
A'C
H CN (S)-isopropyl 6-((1-(2-cyano-1- LRMS
(ESI)
11-128 OilDr cyclopropylethyl)-4-oxo-4,5- calc'd
for
\ N
HN 411, /
N 0 dihydro-1H-pyrazolo [4,3-c] C25H25N603
H
0 pyridin-3-yl)amino)quinoline-2- [M+H]+:
457,
carboxylate found 457
As
H CN (S)-3-cyclopropy1-3-(3((2- LRMS (ESI)
11-129 N, s_ )Ae methylbenzo[d]thiazol-6-y1) calc'd
for
--Fr
H N H N 4.0 N amino)-4-oxo-4,5-dihydro- 1H-
C20H19N605
O pyrazolo[4,3-
c]pyridin-1-y1) [M+H]+: 391,
propanenitrile found 391
Al<sCN (S)-3-cyclopropy1-3-(34(4- LRMS (ESI)
N,H
11-130 (oxazol-2-yl)phenyl)amino)-4- calc'd
for
0-11
\
HN =N oxo-4,5-dihydro-1H-pyrazolo[4,3-
C21H19N602
I \1
H-1
O c]pyridin-l-
yl)propanenitrile [M+H]+: 387,
found 387
A'('
H CN (S)-3-cyclopropy1-3-(3((4- LRMS (ESI)
11-131 N (oxazol-5-yl)phenyl)amino)-4- calc'd
for
\ sN OTh
H N
41/0 \ RI oxo-4,5-dihydro-1H-pyrazolo[4,3- C21H19N602
H
O c]pyridin-l-
yl)propanenitrile [M+H]+: 387,
found 387
125
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
CN
(S)-3-cyclopropy1-3-(343,3- LRMS (ESI)
N,N 0
Ar.µFI
11-132 H
N dimethy1-2-oxoindolin-6-y1) calc'd for
/ \ i
HN HN 4. Me amino)-4-oxo-4,5-dihydro- 1H- C22H23N602
me
0 pyrazolo[4,3-c]pyridin-1- [M+H]+: 403,
yl)propanenitrile found 403
(S)-3-cyclopropy1-3-(344-(1, 1 -
N,HcN LRMS (ESI)
11-133 Me dioxidothiomorpholine-4-
0 calc'd for
HN HN 4It N carbonyl)-3-methylphenyl)
C24H27N6045
0amino)-4-oxo-4,5-dihydro- 1H-
C--s=0 [M+H]+: 495,
ii
0 pyrazolo[4,3-c]pyridin-1-
found 495
yl)propanenitrile
A cN (S)-4-((1-(2-cyano-1- LRMS (ESI)
I,N,sli
11-134 cyclopropylethyl)-4-oxo-4,5- calc'd for
OH
HN H N 4Ik dihydro- 1 H-pyrazo lo [4,3-c] Ci9Hi8N503
o
0 pyridin-3-34)amino)benzoic acid [M+H]+:
364,
found 364
(S)-4-((1-(2-cyano-1- LRMS (ESI)
Ar.1\1,;_icN
11-135 9,0 cyclopropylethyl)-4-oxo-4,5- calc'd for
HN--5;
HN HN 4Ik Me dihydro- 1 H-pyrazo lo [4,3-
C20H21N6045
0
0 c]pyridin-3-yl)amino)-N- [M+H]+: 441,
(methylsulfonyl)benzamide found 441
As
H CN (S)-3-cyclopropy1-3-(34(2- LRMS (ESI)
11-136 N, ¨ r--\0 morpholinoquinolin-6-yl)amino)- calc'd
for
N
H N . / N\-j 4-oxo-4,5-dihydro- 1H-pyrazo lo
C25H26N702
H N
0 [4,3-c]pyridin-1-yl)propanenitrile
[M+H]+: 456,
found 456
s
H CN Me (S)-3-cyclopropy1-3-(34(2-((2 LRMS
(ESI)
11-137 N, ¨ 7----\0 ((2R,5S)-2,5-dimethylmorpholino)
calc'd for
/ N, /
HN HN 411, N '-me quinolin-6-yl)amino)-4-oxo-4,5- C27H30N702
0 dihydro- 1 H-pyrazo lo [4,3-c] [M+H]+: 484,
pyridin-l-yl)propanenitrile found 484
s
H CN Me (S)-3-cyclopropy1-3-(3((2- LRMS (ESI)
11-138 ((2S,5S)-2,5-dimethylmorpholino) calc'd
for
HN 4.N N/ me quinolin-6-yl)amino)-4-oxo-4,5- C27H30N702
/FI
0 dihydro- 1 H-pyrazo lo [4,3-c] [M+H]+: 484,
pyridin-l-yl)propanenitrile found 484
126
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
Ai,N,µFICN Me,. (S)-3-cyclopropy1-3-(34(2- LRMS (ESI)
11-139 ¨ ((2R,5R)-2,5-dimethylmorpholino) calc'd
for
T/ / NCO
HN HN 411, N -me quinolin-6-yl)amino)-4-oxo-4,5-
C27H30N702
0 dihydro-1H-pyrazolo [4,3-c] [M+H]+:
484,
pyridin-l-yl)propanenitrile found 484
As
H CN (S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-140 N, ((S or R)-1,1,1-trifluoro-2- calc'd for
241
/ \ / CF3
HN HN if Me methoxypropan-2-yl)phenyl) C22H23F3N502
OMe
0 amino)-4,5-dihydro-1H-pyrazolo [M+H]+:
446,
[4,3-c]pyridin-1-yl)propanenitrile found 446
s
H CN (S)-3-cyclopropy1-3-(34(4AS or
11-141 N, Me R)-3-ethylmorpholine-4-
/ \ iN 0 LRMS (ESI)
5-me carbonyl)-3-methylphenyl)
HN HN 411, N calc'd for
c
O amino)-4-oxo-4,5-dihydro- 1H-
C26H3iN603
pyrazolo [4,3-c] pyridin-1-
[M+H]+: 475,
yl)propanenitrile (SFC Peak 1,
found 475
Chiralpak AD-H, 21 x 250 (mm),
30% Me0H in CO2, Tr = 3.84)
As
H CN (S)-3-cyclopropy1-3-(34(4AS or
11-142 N, Me R)-3-ethylmorpholine-4-
/ \ iN 0 LRMS (ESI)
dme carbony1)-3-methylphenyl)
HN HN 411, N
O amino)-4-oxo-4,5-dihydro- 1H-
calc'd for
C26H3iN603
pyrazolo [4,3-c] pyridin-1-
[M+H]+: 475,
yl)propanenitrile (SFC Peak 2,
found 475
Chiralpak AD-H, 21 x 250 (mm),
30% Me0H in CO2, Tr = 6.19)
(S)-3-cyclopropy1-3-(34(4AS or
11-143 As
H CN R)-3-isopropylmorpholine-4-
'N Me o Me carbonyl)-3-methylphenyl) LRMS (ESI)
/ \ i
411,
6:Me amino)-4-oxo-4,5-dihydro- 1H- calc'd
for
HN HN N
O pyrazolo[4,3-
c]pyridin-l-y1) C27H33N603
propanenitrile (SFC Peak 1, [M+H]+: 489,
Phenomenex, Lux-4, 21 x250 found 489
(mm), 40% Me0H in CO2, Tr =
5.18)
127
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
Ai,N,si__CN (S)-3-cyclopropy1-3-(34(4AS or
11-144 Me R)-3-isopropylmorpholine-4-
HN HN 411, 0 Me
6:Me carbonyl)-3-methylphenyl) LRMS (ESI)
N
0 amino)-4-oxo-4,5-dihydro- 1H- calc'd
for
pyrazolo[4,3-c]pyridin-1-y1) C24133N603
propanenitrile (SFC Peak 2, [M+H]+: 489,
Phenomenex, Lux-4, 21 x250 found 489
(mm), 40% Me0H in CO2, Tr =
6.33)
s
H CN (S)-3-cyclopropy1-3-(3((3-
II-145 N, MeMe methyl-4-((S or R)-2-methyl-1-
Me
HN N 41k,
(2H-1,2,3-triazol-2-
H
0 NiN)r\\J
yl)propyl)phenyl)amino)-4-oxo-
LRMS (ESI)
4,5-dihydro-1H-pyrazolo [4,3-
calc'd for
c]pyridin-l-yl)propanenitrile (Peak
C25H28N80 [M
1, Chiralpak IA-3, 0.46 x 5 cm, 3
+ H]+: 457,
um; mobile phase: hexane (0.1%
found 457
diethylamine):ethanol= 75:25;
flow: 20 mL/min, pressure: 2.6
MPA, detector: 220/254 nm; Tr =
9.3 min)
s
H CN (S)-3-cyclopropy1-3-(3((3-
II-146 N, MeMe methyl-4-((S or R)-2-methyl-1-
Me
HN N 41k,
(2H-1,2,3-triazol-2-
H
0 NiN)1\\J
yl)propyl)phenyl)amino)-4-oxo-
LRMS (ESI)
4,5-dihydro-1H-pyrazolo [4,3-
calc'd for
c]pyridin-l-yl)propanenitrile (Peak
C25H28N80 [M
2, Chiralpak IA-3, 0.46 x 5 cm, 3
+ H]+: 457,
um; mobile phase: hexane (0.1%
found 457
diethylamine):ethanol= 75:25;
flow: 20 mL/min, pressure: 2.6
MPA, detector: 220/254 nm; Tr =
11.5 min)
As
H CN (S)-3-(3-((2-benzy1-1,1-dioxido- LRMS
(ESI)
7
11-147 N, m tat 2,3-dihydrobenzo[d]isothiazol-5-
calc'd for
HN HN
241
/ \ /
411, SO2 W yl)amino)-4-oxo-4,5-dihydro- 1H- C26H25N603 S
0 pyrazolo[4,3-c]pyridin-1-y1)-3- [M +
H]+: 501,
cyclopropylpropanenitrile found 501
128
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
s
CN (S)-3-Cyclopropy1-3-(343-
N,H
11-148 Me Me methyl-44(S or R)-2-methyl-1-
Me
HN HN 4. N¨N (1H-1,2,3-triazol-1-yl)propyl)
o
c;1\1 phenyl)amino)-4-oxo-4,5-dihydro-
LRMS (ESI)
1H-pyrazolo[4,3-c]pyridin-1-
calc'd for
yl)propanenitrile (Peak 1,
C25H28N80 [M
Chiralpak IA-3, 0.46 x 5 cm, 3
+ H]+: 457,
um; mobile phase: hexane (0.1%
found 457
diethylamine):ethanol= 60:40;
flow: 1.0 mL/min pressure: 3.0
MPA; detector: 220/254 nm; Tr =
7.3)
As
CN (S)-3-Cyclopropy1-3-(343-
N,H
11-149 Me Me methyl-44(S or R)-2-methyl-1-
Me
HN HN 4. N¨N (1H-1,2,3-triazol-1-yl)propyl)
o c;N phenyl)amino)-4-oxo-4,5-dihydro-
LRMS (ESI)
1H-pyrazolo[4,3-c]pyridin-1-y1)
calc'd for
propanenitrile (Peak 2, Chiralpak
C25H28N80 [M
IA-3, 0.46 x 5 cm, 3 um; mobile
+ H]+: 457,
phase: hexane (0.1%
found 457
diethylamine):ethanol= 60:40;
flow: 1.0 mL/min pressure: 3.0
MPA; detector: 220/254 nm; Tr =
15.7)
&sss
CN (S)-3-cyclopropy1-3-(3((3-
N,H
11-150 Me methyl-44(R or S)-2,2,2-trifluoro-
/ \ IN
CF3
HN HN 411, OH 1-hydroxyethyl) phenyl)amino)-4-
0 oxo-4,5-dihydro-1H-pyrazolo[4,3- LRMS
(ESI)
c]pyridin-l-yl)propanenitrile (Peak calc'd for
1, Chiralpak IA 2 x 25 cm, 5 mm; C21H20F3N502
mobile phase: phase A: hexane [M + H]+: 432,
(0.1% diethylamine); phase B: found 432
ethanol (0.1% diethylamine) 30%
in 20 min, flow :20 ml/min;
detector: 220/254 nm; Tr = 7.9)
129
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
AsCN (S)-3-cyclopropy1-3-(3((3-
II-151 Me methyl-4-((R or S)-2,2,2-trifluoro-
CF3
HN HN 411, OH 1-hydroxyethyl) phenyl)amino)-4-
0 oxo-4,5-dihydro-1H-pyrazolo[4,3- LRMS
(ESI)
c]pyridin-l-yl)propanenitrile (Peak calc'd for
2, Chiralpak IA 2 x 25 cm, 5 mm; C21H20F3N.502
mobile phase : phase A: hexane [M + H]+: 432,
(0.1% diethylamine); phase B: found 432
ethanol (0.1% diethylamine) 30%
in 20 min, flow :20 ml/min;
detector: 220/254 nm; Tr = 13.6)
s
H CN (S)-3-(3-((4-((S or R)-
II-152 N N Me It cyclopenty1(2H-1,2,3-triazol-2-
/ \ ;
HN HN !It 1,1Ni yl)methyl)-3-methylphenyl)
0 amino)-4-oxo-4,5-dihydro- 1H-
LRMS (ESI)
pyrazolo[4,3-c]pyridin-1-y1)-3-
calc'd for
cyclopropylpropanenitrile (Peak 1,
C271130N80 [M
Chiralpak IA, 0.46 x 25 cm, 5 mm;
+ H]+: 481,
mobile phase: phase A: hexane
found 481
(0.1% TEA) and phase B: ethanol
(hold 35% Phase B for 20 min);
detector, UV 220/254 nm. Tr =
11.3)
s
H CN (S)-3-(3-((4-((S or R)-cyclopentyl
N
N Me 41 (2H-1,2,3-triazol-2-yl)methyl)-3-
11-153
/ \ ;
HN HN !It 1,1Ni methylphenyl) amino)-4-oxo-4,5-
0 dihydro-1H-pyrazolo [4,3-c]
LRMS (ESI)
pyridin-l-y1)-3-cyclopropyl-
calc'd for
propanenitrile (Peak 2, Chiralpak
C271130N80 [M
IA, 0.46 x 25 cm, 5 mm; mobile
+ H]+: 481,
phase: phase A: hexane(0.1%
found 481
TEA) and phase B: ethanol (hold
35% Phase B for 20 min);
detector, UV 220/254 nm. Tr =
15.8)
130
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(S)-3-(3-((4-((R or S)-1-amino-
AI,NSHoN
11-154 Me 2,2,2-trifluoroethyl)-3-
CF3
HN HN 411, NH2 methylphenyl)amino)-4-oxo-4,5-
0 dihydro-1H-pyrazolo [4,3-
LRMS (ESI)
c]pyridin- 1-y1)-3 -cyclopropyl-
calc'd for
propanenitrile (Peak 1, Chiralpak
C211121F3N60
IA 2 x 25 cm, 20 um; phase A:
[M + H]+: 431,
hexane (0.1% diethylamine);
found 431
phase B: ethanol (0.1%
diethylamine); flow rate: 17
mL/min; detector: 220/254 nm; Tr
= 11.5)
(S)-3-(3-((4-((R or S)-1-amino-
II-155
CN 2,2,2-trifluoroethyl)-3-
N
Me methylphenyl)amino)-4-oxo-4,5-
CF3
HN HN 411, NH2 dihydro-1H-pyrazolo [4,3-c]
LRMS (ESI)
0 pyridin-l-y1)-3-cyclopropyl-
calc'd for
propanenitrile (Peak 2, Chiralpak
C211121F3N60
IA 2 x 25 cm, 20 um; phase A:
[M + H]+: 431,
hexane (0.1% diethylamine);
found 431
phase B: ethanol (0.1%
diethylamine); flow rate: 17
mL/min; detector: 220/254 nm; Tr
= 22.5)
(S)-3-(3-((2-cyclohexy1-1,1-
LRMS (ESI)
d
b
d
dih
3
2
id
di
11-156 0 oxo-,-yroenzo[]
;_icN Y
calc'd for for
isothiazol-5-yl)amino)-4-oxo-4,5-
c25H28N6035
H(----41N/ \ /FIN . so2 dihydro-1H-pyrazolo [4,3-c]
[M + H]+: 493,
0 pyridin-1-y1)-3-
found 493
cyclopropylpropanenitrile
(S)-3-cyclopropy1-3-(34(2-(1-
11-157 As
H CN to methylcyclohexyl)-1,1-dioxido- LRMS
(ESI)
Y
calc'd for for
N, 2,3-dihydrobenzo[d]isothiazol-5-
41
/ \ /
c26H30N6035
HN HN 41t, SO2 yl)amino)-4- oxo-4,5-dihydro- 1H-
[M + H]+: 507,
0 pyrazolo[4,3-c]pyridin-1-y1)
found 507
propanenitrile
(S)-3-cyclopropy1-3-(3-(((S or R)- LRMS (ESI)
11-158 3-hydroxy-2,2-dimethyl- 1,1-
calc'd for for
131
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
AsCN
,H HO me
NN M dioxido-2,3-dihydrobenzo[b] C22H23N504S
thiophen-5-yl)amino)-4-oxo-4,5- [M+H]+: 454,
HN HN
/ \ Me
ifs02 dihydro-1H-pyrazolo [4,3-c] found 454
O pyridin-l-yl)propanenitrile (Peak
1, chiralpak IA 2 x 25cm, 20 um;
phase A: hexane (0.1%
diethylamine) phase B: ethanol
(0.1% dietylamine); flow rate: 16
mL/min. detector: 220/254 nm;
Tr = min)
(S)-3-cyclopropy1-3-(3-(((S or R)-
11-159 AsCN
,H HO me
N N Me 3-hydroxy-2,2-dimethyl- 1,1-
dioxido-2,3 - dihydrob enzo[b]
/ \ I
= SO2 thiophen-5-yl)amino)-4-oxo-4,5-
HN HN LRMS (ESI)
O dihydro-1H-pyrazolo [4,3-c]
calc'd for for
pyridin-l-yl)propanenitrile (Peak
C22H23N5045
2, chiralpak IA 2 x 25cm, 20 um;
[M+H]+: 454,
phase A: hexane (0.1%
found 454
diethylamine) phase B: ethanol
(0.1% dietylamine); flow rate: 16
mL/min. detector: 220/254 nm;
Tr = min)
(S)-3-cyclopropy1-3-(3-(((S)-3-
II-160
Aiµ CN
,H HO el hydroxy-1,1-dioxido-3H-spiro
N11
[benzo[b]thiophene-2,1'-
/ \
HN HN = SO2 cyclohexan]-5-yl)amino)-4-oxo-
LRMS (ESI)
O 4,5-dihydro-1H-pyrazolo[4,3-
calc'd for for
c]pyridin-l-yl)propanenitrile (Peak
C25H28N5045
1, Chiralpak IA 2 x 25 cm, 20 um;
[M+H]+: 494,
phase A: hexane (0.1%
found 494
diethylamine); phase B: ethanol
(0.1% diethylamine); flow rate: 20
mL/min; detector: 220/254 nm; Tr
= 12.5)
(S)-3-cyclopropy1-3-(3-(((S)-3- LRMS (ESI)
11-161 hydroxy-1,1-dioxido-3H-spiro calc'd for
for
[benzo[b]thiophene-2,1'- C25H28N5045
cyclohexan]-5-yl)amino)-4-oxo- [M+H]+: 494,
132
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
Ai.µ CN
HO 4,5-dihydro-1H-pyrazolo[4,3- found 494
N, H el
c]pyridin-l-yl)propanenitrile (Peak
H(----41N/ \ /FIN = 502 2, Chiralpak IA 2 x 25 cm, 20 um;
O phase A: hexane (0.1%
diethylamine); phase B: ethanol
(0.1% diethylamine); flow rate: 20
mL/min; detector: 220/254 nm; Tr
= 19.5)
(S)-3-cyclopropy1-3-(4-oxo-344-
II-162
/i<sCN ((R or S)-2-(trifluoromethyl)
N, H
pyrrolidin-2-yl)phenyl)amino)- LRMS (ESI)
sok_ F3C
HN HN ir 4,5-dihydro-1H-pyrazolo[4,3-c] calc'd
for for
N
O H
PYridin-l-yl)propanenitrile (Peak C23H23F3N60
1, C18 OBD column 19 x 150 mm, [M + H]+: 457,
um; Mobile phase: hexane: found 457
ethanol = 99:1;
Detector: 220/254 nm; Tr = 18)
(S)-3-cyclopropy1-3-(4-oxo-344-
II-163
/i<sCN ((R or S)-2-(trifluoromethyl)
N, H
pyrrolidin-2-yl)phenyl)amino)- LRMS (ESI)
sok_ F3C
HN HN ir 4,5-dihydro-1H-pyrazolo[4,3-c] calc'd
for for
N
O H
PYridin-l-yl)propanenitrile (Peak C23H23F3N60
2, C18 OBD column 19 x 150 mm, [M + H]+: 457,
5 um; Mobile phase: hexane: found 457
ethanol = 99:1;
Detector: 220/254 nm; Tr = 21)
(S)-3-(3-((4-(2-azaspiro[3.3]
LRMS (ESI)
11-164
H CN c..? heptan-2-ylsulfony1)-3-
s
calc'd for for
N Me methylphenyl)amino)-4-oxo-4,5-
P c25H29N6035
HN HN = SO2 dihydro-1H-pyrazolo [4,3-c]
[M + H]+: 493,
O pyridin-1-y1)-3-
found 493
cyclopropylpropanenitrile
(S)-3-cyclopropy1-3-(34(3- LRMS (ESI)
11-165 s
H CNc..? methy1-4-(2-azaspiro[3.3]heptane- calc'd
for for
N Me 2-
carbonyl)phenyl)amino)-4-oxo- C26H29N602 [M
N
HN HN =0 4,5-dihydro-1H-pyrazolo[4,3- + H]+:
457,
O c]pyridin-l-
yl)propanenitrile found 457
(S)-3-cyclopropy1-3-(3((1,1- LRMS (ESI)
133
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
11-166dioxido-3H-spiro[benzo[b] calc'd for for
N,µFICN
\ N II, thiophene-2,1'-cyclopentan]-5- C24H26N503S
H N
411, so2 yl)amino)-4-oxo-4,5-dihydro-1H- [M + H]+:
464,
/FI
O pyrazolo[4,3-c]pyridin-l-y1) found 464
propanenitrile
(S)-3-cyclopropy1-3-(3((1,1-
II-167 As
H CN dioxido-3H-spiro[benzo[b] LRMS (ESI)
N,
el thiophene-2,1'-cyclohexan]-5-
calc'd for for
\ N
C25H28N503S
HN/ . /FIN = SO2 yl)amino)-4-oxo-4,5-dihydro-1H-
[M + 1-1]+: 478,
O pyrazolo[4,3-c]pyridin-1-y1)
found 478
propanenitrile
(S)-3-cyclopropy1-3-(3 42,2-
11 -168 As
H CN Me dimethy1-1,1-dioxido-2,3- LRMS (ESI)
calc'd for for
N,N Me dihydrobenzo[b]thiophen-5-
\
C22H24N5035
H IN
= S02 yl)amino)-4-oxo-4,5-dihydro-1H-
/F [M + 1-1]+: 438,
O pyrazolo[4,3-c]pyridin-1-y1)
found 438
propanenitrile
(S)-3-cyclopropy1-3-(3-(((2R,3S or
LRMS (ESI)
11-169 AsCN
N, N H HQ 25,3R)-3-hydroxy-2-methy1-1,1-
calc'd for for
s Me dioxido-2,3-dihydrobenzo[b]
\
C21H22N5045
HN/ . INN 41t, SO2 thiophen-5-yl)amino)-4-oxo-4,5-
[M + H]+: 440,
O dihydro-1H-pyrazolo[4,3-c]
found 440
pyridin-l-yl)propanenitrile
(S)-3-cyclopropy1-3-(3-(((2R,3S or
LRMS (ESI)
11-170 AsCN
H HO 25,3R)-3-hydroxy-2-methy1-1,1-
calc'd for for
N, N Me dioxido-2,3-dihydrobenzo[b]
\ õ
C21H22N5045
HN/ . INN 41t, SO2 thiophen-5-yl)amino)-4-oxo-4,5-
[M + H]+: 440,
O dihydro-1H-pyrazolo[4,3-c]
found 440
pyridin-l-yl)propanenitrile
(S)-3-cyclopropy1-3-(3-(((2R,3R
LRMS (ESI)
11-171 AsCN
H HO or 25,35)-3-hydroxy-2-methyl-
calc'd for for
N, Me 1,1-dioxido-2,3-dihydrobenzo[b]
N C21H22N5045
HN/ \ INN 41t, SO2 thiophen-5-yl)amino)-4-oxo-4,5-
[M + H]+: 440,
O dihydro-1H-pyrazolo[4,3-c]
found 440
pyridin-l-yl)propanenitrile
(S)-3-cyclopropy1-3-(3-(((2R,3R LRMS (ESI)
11-172 or 25,35)-3-hydroxy-2-methyl- calc'd
for for
1,1-dioxido-2,3-dihydrobenzo[b] C21H22N5045
134
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
.CN
N,H HQ thiophen-5-yl)amino)-4-oxo-4,5- [M +
H]+: 440,
= Me dihydro-1H-pyrazolo [4,3-c] found 440
õ
H(----41N/ \ N 41,0 S02 pyridin-l-yl)propanenitrile
0
(3S)-3-cyclopropy1-3-(3((2-
II-173 s
H CN methyl-1,1-dioxido-2,3- LRMS (ESI)
calc'd for for
N, Me dihydrobenzo[b]thiophen-5-y1)
(-----41
/ \ / C211122N503S
HN HN 41,0 S02 amino)-4-oxo-4,5-dihydro- 1H-
[M + H]+: 424,
O pyrazolo[4,3-c]pyridin-1-y1)
found 424
propanenitrile
(S)-3-cyclopropy1-3-(34(3-
II-174
AsCN methyl-4-((R or S)-2-
N,H
(trifluoromethyl) pyrrolidin-2- LRMS (ESI)
F3C
HN HN 4it N yl)phenyl)amino)-4-oxo-4,5- calc'd for
for
O H dihydro-1H-pyrazolo [4,3- C24H26F3N60
Me
c]pyridin-l-yl)propanenitrile (Peak [M + H]+: 471,
2, Chiralcel OJ-3, 0.46 x 15 cm, 3 found 471
um; mobile phase: n-hexane :
ethanol =70:30. Tr = 20)
(S)-3-cyclopropy1-3-(34(3-
II-175 As
H CN methyl-4-((R or S)-2-
N, (trifluoromethyl) pyrrolidin-2- LRMS (ESI)
24
HN H N 4Ik N
yl)phenyl)amino)-4-oxo-4,5- calc'd for for
O H dihydro-1H-pyrazolo [4,3- C24H26F3N60
Me
c]pyridin-l-yl)propanenitrile [M + H]+: 471,
(Peakl, Chiralcel OJ-3, 0.46 x 15 found 471
cm, 3 um; mobile phase: n-
hexane : ethanol =70:30. Tr = 15)
(S)-3-cyclopropy1-3-(4-oxo-341-
11-176 As
H CN 0 oxo-2-(1-(trifluoromethyl) LRMS (ESI)
calc'd for for
cyclohexyl)isoindolin-5-
N \ IN
C271428F3N602
HN HN =0 yl)amino)-4,5-dihydro-1H-
[M + H]+: 525,
0 pyrazolo[4,3-c]pyridin-1-
found 525
yl)propanenitrile
(S)-3-cyclopropy1-3-(34(2-(4- LRMS (ESI)
11-177 methyltetrahydro-2H-pyran-4-y1)- calc'd
for for
1,1-dioxido-2,3-dihydrobenzo[d] C25H29N6045
isothiazol-5-yl)amino)-4-oxo-4,5- [M + H]+: 509,
135
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
'<s
H CN
0 dihydro-1H-pyrazolo [4,3-c]
Me found 509
N2 pyridin-l-yl)propanenitrile
H NN 411,
Y
SO2
2-(\IN/ \ I
0
(S)-3-cyclopropy1-3-(34(4((R)-1- LRMS (ESI)
11-178
/i<sCN methyl-2-(trifluoromethyl) calc'd for
for
N,H
PYrrolidin-2-y1)phenyl)amino)-4- C24H26F3N60
isikF3C
HN HN ir
Me c]pyridin-l-yl)propanenitrile found 471
N oxo-4,5-dihydro-1H-pyrazolo[4,3- [M + H]+: 471,
0 I
(S)-3-cyclopropy1-3-(34(4((R)-1- LRMS (ESI)
11-179 A<s
H CN methy1-2-(trifluoromethyl) calc'd for
for
N, PYrrolidin-2-y1)phenyl)amino)-4- C24H26F3N60
F3C
HN HN !it
M c]pyridin-l-yl)propanenitrile found 471
N oxo-4,5-dihydro-1H-pyrazolo[4,3- [M + H]+: 471,
0 I
e
(S)-4-((1-(2-cyano-1-
II-180 As
H CN cyclopropylethyl)-4-oxo-4,5- LRMS (ESI)
calc'd for for
'N Mes __Co dihydro-1H-pyrazolo [4,3-c]
/ \ iN C26H31N603 [M
HN HN . o pyridin-3-yl)amino)-N,2-dimethyl-
+ H]+: 475,
0
Me N-(tetrahydro-2H-pyran-4-y1)
found 475
benzamide
(S)-3-cyclopropy1-3-(343-fluoro-
H
II-181 A<µ CN 4-((R or S)-2,2,2-trifluoro-1- LRMS
(ESI)
calc'd for for
N. (isopropylamino)ethyl)phenyl)ami
/ \ IN CF3 C23H25F4N60
HN HN it Nj....
;Vie no)-4-oxo-4,5-dihydro-1H-
- [M + H]+: 477,
o H Me pyrazolo[4,3-c]pyridin-l-y1)
F
found 477
propanenitrile
(S)-3-cyclopropy1-3-(343-fluoro-
H
II-182 Aµ CN 4-((R or S)-2,2,2-trifluoro-1- LRMS
(ESI)
calc'd for for
N. (isopropylamino)ethyl)phenyl)ami
/ \ IN CF3 C23H25F4N60
HN HN it Nj....
;Vie no)-4-oxo-4,5-dihydro-1H-
- [M + H]+: 477,
o H Me pyrazolo[4,3-c]pyridin-l-y1)
F
found 477
propanenitrile
(S)-3-cyclopropy1-3-(34(44R or
H
LRMS (ESI)
11-183 A<s CN S)-1-(ethylamino)-2,2,2-
calc'd for for
trifluoroethyl)-3-fluorophenyl)
/ \ N'IN CF3 C22H23F4N60
,Ivie amino)-4-oxo-4,5-dihydro- 1H-
H HN . N.¨/ [M + H]+: 463,
O H pyrazolo[4,3-c]pyridin-1-y1)
F
found 463
propanenitrile
136
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
ACN (S)-3-cyclopropy1-3-(34(44R or
N, H LRMS (ESI)
/
11-184 S)-1-(ethylamino)-2,2,2-
\ iN
cF3 calc'd for for
Vie trifluoroethyl)-3-fluorophenyl)
HN HN . N___-/
C22H23F4N60
0 H amino)-4-oxo-4,5-dihydro- 1H-
F
[M H]+: 463,
pyrazolo[4,3-c]pyridin-1-y1)
found 463
propanenitrile
s
CN (S)-3-(3-((4-((R or S)-1-(tert-
N, H
11-185 butylamino)-2,2,2-trifluoroethyl)-
CF3
Me
HN HN = N__eMe 3-fluorophenyl)amino)-4-oxo-4,5-
LRMS (ESI)
0 H Me
F dihydro-1H-pyrazolo [4,3-c]
calc'd for for
pyridin-l-y1)-3-cyclopropyl-
C24H27F4N60
propanenitrile (Peak 2,
[M + H]+: 491,
Phenomenex Lux Cellulose-4 5 x
found 491
425 cm, 5 um; mobile phase:
carbon dioxide : methanol with
0.1%DEA = 60 : 40. Tr = 4.4)
(S)-3-(3-((4-((R or S)-1-(tert-
11-186 s CN butylamino)-2,2,2-trifluoroethyl)-
N, H
/
3-fluorophenyl)amino)-4-oxo-4,5-
\ iN
cF3 LRMS (ESI)
Me HN HN e 4It N_4:-Me
-1H-pyrazolo [4,3-c]
calc'd for for
0 H Me
F pyridin-l-y1)-3-cyclopropyl-
C24H27F4N60
propanenitrile (SFC Peak 1
[M + H]+: 491,
Phenomenex Lux Cellulose-4 5 x
found 491
425 cm, 5 um; mobile phase:
carbon dioxide : methanol with
0.1%DEA = 60 : 40. Tr = 4.1)
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-187
sCN ((S or R)-2-(trifluoromethyl) calc'd
for for
N, H
tetrahydrofuran-2-yl)phenyl) C23H23F3N502
F3C
HN H N =0 amino)-4,5-dihydro-1H-pyrazolo [M +
H]+: 458,
o [4,3-c]pyridin-1-yl)propanenitrile found 458
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-188 CN
/<s ((S or R)-2-(trifluoromethyl) calc'd
for for
N, H
tetrahydrofuran-2-yl)phenyl) C23H23F3N502
F3C
HN H N =0 amino)-4,5-dihydro-1H-pyrazolo [M +
H]+: 458,
o [4,3-c]pyridin-1-yl)propanenitrile found 458
(S)-3-cyclopropy1-3-(3-(((R or S)- LRMS (ESI)
11-189 2-hydroxy-2-(trifluoromethyl)-2,3- calc'd
for for
137
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
AsCN OH dihydro-1H-inden-5-yl)amino)-4- C22H21F3N502
/
H
NN CF3 oxo-4,5-dihydro-1H-pyrazolo[4,3- [M + H]+:
444,
\ ;a
HN HN ilk c]pyridin-l-yl)propanenitrile found 444
0
As/
CN OH (S)-3-cyclopropy1-3-(3-(((R or S)- LRMS (ESI)
H
11-190 N;N CF3 2-hydroxy-2-(trifluoromethyl)-2,3- calc'd
for for
\ aHN HN ilk dihydro-1H-inden-5-yl)amino)-4- C22H21F3N502
0 oxo-4,5-dihydro-1H-pyrazolo[4,3- [M + H]+:
444,
c]pyridin-l-yl)propanenitrile found 444
(S)-3-cyclopropy1-3-(343-fluoro-
II-191 sCN 4-((R or S)-2,2,2-trifluoro-1-
N,H
hydroxyethyl)phenyl)amino)-4- LRMS (ESI)
/\ IN
CF3
HN HN . oxo-4,5-dihydro-1H-pyrazolo[4,3- calc'd for for
OH
O F c]pyridin-l-yl)propanenitrile (Peak
C20H18F4N.502
2, Chiralpak IA, 2 x 25 cm, 5 um; [M + H]+: 436,
mobile phase ethanol in n-hexane found 436
(50%); detector: 220/254 nm; Tr =
13)
(S)-3-cyclopropy1-3-(343-fluoro-
II-192 sCN 4-((R or S)-2,2,2-trifluoro-1-
N,H
hydroxyethyl)phenyl)amino)-4- LRMS (ESI)
/\ IN
CF3
HN HN . oxo-4,5-dihydro-1H-pyrazolo[4,3- calc'd for for
OH
O F c]pyridin-l-yl)propanenitrile (Peak
C20H18F4N.502
1, Chiralpak IA, 2 x 25 cm, 5 um; [M + H]+: 436,
mobile phase ethanol in n-hexane found 436
(50%); detector: 220/254 nm; Tr =
5.8)
(S)-3-(3-((3-chloro-4-((R or S)-
11-193 2,2,2-trifluoro-1-hydroxyethyl)
CN
N,N H
phenyl)amino)-4-oxo-4,5-dihydro- LRMS (ESI)
/\ I
CF3
HN H N 4it 1H-pyrazolo[4,3-c]pyridin-l-y1)-3- calc'd for for
OH
O cyclopropylpropaneni
Cl trile (Peak 1
C20H18C1F3N50
Chiralpak IA, 2 x 25 cm, 5 um; 2 [M H]+:
mobile phase ethanol in n-hexane 452, found 452
(50%); detector: 220/254 nm; Tr
=5.7)
138
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
AI,CN (S)-3-(3-((3-chloro-4-((R or S)-
N,H
11-194 2,2,2-trifluoro-l-hydroxyethyl)
CF3
HN HN . phenyl)amino)-4-oxo-4,5-dihydro- LRMS
(ESI)
OH
O 1H-pyrazolo[4,3-c]pyridin-1-y1)-3- calc'd for for
CI
cyclopropylpropanenitrile (Peak 2, C20H18C1F3N50
Chiralpak IA, 2 x 25 cm, 5 um; 2 [M H]+:
mobile phase ethanol in n-hexane 452, found 452
(50%); detector: 220/254 nm; Tr
= 25)
(S)-3-cyclopropy1-3-(3-(((R or S)- LRMS (ESI)
11-195 CN A's 2-hydroxy-2-methyl-2,3-dihydro- calc'd
for for
N,H OH
1H-inden-5-yl)amino)-4-oxo-4,5- C22H24N.502 [M
Me
HN HN if dihydro-1H-pyrazolo [4,3-c] + H]+: 390,
O pyridin-l-yl)propanenitrile found 390
(S)-3-cyclopropy1-3-(3-(((R or S)- LRMS (ESI)
11-196 CN A's 2-hydroxy-2-methyl-2,3-dihydro- calc'd
for for
N,H OH
1H-inden-5-yl)amino)-4-oxo-4,5- C22H24N.502 [M
Me
HN HN if dihydro-1H-pyrazolo [4,3-c] + H]+: 390,
O pyridin-l-yl)propanenitrile found 390
(S)-3-(3-((4-((R or S)-1-(tert-
11-197 AµCN butylamino)-2,2,2-trifluoroethyl)-
H
N 3-chlorophenyl)amino)-4-oxo-4,5- LRMS
(ESI)
CF3
M
HN HN e 4, N__eMe dihydro-1H-
pyrazolo [4,3-c] calc'd for for
0 H Me pyridin-l-y1)-3-cyclopropyl-
C24H27C1F3N60
CI
propanenitrile (Peak 1, Chiralpak [M + H]+: 507,
IA, 2 x 25 cm, 5 um; mobile found 507
phase:ethanol in n-hexane (10%).
Tr = 16)
(S)-3-(3-((4-((R or S)-1-(tert-
11-198 CN butylamino)-2,2,2-trifluoroethyl)-
H LRMS (ESI)
N 3-chlorophenyl)amino)-4-oxo-4,5-
/ \ ;N CF3 calc'd for for
M
HN HN e it N__eMe dihydro-1H-pyrazolo [4,3-c]
C24H27C1F3N60
0 H Me pyridin-1-y1)-3-cyclopropyl-
CI
[M + H]+: 507,
propanenitrile (Chiralpak IA, 2 x
found 507
25 cm, 5 um; mobile phase:ethanol
inn-hexane (10%). Tr = 26.7)
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-199 ((R or S)-2-(trifluoromethyl) calc'd
for for
139
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
A CN piperidin-2-yl)phenyl)amino)-4,5-
C24H26F3N60
dihydro-1H-pyrazolo [4,3-c] [M + H]+: 471,
F3C
HN HN , N pyridin-l-yl)propanenitrile found 471
O H
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
I1-200A CN ((R or S)-2-(trifluoromethyl) calc'd
for for
piperidin-2-yl)phenyl)amino)-4,5- C24H26F3N60
F3C
HN HN , N dihydro-1H-pyrazolo [4,3-c] [M + H]+:
471,
O H pyridin-l-yl)propanenitrile found 471
(R or S)-methyl 2-(4-((1-((S)-2-
LRMS (ESI)
11-201
ACN cyano-l-cyclopropylethyl)-4-oxo-
N,H calc'd for for
4,5-dihydro-1H-pyrazolo[4,3-c]
F3C C25H26F3N603
HN HN =N pyridin-3-yl)amino)pheny1)-2-
[M + H]+: 515,
0 Me0-- (trifluoromethyl)pyrrolidine-1-
µ
0 found 515
carboxylate
(R or S)-methyl 2-(4-((1-((S)-2-
LRMS (ESI)
11-202
ACN cyano-1-cyclopropylethyl)-4-oxo-
N,H calc'd for for
4,5-dihydro-1H-pyrazolo[4,3-c]
F3C C25H26F3N603
HN HN =N pyridin-3-yl)amino)pheny1)-2-
[M + H]+: 515,
0 Me0-- (trifluoromethyl)pyrrolidine-1-
µ
0 found 515
carboxylate
(S)-3-cyclopropy1-3-(342-(4,4-
F LRMS (ESI)
11-203 difluoro-l-methylcyclohexyl)-1,1-
A`'121CN 0111 F
dioxido-2,3-dihydrobenzo calc'd for for
Y c26H29F2N603s
Hc:44
NN . so2 [d]isothiazol-5-yl)amino)-4-oxo-
[M + H]+: 543,
0 4,5-dihydro-1H-pyrazolo[4,3-c]
found 543
pyridin-l-yl)propanenitrile
(S)-3-cyclopropy1-3-(4-oxo-344-
II-204 As
H CN ((S or R)-2,2,2-trifluoro-1-
N, hydroxy-1-(pyridin-2-yl)ethyl) LRMS
(ESI)
241
/ \ / OH
HN HN 4. C F3 phenyl)amino)-4,5-dihydro-1H- calc'd
for for
O N / \ pyrazolo[4,3-c]pyridin-l-y1)
C25H22F3N602
--
propanenitrile (SFC Peak 1, [M + H]+: 495,
Chiralcel OJ-H, 21 x 250 (mm), found 495
35% Me0H +0.25% Dimethyl
Ethyl Amine, in CO2, Tr = 2.65)
140
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
H
.sCN (S)-3-cyclopropy1-3-(4-oxo-34
N, 4-
II-205 ((S or R)-2,2,2-trifluoro-1-
H2-41N/ \ INN = OH CF3 hydroxy-1-(pyridin-2-yl)ethyl) LRMS (ESI)
0 Ni \ phenyl)amino)-4,5-dihydro-1H- calc'd
for for
¨
pyrazolo[4,3-c]pyridin-1-y1) C25H22F3N602
propanenitrile (SFC Peak 2, [M + H]+: 495,
Chiralcel OJ-H, 21 x 250 (mm), found 495
35% Me0H +0.25% Dimethyl
Ethyl Amine, in CO2, Tr = 4.04)
(S)-3-cyclopropy1-3-(4-oxo-344-
II-206 As
H CN ((S or R)-2,2,2-trifluoro-1-
2
N,4 OH hydroxy-1-(pyridin-4-yl)ethyl) LRMS (ESI)
/ \ /
HN HN . CF3 phenyl)amino)-4,5-dihydro-1H- calc'd for for
ci / \ pyrazolo[4,3-c]pyridin-1-y1)
C25H22F3N602
¨N
propanenitrile (SFC Peak 1, [M + H]+: 495,
Chiralpak IC, 21 x 250 (mm), 35% found 495
Me0H +0.25% Dimethyl Ethyl
Amine, in CO2, Tr = 3.07)
(S)-3-cyclopropy1-3-(4-oxo-344-
11-207 As
H CN ((S or R)-2,2,2-trifluoro-1-
N, hydroxy-1-(pyridin-4-
4
/ \ / OH LRMS (ESI)
HN HN . CF3 yl)ethyl)phenyl)amino)-4,5-
calc'd for for
ci / \ dihydro-1H-pyrazolo [4,3-c]
¨N C25H22F3N602
pyridin-l-yl)propanenitrile (SFC
[M + H]+: 495,
Peak 2, Chiralpak IC, 21 x 250
found 495
(mm), 35% Me0H +0.25%
Dimethyl Ethyl Amine, in CO2, Tr
= 3.40)
(S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-208 As
H CN ((R or S)-2,2,2-trifluoro-1- calc'd for
for
N, thiomorpholinoethyl)phenyl)amin r ri p xi- (--,Q
/ \ /N CF3
.... 24, r26, 3, 'I 6 V 1-7
HN HN = o)-4,5-dihydro-1H-pyrazolo[4,3- [A4 H]+: 503,
O N¨)
C---s c]pyridin-l-yl)propanenitrile found 503
As
H CN (S)-3-cyclopropy1-3-(4-oxo-344- LRMS (ESI)
11-209 / N, ni ((R or S)-2,2,2-trifluoro-1- calc'd for
for \ i
CF3
thiomorpholinoethyl)phenyl)amin C24H26F3N605
HN HN 41,
N¨)
0
C o)-4,5-dihydro-1H-pyrazolo[4,3- [M +
H]+: 503,
¨s
c]pyridin-l-yl)propanenitrile found 503
141
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Intermediate 1-113
(S)- 4- ((1- (2-cyano-1-cyclopr op ylethyl)-4-oxo-4,5-dihydr o-1H-p yr azolo
[4,3-c]p yr idin-3-
yl)amino)-2-methylbenzoic acid
AµCN
N,H
Me
N
HN HN git OH
0 I-113
Step 1: (S)- 44(4-(benzyloxy)-1-(2-cyano-1-cyclopropylethyl)-1H-pyrazolo[4,3-
c]pyridin-3-yflamino)-
2-methylbenzoic acid
'<sCN
H
N Me
N¨ HN git OH
OBn I-113a
An oven dried pressure tube equipped with magnetic sir bar under an atmosphere
of N2 was charged with (S)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-
1-y1)-3-
cyclopropylpropanenitrile (2 g, 6 mmol), 4-bromo-2-methylbenzoic acid (2.2 g,
10.5 mmol),
potassium acetate (1 g, 10.5 mmol), and t-Bu XPhos 3rd Generation precatalyst
(524 mg, 0.7
mmol). The flask was evacuated, and purged with N2 (3 times) followed by the
addition of t-
amyl alcohol (15 mL). The reaction mixture stirred, and heated to 90 C for 16
h. The reaction
mixture was concentrated in vacuo, and purified by column chromatography on
silica gel
(hexanes/Et0Ac gradient) to yield (S)-4-((4-(benzyloxy)-1-(2-cyano-1-
cyclopropylethyl)-1H-
pyrazolo[4,3-c]pyridin-3-yl)amino)-2-methylbenzoic acid II-204a (1.5 g, 3.21
mmol, 53%).
LRMS (ESI) calc'd for C27H26N503 [M+H]': 468, found 468.
142
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Step 2: fS)- 4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-c]pyridin-
3-yl)amino)-2-methylbenzoic acid
AI,CN
H
N Me
0
HN HN . OH
0 I-113
A round bottom flask with magnetic sir bar was charged with (S)-4-((4-
(benzyloxy)-1-(2-cyano-1-cyclopropylethyl)-1H-pyrazolo[4,3-c]pyridin-3-
y1)amino)-2-
methylbenzoic acid I-113a (1.5 g, 3.2 mmol), Et0Ac (32 ml), and Pd/C (683 mg,
0.2 mmol, 10%
by wt). The reaction mixture was stirred under an atmosphere of H2 for 4 h.
The reaction
mixture was filtered through a pad of celite, and the organics were
concentrated in vacuo to
afford a residue that was purified by column chromatography on silica gel
(hexanes/Et0Ac
gradient) to yield (S)-4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-3-yl)amino)-2-methylbenzoic acid (800 mg, 2.1 mmol, 66%). LRMS (ESI)
calc'd for
C20H20N503 [M+H]': 378, found 378. 1H NMR (500 MHz, DMS0): 6 11.15 (d, J =
5.75 Hz;
1H), 8.35 (s, 1H), 7.83 (d, J= 8.46 Hz, 1H), 7.62 ¨ 7.60 (m, 1H), 7.21 (t, J=
6.52 Hz, 1H), 6.61
(d, J= 7.33 Hz, 1H), 4.23 (m, 1H), 3.29 ¨ 3.24 (m, 2H), 2.54 (s, 3H), 1.47 (m,
1H), 1.19 (m, 1H),
0.65 (m, 1H), 0.52 (m, 1H), 0.43 (m, 1H), 0.33 (m, 1H).
Compound III-1
(S) -4- ((1- (2-cyano-1-cyclopr opylethyl)-4-oxo-4,5-dihydr o-1H-pyr azolo
[4,3-c]pyr idin-3-
yl)amino)-N,2-dimethyl-N-(2,2,2-trifluor oethyl)benzamide
A'CN
H
N Me
HN HN = N¨N
0 N4 CF3 III-1
A reaction vial with magnetic sir bar was charged with (S)-441-(2-cyano-1-
cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2-
methylbenzoic
acid I-113 (20 mg, 0.05 mmol), hydroxybenzotriazole (HOBt) (16 mg, 0.1 mmol),
1-Ethy1-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (20 mg, 0.1 mmol), Hunig's base (37 uL,
0.2 mmol),
and DMF (0.53 mL). To this reaction mixture, N-methyl-2,2,2-
trifluoroethanamine (18 mg, 0.16
mmol) was added. The reaction mixture was stirred at rt for 16 h. The reaction
mixture was
purified by reverse phase chromatography to yield (S)-441-(2-cyano-1-
cyclopropylethyl)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N,2-dimethyl-N-(2,2,2-
143
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
trifluoroethyl)benzamide III-1 (15.3 mg, 0.03 mmol, 61%). LRMS (ESI) calc'd
for
C23H24F3N602 [M+H]+: 473, found 473. 1H NMR (DMSO, 500MHz): 6 1H NMR (499 MHz,
DMS0): 6 11.12 (d, J= 5.76 Hz, 1H), 8.18 (s, 1H), 7.64 ¨ 7.60 (m, 2H), 7.21
(t, J = 6.54 Hz,
1H), 7.07 (d, J= 8.23 Hz, 1H), 6.60 (d, J= 7.33 Hz, 1H), 4.36 (br s, 2H), 4.22
(m, 1H), 3.44 (s,
3H), 2.90 (s, 2H), 2.20 (s, 3H), 1.46 (m, 1H), 0.65 (m, 1H), 0.52 (m, 1H),
0.43 (m, 1H), 0.33 (m,
1H).
Table 15 discloses Examples that were prepared in analogy to Compound III-1
starting with
Intermediate I-113.
Table 15.
Example Structure Compound Name LRMS
(S)-4-((1-(2-cyano-1-
III-2As
N', H CN cyclopropylethyl)-4-oxo- LRMS
(ESI)
Me 4,5-dihydro-1H-pyrazolo Calc'd for
0
[4,3-c]pyridin-3-y1)
C24H26F3N602
HN HN 41, N----\ amino)-N-ethyl-2-methyl- [M+H]+:
487,
0 K CF3
N-(2,2,2-trifluoroethyl) found 487.
Me
benzamide
(S)-4-((1-(2-cyano-1-
111-3 CN cyclopropylethyl)-4-oxo-
H LRMS (ESI)
N Me 4,5-dihydro-1H-pyrazolo
0 Calc'd for
[4,3-c]pyridin-3-y1)
HN HN 4. N
C26H31F3N702
¨\ amino)-N-(2-
0 C F3 [M+H]+:
530,
(dimethylamino)ethyl)-2-
found 530.
Me--N, methyl-N-(2,2,2-
Me
trifluoroethyl)benzamide
(S)-3-cyclopropy1-3-(3-
III-4 'A.CN ((3-methyl-4- LRMS (ESI)
H
N Me (thiomorpholine-4- Calc'd for
0
carbonyl)phenyl)amino)- C24H27N602S
HN HN . 4-oxo-4,5-dihydro-1H- [M+H]+: 463,
--)
0 N
C--S pyrazolo[4,3-c]pyridin-1-
found 463.
yl)propanenitrile
144
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
A
(S)-3-cyclopropy1-3-(3-
i
II1-5 s " CN ((3-methyl-4-(4- LRMS (ESI)
N, H
Me methylpiperazine-1- CaIc'd for
0
HN HN =
carbonyl)phenyl) amino)- C25H30N702
0 IN--- 4-oxo-4,5-dihydro-1H- [M+H]+: 460,
\--N pyrazolo [4,3 -c]pyridin- 1- found
460.
Me
yl)propanenitrile
(S)-3-cyclopropy1-3-(3 -
III-6 ((3 -methyl-4-((S)-2-
LRMS (ESI)
AsCN
N, H (trifluoromethyl)pyrrolidin
CaIc'd for
Me e-l-carbonyl)phenyl)
0
C25H26F3N602
HN HN 41, H C F3 amino)-4-oxo-4,5-dihydro-
[M+H]+: 499,
0 1H-pyrazolo [4,3-c]
found 499.
pyridin-l-y1)
propanenitrile
(S)-4-((1-(2-cyano- 1 -
111-7 CN cyclopropylethyl)-4-oxo- LRMS (ESI)
N, H
HI
N
Me 4,5-dihydro-1H-pyrazolo CaIc'd for
0
HN 441t
N....O....me [4,3- c]pyridin-3-y1) C27}134N702
amino)-N,2-dimethyl-N- [M+H]+: 488,
0
Me/
(1-methylpiperidin-4-y1) found 488.
benzamide
(S)-4-((1-(2-cyano- 1-
LRMS (ESI)
111-8 CN cyclopropylethyl)-4-oxo-
N, H CaIc'd for
Me 4,5-dihydro-1H-pyrazolo
0 C23H27N602
[4,3-c]pyridin-3-y1)
HN HN = N---\ amino)-N-ethyl-N,2-
Me [M+H]+: 419,
0 Me found 419.
dimethylbenzamide
(S)-3-cyclopropy1-3-(3 -
III-9 CN ((3-methy1-4-(morpho1ine- LRMS (ESI)
N, H
4- CaIc'd for
Me
0
carbonyl)phenyl)amino)- C24H27N603
HN HN =NI-
4-oxo-4,5-dihydro-1H- [M+H]+: 447,
0 I
pyrazolo [4,3 -c]pyridin- 1- found 447.
\-0
yl)propanenitrile
145
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(S)-3-cyclopropy1-3-(3-
III-10 As
CN ((4-(3,3-dimethyl LRMS (ESI)
Me pyrrolidine-l-carbony1)-3- Calc'd for
0
methylphenyl)amino)-4- C26H31N602
HN HN 441t NOs.... oxo-4,5-dihydro-1H- [M+H]: 459,
O Me
pyrazolo [4,3 -c]pyridin- 1- found 459.
Me
yl)propanenitrile
(S)-3-cyclopropy1-3-(3-
As
III-11 ' CN ((4-(3,3-dimethyl LRMS (ESI)
N,H
Me azetidine-l-carbony1)-3- Calc'd for
0
46
methylphenyl)amino)-4- C25H29N602
HN HN
y---7 oxo-4,5-dihydro-1H- [M+H]: 445,
0
1-1---Me pyrazolo [4,3 -c]pyridin- 1- found
445.
Me
yl)propanenitrile
(S)-3-cyclopropy1-3-(3-
III-12s
= CN ((4-(2,2-dimethyl LRMS (ESI)
N,H
Me morpholine-4-carbonyl)-3- Calc'd for
0
methylphenyl)amino)-4- C26H31N603
HN HN 41, NMe oxo-4,5-dihydro-1H- [M+H]: 475,
O ---\/¨Me
pyrazolo [4,3 -c]pyridin- 1- found 475.
\-0
yl)propanenitrile
(S)-3-cyclopropy1-3-(3-
III-13 ((4-((2R,5R)-2,5-
AsCN dimethylpyrrolidine-l-
LRMS (ESI)
N,H Calc'd for
Me carbonyl)-3-methylphenyl)
0 C26H31N602
amino)-4-oxo-4,5-dihydro-
HN HN 41, s
Me [M+H]+: 459,
O 1H-pyrazolo[4,3-
found 459.
Me c]pyridin-l-y1)
propanenitrile
(S)-3-cyclopropy1-3-(3-
III-14 A\i, ((4-((R)-3-fluoro LRMS (ESI)
= CN
N,H pyrrolidine-l-carbony1)-3- Calc'd for
Me
0 methylphenyl)amino)-4- C24H26FN602
HN HN .
!\1¨\ oxo-4,5-dihydro-1H- [M+H]: 449,
0
l'"F pyrazolo [4,3 -c]pyridin- 1- found
449.
yl)propanenitrile
146
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(S)-3-cyclopropy1-3-(3-
III-15µCN ((4-((S)-3-fluoro LRMS (ESI)
Ai<
N, H pyrrolidine-1-carbony1)-3- Calc'd for
Me
/ \ iN 0 methylphenyl)amino)-4- C24H26FN602
HN HN .oxo-4,5-dihydro-1H- [M+H]:
449,
0
NO.....F pyrazolo[4,3-c]pyridin-1-
found 449.
yl)propanenitrile
Compound IV-1
(S)-3-cyclopr op y1-3- (3- 43-methy1-4-((S)-2-methylp iper idine-1-carb
onyl)phenyl)amino)-4-
oxo-4,5-dihydr o-1H -p yr a zolo [4,3-clp yr idin-1-yl)pr op anenitr ile
A,
= CN
N,H
Me
0
Me
HN HN =
0
a IV-1
An oven dried round bottom flask with magnetic sir bar under an atmosphere of
N2 was charged with (S)-4-((1-(2-cyano-1-cyclopropylethyl)-4-oxo-4,5-dihydro-
1H-
pyrazolo[4,3-c]pyridin-3-yl)amino)-2-methylbenzoic acid I-113 (20 mg, 0.05
mmol), DMF (177
uL), (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid
hexafluorophosphate; HATU) (81 mg, 0.2 mmol), Huenig's base (74 uL, 0.4 mmol),
and (S)-2-
methylpiperidine (15 mg, 0.2 mmol). The resulting reaction mixture was stirred
for 12 - 16 h,
and was concentrated in vacuo. The crude oil was purified by column
chromatography on silica
gel eluting with Hexanes/Et0Ac gradient to yield (S)-3-cyclopropy1-3-(343-
methy1-44(S)-2-
methylpiperidine-1-carbonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-1-
yl)propanenitrile IV-1 (14 mg, 0.03 mmol, 60%). LRMS (ESI) Calc'd for
C26H31N602 [M+H]':
459, found 459. 1H NMR (500 MHz, DMS0): 6 11.09 (d, J= 5.81 Hz, 1H), 8.10 (m,
1H), 7.58
(m, 1H), 7.19 (t, J= 6.59 Hz, 1H), 6.58 (d, J= 7.34 Hz, 1H), 4.19 (m, 1H),
3.31 (m, 1H), 3.18
(m, 1H), 2.98 (m, 1H), 2.52 (s, 3H), 2.22 ¨ 2.19 (m, 3H), 1.55 ¨ 1.51 (m, 5H),
1.26 ¨ 1.20 (m,
4H), 0.63 (m, 1H), 0.51 (m, 1H), 0.41 (m, 1H), 0.33 (m, 1H).
The following Examples outlined in Table 16 were prepared by analogy using the
general
procedure outlined above for Compound IV-1 above.
Table 16.
Intermediate Structure Name MS
147
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(S)-3-cyclopropy1-3-(3- LRMS (ESI)
'A'sCN
((3-methyl-4-((R)-2- CaIc'd for
H
IV-2 N Me Me methylpiperidine- 1- C26H31N602
0 carbonyl)phenyl) amino)- [M+H]+:
HN HN 4-oxo-4,5-dihydro-1H- 459, found
0
0- pyrazolo [4,3-c] pyridin- 459.
1-y1) propanenitrile
A (S)- 3-cyclopropy1-3-(3- LRMS (ESI)
<sCN
H ((4-(4,4-difluoro Calc'd for
N
IV-3 M
piperidine-1-carbony1)-3- C26H31N602
e 0
HN \ HN =
4 methylphenyl)amino)-4- [M+H]+:
0 oxo-4,5-dihydro-1H- 481, found
F pyrazolo [4,3 -c]pyridin- 1- 481.
F yl)propanenitrile
(S)-3-cyclopropy1-3-(3- LRMS (ESI)
IV-4
((4-(4-hydroxy-4-methy1 Calc'd for
N,HCN piperidine-l-carbony1)-3- C26H31N603
Me
/ \ iN 0 methylphenyl)amino)-4- [M+H]+:
HN HN fii 1(4 oxo-4,5-dihydro-1H- 475, found
0 pyrazolo[4,3-c]pyridin-1- 475.
Me yl)propanenitrile
OH
(S)-3-cyclopropy1-3-(3- LRMS (ESI)
Al<µCN ((4-(4-methoxy Calc'd for
H
N
IV-5 H Me piperidine-l-carbony1)-3- C26H31N603
0
HN .
methylphenyl)amino)-4- [M+H]+:
N
Q oxo-4,5-dihydro-1H- 475, found
0
pyrazolo[4,3-c]pyridin-1- 475.
OMe
yl)propanenitrile
(S) 3-cyclopropy1-3-(3- LRMS (ESI)
Ai<µCN ((4-(4-(2-hydroxypropan- Calc'd for
N,H
IV-6 Me 2-y1) piperidine-1- C28H35N603
0
carbonyl)-3-methyl [M+H]+:
HN HN . N phenyl)amino)-4-oxo- 503, found
0
4,5-dihydro-1H-pyrazolo 503.
Me
HO Me [4,3-c]pyridin-1-y1)
propanenitrile
148
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(S)-4-((1-(2-cyano-1- LRMS (ESI)
cyclopropylethyl)-4-oxo- Calc'd for
'is
IV-7 H CN 4,5-dihydro-1H-pyrazolo C26H33N603
N Me
0 [4,3-c] pyridin-3-y1) [M+H]+:
H N HN 41, N Me amino)-N-(3-
hydroxy-3- 477, found
ivi
0 ---\---+M( OH methylbuty1)-N,2- 477.
dimethylbenzamide
(S)-3-(3-((4-(azepane-1- LRMS (ESI)
Al,µ CN
carbonyl)-3-methyl Calc'd for
N , H
IV-8 Me phenyl)amino)-4-oxo- C26H31N602
0
4,5-dihydro-1H- [M+H]+:
H N H N =N --"N pyrazolo[4,3-c]pyridin-1- 459, found
0
y1)-3-cyclo 459.
propylpropanenitrile
(S)- 3-cyclopropy1-3-(3- LRMS (ESI)
Aµ CN ((4-(3-fluoroazetidine-1- Calc'd
for
N , H
IV-9 Me carbonyl)-3 -methyl C23H24FN602
H N .
/ \ iN 0
HN
phenyl)amino)-4-oxo- [M+H]+:
Niq 4,5-dihydro-1H- 435, found
0
pyrazolo[4,3-c]pyridin-1- 435.
F
yl) propanenitrile
(S)- 3-cyclopropy1-3-(3- LRMS (ESI)
((4-(3-methoxyazetidine- Calc'd for
N , H
IV-10 Me 1-carbonyl)-3-methyl C24H27N603
0
phenyl)amino)-4-oxo- [M+H]+:
H N H N #
Nq 4,5-dihydro-1H- 447, found
0
OMe pyrazolo[4,3-c]pyridin-1- 447.
yl) propanenitrile
(S)-3-(3-((4-((1R,5S)-8- LRMS (ESI)
oxa-3-azabicyclo Calc'd for
IV-11A [3.2.1]octane-3- C26H29N603 sCN
N , H
carbonyl)-3 -methyl [M+H]+:
Me
0 phenyl)amino)-4-oxo- 473, found
HN HN .
NH 4,5-dihydro-1H- 473.
0 pyrazolo[4,3-c]pyridin-1-
, 0
H' y1)-3-cyclo
propylpropanenitrile
149
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(S)-4-((1-(2-cyano-1- LRMS
(ESI)
cyclopropylethyl)-4-oxo- CaIc'd for
IV-12 i<sCN
N,H e M 4,5-dihydro-1H-pyrazolo
C27H33N602
/ \ iN 0 [4,3-c] pyridin-3-y1)
[M+H]+:
HN =HN amino)-N-cyclohexyl- 473, found
N.........ED,
0 Me N,2-dimethylbenzamide 473.
k(S)-tert-butyl (1-(4-((1- LRMS
(ESI)
Nls H CN (2-cyano-1- Calc'd
for
IV-13 Me cyclopropylethyl)-4-oxo- C3
1H4ON7 04
/ \ 1N 0
4,5-dihydro-1H- [M+H]+:
HN HN 4.
0
Q pyrazolo[4,3-c] pyridin-
574, found
3-yl)amino)-2- 574.
N¨Boc
/ methylbenzoyl)
Me
piperidin-4-y1)
(methyl)carbamate
Example V-1
(S or R)-3- (34(4-flu or ophenyl)amino)-4-oxo-4,5-dihydr o-1H-pyr azolo [4,3-
clpyr idine-1-
yl)butanenitr ile
MeCN
N,
HN HN = F
0 V-1
To (R or S)-3-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-
yl)butanenitrile I-108A (30 mg, 0.098 mmol), 1-bromo-4-fluoro-benzene (25.5
mg, 0.146 mmol),
Pd2(dba)3 (22.4 mg, 0.024 mmol), 2-di-tert-butylphosphino-3,4,5,6-tetramethy1-
2',4',6'-
triisopropy1-1,1'-biphenyl (28.2 mg, 0.06 mmol), and potassium acetate (19 mg,
0.195 mmol) in
a degassed sealed reaction vial, was added isopropanol (0.360 mL). The
reaction mixture was
heated to 80 C overnight. The reaction was cooled to rt, and 0.2 mL of
trifluoroacetic acid was
added. The reaction was stirred at room temperature for an additional 3 h. The
reaction mixture
was diluted with 3.5mL of DMSO, filtered using a 0.2 micron WHATMAN syringe,
and purified
with reverse phase chromatography to afford compound, V-1. LRMS (ESI) calc'd
for
C16F115FN50 [M+H] ': 312, found 312.
150
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
The following Examples outlined in Table 17 were prepared by analogy using the
general
procedure outlined above for Compound V-1 above.
Table 17.
Example Structure Compound Name MS
(3R or S)-3-[4-oxo-3-({4-
LRMS (ESI)
[(1S or R)-2,2,2-trifluoro-1-
MerCN calc'd for
V-2 hydroxy-l-methylethyl]
N, C19H19F3N502
CF3 phenyl} amino)-4,5-dihydro-
[M+H]+: 406,
H'
HN # OH 1H-pyrazolo[4,3-c]pyridin-1-
Me found 406.
O yl]butanenitrile (from I-2A)
(3R or S)-3-[4-oxo-3-({4-
LRMS (ESI)
[(1S or R)-2,2,2-trifluoro-1-
MerCN calc'd for
V-3 hydroxy-l-methylethyl]
N, C19H19F3N502
CF3 phenyl} amino)-4,5-dihydro-
[M+H]+: 406,
H'
HN # OH 1H-pyrazolo[4,3-c]pyridin-1-
Me found 406.
O yl]butanenitrile (from I-2B)
(3R or S)-3-(3-{[(1S or R)-1-
MerCN LRMS (ESI)
hydroxy-1-(trifluoro-methyl)-
N, calc'd for
V-4N
/ \ /
*a CF3 2,3-dihydro-1H-inden-5-yl]
C20H19F3N502
HN HN OH amino} -4-oxo-4,5-dihydro-
[M+H]+: 418,
O 1H-pyrazolo [4,3-c]pyridin-1-
found 418.
yl) butanenitrile (from I-3A)
(3R or S)-3-(3-{[(1S or R)-1-
hydroxy-1-(trifluoro- LRMS (ESI)
methyl)-2,3-dihydro-1H- calc'd for
V-5 MeCN
inden-5-yl] amino} -4-oxo- C20H19F3N.502
N,
i *a CF3 4,5-dihydro-1H-
pyrazolo [M+H]+: 418,
HN HN OH [4,3-c]pyridin-1- found 418.
O yl)butanenitrile (from I-3B)
(3R or S)-3-{3-[(1,1-dioxido-
LRMS (ESI)
2,3-dihydro-1-
MeCN calc'd for
V-6 benzothiophen-5-y1) amino]-
N, C18t118N503S
/ \ iN 4-oxo-4,5-dihydro-1H-
HN HN 41t, SO2 pyrazolo[4,3-
c]pyridin-1- [M+H]+: 384,
found 384.
0 yl}butanenitrile
151
CA 02901770 2015-08-19
WO 2014/146493 PCT/CN2014/000299
(3R or S)-3-{3-[(1,1-dioxido- LRMS (ESI)
MeCN
1-benzothiophen-5- calc'd for
V-7 N,
yl)amino]-4-oxo-4,5-dihydro- C18H16N5035
HN HN 4It SO2 1H-pyrazolo[4,3-c]pyridin-1-
[M+H]+: 382,
0 yl}butanenitrile found 382.
4-({1-[(1S or R)-2-cyano-1- LRMS (ESI)
MeCN
methylethy1]-4-oxo-4,5- calc'd for
V-8 N,
dihydro-1H-pyrazolo[4,3- C17H15N60
HN IìN . CN c]pyridin-3-y1} amino) [M+H]+: 319,
0 benzonitrile found 319.
(3R or S)-3-(4-oxo-3-{[4- LRMS (ESI)
MeCN
(trifluoromethyl)phenyl]amin calc'd for
N,
o}-4,5-dihydro-1H- C17H14F3N50
V-9
HN HN = C F3 pyrazolo[4,3-
c]pyridin-1- [M+H]+: 362,
0 yl)butanenitrile found 362.
(3R or S)-3-(3-{[4-(methyl- LRMS (ESI)
MeCN
sulfonyl)phenyl]amino} -4- calc'd for
V-10 N,
oxo-4,5-dihydro-1H- C17H18N5035
HN HN 41, SO2Me pyrazolo[4,3-c]pyridin-1-y1) [M+H]+: 372,
0 butanenitrile found 372.
MeCN (3R
(ESI)
(3R or S)-3-{4-oxo-3-[(3,4,5-
N, calc'd for
V-11 F trifluorophenyl) amino]-4,5-
Ci6Hi2F3N50
HN HN . F dihydro-1H-pyrazolo[4,3-
[M+H]+: 348,
0 c]pyridin-l-yl}butanenitrile
F found 348.
(3R or S)-3-{3-[(2-methyl-
LRMS (ESI)
1,1-dioxido-2,3-dihydro-1,2-
MeCN calc'd for
V-12 benzisothiazol-5-y1) amino]-
N, Me C19H19N6035
N, 4-oxo-4,5-dihydro-1H-
HN HN . 02 pyrazolo[4,3-
c]pyridin-1- [M+H]+: 399,
found 399.
0 yl}butanenitrile
(3R or S)-3-{3-[(2-fluoro- LRMS (ESI)
MeCN
pyridin-4-yl)amino]-4-oxo- calc'd for
V-13 N,
.....F 4,5-dihydro-1H-pyrazolo C15H14FN60
HN
N [4,3-c]pyridin-1- [M+H]+: 313,
0 yl}butanenitrile found 313.
1 52
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(3R or S)-3-{4-oxo-3-[(1- LRMS (ESI)
MeCN
oxo-2,3-dihydro-1H-inden-5- calc'd for
V-14 N,
yl)amino]-4,5-dihydro-1H- C19H18N5 02
HN HN 4.1 I 1 0 pyrazolo[4,3-c]pyridin-1- [M+H]+: 348,
0 yl}butanenitrile found 348.
(3R or S)-3-[3-(2,3-dihydro- LRMS (ESI)
MeCN
1-benzofuran-5-ylamino)-4- calc'd for
V-15 N,
oxo-4,5-dihydro-1H- C18H18N502
HN HN 41k, 0 pyrazolo[4,3-c]
pyridin-1- [M+H]+: 336,
O yl]butanenitrile
found 336.
(3R or S)-3-[3-(1,3- LRMS (ESI)
MerCN
benzodioxo1-5-ylamino)-4- calc'd for
V-16 N, 0,,
I oxo-4,5-dihydro-1H- C17H16N503
HN HN 441t 0 pyrazolo[4,3-
c]pyridin-1- [M+H]+: 338,
O yl]butanenitrile
found 338.
LRMS (ESI)
MeCN (3R or S)-3-[4-oxo-3-
calc'd for
V-17 N, (quinolin-6-ylamino)-4,5-
¨
/ dihydro-1H-pyrazolo[4,3- C19H17N60
HN HN = N
c]pyridin-l-yl]butanenitrile [M+H]+: 345,
O found 345.
(3R or S)-3-(3- {[3-fluoro-4- LRMS (ESI)
MerCN
(methylsulfonyl)phenyl]amin calc'd for
V-18 N F
/ \ ;N o}-4-oxo-4,5-dihydro-1H- C17H17FN5035
H'
HN 41, S 0 2 Me pyrazolo[4,3-c]pyridin-1- [M+H]+: 390,
0 yl)butanenitrile found 390.
LRMS (ESI)
MeCN (3R or S)-3-[4-oxo-3-
calc'd for
V-19 N N:----\ (quinoxalin-6-ylamino)-4,5-
d
dihydro-1H-pyrazolo [4,3- CisHi6N70
HN HN = N
c]pyridin-l-yl] butanenitrile [M+H]+: 346,
O found 346.
LRMS (ESI)
MeCN (3R or S)-3-{3-[(4-
calc'd for
V-20 N chlorophenyl)amino]-4-oxo-
/ \ ;N C16H15C1N50
4,5-dihydro-1H-pyrazolo[4,3-
HN HN . Cl
c]pyridin-l-yl}butanenitrile [M+H]+: 328,
O found 328.
153
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
N-tert-butyl-4-({1-[(1S or R)-
LRMS (ESI)
2-cyano-1-methylethy1]-4-
MeCN calc'd for
V-21 oxo-4,5-dihydro-1H-
N, Me C20H25N603S
\ IN HN*Vle pyrazolo[4,3-c]pyridin-3-
[M+I-1] : 429,
HN HN= IC'2 Me yl} amino)
found 429.
0 benzenesulfonamide
(3R or S)-3-{3-[(2-tert-butyl-
LRMS (ESI)
1,1-dioxido-2,3-dihydro-1,2-
Me Me rCN calc'd for
V-22 )<Me benzisothiazol-5-yl)amino]-4-
N,
iN N Me oxo-4,5-dihydro-1H-
C21H25N603 S
[M+1-1] : 441,
HN HN 41, pyrazolo[4,3-c]pyridin-1-
found 441.
0 yl}butanenitrile
Example VI-1
(S)-methyl 3((4-(azetidin-1-ylsulfonyl)phenyl)amino)-1-(2-cyano-1-cyclopr op
ylethyl)-4-
oxo-4,5-dihydr o-1H -p yr azolo [4,3-clp yr idine-7-carb oxylate
Me0
Ns
iN
HN HN
0 VI-1
Step 1: (S)-3-(3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-7-bromo-4-oxo-4,5-
dihydro-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile
CN
Br H
Ns
iN
HN HN=th)2
VI-laO
To(S)-3-(3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-c] yridine-1-y1)-3-cyclopropylpropanenitrile (435 mg, 0.992 mmol)
in acetonitrile
(2 mL) was added NBS (194 mg, 1.091 mmol). The reaction mixture was stirred at
room
temperature for 6 hours. LC-MS show the formation of desired product, bis-
brominated product
and starting material. The reaction was quenched with aqueous sodium
thiosulfate. After
stirring for 20 min the reaction was diluted with Et0Ac and brine. The
reaction mixture was
adjusted to pH = 6.5 using aqueous NH4C1. The organics were separated, washed
with brine,
dried and concentrated. The crude mixture was purified by flash column (dry
loaded on silica)
154
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
and eluted with Ethyl acetate/DCM. Three fractions were collected and LC-MS
showed the
second fraction is the desired product (S)-3-(3-((4-(azetidin-l-
ylsulfonyl)phenyl)amino)-7-
bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c] yridine-1-y1)-3-
cyclopropylpropanenitrile. LRMS
(ESI) calc'd for C21H22BrN603S [M+H]+: 517, found 517. 1H NMR (400 MHz, DMSO-
d6): 6
8.12 (s, 1H), 7.62 (s, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.28 (d, J= 7.2 Hz, 2H),
4.02 (br, 1H), 3.60-
3.5 (m, 5H), 3.10-3.02 (m, 2H), 2.14 (m, 2H), 0.90-0.52 (m, 5H).
Step 2: (S)-methyl 3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-1-(2-cyano-1-
cyclopropylethyl)-
4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxylate
The reaction mixture containing (S)-3-(3-((4-(azetidin-l-
ylsulfonyl)phenyl)amino)-7-bromo-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-l-
y1)-3-
cyclopropylpropanenitrile (120mg, 0.232 mmol), PdC12(dppf) (26 mg, 0.035
mmol), methanol (2
mL) in DMSO (2 mL) was placed in CO (25 psi) and heated to 70 C for 22 hours.
After the
reaction is completed, the mixture was filtered and purified using prep-HPLC
to give the dired
product. LRMS (ESI) calc'd for C23H25N6055 [M+H]+: 497, found 497. 1H NMR (400
MHz,
DMSO-d6): 6 12.00 (s, 1H), 8.82 (s, 1H), 8.10 (d, J= 7.2 Hz, 2H), 7.70 (d, J =
7.2 Hz, 2H), 5.51
(br, 1H), 3.82 (s, 3H), 3.60 (m, 1H), 3.42-3.20 (m, 6H), 2.04 (m, 2H), 0.72-
0.42 (m, 5H).
Example VI-2
(S)-3-(3((4-(azetidin-1-ylsulfonyl)phenyl)amino)-7-(hydr oxymethyl)-4-oxo-4,5-
dihydr o-1H -
p yr azolo [4,3-c]p yr idin-1-y1)-3-cyclopr opylpr op anenitr ile
Al.,
H 0 CNH
\ -3
N
/ \ ; N N
H N H N = Si 02
0 VI-2
To (S)-methyl 3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-1-(2-cyano-1-
cyclopropylethyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxylate
(25 mg, 0.050
mmol) in THF (2 mL) was added LiBH4 (0.076 mL, 0.151 mmol). The formed mixture
was
stirred at 50 C for overnight. The reaction mixture was filtered and purified
using prep-HPLC to
give the desired product (S)-3-(3-((4-(azetidin-1-ylsulfonyl)phenyl)amino)-7-
(hydroxymethyl)-
4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile.
LRMS (ESI)
calc'd for C22H25N6045 [M+H]+: 469, found 469. 1H NMR (400 MHz, DMSO-d6): 6
8.88 (s,
1H), 8.00 (d, J= 7.2 Hz, 2H), 7.68 (d, J= 7.2 Hz, 2H), 7.08 (s, 1H), 5.38 (br,
1H), 4.50-4.30 (m,
3H), 3.60-3.20 (m, 7H), 1.84 (m, 2H), 0.72-0.42 (m, 5H).
155
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Example 11-168
(S)-methyl 3((4-(azetidin-1-ylsulfonyl)phenyl)amino)-1-(2-cyano-1-cyclopr op
ylethyl)-4-
oxo-4,5-dihydr o-1H -p yr azolo [4,3-clp yr idine-7-carb oxylate
Ai<sCN
N,H Me
Me
\ IN
HN HN=
SO2
0 11-168
Step 1: 5-((4-(benzyloxy)-1-((S)-2-cyano-1-cyclopropylethyl)-1H-pyrazolo[4,3-
c]pyridin-3-
y1)amino)-2,2-dimethyl-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-3-y1 1H-
imidazole-1-
carboxylate
Al<sCN
me
Me
µ,1\1
N = SO2
H
OBn II-168a
To a 25 mL round bottom flask was place a solution of (3S)-3-(4-(benzyloxy) -3-
((3-hydroxy-2,2-dimethy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-yl)amino)-
1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile (100 mg, 0.18 mmol),
4-
dimethylaminopyridine (5 mg, 0.04 mmol), di(1H-imidazol-1-y1) methane thione
(48 mg, 0.27
mmol) and DCM (5 mL) was added, the mixture was stirred at ambient temperature
for
overnight. Water (10 mL) was added and the mixture was extracted with Et0Ac (2
x 20 mL).
The combined organic fractions was washed with brine (saturated, 2 x 20 mL),
dried with
Na2504 and filtered. The filtrate was concentrate in vacuo and the residue was
purified by
column chromatography on silica gel, eluting with Et0Ac/petroleum ether (1/5)
to to obtain 0-
(5-((4-(benzyloxy)-1-((R)-2-cyano-1-cyclopropylethyl)-1H-pyrazolo[4,3-
c]pyridin-3-y1)amino)-
2,2-dimethyl-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-3-y1)1H-imidazole-1-
carbothioate: MS
(ESI) calc'd for C33H31N70452 [M+H]+: 654, found 654.
Step 2: (S)-3-(4-(benzyloxy)-3-((2,2-dimethy1-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-
yl)amino)-1H-pyrazolo[4,3-c]pyridin-l-y1)-3-cyclopropylpropanenitrile
156
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
A<sCN
N, H Me
Me
N¨ HN . S02
OBn II-168b
To a 25 ml round-bottom flask was place a solution of 0-(5-((4-(benzyloxy)-1-
((R)- 2-cyano-1-cyclopropylethyl)-1H-pyrazolo[4,3-c]pyridin-3-y1)amino)-2,2-
dimethyl-1,1-
dioxido-2,3-dihydrobenzo[b]thiophen-3-y1)1H-imidazole-1-carbothioate (97 mg,
0.15 mmol),
dibutyl(pentyl)stannane (85 mg, 0.29 mmol), 2,2'-azobisisobutyronitrile (24
mg, 0.14 mmol) in
toluene (10 mL). The mixture was degassed with nitrogen for 3 times and
stirred for 2 h at
110 C. The mixture was concentrated in vacuo to give a residue. The residue
was purified by
column chromatography on silica gel, eluting with Et0Ac/petroleum ether (1/5)
to obtain (S)-3-
(4-(benzyloxy)-3-((2,2-dimethy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile: MS (ESI) calc'd for
C29H29N5 05S
[M+H]+: 528, found 528.
Step 3: fS)-3-cyclopropy1-3-(3-42,2-dimethyl-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile
Al<sCN
N, H Me
Me
HN HN . S02
0 II-168
To a 50 mL three neck round-bottom flask was placed a mixture of (S)-3-(4-
(benzyloxy) -3-((2,2-dimethy1-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-1H-
pyrazolo[4,3-c]pyridin-1-y1)-3-cyclopropylpropanenitrile (50 mg, 0.09 mmol),
wet palladium on
carbon (30 mg, 10%) in Me0H (15 mL) under hydrogen (1.5 atm). The mixture was
stirred for
12 h at ambient temperature. The reaction mixture was filtered. The filtrate
was concentrated in
vacuo to give (S)-3-cyclopropy1-3-(34(2,2-dimethyl-1,1-dioxido-2,3 -
dihydrobenzo[b]thiophen-
5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-l-y1)propanenitrile.
MS (ESI) calc'd
for C22H23N5055 [M + H]+: 438, found 438; 1H NMR (300 MHz, DMSO-d6) d 11.16
(s, 1H),
8.63 (s, 1H), 7.92 (s, 1H), 7.73 (dd, J = 8.4, 1.8 Hz, 1H), 7.58 (d, J = 8.4
Hz, 1H), 7.23 (d, J = 7.5
Hz, 1H), 6.63 (d, J = 7.2Hz, 1H), 4.25-4.23(m, 1H), 3.39-3.31 (m, 4H), 1.47-
1.46 (m, 1H), 1.36
(s, 6H), 0.69-0.31 (m, 4H).
The following Examples outlined in Table 18 were prepared by analogy using the
general
procedure outlined above for Compound 11-168 above.
157
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
Structure Compound Name
MS
Example
AsCN (S)-3-cyclopropy1-3-(3-((1,1-
11-167 N, H el dioxido-3H-
spiro[benzo[b] (ESI) calc'd for
thiophene-2,1'-cyclohexan]-5- C25 H27N5
03 S
HN HN it SO2
yl)amino)-4-oxo-4,5-dihydro-1H- [M+H]+: 478,
0
pyrazolo[4,3-c]pyridin-1-y1) found 478
propanenitrile
AsCN (S)-3-cyclopropy1-3-(3-((1,1-
11-166 NsH ii, dioxido-3H-
spiro[benzo[b] (ESI) calc'd for
/ \ ,N
1 41, s02 thiophene-
2,1'-eyelopentan]-5- C25 H27N5 03 S
HN HN
yl)amino)-4-oxo-4,5-dihydro-1H- [M+H]+: 478,
0
pyrazolo[4,3-c]pyridin-1- found 478
yl)propanenitrile
Examples 11-169, 11-170, 11-171, and 11-172
(S)-3-cyclopropy1-3-(3-(((2R,3S; 2R,3R; 2S,3S; and 2S,3R)-2,3-dimethy1-1,1-
dioxido-2,3-
dihydr obenzo[b ] thiophen -5-yl)amin o)-4-oxo-4,5-dihydr o-1H -p yr azolo
[4,3-c]p yr idin -1-
yl)pr op anenitr ile
CN
H HO
N Me
HN HN = S02
0
11-169, 11-170, 11-171, and 11-172
Step 1: f3S)-3-Cyclopropy1-3-(3-42-methy1-1,1-dioxido-3-oxo-2,3-
dihydrobenzo[b]thiophen -5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile
" H CN 0
N Me
'
/ \ ¨(N /
.
Hq1-IN =
SO2
0 II-169a
5-Bromo-2-methylbenzo[b]thiophen-3(2H)-one 1,1-dioxide (0.17 g, 0.62 mmol),
(S)-3-(3-amino-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)-3-
cyclopropylpropanenitrile
(0.10 g, 0.41 mmol), tris(dibenzylideneacetone)dipalladium(0)-chcloroform
adduct (43 mg, 0.04
158
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (35 mg, 0.08
mmol), potassium
acetate (81 mg, 0.82 mmol) in 2-propanol (30 mL) was degassed with nitrogen
for 3 times and
stirred under nitrogen for 16 h at 80 C. The reaction mixture was quenched
with water (20 mL),
diluted with water (20 mL) and extracted with Et0Ac (3 x 50 mL). The combined
organic
layers was washed with water (1 x 20 mL) and brine (1 x 20 mL), dried over
anhydrous Na2SO4
and filtered. The filtrate was concentrated under vacuum. The residue was
purified by column
chromatography on silica gel, eluting with Et0Ac/petroleum ether (3/1) to
obtain (3S)-3-
cyclopropy1-3-(3-42-methyl-1,1-dioxido-3-oxo-2,3-dihydrobenzo[b]thiophen-5-
yl)amino)-4-
oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile. MS (ESI) calc'd
for
C21H19N5045 [M + 1]+ 438, found 438.
Step 2: kS)-3-Cyc1opropy1-3-(3-(42R,3S; 2R,3R; 2S,3 S; and 25,3R)-3-hydroxy-2-
methy1-1,1-
dioxido-2,3-dihydrobenzo [b]thiophen-5-yl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-y1)propanenitrile
AsCN
H HO
N Me
H'
HN . SO2
0
11-169, 11-170, 11-171, and 11-172
Sodium borohydride (47 mg, 1.23 mmol) was added in portions to a stirred
solution of (3S)-3-cyclopropy1-3-(3-42-methyl-1,1-dioxido-3-oxo-2,3-
dihydrobenzo[b]thiophen-5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-l-
y1)propanenitrile (0.18 g, 0.41 mmol) in Me0H (20 mL) at ambient temperature
an stirred for 30
min at ambient temperature. The reaction mixture was quenched with water (20
mL), diluted
with water (20 mL) and extracted with Et0Ac (3 x 50 mL). The combined organic
layers was
washed with water (1 x 20 mL) and brine (1 x 20 mL), dried over anhydrous
sodium sulfate and
filtered. The filtrate was concentrated under vacuum to give the crude
product. The crude
product was purified by Flash-Prep-HPLC. Condition: Column Xbridge C18 ,
19*150mm;
Detector UV; Wave Length 254/220nm; Mobile Phase and Gradient Phase A: water
with 10
mmol NH4HCO3; Phase B: ACN. Gradient time: 0-12 min. B%:22%-37%. trans (S)-3-
cyclopropy1-3-(3-4-3-hydroxy-2-methyl-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-
5-yl)amino)-
4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile was obtained
at 5.63 min and
cis (S)-3-cyclopropy1-3-(3-4-3-hydroxy-2-methyl-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-y1)propanenitrile was
obtained at
6.25 min. Trans (S)-3-cyclopropy1-3-(3-43-hydroxy-2-methyl-1,1-dioxido-2,3-
dihydro
benzo[b]thiophen-5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-l-
y1)propanenitrile
was purified by Chiral-Prep-HPLC with the following conditions: Column,
Chiralpak IBO,
159
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
46*25cm, Sum; mobile phase: Hex: ethanol =50:50; Detector, UV 254 nm. 10 mg
(5%) of 1-
((S)-1-cyclopropylpropy1)-3-(((2R,3S or 2S,3R)-3-hydroxy-2-methy1-1,1-dioxido-
2,3-
dihydrobenzo[b]thiophen-5-yl)amino)-1H-pyrazolo[4,3-c]pyridin-4(5H)-one at 7.5
min; MS
(ESI) calc'd for C21H21N5045 [M + 1]+: 440, found 440; 1H NMR(400 MHz, DMSO-
d6) d
11.16 (brs, 1H), 8.74 (s, 1H), 8.03 (s, 1H), 7.81 (d, J= 8.4 Hz, 1H), 7.62 (d,
J = 8.4 Hz, 1H),
7.24 (t, J= 6.4 Hz, 1H), 6.64 (t, J= 6.8 Hz, 1H), 6.37 (d, J = 7.2 Hz, 1H),
4.75 (t, J = 7.6 Hz,
1H), 4.30-4.28 (m, 1H), 3.32-3.27 (m, 3H), 1.47-1.43 (m, 1H), 1.45 (d, J= 6.8
Hz, 3H), 0.67-
0.64 (m, 1H), 0.57-0.53 (m, 1H), 0.46-0.42 (m, 1H), 0.36-0.32 (m, 1H); and (S)-
3-cyclopropy1-3-
(3-(((2S,3R, or 2R,3S)-3-hydroxy-2-methy1-1,1-dioxido-2,3
¨dihydrobenzo[b]thiophen-5-
yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)propanenitrile at
15.5 min: MS
(ESI) calc'd for C21H21N5045 [M+1]+: 440, found 440; 1H NMR(400 MHz,DMSO-d6) d
11.16
(brs, 1H), 8.74 (s, 1H), 8.04 (s, 1H), 7.81 (d, J= 8.8 Hz, 1H), 7.62 (d, J=
8.8 Hz, 1H), 7.24 (t, J
= 6.4 Hz, 1H), 6.64 (t, J = 7.2 Hz, 1H), 6.38 (d, J= 7.2 Hz, 1H), 4.75 (t, J=
7.2 Hz, 1H), 4.31-
4.26 (m, 1H), 3.36-3.27 (m, 3H), 1.47-1.43 (m, 1H), 1.44 (d, J= 6.8 Hz, 3H),
0.67-0.65 (m, 1H),
0.55-0.53 (m, 1H), 0.45-0.42 (m, 1H), 0.35-0.32 (m, 1H).
Cis (S)-3-cyclopropy1-3-(3-((3-hydroxy-2-methy1-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen -5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-1-
y1)propanenitrile was purified by Chiral-Prep-HPLC with the following
conditions: Column,
Chiralpak IBO, 46*25cm, Sum; mobile phase: Hex: ethanol = 50:50; Detector, UV
254 nm. (S)-
3-cyclopropy1-3-(3-(((2S,3S, or 2R,3R)-3-hydroxy-2-methy1-1,1-dioxido-2,3-
dihydrobenzo[b]thiophen-5-yl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-
c]pyridin-1-
yl)propanenitrile was obtained at 7 min: MS (ESI) calc'd for C21H21N5045 [M +
1]+: 440, found
440; 1H NMR (400 MHz, DMSO-d6) d 11.16 (brs, 1H), 8.70 (s, 1H), 8.00 (s, 1H),
7.82 (d, J =
8.4 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.23 (t, J = 6.4 Hz, 1H), 6.64 (d, J=
7.6 Hz, 1H), 6.05 (d, J
= 5.6 Hz, 1H), 5.22 (t, J= 6.0 Hz, 1H), 4.29-4.27 (m, 1H), 3.67-3.64 (m, 1H),
3.37-3.28 (m, 2H),
1.47-1.45 (m, 1H), 1.25 (d, J= 7.2 Hz, 3H), 0.69-0.66 (m, 1H), 0.57-0.54 (m,
1H), 0.46-0.43 (m,
1H), 0.36-0.33 (m, 1H); and (S)-3-cyclopropy1-3-(3-(((2R,3R, or 25,35)-3-
hydroxy-2-methy1-
1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-yl)amino)-4-oxo-4,5-dihydro-1H-
pyrazolo[4,3-
c]pyridin-1-yl)propanenitrile was obtained at 17 min: MS (ESI) calc'd for
C21H21N5045 [M +
1]+: 440, found 440; 1H NMR (400 MHz, DMSO-d6) d 11.16 (brs, 1H), 8.70 (s,
1H), 8.04 (s,
1H), 7.81 (d, J= 8.8 Hz, 1H), 7.60 (d, J= 8.8 Hz, 1H), 7.24 (t, J = 6.4 Hz,
1H), 6.64 (d, J = 7.2
Hz, 1H), 6.05 (d, J= 6.0 Hz, 1H), 5.23 (t, J= 6.0 Hz, 1H), 4.29-4.27 (m, 1H),
3.68-3.64 (m, 1H),
3.38-3.24 (m, 2H), 1.47-1.45 (m, 1H), 1.25 (d, J= 7.2 Hz, 3H), 0.69-0.66 (m,
1H), 0.57-0.54 (m,
1H), 0.46-0.43 (m, 1H), 0.36-0.33 (m, 1H).
BIOLOGICAL ASSAYS
Jak Biochemical HTRF Assay Protocol
The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2
was measured using a recombinant purified GST-tagged catalytic domain for each
enzyme
160
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
(Invitrogen JAK1 #M4290, JAK2 #M4290, JAK3 #M4290, Tyk2 #M4290) in an HTRF
format
biochemical assay. The reactions employed a common peptide substrate, LCB-
EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First,
250 nL
of diluted compounds in DMSO were dispensed into the wells of a dry 384-well
Black plate
(Greiner #781076) using a Labcyte Echo 555 acoustic dispenser. Subsequent
reagent additions
employed an Agilent Bravo. Next, 18 iut of 1.11X enzyme and 1.11X substrate in
1X assay
buffer (Invitrogen kinase buffer # PV3189, 2 mM DTT, 0.05% BSA) were added to
the wells
and shaken and then preincubated for 30 minutes at room temperature to allow
compound
binding to equilibrate. After equilibration, 2 iut of 10X ATP in lx assay
buffer was added to
initiate the kinase reaction and the plates were shaken and then incubated at
room temperature
for 120 minutes. At the end of the incubation, 20 iut of 2X stop buffer
(streptavidin-Dylight 650
(Thermo #84547B/100mL), Eu-tagged pY20 antibody (Perkin Elmer #AD0067), EDTA,
HEPES,
and Triton) was added to quench the reaction. Plates were shaken and
centrifuged and then
incubated 60 minutes at room temperature and then read on a Perkin Elmer
Envision (?ex = 337
nm, kern = 665 and 615 nm, TRF delay time = 20 s). HTRF signal = 10,000 * 665
nm reading /
615 nm reading. After normalization to untreated controls, the percent
inhibition of the HTRF
signal at each compound concentration was calculated. The plot of percent
inhibition versus the
log of compound concentration was fit with a 4-parameter dose response
equation to calculate
IC50 values.
Final reaction conditions were:
Enzyme [E] (nM) [S] ( M) [ATP] ( M) [Eu-pY20] (nM) [SA-Dylight] (nM)
JAK1 1.405 0.75 31.8 9 312.5
JAK2 0.052 0.75 8.5 9 312.5
JAK3 0.031 0.75 2.9 9 312.5
Tyk2 2.612 0.75 6.9 9 312.5
Compound concentrations tested were 1496, 499, 175, 49.9, 18.7, 6.2, 2.1,
0.75, 0.24, 0.075, and
0.0125 nM, with 1.25% residual DMSO.
BIOLOGICAL DATA
Examples of the instant invention were evaluated in JAK1 and JAK2 in vitro
binding assays as
described above. The following table tabulates the JAK1 IC50 values and JAK2
IC50 values
disclosed for the instant invention.
Example JAK1 IC50 JAK2 IC50
II-1 3.09 3.46
11-2 25.17 33
11-3 0.23 0.51
11-4 10.43 25.79
161
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-5 6.86 9.85
11-6 20.36 52.2
11-7 0.14 0.28
11-8 4.67 11.17
11-9 18.53 4.54
II-10 6.86 23.08
II-11 64.92 16.92
11-12 75.14 178.9
11-13 4.42 4.51
11-14 5.91 16.68
11-15 10.03 4.95
11-16 10.41 13.29
11-17 0.35 2.2
11-18 0.17 0.66
11-19 0.08 0.44
11-20 0.12 0.68
11-21 0.12 0.33
11-22 0.10 0.72
11-23 0.04 0.28
11-24 0.35 1.96
11-25 0.78 4.92
11-26 0.19 0.93
11-27 3.39 13.63
11-28 0.05 0.70
11-29 1.47 9.90
11-30 0.26 1.39
11-31 0.37 1.86
11-32 0.99 4.30
11-33 0.11 1.32
11-34 0.92 2.61
11-35 1.12 5.57
11-36 0.37 3.59
11-37 0.12 0.42
11-38 0.11 0.31
11-39 0.14 0.34
11-40 0.18 0.59
11-41 0.22 0.65
162
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-42 0.12 0.29
11-43 0.27 0.30
11-44 0.13 0.38
11-45 0.10 0.40
11-46 0.17 0.30
11-47 0.15 0.32
11-48 0.95 0.83
11-49 0.57 1.32
11-50 0.08 0.40
11-51 0.08 0.55
11-52 0.12 0.73
11-53 0.62 1.07
11-54 2.75 3.49
11-55 0.40 0.67
11-56 0.36 0.72
11-57 0.57 1.22
11-58 0.34 0.81
11-59 0.69 1.14
11-60 0.49 0.97
11-61 0.61 0.73
11-62 1.28 2.70
11-63 1.15 2.80
11-64 0.32 0.38
11-65 0.34 0.52
11-66 0.40 0.51
11-67 0.20 0.54
11-68 0.34 0.72
11-69 1.03 2.18
11-70 0.46 1.05
11-71 0.25 0.50
11-72 0.50 1.90
11-73 0.33 0.79
11-74 0.26 0.33
11-75 0.46 0.91
11-76 0.22 0.39
11-77 0.27 0.49
11-78 0.64 1.24
163
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-79 0.62 1.30
11-80 0.61 0.84
11-81 0.42 0.46
11-82 0.66 1.22
11-83 1.86 1.91
11-84 0.57 0.94
11-85 0.46 1.17
11-86 0.15 0.30
11-87 0.31 0.36
11-88 0.40 1.33
11-89 0.29 0.80
11-90 0.18 0.62
11-91 0.50 1.07
11-92 0.07 0.18
11-93 0.48 1.96
11-94 0.13 0.67
11-95 0.39 0.80
11-96 0.14 0.21
11-97 0.20 0.50
11-98 0.31 0.64
11-99 0.29 0.83
II-100 0.29 0.84
II-101 0.22 0.70
11-102 0.31 0.84
11-103 0.09 0.23
11-104 0.46 0.73
11-105 0.32 0.43
11-106 0.19 0.45
11-107 0.40 0.72
11-108 0.20 0.23
11-109 0.16 0.19
II-110 0.12 0.31
II-111 0.20 0.46
11-112 0.11 0.28
11-113 0.16 0.27
11-114 0.15 0.61
11-115 0.24 1.00
164
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-116 0.07 0.54
11-117 1.50 3.64
11-118 0.33 0.44
11-119 4.33 10.02
11-120 0.98 1.59
11-121 0.10 0.14
11-122 0.19 0.57
11-123 1.04 5.31
11-124 0.12 2.47
11-125 0.28 4.52
11-126 0.08 1.22
11-127 0.70 3.57
11-128 0.16 1.93
11-129 0.10 1.49
11-130 0.24 2.71
11-131 0.19 2.19
11-132 0.10 0.24
11-133 0.41 0.52
11-134 0.13 2.92
11-135 0.14 2.34
11-136 0.12 1.53
11-137 0.29 2.95
11-138 0.29 3.01
11-139 0.40 3.80
11-140 0.22 0.63
11-141 0.35 0.25
11-142 0.40 0.27
11-143 0.46 0.25
11-144 0.43 0.35
11-145 1.82 1.82
11-146 0.43 0.58
11-147 0.06 1.04
11-148 0.07 0.34
11-149 0.07 0.19
11-150 0.22 2.07
11-151 0.16 0.74
11-152 5.50 2.73
165
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-153 1.04 1.00
11-154 0.41 1.03
11-155 0.32 0.62
11-156 0.10 0.89
11-157 0.11 0.60
11-158 0.59 1.42
11-159 0.17 0.50
11-160 0.61 0.65
11-161 0.12 0.21
11-162 0.17 0.16
11-163 0.14 0.26
11-164 1.31 2.65
11-165 0.31 0.65
11-166 0.13 0.41
11-167 0.13 0.47
11-168 0.10 0.37
11-169 0.83 2.81
11-170 0.19 0.42
11-171 0.26 2.02
11-172 0.27 0.82
11-173 0.09 0.53
11-174 0.68 0.46
11-175 0.51 1.10
11-176 1.13 0.59
11-177 0.07 0.18
11-178 0.35 0.71
11-179 0.40 1.24
11-180 0.64 0.55
11-181 0.40 0.37
11-182 0.62 0.58
11-183 0.39 0.46
11-184 0.25 0.48
11-185 2.56 4.03
11-186 2.05 1.92
11-187 0.45 1.33
11-188 0.82 1.30
11-189 0.72 1.15
166
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
11-190 0.88 1.48
11-191 0.34 2.44
11-192 0.20 1.38
11-193 0.43 3.83
11-194 0.43 3.16
11-195 0.55 1.03
11-196 0.55 0.96
11-197 2.95 3.32
11-198 3.62 10.01
11-199 0.10 0.10
11-200 0.07 0.06
11-201 0.29 0.34
11-202 1.17 0.94
11-203 0.30 0.72
11-204 0.13 0.41
11-205 0.55 0.44
11-206 0.20 0.33
11-207 0.11 0.21
11-208 1.55 1.71
11-209 0.72 0.77
III-1 0.38 0.93
111-2 0.46 0.81
111-3 2.21 2.52
111-4 0.37 0.51
111-5 1.23 1.20
111-6 0.75 0.73
111-7 2.37 2.72
111-8 0.49 0.88
111-9 0.45 0.61
III-10 0.95 0.62
III-11 0.61 0.79
111-12 0.79 0.62
111-13 0.81 0.52
111-14 0.61 0.81
111-15 0.47 0.86
IV-1 0.45 0.39
IV-2 0.60 0.59
167
CA 02901770 2015-08-19
WO 2014/146493
PCT/CN2014/000299
IV-3 0.52 0.71
IV-4 0.68 0.88
IV-5 0.58 0.70
IV-6 0.28 0.53
IV-7 0.82 2.24
IV-8 0.48 0.53
IV-9 0.23 1.10
IV-10 0.20 1.07
IV-11 0.54 0.52
IV-12 1.05 1.07
IV-13 0.91 0.64
V-1 7.89 35.60
V-2 2.67 8.30
V-3 1.50 5.87
V-4 0.94 6.06
V-5 1.42 3.93
V-6 1.60 9.69
V-7 4.03 28.14
V-8 5.49 24.25
V-9 7.38 41.99
V-10 4.05 14.84
V-11 49.63 168.7
V-12 0.88 8.53
V-13 20.75 106.1
V-14 6.99 27.86
V-15 6.55 24.16
V-16 15.82 50.25
V-17 1.99 23.82
V-18 14.46 32.48
V-19 18.14 76.08
V-20 6.07 39.73
V-21 2.99 4.97
V-22 1.75 3.30
V-23 0.21 2.52
VI-1 11.42 15.29
VI-2 3.91 3.22
